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Abstract  
 
Background: Current evidence indicates that DNA damage response (DDR) is a 
highly complex process that involves various pathways working in an orchestrated and 
interwoven manner in response to different types of damage to DNA. Although specific 
defects of DDR remain to be deciphered in cancer as a general, there is certainly an 
undeniable relationship between a particular dysfunction of DDR and the phenotype of 
tumour [1, 2]. It has been demonstrated that familial forms of breast and ovarian cancer are 
characterised by defects in one of the main mechanisms of DDR homologous recombination 
(HR) as a result of germline loss-of-function mutations in one of HR modifying genes, such 
as BRCA1 and BRCA2 [1, 3, 4]. Defects of genes involved in other DDR pathways are also 
associated with specific types of cancers; for instance hereditary non polyposis colorectal 
cancer (HNPCC) is strongly associated with specific mutations in the DNA mismatch repair 
pathway. Several previous studies have demonstrated that impaired DDR play a fundamental 
role in the pathogenesis and behaviour of breast cancer (BC). However, characterisation of 
this complex process, the expression and co-expression of the key proteins involved in the 
various DDR pathways and their prognostic significance in BC remain to be defined. In BC, 
it is reported that genes involved in DNA double strand breaks (DSB) repair are the most 
important. Two main pathways are involved in the repair of DNA-DSB; HR and Non 
Homologous End Joining (NHEJ) [3]. The common characteristics of global DDR are 
multiple genes induction directly associated with sensing and repair of DNA, arrest of cell 
cycle, and cell division inhibition. As a result DDR process does not only include genes 
activation involved in damage sensing as well as repair but additionally genes involved in 
control of cell-cycle [5]. Despite the fact that DDR may possibly involve activation of several 
pathways (such as SUMOylation (SUMO)) [6, 7] and many genes are engaged in different 
overlapping mechanisms, each pathway is characterised by activation and expression of a 
unique set of genes. This could allow discovering the active or aberrant pathway in a given 
tumour [1, 4, 5].  
 
This study explores the hypothesis that investigation of alterations in the different 
pathways of DNA-DSB, may contribute to the characteristics of BC. Therefore, the aim was 
to perform a comprehensive profiling of key proteins involved in the different DNA-DSB 
repair pathways in the different molecular classes of BC. This approach aims to address the 
inherent problems arising from the complexity of DDR mechanism in BC with the potential 
of discovering a key pathway that is active or inactive in specific forms of BC that can be 
helpful to identify DNA repair status in individual BC patients.  
 
Method: The study cohort comprises three BC groups: A) Large series of unselected 
primary sporadic operable invasive tumours (n=1904) in addition to B) 386 cases of 
oestrogen receptor (ER) negative tumours and C) a well-characterised series of BC from 
patients with known BRCA1 germline mutations (n=24). The proteins investigated in this 
study are known to participate in different DNA-DSB repair pathways including, DNA 
GDPDJH VHQVRUV $70 DQG $75 +5 UHSDLU %5&$ %$5' 5DG Ȗ+$; DQG
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SMC6L1), DNA damage checkpoint signalling protein (CHK1 and CHK2), NHEJ repair 
(KU70/KU80, and DNA-PK), and SUMO (PIAS1, PIAS4, and UBC9). Because subcellular 
localisation of DDR proteins may affect their function, two markers that have role in nuclear 
transport in the cell were examined (NPM and KPNA2). The expression of these proteins was 
assessed using the well-established immunohistochemical technique utilising tissue 
microarray technology. The expression of proteins was further evaluated in various cell lines; 
BRCA1 deficient HeLaSilenciX® cells, and control BRCA1 proficient HeLaSilenciX®, 
MDA-MB-436 (BRCA1 deficient), and MCF-7 (BRCA1 proficient and ER+) using Reverse 
Phase Protein Microarray (RPPA).  
 
Results: Both cytoplasmic and nuclear expression was observed for expression of 
Rad51, SMC6L1, BRCA1, BARD1; (HR markers), PIAS1, UBC9 (SUMO markers)Ȗ+$;
(DNA-DSB marker) and CHK1 (checkpoint signalling protein). In contrast, both NHEJ 
markers and most of the DNA damage sensors (ATM and ATR), CHK2 and PIAS4 were 
mainly expressed in the nucleus. Generally, tumours that showed positive 
cytoplasmic/negative nuclear expression such as CHK1, PIAS1, Rad51, and BRCA1, and 
positive nuclear NHEJ markers showed an association with a poor outcome and adverse 
prognostic characteristics including high histologic grade, high mitotic frequency, high 
nuclear pleomorphism and larger tumour size in addition to ER negativity, and triple negative 
breast cancer (TNBC). Conversely, nuclear+/cytoplasmic- expression showed an association 
the better outcome. Interestingly, ATM protein expression showed no association with the 
expression of the two NHEJ markers, whereas ATR showed an association with cytoplasmic 
expression of BRCA1 and BARD1 and was positively associated with NHEJ markers. In 
non-TNBC, tumours showing BRCA1-/KU70/KU80- phenotype had worse breast cancer 
specific survival (BCSS) than positive expression (P<0.0001), whereas in the TN cohort, 
complex of KU70/KU80-&DNA-PK+ had the worst BCSS (P=0.001), and both are 
independent prognostic markers for BC. 
 
KPNA2, but not NPM was highly associated with poor BCSS (P<0.0001). At least 
one of nucleocytoplasmic transport markers (NPM or KPNA2) was significantly associated 
with the subcellular localisation of the most of the markers that showed cytoplasmic 
H[SUHVVLRQLQFOXGLQJ60&/Ȗ+$;%5&$%$5'8%&3,$6 ,Rad51 and CHK1.  
RPPA was used to investigate the protein expression in different cell lines, although the 
correlation between RPPA and IHC was not significant, the results of RPPA were consistent 
with that demonstrated by IHC further supporting the finding of the current study. 
 
 Conclusion: This study highlight the complexity of DDR related proteins and the 
overlap between different pathways involved in DDR. The finding of this study may help in 
the classification of BC and therefore, targeting active pathways in the development of drugs 
would enhance better SDWLHQWV¶RXWFRPHV. Major prognostic and predictive variables can be 
very important in choosing suitable treatment plans, identifying the risk of recurrence and 
classifying patients for clinical trials. Our results show that the HR- repair marker Rad51, 
complex of HR and NHEJ repair markers (BRCA1&KU70/KU80) in non-TNBC, and a 
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complex of NHEJ markers (KU70/KU80&DNA-PK) are all independent prognostic markers 
for BC. In addition to expression, subcellular localisation of DDR proteins appeared to be a 
major factor in their role.  Particularly, HR repair markers (but not NHEJ) showed worse 
features of cytoplasmic location of expression, whereas nuclear expression was associated 
with more favourable features. Finally, the results of this study provide further evidence to 
support combined use of IHC with the parallel analytic capability of protein microarray 
RPPA to investigate protein alterations in human tumours. 
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Abbreviation Definition 
KPNA2 .DU\RSKHULQĮ-2 
KRAB Krüppel-Associated Box 
LEF1 Lymphoid Enhancer-binding Factor 1 
Lig I Ligase I 
Lig IIIĮ OLJDVH,,,Į 
LN Lymph Node 
MDC1 Mediator of DNA Damage Checkpoint protein1 
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MDM2 Mouse Double Minute 2 homolog 
MEV Multi Experiment Viewer 
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M phase Mitosis phase 
MLF1 Myeloid Leukemia Factor 1 
MMR Mismatch Repair 
MRN MRE11±RAD50±Nbs1 
MTA1 Metastasis- Associated Protein 
MPG I Moderate Prognostic Group I 
MPG II Moderate Prognostic Group II 
MUC1 Mucin 1 
MYC Myelocytomatosis 
 Nbs1 Nijmegen breakage syndrome1 
NER Nucleotide Excision Repair 
NES Nuclear Export Sequence 
NGFR Nerve Growth Factor Receptors 
NHEJ Non-Homologous End-Joining Pathway 
NIH National Institutes of Health 
NIR Near Infrared 
NIBC Non Inflammatory Breast Cancer 
NICE National Institute for health and Care Excellence 
NLS Nuclear Localisation Signal 
NPCs Nuclear Pore Complexes 
NPI Nottingham Prognostic Index 
NPM Nucleophosmin 
NRG Neuregulin 
NTS Non-Transcribed Strand 
NST No Special Type 
PARP Poly ADP Ribose Polymerase  
PBS Phosphate Buffered Saline 
PCNA Proliferating Cell Nuclear Antigen 
PCR Polymerase Chain Reaction 
PgR Progesterone Receptor 
PIAS Protein inhibitor of activated signal transducer 
PIAS1-4 Protein Inhibitor of Activated STAT1-STAT4 
3ROȕ PRO\PHUDVHȕ 
PPG Poor Prognostic Group 
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Abbreviation Definition 
PTEN Phosphatase and Tensin Homolog 
Rac1 Ras-related C3 botulinum toxin substrate 1 
RING Really Interesting New Gene 
RNAi RNA interference 
RNAPII RNA Polymerase II 
RS Recurrence Score 
ROS Reactive Oxygen Species 
RPA Replication Protein A 
RPPA Reverse Phase Protein Microarray 
RTK Receptor Tyrosine kinases 
SAE1 SUMO-conjugation System Consisting of an E1 Activating Enzyme 
SAP Scaffold Attachment factor-A/B/acinus/PIAS 
SCID Severe Combined ImmunoDeficiency 
SDS Sodium Dodecyl Sulphate 
SES Socio-Economic Status 
siRNA Short interfering RNA 
SMA Smooth Muscle Actin 
SMC Structural Maintenance of Chromosome 
S phase Synthesis phase 
SSB Single Strand Break 
ssDNA single stranded DNA 
STAT Signal Transducer and Activator of Transcription 
SUMO Small Ubiquitin-Related Modifier 
SVM Support Vector Machines 
TAILORx Trial Assigning IndividuaLized Options for Treatment 
TBS Tris Buffered Saline 
TCR Transcription Coupled Repair 
TDLU Terminal Duct Lobular Unit 
TEBs Terminal End Buds 
TFIIH Transcription Factor-IIH 
T1GFR Type 1 Growth Factor Receptor 
TMA Tissue Microarray Array 
TN Triple Negative 
TOPB1 DNA Topoisomerase 2-Binding Protein 1 
TrkA Tyrosine Kinase receptor type 1 
TS Transcribed Strand 
UBC9 Ubiquitin-Conjugating Enzyme 9 
UTRN Utrophin 
 UV Ultraviolet Light 
V(D)J Variable, Diverse, and Joining 
VI Vascular Invasion 
VPG Very Poor Prognostic Group 
W.B Western Bolt 
XPC Xeroderma Pigmentosum, complementation group C 
XRCC1 X-Ray repair Cross-Complementing protein 1 
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Chapter 1 
 
1.1 Introduction  
 
1.1.1 Normal Breast Development: Anatomy and Histology 
 
The development of the mammary gland is complex: proliferation, apoptosis, 
differentiation and migration are all important in the development of the remarkably 
organised, branched ductal network of epithelial cells. Despite the existence of the mammary 
gland in embryos, the majority of the branching morphogenesis required for the development 
of the ductal tree appears at puberty, along with the release of ovarian hormones. At this time, 
the distal ends of the mammary ducts will develop into bulbous structures composed of 
several layers of epithelial cells, known as terminal end buds (TEBs)[8]. These types of TEBs 
proliferate and ramify and will attempt to invade the adipose tissue, in order to permit the 
development of a complex branching structure: this action occurs over a period of 10-12 
weeks. Following this developmental phase, the TEBs then regress [9]. However, the 
complex signalling pathways regulate the proliferation of luminal cells. 
 
There are many hormones that have a bearing on stromal cells, in terms of activating 
the process of branching, such as oestrogen, progesterone and prolactin [10]. During puberty, 
both oestrogen and epidermal growth factor (EGF) equally regulate ductal elongation and 
branching. Various other growth factors (for example, fibroblast growth factor (FGF) [11], 
insulin growth factor (IGF)[12], neuregulin (NRG), amphiregulin and receptors ERBB2/3/4 
[13-15]) are also implicated in the development and branching of embryonic mammary gland 
morphogenesis. Hormones such as progesterone, prolactin and placental lactogens promote 
alveolar proliferation and differentiation during pregnancy [16]. An awareness of the 
macroscopic anatomy of the breast and its changes offers several clinical applications, in 
terms of breastfeeding/lactation support and the discovery, diagnosis and management of the 
removal of benign and malignant lesions. With regards to the latter, the epithelial cells lining 
the duct walls are the origin of the majority of breast malignancies [17], underlining the 
importance of an extensive understanding of the anatomy of the breast.  
 
A couple of different hypotheses concerning cell of origin of BC have already been 
suggested [18-21]. The first theory states that BC stems from a common epithelial stem cell 
and subsequent genetic alterations determine the phenotype, while a second hypothesis 
postulates that BC could possibly originate from distinct cancer stem cells and progenitor 
cells. Consequently, the phenotype in the latter situation is partially influenced by the 
epithelial cell of origin differentiation. Primarily based on observational data from molecular 
studies, for example using gene expression arrays as well as gene transfection models, 
produced results in line with the theory postulating that biology of the tumour of a BC, at 
least to some extent, mirrors the biology of the tissue/epithelial cell of origin at the initiation 
time. It could possibly be that the two theories do not oppose each other and that tumours 
may possibly grow from different precursor cells such as occasionally coming from a stem 
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cell and sometimes from diversely developed progenitor cells. It is therefore hypothesised 
that the type of mutations acquired, the differentiation potential of the cancer cells, and the 
cell of origin are very likely to make a decision whether a tumour follows a Cancer Stem Cell 
(CSC) model [22].  
 
In the early 1990s, clinical findings and genetic analyses of a number of cancers led to 
the hypothesis that six genetic mutations are essential to alter a normal somatic cell into a 
cancer cell [23, 24]. These six mutations showed specific features such as; self-sufficiency 
for growth signals, insensitivity to signals of antigrowth, apoptosis evasion, unlimited ability 
to replicate, sustained angiogenesis, as well as tissue invasion and metastasis. Stem cells 
possess the strongest potential for proliferation and a considerably longer life span compared 
to their progeny and as a consequence has a very higher chance to increase genetic mutations 
[25]. The realisation that the adult body contains small numbers of stem cells provided a 
substitute probability for the cancer origin. Possibly only single or two mutations, including 
self-sufficiency in growth or insensitivity to antigrowth signals, are required for stem cells to 
trigger tumorigenesis rather than six mutations, a rare event in any cell type.  
 
In 1994, John Dick and his colleagues revealed that leukemia-initiating stem cells 
existing in the peripheral blood of acute myeloid leukaemia (AML) patients [26]. In 2003, a 
study by Clarke et al effectively demonstrated the presence of stem cells in BC [27] who used 
a model in which human BC cells were grown in immunocompromised mice, and observed 
that only a minority of cells of BC possessed the capability to develop new tumours. The 
authors were able to distinguish the tumorigenic (tumour initiating) from the cancer of non-
tumorigenic cells depending on expression of cell surface marker. Clearly they were able to 
SURVSHFWLYHO\ LGHQWLI\ DQG LVRODWH WKH WXPRULJHQLF FHOOV DV &'&'íORZ/LQHDJHí LQ
eight of nine patients. Only 100 cells with this phenotype were able to develop tumours in 
mice, while tens of thousands of cells with alternate phenotypes did not develop tumours. The 
tumorigenic subpopulation could possibly be serially passaged: each time cells inside this 
population developed new tumours that contain DGGLWLRQDO &'&'íORZ/LQHDJHí
tumorigenic cells and the phenotypically diverse combined populations of non-tumorigenic 
cells existing in the initial tumour. The chance to prospectively discover tumorigenic cancer 
cells will certainly help the pathways elucidations that control their growth as well as 
survival. Additionally, considering these cells drive development of tumour, strategies 
intended to aim for this particular population may possibly result in more efficient treatments. 
7KXV &'&'íORZ/LQHDJHí FHOOV FRPLQJ IURP WKH PDMRULW\ RI WXPRXUV DSSHDU WR
express properties of cancer stem cells. Unequivocal demonstration of the stem cell capacity 
of these cells will need model systems development effective at generation of tumour from an 
individual cell [28]. Importantly, Clarke et al show that there is certainly BC cells hierarchy 
in which some cells are able to proliferate substantially, while most of tumour cells that could 
be extracted out of this population currently have only limited proliferative potential in vivo.  
 
It can be hypothesised that tumours originating from migrating uncommitted stem 
cells are an uncommon event otherwise individuals would develop tumours early in life in 
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several organs and this would very seriously threaten human viability. Nevertheless, a 
progenitor cell/stem cell, that is in charge of the development of breast duct (lobe specific) 
possessing its main influence at or after puberty, during menstrual cycle and at 
pregnancies/lactation, could possibly be the reason for development of the tumour in women, 
who already would have a chance of given birth to children, thus not necessarily reducing 
reproduction of humans [18].  
 
Although the origins of breast carcinoma cells have been studied for decades, 
controversy remains, in regards to this. The normal parenchymal cells of the mammary gland 
are composed of two main functional units, ducts and lobules, which are lined by two cell 
layers: the inner/luminal layer and a distinct outer cell layer, which is juxtaposed to the 
basement membrane [29, 30]. These units are divided into two main types: luminal/glandular 
cells and basal/myoepithelial cells. Figure 1.1 shows the normal parenchymal cells of 
mammary gland. This division is based upon morphological classification (completely 
remodelled by using the expression profile analysis through complementary DNA (cDNA) 
microarray), immunophenotypes and the expression of the various markers of these cells. In 
general, the luminal cells of the inner layers have been linked with the expression of the low 
molecular weight of cytokeratins (CKs), such as CK7, CK8, CK18 and CK19 [31]. They also 
tend to express Oestrogen Receptors (ER) and other markers, including Progesterone 
5HFHSWRUV 3J5 0XFLQ  08&, Į-6-integrin, B-cell lymphoma 2 (Bcl2) and Epithelial 
Membrane Antigens (EMA) [31]. It is accepted that myoepithelial cells are related to high 
PROHFXODU ZHLJKW µEDVDO¶ F\WRNHUDWLQV VXFK DV &. &. &. Smooth Muscle Actin 
(SMA) and smooth muscle myosin heavy chain; calponin; P63 [32, 33]; caldesmon; ȕ4 
integrin; CD10; P-cadherin; Nerve Growth Factor Receptors (NGFR); laminin; S-100 and 
caveolin 1 [31, 34, 35]. Moreover, myoepithelial cells are characteristically absent, with 
regards to the majority of the markers of luminal cells [36]. The term basal-like is used as a 
synonym for the basal/myoepithelial cells of the normal breast, based on the similarities 
between the molecular profile of these cells [37]. This term generally applies to the 
expression of a specific sub-population of basal CK to many cells, either in the luminal or the 
basal site [34].  
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1.1.2 Breast Cancer Epidemiology  
 
BC is a leading cause of death in women around the world. The rate varies (it is up to 
five times more prevalent in some countries than others), but is increasing in some areas that 
were previously classified as having a low occurrence of BC [38]. The incidence of this 
disease amongst women in Europe and North America is approximately 2.7% of the 
population up to the age of 55 and 7.7% in those aged 75 and over [38, 39]. However, in 
England, there were 41,259 new cases of clinically-diagnosed BC in 2010, a rise of 1.8% 
(731 cases) from 2009. In 2010, there were 126 new cases per 100,000 females, compared to 
125 new cases per 100,000 females in 2009. These prevalence rates have risen by an 
alarming rate of 90% between 1971 and 2010. More than 9,700 women died as a result of BC 
in England in 2011, a rate of twenty-four deaths per 100,000 females. Between 1971 and 
2011, this mortality rate dropped by 37%. 
 
 
1.1.3 Pathogenesis and Aetiology 
 
BC expresses various biological and clinical behaviours: this diversity is shown in the 
underlying morphologic and molecular differences, with a range of histologic features and 
molecular pathologic markers that are useful in predicting clinical outcomes and in selecting 
appropriate therapy [40].  
 
Previously, it was understood that BCs usually originate in the mammary epithelium, 
through a well-defined, but non-obligatory, sequence of histological alterations; from normal 
epithelium through to hyperplasia, atypical hyperplasia, in-situ carcinoma and, finally, 
invasive, malignant disease [19-21]. In the standard model of multi-stage tumour growth, the 
development of a normal epithelial cell progresses into a premalignant atypical cell and, 
subsequently, clonal enlargement results in a pre-malignant lesion, in-situ (step 1). As time 
Figure 1.1 Normal parenchymal cells of mammary gland. Luminal cells of the inner layers have been linked 
with the expression of the low molecular weight of cytokeratins (CKs), such as CK7, CK8, CK18 and CK19, 
whereas the outer layers (basal) express high molecule CKs such as CK5, CK17 and CK14.   
Chapter 1                                                                                               General Introduction 
33 
 
passes, this lesion has the potential to become invasive (step 2) and to disseminate, followed 
by invasion of the immune system and metastases (step 3) [41]. However, at each and every 
step, a significant genetic/epigenetic event is thought to occur that offers the cell new 
features, along with causing a clonal selective advantage for that cell: this model has been 
verified by a number of molecular studies [41-43]. In addition, a number of studies have 
implemented comprehensive gene expression and genetic profiling studies in order to 
compare in-situ, invasive, and metastatic BCs but however, these studies didn't determine 
tumour stage±specific gene signatures [44-46]. Nevertheless, generally, these studies have 
targeted in depth only the tumour of epithelium cells, whereas the potential involvement of 
other epithelial and myoepithelial cells as well as the stroma in the progression of the tumour 
have not been investigated in details. Nevertheless, the rate of normal mutation is limited to 
the genetic differences that are usually necessary for growth of a tumour. It is thus often 
suggested that mutations causing genomic instability appear as the initiating event and 
generate pressure, in order to induce tumourigenesis [47, 48]. Generally, the majority of these 
hypotheses believe that genomic instability arises from mutations in the various genes 
associated with cellular functions, such as the repair of DNA and chromosomal segregation. 
Furthermore, mutations in these genes do not have a direct selective advantage or 
disadvantage; they only influence the rates of the mutation of other genes[41].  
 
There is a list of many different genes that are supposedly implicated in the 
tumorigenesis of BC. In sporadic BC, the amplification of genes such as Myelocytomatosis 
(MYC), Excess Microsporocytes1 (EMS1), Cyclin D1 (CCND1) and ERBB2 are essential in 
the development of such cancer. In addition, growth factors, such as EGF and IGF-1, 
demonstrate some role in the growth or proliferation of BC [49-54]. BC type 1 susceptibility 
protein (BRCA1), as a tumour suppressor, has an essential role in maintaining genomic 
stability. It interacts with various proteins and, in addition, the complexes formed with 
BRCA1-associated RING domain protein 1 (BARD1) are involved in the recognition and 
repair of DNA [55]. Germline mutations in BRCA1 confer susceptibility to breast and ovarian 
cancer. BRCA1 mutations can occur across the gene and comprise different types including 
insertions, deletions, frame-shifts, base substitutions or inferred regulatory mutations. In 
sporadic BC, BRCA1 is infrequently mutated and previous studies did not identify coding 
region mutations and non-coding regulatory region mutations are extremely rare. In contrast, 
reduced BRCA1 protein expression has been reported in a subset of these cancers, suggesting 
impaired function of BRCA1 [55-59]. However, this proposed dysfunctional status could be 
due to epigenetic defect or abnormalities in any pathway is directly or indirectly related to 
BRCA1 such as BRCA/Fanconi Anaemia (FA) pathway [60]. Evidence is accumulating that 
dysfunction of BRCA1, could possibly be essential in the pathogenesis of a significant 
proportion of sporadic, non-familial BCs. This concept arises from several lines of evidence, 
which includes both phenotypic analyses of tumours and mechanistic studies showing 
inactivation of components of these pathways. Underlying different DNA-repair defect, 
arising from loss of homologous recombination that has been proposed is a defining tumours 
property with BRCA/FA pathway inactivation. The FA proteins are implicated in similar 
DNA-repair pathways to BRCA1. There is an evidence shows that a significant proportion of 
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sporadic cancers inactivate the pathways of BRCA/FA by methylation of Fanconi Anemia, 
Complementation group F (FANCF) [61]. However, methylation of FANCF has been 
observed in different types of sporadic cancer, such as ovarian, breast and oral cancers, and 
non-small-cell lung and cervical carcinomas [61-63]. Other important and related genes 
involved in BC include BRCA2 and TP53.  BRCA2 mutational inactivation is infrequent, 
mainly as it requires both gene copies to become mutated or even completely lost [55, 64]. 
Mutation of TP53 remains the most frequent genetic change revealed in human neoplasia. 
Just like the BRCA1 mutation, the TP53 mutation is associated with more aggressive disease 
and poor overall survival; however, it accounts for only a small proportion of hereditary BC 
[65].  
 
The subtypes of ER-ĮDQG(5-ȕDUHHQFRGHGE\GLIIHUHQWP51$VEXWVKRZDVLPLODU
structural and functional domain composition [66]. ER regulates gene expression through 
ER-dependent and ER-independent mechanisms, ending with the stimulation of gene 
transcription, such as that of cell cycle control proteins. Despite the fact that the ER-Į and 
ER-ȕ genes show a large degree of homology, it is generally believed that their distributions 
and functions are significantly distinct in many tissues. The recent development of reliable 
antibodies to ER-ȕ KDV RIIHUHG DQ HYDOXDtion of the hypothesis that the likelihood of 
malignant transformation in morphologically benign breast lesions can be precisely identified 
by the distribution and amount of expression of ER-ȕLQDFFRUGDQFHZLWKWKDWRI(5-Į[67]. 
The overexpression of ER-Į FDQ RIWHQ EH VHHQ LQ WKH HDUO\ VWDJHV RI BC [68] and the 
relevance of ER-ȕin BC is much less distinct than that of ER-Į7KHH[LVWHQFHRIP51$RI
ER-ȕKDVEHHQUHYHDOHGERWKLQQRUPDODQGPDOLJQDQWPDPPDU\JODQGWLVVXH[69]. However, 
Shaaban et al revealed that a decreased level of ER-ȕLQDFFRUGDQFHZLWK(5-ĮLVDGHILQLWLYH
predictor of individual cases of hyperplasia of the type more likely to develop into invasive 
BC, thus supporting the idea that transcriptional activity of ER-ĮLVGLUHFWO\FRQWUROOHGE\(5-
ȕ [70]. However, isoforms of PgR, PgR-Į and PgR-ȕ show distinctive physiological 
functions, yet their separate functions in BC are not clear [71]. 
 
Despite the fact that both normal and pre-invasive breast cells show peripheral 
myoepithelial layers, significant differences exist between them [72]. The transition from 
hyperplasia to atypical hyperplasia is clinically related to a higher risk of BC and the 
subsequent phase is usually a marker of progression to carcinoma in-situ which can be 
defined as a proliferation of cells together with cytological features of malignancy, but 
without stromal invasion throughout the basement membrane [41]. Malignant tumours are 
recognised by aberrant cellular differentiation, together with disorganised growth and 
increased proliferation rates and the ability to invade [73]. Cells become invasive when they 
migrate from the basement membrane and invade the stroma. As a result of dissemination 
through the lymph vessels, invasive cells can metastasise, either to loco-regional lymph nodes 
or to distant organs. Most invasive breast carcinomas are ductal (75±85%) and infiltrating 
lobular carcinoma that comprises approximately 10% of all BCs. Although ductal and lobular 
terminology were derived from breast ducts and lobules to reflect the site of origin, the well-
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known model in evolution of BC published by Wellings and Jensen suggested that the origin 
of most BCs is the Terminal Duct Lobular Unit (TDLU) [74, 75].  
 
1.1.4 Risk Factors for Breast Cancer 
 
Epidemiological BC studies have proven that hormonal factors play a major role in 
the causation of the disease, which is mainly linked to ER. However, there are many other 
factors that contribute to an increased  risk of BC, such as early menarche, late menopause, 
high-levels of endogenous oestradiol and obesity in postmenopausal women [38].  
 
 
1.1.4.1 Age  
 
The age of a patient is highly related to the incidence of BC; the risk doubles every 10 
years up to the menopause, when the level of increase drops significantly [76]. Indeed, in 
some countries, there is a flattening of the age incidence curve just after menopause [77-85]. 
Age-adjusted prevalence and the death rate for BC differ markedly between countries, by up 
to a five-fold increase. The variation between Far Eastern and Western countries is 
decreasing, although it remains that the death rates in Western countries are five times that of 
those in the Far East. In migrants from Japan to Hawaii, it was demonstrated that the rate of 
the incidence of BC assumed the rate of the host country over two generations. This 
highlights the fact that environmental factors are generally of higher importance than genetic 
factors. Figure 1.2 shows the incidence rate of BC by age group for women in the UK. The 
average woman under the age of 40 has a significantly lower chance of developing BC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.1.4.2 Hormonal Factors 
 
It has been consistently demonstrated that ER is usually induced and enhanced in 
mammary tumours in rodents. Women who have a bilateral oophorectomy before the age of 
Figure 1.2 Incidence rate of breast cancer by age group for women in the UK. The average woman 
under the age of 40 has a significantly lower chance of developing breast cancer. Taken from 
Cancer Research UK.   
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thirty-five have only a 40% associated risk of BC, compared to women who go through a 
normal menopause[86]. The increased risk of women who experience normal menopause is 
thus due to hormonal influence, via ER [86, 87].  
 
Many experts have analysed the relationship between lactation and the incidence of 
premenopausal BC in cohort studies, with varying outcomes. Two independent studies have 
claimed an inverse association between lactation and the possibility of premenopausal or 
early-onset BC [88, 89], while two other studies showed no association [90, 91]. Such 
inconsistent findings may possibly be due to variation in age at diagnosis between the studies 
populations. However, in studies that indicate a protective association, cases were 
considerably younger. This is consistent with several cohort studies that observed there was 
no association between lactation and post-menopausal BC [90-92]. However, extended 
durations of lactation might confer protection for older women [93]. 
 
Recent epidemiological studies have inconsistently revealed a modestly-increased BC 
risk associated with hormone replacement therapy (HRT) [94] (specifically, those women 
using a combination of progestin with oestrogen, rather than oestrogen alone, or those who 
experienced long-term use of HRT [95, 96]). Limited knowledge is known, with regards to 
the different formulations of HRT (and progestins in particular).  
 
 
1.1.4.3 Family History 
 
It has been hypothesised that BCs in women with an inherited predisposition to such 
cancers tend to be phenotypically and prognostically distinct. Despite the fact that family 
history is a well-established aetiological risk factor for BC, its association with survival is 
still ambiguous. Many different studies have recorded an increased survival for females with 
a family history of BC [97-100], whereas other studies state little or no difference in survival 
rates [101-103] or, even worse, in survival [104, 105]. Susceptibility to BC is usually 
inherited as an autosomal dominant, with limited penetrance. Yet it is believed that only 20% 
to 25% of the occurrence of BC in first-degree relatives of women affected by the disease 
may be related to mutations in well-known genes: this includes the high-penetrance 
susceptibility genes BRCA1 and BRCA2, in addition to the moderate and low-penetrance 
genes identified up to the present time [106, 107]. In the UK, out of the whole of recognised 
BCs, the mutation of BRCA1 accounts for around 2% of the total incidence of the disease 
[108].  
 
Table 1.1 shows additional common risk factors of BC.  
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Table 1.1 Additional Risk Factors of Breast Cancer 
Risk Factors  
Socio-Economic Status 
(SES) 
SES has been associated with most of the recognised or suspected risk factors for BC 
incidence and progression. SES includes access to medical care across the world, 
screening programmes, self-awareness and level of education[109]. 
Body Weight 
High body mass index (BMI) has been linked to an elevated risk of BC in post-
menopausal women[110]. Obese post-menopausal women present 10-30% higher risk 
of developing BC, whereas the risk is reduced by 20% in obese pre-menopausal women 
[110]. Higher serum oestrogen levels and enhanced local production of oestrogen have 
already been considered primary mediators of how increased body weight promotes 
development of BC in post-menopausal women [111]. In pre-menopausal women, the 
reduction in the risk would probably be as a result of an ovulatory menstrual cycle 
stimulated by obesity whereas, in post-menopausal women, there is trend for an 
oestrogen increase in the circulation as a result of hormones conversion in the fatty 
tissue as the main source of oestrogen in post-menopausal women [112]. 
Body Height In UK, there is a highly significant trend of risk of BC with relative risk of 1.16 for 
every 10cm greater in height [113]. 
Breast Density 
High breast density is a common and strong risk factor for BC [114]. Post-menopausal 
hormone therapy, particularly oestrogen and progestin, enhances density of the breast 
[115] as well as the risk of BC [116]. Regardless of whether density of breast provides 
a higher effect on the risk of BC for some subgroups of women identified by 
menopausal status and use of post-menopausal hormone therapy remains unknown 
[117]. 
Smoking and Alcohol 
Consumption 
On the basis of epidemiological data, alcohol and tobacco has been classified as human 
carcinogens [118]. 
Diet 
There is an increase of BC risk by 13% with the higher level of fat intake [119].  In a 
large study carried out on European women, there was a positive correlation found 
between intake of high fat and risk of BC and this was mainly observed among post-
menopausal women [120]. 
Ethnicity 
A number of studies have linked ethnicity with the prognosis of BC [121, 122]. It has 
been stated that variation in survival between different ethnic groups is a reflection of 
many factors such as effect of place of birth as well as residence place [123]. A study 
by Komenaka et al on Hispanic whites and African Americans populations showed that 
African American patients had poorer BC±specific survival than non-Hispanic white 
patients. [124]. On the other hand, Soliman et al showed that Egyptian women less than 
60 years had higher mortality rate and lower rate after 60 years compared to African-
American women [125]. 
 
 
1.1.5 Overview of the Prognostic Factors for Breast Cancer  
 
A wide variety of clinical and pathological factors are consistently used to categorise 
patients with BC, in order to be able to evaluate prognosis and identify suitable therapy. Such 
factors are age of patient, status of axillary lymph nodes, tumour size, histological features 
(mainly histological grade and lymphovascular invasion), the status of hormone receptors 
and, finally, the status of Human Epidermal Growth Factor Receptor 2 (HER-2) [126]. 
Taking into account these factors in combination is of more significant clinical value than 
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considering each in isolation and this combined strategy creates the structure of several 
schemas, which are used to classify patients into risk groups. Such schemas include the St 
Gallen criteria [127, 128], the National Institutes of Health (NIH) consensus criteria [129] 
and the Nottingham Prognostic Index [130]. 
 
 
1.1.5.1 Clinico-pathological Factors as Prognostic Factors 
 
1.1.5.1.1 Age at Diagnosis 
 
Age upon diagnosis of BC KDVDVLJQLILFDQWHIIHFWRQWKHUDWHRIDSDWLHQW¶VVXUYLYDO
Females under 35 years demonstrate significantly worse survival rates, in comparison to 
females aged 70 years and over [131, 132]. Younger patients are more likely to have poor 
clinical characteristics, such as larger tumour size and higher histological grade, lymphatic 
vessel and the involvement of lymph nodes [122, 133]. In addition, tumours in younger 
women are usually associated with the overexpression of mutated P53 protein, the 
amplification of HER-2, negativity of ER or PgR and Basal-Like BCs (BLBC)[122, 134]. 
Furthermore, it has been estimated that these women have a higher morbidity risk compared 
to other age groups [132]. 
 
 
1.1.5.1.2 Histological Type  
 
The histological type of invasive BC presents valuable prognostic information [135, 
136]. With regards to its relationship with BC, along with outcomes, histological typing 
needs to be regularly conducted for every case of invasive BC. Ductal carcinoma of no 
special type (NST), accounting for up to 75% of all BCs, has the worst prognosis, whereas 
tubular BC demonstrates the best prognosis. However, some other special types of invasive 
carcinoma fall in between these two prognostic extremes, including mixed ductal NST and 
classical lobular carcinoma, with 55% of patients experiencing a 10-year survival rate [137-
139]. Inflammatory BC (IBC) has the most severe prognosis, in terms of stage III tumours, 
when compared to non-inflammatory BC [140]. Despite the prognostic significance of the 
histological type of a tumour, its part in the decision of clinical management is reasonably 
limited [141]. 
 
 
1.1.5.1.3 Tumour Size 
 
Size of tumour is one of the most highly-effective prognostic factors and is a predictor 
of the behaviour of BC; the larger the tumour, the worse the SDWLHQWV¶ RXWFRPHV [142]. 
Indeed, the size of a tumour is an indication of how long has tumour been present. In 
addition, the size of a tumour can be used by radiologists as a standard tool in the screening 
of BC, in revealing impalpable nodules simply through mammography [143]. The rate of the 
occurrence of metastases to the axillary nodal in patients with tumours smaller than 1cm in 
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size ranges between 10-20%. Additionally, patients who are node-negative and have tumours 
smaller than 1cm have an approximate 90% ten-year disease-free survival rate [144]. 
Screening data, together with measurements of a tumour, presents population-based estimates 
of tumour growth, as does screen test sensitivity directly associated with the size of a tumour. 
There are certainly significant differences in tumour growth in BC, with faster growth rates 
amongst younger women [145]. The growth of a tumour can be simply determined by 
comparing the tumour sizes of clinically-detected and screening-detected cases; however, the 
applied statistical models only employ such data to some extent. Chen et al [146] applied 
tumour size within a classical Markov model, while Van Oortmarssen et al [147] 
incorporated tumour size in a simulation approach, yet each of these studies only classified 
size of tumour into two or three classes. Some clinical observation studies, however, 
completely apply measurements of tumour size, together with tumour growth, modelled as 
being a continuous function of tumour size [145]. 
 
 
1.1.5.1.4 Tumour Histological Grade 
 
Grade of tumour is an important predictor of overall and disease-free survival [131, 
148, 149] and categorisation is based on the level of similarity to normal tissue; for example, 
well, moderate and poorly differentiated. A modification of the Bloom-Richardson 
histological grading of invasive breast carcinoma, the Nottingham Grading System is one of 
the most powerful factors in offering important prognostic information [150]. Grading 
contributes to the management of treatment for patients receiving adjuvant therapy, in 
addition to inclusion in the Nottingham Prognostic Index (NPI) [151, 152]. The Nottingham 
Grading System consists of three tiers, dependent upon the reporting of three factors showing 
the degree of tumour differentiation: these are tubule formation level, mitotic frequency and 
nuclear pleomorphism. The histological grade helps to measure the biological aggressiveness 
of tumours and, in most cases, this does not alter as time passes [151, 152]. In studies carried 
out over the space of 10 years, in which the survival rates based on histological tumour grade 
in combination with the stage of lymph node involvement and size of tumour were assessed, 
patients presenting as histological grade 3 and stage 1 experienced similar survival rates as 
those patients with histological grade 1 and stage II disease. Regardless of the status of the 
lymph nodes, patients with a histological grade 1 tumour less than 1cm in size had an 
excellent prognosis, with an approximate 99% 5-year survival rate [152, 153].  
 
 
1.1.5.1.5 Lymph Node Status (LN) 
 
The presence of metastatic BC within the axillary lymph nodes is a very important 
predictor of overall and disease-free survival rates [131, 148, 149]. It has been observed that 
there are five variables in this, in which infiltrated lymph node staging was, by far, the 
identifying factor in predicting early recurrence. It was also second most prominent in 
gauging the probability of survival, after tumour size [148]. 
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1.1.5.1.6 Nottingham Prognostic Index  
 
The NPI includes three important prognostic factors (status of lymph nodes, tumour 
size and histological grade) and the prognostic significance has been confirmed by several 
studies conducted across the world [137]. The calculation of the NPI was described 
previously, as follows [154, 155]: lymph node (LN) stage (1±3) + Grade (1±3) + maximum 
diameter (cm × 0.2), offering a NPI range from 2.08 (LN negative, grade 1, 0.4 cm) to 6.8 
(LN Stage 3, grade 3, size 4.9 cm). The NPI is a useful tool regarding the prognosis of 
patients' risk, in addition to stratification, offering improved prognostic significance more 
than any of its individual components. NPI predicts the survival rate of invasive breast 
carcinoma patients and is needed in the assigning of patients into therapeutic routines. In 
HDUOLHUVWXGLHVWKUHHVXEVHWVRIULVNJURXSVZHUHGHVLJQDWHGJRRGSURJQRVLVPRGHUDWH
prognosis (3.41-5.4) and poor prognosis (>5.4) [155, 156]. However, Blamey et al reported 
six different NPI groups: an Excellent Prognostic Group (EPG), with an observed NPI range 
of 2.08±2.4, a Good Prognostic Group (GPG), with an observed NPI range of 2.42 to င3.4, a 
Moderate Prognostic I Group (MPG I), with an observed NPI range of 3.42 to င4.4, a 
Moderate Prognostic II Group (MPG II), with an observed NPI range of 4.42 to င5.4, a Poor 
Prognostic Group (PPG), with an observed NPI range of 5.42 to င6.4, and a Very Poor 
Prognostic Group (VPG), with an observed NPI range of 6.5±6.8 [157]. 
 
 
0DPPD3ULQWAssay 
 
The MammaPrint (Agendia BV, The Netherlands) is the first fully commercialised 
microarray-based multigene assay constructed to individualise treatment method for BC 
patients. In addition it helps to assess the risk that a breast tumour will metastasise to other 
parts of the body. MammaPrint offers a prognostic test for most women under the age of 61 
years with either ER+ or ER- BC with negative lymph nodes. The test of MammaPrint 
requires freshly prepared tissues collected into an RNA preservative solution. The 70 genes 
that comprise the assay of MammaPrint are focused mainly on proliferation with other genes 
related to invasion, metastasis, integrity of stroma and angiogenesis [158]. MammaPrint 
assay has advantages over other known tests such as Fluorescence In Situ Hybridization 
(FISH) or Polymerase Chain Reaction (PCR) mainly because, in a single analysis, 
MammaPrint can evaluate the expression of all of the genes that could be involved in a 
cancer, instead of just a few. This can make the identification of cancer subtype more 
accurate than single gene tests [159]. Saghatchian et al have created a MammaPrint profile 
from frozen tumours of patients operated from primary BC and classified the samples as 
genomic high risk (were mainly ductal carcinomas (93%), grade 3 (60%), ER and PgR-
negative, and HER-2 positive (25%), or genomic low risk (the 5-year overall survival was 
97% vs. 76% for in the genomic high risk group (P < 0.01); distant metastasis free survival at 
5 years was 87% for genomic low risk patients and 63% for genomic high risk patients (P < 
0.01) [160].  
 
Chapter 1                                                                                               General Introduction 
41 
 
1.1.5.1.8 Oncotype DX Breast Cancer Assay 
 
The Oncotype DX BC assay is a reverse transcriptase polymerase chain reaction assay 
on RNA extracted from sections of formalin-fixed, paraffin-embedded tissue samples. It was 
initially developed for women with early-stage invasive BC with ER+ cancers and node 
negative. Generally in these cases, anti-hormonal therapy, such as Tamoxifen or aromatase 
inhibitors, is planned, and therefore, Oncotype DX can help to predict the benefit of 
chemotherapy and the probability of distant BC recurrence [161, 162]. Around 25,000 genes 
in the genome of human, Genomic Health determined 250 candidate genes possibly involved 
in tumour behaviour of BC. These genes were subsequently tested in over 400 patients from 
three independent clinical studies to be able to determine a 21 gene panel highly correlated 
with distant recurrence-free survival [163]. The panel includes 16 cancer genes and five 
reference genes used to normalise the cancer genes expression. The three clinical studies also 
developed the base for the Recurrence Score (RS) calculation, which helps to combine the 
data of gene expression from the 21-gene panel into a single result as well as addresses 3 of 
the 7 metastatic pathways [162]. Flanagan et al studied 42 BC cases and evaluated them by 
Oncotype DX. However, these cases were retrospectively reviewed to identify the age of the 
patient, the size of the tumour, histologic grade, ER, PgR, and HER-2 status. they found that 
RS is significantly correlated with tubule formation, nuclear grade, mitotic count, 
immunohistochemical score of ER, PgR and HER-2 status, and that the equation 
RS=13.424+5.420 (nuclear grade) +5.538(mitotic count) í (5 LPPXQRKLVWRFKHPLFDO
score) í (PgR immunohistochemical score) +9.486 (HER-2) predicts the RS with an R2 
of 0.66, revealing that the full model accounts for 66% of the data variability. Despite the fact 
that the Oncotype DX RS remains potential, further validation of its independent value 
beyond that of histopathologic analysis is recommended before it can be applied in clinical 
decision making [162]. However, National Institute for health and Care Excellence (NICE) 
has today recommended the use of a test as an alternative that can help clinicians make a 
decision whether to recommend chemotherapy in people who have early BC. Oncotype DX is 
being assessed in lymph node negative, HER-2 negative,  ER positive BCs in a prospective 
trial, the Trial Assigning IndividuaLized Options for Treatment (Rx) (TAILORx) [164], 
launched 2006 May, enrolled 10,000 people with intermediate results on the test; results are 
expected to be accomplished in 2014.  
 
 
1.1.6 Classification of Breast Cancer 
 
The application of high-throughput technologies, such as cDNA microarray and 
Tissue Micro Array technology (TMA), and analytical tools that review thousands of genes 
and their products in clinical breast material have created a step towards the categorisation of 
BC, depending on gene or protein expression patterns. Perou et al applied hierarchical 
clustering to a set of 65 breast tissue specimens from 42 patients (one ductal carcinoma in-
situ, one fibroadenoma, two lobular carcinomas, 36 invasive ductal carcinomas and 2 normal 
breast samples) [165]. The tumours were classified into different molecular subtypes, in 
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accordance with similarities in gene expression, heterogeneous clinico-pathological features 
and responsiveness to therapy. The prognostic association of these results have been 
corroborated by comparable expression in other groups and the researches of Sorlie et al and 
others support these results [166, 167].                 
 
BC is broadly divided into two groups: ER positive (ER+) and ER negative (ER-), 
leading to subdivisions into more biologically and clinically relevant subgroups [165, 166]. 
ER+ tumour subgroups are known as the luminal group, due to their expression of genes that 
encode the characteristics of the proteins of luminal epithelial cells. ER- tumours are 
subdivided into HER-2 positive, BLBC and normal breast-like tumours [168]. BLBCs are 
characterised by the expression of basal epithelial cell markers (such as CK5[33], CK14 and 
CK17[30, 165]) and other markers, such as nestin [169], c-kit [170] and Epidermal Growth 
Factor Receptor (EGFR) [33]. The variation of gene expression within these subtypes is 
expected to characterise different tumour subtypes, influencing overall outcome and response 
to treatment. BCs with an HER-2 positive phenotype and basal-like categories have the 
poorest prognosis [34, 37, 165].   
 
 
1.1.6.1 Molecular Classification of Breast Cancer 
 
Morphologically identical BCs can show divergent clinical outcomes and responses to 
treatment. This can mainly be related to variations of molecular features that vary among 
histologically similar types of cancer. As a result, molecular classification can be as powerful 
as histopathology in predicting behaviour of tumours and even more powerful as a predictive 
for treatment response. The accumulation of genomic aberrations is an essential aspect of the 
development of solid-tumours and especially breast tumour. However, identification of 
behaviours through assessment of genomic and epigenomic characteristics of tumours may 
expose primary mechanisms of disease evolution and identify potential candidates for therapy 
intervention. Recent improvement of high-throughput molecular methods provides new 
chances for capturing the wide variety of genomic and biologic variability in tumours [171]. 
By classifying breast tumours based on their particular DNA Copy Number Alterations 
(CNA) patterns, three classes were revealed and known as the 1q/16q, amplifier, and complex 
subtypes. Tumours of the 1q/16q genomic subtype had better disease-specific survival than 
the amplifier and complex subtypes. In contrast, BLBC (as defined based on gene expression 
profile) were found mainly within the complex genomic subtype [171]. 
 
Jönsson et al have identified global DNA copy number and profiling of gene-
expression breast tumours. However, they found various amplicons to co-occur, the 8p12 and 
11q13.3 regions appearing the most repeated combination apart from amplicons on the same 
arm of the chromosome. Using unsupervised hierarchical clustering with 133 significant 
GISTIC regions, six genomic subtypes were revealed, termed 17q12, basal-complex, luminal-
simple, luminal-complex, amplifier, and mixed subtypes. However, tumours of luminal A 
type were distributed in two main genomic subclasses, luminal-simple and luminal-complex, 
the simple group developing a greater prognosis, in contrast the complex group included as 
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well luminal B and most of BRCA2-mutated tumours. The basal-complex subtype 
demonstrated comprehensive genomic homogeneity and harboured the greater number of 
tumours with a mutation in BRCA1 [172].  However, Cornen et al [173] have showed that 
mutations of KCNB2 (Potassium voltage-gated channel subfamily B member 2) were 
associated with luminal B tumours while candidate tumour suppressor genes such as Midasin 
(MDN1) (6q15) and Utrophin (UTRN) (6q24), were mutated in this subtype. 
 
Bergamaschi et al [174] have analysed ER negative tumours and demonstrated that 
HER-2 positive tumours showed amplification at 17q12-q21, whereas, the recurrent CNAs 
identified in BLBC had increases at 1q12-q41, 6p12-p25, 7q22-q36, 10p12-p15, 17q25 and 
21q22, but losses at 3q12, 4p15-p32, 4q31-q35, 5q11-q31, 14q22-q23, 17q and 20p [211]. 
However, CNAs of some of these subtypes were harbouring BRCA1, EGFR and had a 
dysfunction in the pathways of caveolin1 [174-176]. It has been shown that, within BLBC, 
loss of the function of BRCA1 is more frequent than in other BC biological subtypes, might 
be suggestive of defective double strand DNA repair pathways [177, 178]. In regards to 
double strand DNA repair, [179] Gao et al have showed that Rad51 135G/C polymorphism 
may be identified as a susceptibility locus for BC. Recently, Curties et al [180] have 
presented an incorporated analysis of CNAs and gene expression in primary breast tumours. 
However, they found that inherited variants (copy number variants as well as single 
nucleotide polymorphisms) and additionally acquired somatic CNAs were related to 
expression in 40% of genes, with the landscape dominated by cis and trans-acting CNAs. In 
addition they have discovered genes of putative cancer, such as deletions in PPP2R2A, 
MTAP and MAP2K4. However, using paired profiles of DNA±RNA shown novel subgroups 
with different clinical outcomes, which reproduced in the validation cohort were identified, 
such as a high-risk, ER-positive 11q13/14 cis-acting subgroup and a good prognosis 
subgroup lacking of CNAs. In addition, several signalling molecules, transcription factors 
and genes of cell division were related in trans with this deletion event in the BLBC, which 
includes alterations in AURKB, BCL2, BUB1, CDCA3, CDCA4, CDC20, CDC45, CHK1, 
FOXM1, HDAC2, IGF1R, KIF2C, KIFC1, MTHFD1L, RAD51AP1, TTK and UBE2C. 
Significantly, TTK (MPS1), a dual specificity kinase that helps AURKB in alignment of 
chromosome during mitosis, and recently revealed to enhance aneuploidy in BC [181], was 
seen up-UHJXODWHG+RZHYHUFOXVWHU DQDO\VLVSURSRVHGJURXSV EDVHGRQ'XQQ¶V LQGH[
Cluster 1: many intermediate prognosis groups of predominantly ER+ cancers were 
documented, such as a 17q23/20q cis-acting luminal B subgroup, Cluster 2: ER+ subgroup 
consist of 11q13/14 cis-acting luminal tumours, in addition, high frequencies of amplification 
was found for both CCND1 and EMSY. Therefore based on the findings, the 11q13/14 
amplicon could possibly be influenced by a gene cassette instead of only one oncogene. 
Cluster 3: this group showed low genomic instability, however, it was mainly luminal A 
cases, and was enriched for histopathology types that usually have good prognosis, such as 
invasive lobular and tubular carcinomas. Cluster 4: similar to Cluster 3 by showing good 
prognosis, but however, it showed both ER+ and ER-, in addition, most of the cases were 
extensive lymphocytic infiltration. Cluster 5: The ERBB2-amplified cancers characterized by 
HER2-enriched (ER-) and luminal (ER+) cases. Cluster 6: many intermediate prognosis 
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groups of predominantly ER+ cancers were documented, such as an 8p12 cis-acting luminal 
subgroup. Cluster 7: Luminal A subgroup with favourable outcome and was characterised by 
the lack of the 1q alteration at the same time maintaining the loss of 16p gain/16q with 
greater frequencies of amplification of 8q. Cluster 8: showed similar CNA profiles to cluster 
7, so it was luminal A subgroup with favourable outcome and was characterised by the 
classical 1q gain/16q loss.  Cluster 9: many intermediate prognosis groups of predominantly 
ER+ cancers were documented such as an 8q cis-acting/20q amplified mixed subgroup. 
Finally Cluster 10: this was BLBC with stable and mainly high genomic instability, in 
general it showed relatively good long-term outcome and characteristic cis-acting alterations 
(5 loss/8q gain/10p gain/12p gain), additionally, alterations of several transcription factors 
and many cell division genes were observed in BLBC [180].   
 
Although there is no international agreement or consensus regarding the definition of 
various molecular classes in BC, the most commonly reported molecular classes based on 
gene expression profiling are as follows;  
 
 
1.1.6.1.1. Normal Breast-like Class 
 
Normal breast-like subtypes have a similar gene expression profile to that of normal 
breast tissue, with a high level of many genes characteristic of adipose cells and other types 
of non-epithelial cell [165, 182]. However, there is some concern that this subtype may not 
exist and is due to technical artifact, where samples have mainly consisted of normal breast 
tissue, rather than tumour [183]. In addition, Holm et al have stated that normal-like tumours 
did not show unique profiles of methylation [184]. 
 
 
1.1.6.1.2. Luminal Class 
 
This is the largest class of BC mainly characterised by hormone receptor expression. 
There are at least two main luminal subgroups, commonly known as luminal A and luminal B 
tumours [165, 166]. However, a luminal C subgroup has also been reported in several studies, 
but this is less well-defined than the luminal A and luminal B subgroups [166, 167]. Luminal 
A tumours are frequently characterised by the positive expression of ER and negative HER-2, 
whereas luminal B is related to positivity of ER+ and overexpression of HER-2 and/or high 
proliferation status [166, 182]. Luminal B tumours have a significantly worse prognosis than 
luminal A tumours, and show lower expression of ER than luminal A [185, 186]. Luminal B 
tumours express luminal CK8, CK18, CK19 and genes related with the activation of ER, such 
as LVI and cyclin D1, although some carry mutations in TP53, which are usually grade 1 
[165, 182]. In most cases, luminal subtypes carry a good outcome [168]. Yanagawa et al 
showed that luminal A cases showed lower expression of the Ki-67 antigen, compared to 
luminal B [187]. Luminal B BCs with Ki-67 levels of at least 14% showed a poorer prognosis 
for both BC recurrence and survival compared with luminal A tumours with level of Ki-67 
less than 14% [188]. In addition, Feeley et al[189] have defined luminal A as being ER 
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positive, HER2 negative, and Ki-67 low (<14% cells positive), whereas luminal B subtype as 
being ER positive, HER2 negative, and Ki- KLJK  FHOOV SRVLWLYH In their study, 
patients with luminal B tumours showed worse disease-free survival than tumours of luminal 
A. However, when they used status of TP53 or negativity of PgR rather than Ki-67 in order to 
classify ER-positive luminal tumours, a similar outcome finding to those obtained using the 
proliferation index was observed. Therefore, Ki-67 index, status of TP53, or negativity of 
PgR can be helpful to segregating ER-positive, HER2-negative tumours into prognostically 
significant subgroups with significantly various clinical outcomes. These biomarkers 
particularly in combination may possibly be applied clinically to direct patient management. 
However, few chromosome rearrangements have been seen in luminal A tumours, whereas, 
luminal B tumours showed many more rearrangements, which occurred mostly within 
amplicons. Additionally, BC cell lines with luminal expression patterns show frequent 
amplification of DNA, however, this was luminal B rather than A subtype [190]. 
 
 
1.1.6.1.3 HER-2-Positive Class 
 
HER-2 is overexpressed in 10-20% of BCs and is associated with a poor outcome. 
HER-2 amplification plays a direct role in the pathogenesis of BCs, which has been a focus 
for therapeutic agents targeted directly at this amplification. In addition, the HER-2 status is 
predictive, with regards to response to certain chemotherapeutic agents (for example, 
doxorubicin (Adriamycin) and HER2-targeted therapies (trastuzumab, pertuzumab and 
lapatinib [34, 191]).  
 
Holm et al [184] have stated that HER-2-enriched molecular subtypes did not show 
unique profiles of methylation. Although gene expression profiling has identified a HER-2-
enriched subtype, it needs to be considered that tumours of HER-2-positive are observed in 
all molecular subtypes of BC [192, 193], and that expression profiles of HER-2-positive 
tumours are very heterogeneous [194]. However, the study of Holm et al added support to the 
heterogeneous picture of HER-2-positive BC, and proposed that amplification of HER-2 does 
not have an effective feature influence on patterns of methylation. However, BC cell lines 
with luminal expression patterns show frequent amplification of DNA, which typifies HER-2 
subtype tumours [190]. Bignell et al have investigated amplicon associated rearrangements at 
the DNA sequence level. In a single ERBB2-amplified BC line, they determined at 17q12-
q21 (ERBB2) the exact inverted duplication architecture predicted by a Breakage-Fusion-
Bridge (BFB) process of sister chromatid. On the other hand, amplicons in other places in the 
genome involved direct repeats of head-to-tail, showing that different amplification 
mechanisms are not mutually exclusive, and can also arise inside the same cancer cell [195]. 
 
 
 
 
 
Chapter 1                                                                                               General Introduction 
46 
 
1.1.6.1.4 Basal-like Breast Cancer Class 
 
Approximately 15% of BCs are basal-like in origin and are associated with a higher 
histological grade, poor overall survival and younger patient age [196, 197]. Myoepithelial 
cells are characteristically negative for the majority of the markers of luminal cells [36]. The 
term ¶EDVDO-OLNH¶ is used as a synonym for the basal/myoepithelial cells of a normal breast, 
based on the similarities of their molecular profiles [37], and this term generally stems from 
the expression of a specific sub-population of basal CK to many cells, either at the luminal or 
basal site [34]. In the initial gene expression profiling studies of Sorlie and Perou et al [165], 
both CK5 and CK17 were identified as key markers in BLBC[198]; however, CK17 protein, 
using immunohistochemistry, is expressed in very few tumours and in the absence of CK14 
and CK5 [199]. Various studies have shown the implication of some basal-like genes in 
cellular proliferation, suppression of apoptosis, extracellular remodelling, cell migration, 
invasion and other markers of cancer [23, 37, 186]. 
 
 
1.1.6.1.4.1 Triple Negative Breast Cancer  
 
Triple Negative (TN) BC and BLBC have become a key topic of research interest, 
due to their aggressive behaviour and lack of targeted therapy [165] 7KH WHUP µWULSOH
QHJDWLYH¶UHIHUVWRWKHODFNRI(53J5DQG+(5-2 expression and is highly associated with a 
poor prognosis [200]. Patients with these phenotypes are unlikely to benefit from current 
endocrine or HER-2 targeted therapies; however, it should be considered that the 
characterisation of TN and BLBC remains controversial. Although the terms appear 
synonymous, many biological phenomena, immunophenotypes and responses to 
chemotherapy are different between TN and BLBC; therefore, they remain pathologically and 
biologically heterogeneous [201]. The refinement of the TN phenotype through the use of 
additional basal markers may be helpful in reducing the heterogeneity of TN tumours and 
expanding understanding of the clinical and biological features of these tumours. 
Consequently, this can justify a specific therapeutic target for each individual tumour class 
and thus help personalise treatment for BC patients.  
 
Recently, several differences between TN and BLBC have been reported, through the 
use of CD44+/CD24-[202, 203], cell cycle regulators and immunologic markers, such as P53 
and MUC2/MHC class 1 [200, 202-205]. Rakha et al supported these studies, which showed 
an association between a high proliferation rate and BLBC. In contrast, when compared with 
TN, BLBC did not significantly show a difference in tumour grade, size or vascular invasion 
[205]. A study of 823 BLBC patients receiving anthracyclines, defined as negative for HER-2 
and ER but positive for either EGFR or CK5/6, received less benefit from the anthracyclines 
than those patients in the TN group, who were negative for all these markers [206]. Cheang et 
al also supported this result. [196]. Despite this, potential clinical trial plans are undoubtedly 
needed, in order to consider the advantages of various chemotherapies, with regards to 
BLBC. 
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1.1.6.1.4.2 BRCA1 and Basal-Like Breast Cancer 
 
There is evidence that there is a link between BLBC and BRCA1 deficiency, where 
the more aggressive BLBC is related to a germ-line mutation of BRCA1 [177]. It has been 
confirmed that, within BLBC, loss of the function of BRCA1 is more frequent than in other 
BC biological subtypes (see Table 1.2) [178]. The morphological characteristics and 
immunohistochemical features of BLBC are significantly similar to BRCA1 mutation 
tumours, particularly in terms of the definition of the negativity of ER, PgR, the somatic 
mutation of TP53 and HER-2 [58, 207]. 
 
However, Turner et al have demonstrated that the expression of basal CKs in a 
tumour is not likely to arise from of a dysfunction in the BRCA1 pathway [58]. A select 
number of regulators involved in signal transduction have shown many promising roles in 
BLBC and EGFR is considered a component of BLBC [178]. The expression of EGFR in 
relation to BRCA1 and the various markers of BLBC has been considered in some studies 
[166, 178]: Turner et al showed that the expression of EGFR was associated with positive 
expression of BRCA1, P-cadherin and CK5/6 with ER-[178], whilst EGFR was significantly 
prognostic in patients with germ-line BRCA1 mutations. Therefore, it is expected that BLBC 
segregates, together with BRCA1 tumours, in microarray expression profile data. These two 
tumours are rarely harbour amplification of the CCND1 gene [208].  
 
The BRCA1 pathway participates in a number of cellular processes, beside its 
functions in response to DNA damaging, transcriptional regulation, ER signalling and X-
chromosome inactivation. Of these various functions, the inhibition of ER-Į signalling is 
associated with the expression of exogenous BRCA1 [209]. It has also been shown that ER-Į 
mediated transcription is a result of the knockdown of BRCA1 through RNA interference; 
therefore, it is believed that these factors may explain the development of ER-negative 
tumours, but the physiological features remain unclear [209]. X-chromosome inactivation is 
present in both BRCA1 BC and sporadic BLBC [210].  
 
Many transcriptional factors are preferentially expressed in BLBC, such as c-Myc, 
Forkhead box C1 (FOXC1) and E2F-5 [34, 211]. The stimulation of BRCA1 expression by 
ER results from the influence of ER affecting the growth of breast cells. This proliferation-
mediated increase may proceed through the E2F site in the proximal promoter. On the 
contrary, it is suggested that P53 inhibits BRCA1 expression by preventing E2F binding to 
this site [212]. There are other regulators of BRCA1,such as GABP-Į/ȕ which is the 
downstream mediator of the signalling of neuregulin in nerve cells [211]. 
 
Laminin, an extracellular matrix protein involved in cell adhesion, is also suggested to 
be a negative regulator of BRCA1 expression and thus is associated with BLBC [211]. Įȕ
integrin is an interacting partner for most laminins, which plays a role in modulating the 
signalling pathways of proliferation and survival. Lu et al highlighted the preferential 
H[SUHVVLRQRIĮȕLQWHJULQLQ%/%&ZKLFKZDVDEVHQWLQQRQ-basal tumours [213]. Inhibitor 
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of DNA-binding/differentiation protein (ID4), which is a negative regulator of BRCA1, is 
over-expressed in BLBC, leading to dysfunction in the upstream pathways that regulate the 
expression of BRCA1. This mechanism has been suggested to play a role in the suppression 
of BRCA1 in sporadic BLBC [58]. 
 
Recently, a study based on the similarities between the gene expression profiles of 
BRCA1 and BLBC showed a high expression of Ets1 (transcription factor that binds to DNA 
at the palindromic Ets-binding site) in hereditary BRCA1 BCs. Bosman et al investigated the 
function of Ets1 in BLBC, in terms of the regulation of the Į/ȕcrystallin gene, and it was 
found that the Į/ȕ crystallin was over-expressed in BLBC, due to its Ets1 activity; silencing 
Ets1 decreased the promoter activity of the Į/ȕ crystallin. ȕ crystallin plays a role in the 
mechanism of cell death, suppressing apoptosis and resistance against chemotherapy [214-
216]. According to the study of Bosman et al Ets1 was reported as a predictive marker, in 
addition to more than ten proteins, in the identification of BLBC by immunohistochemistry. 
It is important to study the co-expression of Ets1 and Į/ȕcrystallin, in order to evaluate their 
prognostic value in BLBC [216].  
 
Previous evidence hypothesised that epigenetic alterations, such as BRCA1 
hypermethylation, may play a determinant role in tumour initiation or in the progression of 
malignant tumours [217]. However, in BC, the loss of gene expression through the 
hypermethylation of CPG islands has been determined for a number of genes, such as P16 
and Glutathione S-Transferase P1 (GSTP1) [202]. Many studies have thus explored these 
epigenetic changes as a detection marker in helping to understand the role of the inactivation 
of BRCA1 in BC. Finally, the disorder of BRCA1 may lead to a specific profile of methylation 
in tumours, such as in the expression of an altered P21 in BRCA1 negative cell lines, which 
has been associated with the regulation of DNA methylation and its role in the management 
of the cell-cycle [217]. Although many studies highlighted the decrease in BRCA1 mRNA 
expression and methylation, others did not identify this association [218, 219]. Matros et al 
studied the expression of the BRCA1 promoter methylation in different breast tumours and, in 
BLBC, there was infrequent BRCA1 methylation, while the expression of BRCA1 and the 
mitotic rate were high [167]. 
 
BRCA1 also interacts with diverse groups of proteins, including BARD1. Inactivation 
of BARD1 induces the basal-like phenotype (ER-, PgR, HER-2-, CK5+, CK14+, P53 lesion 
and vimentin), with an occurrence, pathology and latency that are identical to those that 
develop in BRCA1 and BRCA1/BARD1 mutant mice [220]. Although this shows the function 
of BARD1 as a tumour suppressor, it should be noted that it was a null mutation, whereas all 
BARD1 lesions reported so far in humans were of a missense mutation [221, 222]. 
Disagreement remains, with regards to the similarity between BRCA1 and BLBC, as to 
whether this is due to a specific decrease in the expression of BRCA1 in BLBC or is just a 
general marker of high-grade tumours [178]. 
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Table 1.2 Similarities between BLBC and BRCA1Mutation Tumours in Previous Studies 
Parameters BRCA1 Phenotype Non-basal BLBC Basal Definition References 
Grade III 
High grade 3 Mixed High grade 3 ER-/PgR-& CK14+ [37, 223-226] 
ND 46% luminal-A 66% Combined [204, 227, 228] 
74% 46% (ER+) 100% ND [229] 
Proliferation High Luminal B>A High Combined [37, 165, 185, 230] 
HER-2 
Rare Luminal A+ Rare TN [224, 231] 
HER-2- Luminal A+ HER-2- TN [165, 228, 232] 
HER-2- 
HER-2+ 
(26%) 
100% HER-2- 
ER-, HER-2-
/low,CK5/6+ and/or 
EGFR+ 
[207] 
EGFR 
Overexpression ND Overexpression TN and EGFR+ 
[37, 224, 227, 233-237] 
60-70% 8% 60-80% TN and EGFR+ 
(67%, 14/21) 
Luminal (100%)  
HER-2+ (58.3%) 
 
15-35% 
ER-, HER-2- 
low,CK5/6+ and/or 
EGFR+ 
Basal CKs 
Basal CK+ 
88% 
Basal CK+ 
(7.3%) 
Basal CK+ 
TN, CK5/6+ and/or 
CK14+ and/or CK17+ 
 
[165, 182, 207, 224, 238-
240] 
57%-88% ND ND CK5/6
+
 and/or CK14+ 
and/or CK17+ [207, 238] 
TN 90% ND 90-80% Any Basal CK+ [37, 165, 238] 
ER 
ER- ER+ ER- TN and basal CK+ [165, 224, 230, 238] 
ER-(36%, 96/268) ND ND ND [228] 
ND ER+ (100%) ER+ (0%) Combined [227] 
PgR PgR- PgR+ PgR- TN  [224, 228, 231] 
This table shows different studies regarding the similarities between BLBC and BRCA1 mutation tumours. TN= triple Negative BC.  ER= oestrogen 
receptor, PgR= progesterone receptor.  Combined=TN and any positive basal-like biomarker including, but not limited to basal CK. ND= no data. 
 
 
1.1.7 DNA Damage Signalling and Repair 
 
The stability of the genome, maintained by the DNA molecule, is not certain for the 
entire lifetime of human beings. The contribution of DNA damage to human disease is 
exemplified in a set of uncommon genetic diseases that have, at their basis, various aspects of 
DNA metabolism [241]. DNA is regularly open to danger, as a result of exogenous and 
endogenous agents. Exogenous aggressors include Ultraviolet Light (UV) light, irradiation 
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and genotoxic agents, such as those found in cigarette smoke. Endogenous agents originate 
from the products of normal cellular metabolism (e.g., Reactive oxygen species (ROS)) and 
the spontaneous disintegration, under physiological conditions, of some chemical bonds in 
DNA [242]. ROS is able to stimulate base and sugar modification, base loss, strand cleavage 
and DNA protein cross-links [243]. 
 
The value of DNA repair is underlined by any deficiency of DNA repair, which is 
definitely related to hypersensitivity to DNA-damaging agents, bringing about accumulation 
of mutations in the genome [244] and also with genomic instability syndromes, which usually 
significantly improve the incidence of cancer [245]. Thus, the epidemiology of DNA repair 
and its influence on the susceptibility of human beings to cancer is an important area of 
research. A number of pathways that result in genomic instability have already been 
identified, such as the Base, or Nucleotide Excision Repair disruption (BER)(NER) 
respectively, Double Strand Break Repair (DSBR), Mismatch Repair (MMR) and DNA 
damage signalling pathways [245, 246]. One fundamental factor to consider is that breast 
(mammary) tissue has a higher chance of DNA damage occurring, due to the massive 
UHPRGHOOLQJRIVXFKWLVVXHWKURXJKRXWDZRPDQ¶VOLIH 
 
 
1.1.7.1 Base Excision Repair 
 
BER pathway is the primary mechanism of repairing DNA damage, especially that of 
an endogenous origin or an exogenous origin [247]. BER is initiated by damage specific 
DNA glycosylases that generate the damaged base through hydrolysis of the N-glycosylic 
bond linking the base of DNA to the backbone of sugar phosphate. Thus, the developing 
abasic site (Apurinic/Apyrimidinic-site (AP-site)) is highly processed by AP-Endonuclease 1 
(APE1), which cleaves the phosphodiester bond 5'- to the AP-site, bringing in a DNA single 
strand break (SSB) and a 5'-sugar phosphate. Upon this, SSB is repaired by a DNA repair 
FRPSOH[WKDWFRPSULVHVRI'1$SRO\PHUDVHȕ3ROȕX-Ray repair Cross-Complementing 
protein 1(XRCC1)LQDGGLWLRQWR'1$OLJDVH,,,Į/LJ,,,Į) [248, 249]3ROȕKDV$3O\DVH
activity, which erases the 5'-sugar phosphate, in addition to working as a polymerase for 
DNA, bringing a single nucleotide to the 3'-end of the sugar phosphate of arising single-
nucleotide [250]. Finally, Lig III finalises and seals the ends of DNA, consequently finishing 
the repair of DNA [5, 251, 252]. This particular process is often known as the short and 
simple patch pathway of BER (Figure 1.3), through which the majority of cells achieve repair 
[253, 254]. When the 5'-VXJDUSKRVSKDWHLVUHVLVWDQWWRFOHDYDJHE\3ROȕDPRYHWR3ROįİ
arises, which introduces 2-8 additional nucleotides directly into the gap of the repair; for this 
reason, any resulting structure of flap is simply eliminated by Flap Endonuclease-1 (FEN-1), 
in a Proliferating Cell Nuclear Antigen (PCNA)-dependent process. DNA ligase I 
subsequently seals the remaining nick in the actual backbone of DNA, which is known as 
long-patch BER [255, 256] (see Figure 1.3). 
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1.1.7.2 Nucleotide Excision Repair 
 
The NER is probably the most versatile and flexible of all DNA repair pathways and 
is the major repair mechanism in eliminating the plethora/bulk of structurally unrelated DNA 
lesions, such as UV-light-induced photolesions, cyclobutane pyrimidine dimers, cross-links 
of intrastrand, massive chemical adducts and bulky adducts, produced as a result of exposure 
to genotoxic agents and oxidative damage [257, 258]. BER is recognised as the main pathway 
for these lesions, but NER may be considered as a backup system [259, 260].  
 
A powerful property of NER is that it is usually paired to transcription, commonly 
contributing to the favoured repair associated with the transcribed strand (TS) (over that of 
the non-transcribed strand (NTS) in active genes), a sub-pathway known as transcription 
coupled repair (TCR). The mechanical aspects of TCR continue to be ambiguous, despite the 
fact that it is usually considered that RNA polymerase II (RNAPII) acts as a damage sensor 
that alerts the pathway of NER once it encounters a blocking lesion in the TS [261]. As a 
result, RNAPII can easily alternate to Xeroderma pigmentosum, complementation group C 
(XPC) and DNA-Damage Binding (DDB) complexes, in recognition of the lesion. 
Furthermore, XP group C patients, who are deficient in global genomic repair (GGR), still 
retain TCR. GGR regulates the non-transcribed domains repair of the genome, while TCR 
eliminates any lesions resulting from the transcribed strand of active genes. Usually, the 
initial step of NER is the realisation of damaged residues, in addition to the formation of a 
small bubble structure with or without damaged bases, completed by XPC-hHR23B (human 
Rad23B homolog) and the 9 subunits of transcription factor-IIH (TFIIH), XPA and 
Figure 1.3 Basic Pathways of Base Excision Repair (BER). Where A; shows the long patch and 
%VKRUWSDWFK,WVWDUWVE\'1$JO\FRV\ODVHUHFRJQLVLQJDQGUHPRYLQJWKHGDPDJHGEDVH,I¶
VXJDUSKRVSKDWH UHVLVWDQFH WRFOHDYDJHE\3ROȕ WKHQ3RO įİZLOO WDNHSODFHDQGVWDUW YLD WKH
long patch pathway. 
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Replication Protein A (RPA) respectively. The double incision of the damaged DNA strands 
¶DQG¶WRWKHOHVLRQLVSHUIRUPHGE\WZRHQGRQXFOHDVHV;3*DQG(5&&H[FLVLRQUHSDLU
cross complementing)-;3)'1$3ROįDQG3ROİZLWKHDFKRWKHUXWLOLVLQJWKHVOLGLQJFODPS
PCNA, the pentameric clamp loader, and the DNA ligase I (Lig I). These are accountable for 
the generation of an oligonucleotide that contains the lesion, synthesis and the ligation of the 
producing gap. With the exclusion of XPC-hHR23B, the genes engaged in GGR are also 
necessary for TCR. Furthermore, TCR requires other genes, such as CSA (Cockayne 
syndrome type A) and CSB (Cockayne syndrome type B) [5, 251, 262, 263](see Figure 1.4). 
 
Deficiencies in the pathway of TCR can lead to a variety of many other genetic 
diseases, such as Cockayne Syndrome [251, 252], where the patients are certainly not 
susceptible to cancer, yet are afflicted by developmental defects and several neurological 
problems, usually serious, from an early age. 
 
 
1.1.7.3 Double Strand Break Repair  
 
Breaks in both DNA strands give rise to the most serious lesion that threatens genome 
stability. There are approximately 10 DSBs occurring per day per cell, with regards to the 
metaphase chromosome and breaks of chromatid in early passage primary human or mouse 
fibroblasts [264-266]. In mitosis phase multi-cellular eukaryote cells, DSBs are typically 
pathological (accidental), apart from the specific subgroup of physiologic DSBs of the 
vertebrate immune system and, particularly, in early lymphocytes. The main pathological 
causes of DSBs inside wild type cells include replication across a nick, causing an increase in 
breaks of chromatid all through the Synthesis phase (S phase). These types of DSBs are 
usually (and preferably) repaired by Homologous Recombination (HR), through the use of 
Figure 1.4 Pathways for Nucliotide Excision Repair (NER) . It removes ssDNA that contains the 
damage and undamaged remains as template to synthesis a short complementry. Global genomic repair 
(GGR) regulates the non-transcribed domains repair of the genome, while transcription coupled repair 
(TCR) eliminates any lesions resulting from the transcribed strand of active genes. 
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the surrounding sister chromatid. Each of the remaining pathological types of DSBs are 
generally repaired by Non Homologous End Joining (NHEJ), due to the fact that they 
normally arise once there is no nearby homology donor and/or simply because they take place 
outside of the S phase. Factors in this include ROS from oxidative metabolism, ionising 
radiation (IR) and the inadvertent action of nuclear enzymes [267]. A number of genes 
identified as BC susceptibility genes, including BRCA1, BRCA2, ATM, P53 and CHK2, are 
very important DSBR genes [262]. Details of these pathways are presented in Chapter 4.  
 
 
1.2 Hypothesis of the Study 
 
Deficiencies in the signalling of DNA-damage response (DDR) pathways play 
fundamental roles in the pathogenesis of several human cancers, including hereditary BC. 
There is compiling evidence that DDR play an important role in the pathogenesis and 
behaviour of sporadic BC and those DDR mechanisms are different among various tumour 
classes. Targeting DDR in hereditary BC has proven successful using specific DDR protein 
inhibitors such as Poly ADP Ribose Polymerase (PARP) inhibitors.  Therefore, assessment of 
impaired DDR in sporadic BC will have major implication in the management of BC taking 
into account that BC with defective DDR show aggressive features and poor response to 
current treatment modalities. Identification of subclasses with defective DDR may improve 
treatment of these aggressive tumours using commercially available or novel DDR-related 
protein inhibitors. However, the complexity of DDR in addition to the molecular 
heterogeneity of BC make studying individual genes related to DDR in an unselected series is 
less likely to identify the target subclass. As a result, the hypothesis of this study is that 
investigating the expression patterns of a large panel of DDR-related biomarkers in a well-
characterised annotated series of sporadic BC could help in deciphering the process of DDR, 
identify the active pathway that can be targeted in specific subclasses, improve our 
understanding of its role in the different molecular classes and add prognostic and predictive 
information.  
 
 
1.3 Aims of the Study 
 
The aim of this study is therefore to investigate alterations in the different pathways of 
DDR occur in a large clinically and molecularly annotated series of BC which will help 
identify tumours with impaired DDR, improve our understanding of its role in the different 
molecular classes, narrow down the target pathway-related markers and may have potential 
therapeutic implications. This study will investigate different clinical and molecular types of 
BC, with regards to expression of proteins involved in the DDR pathway (in particular, DNA 
damage sensors and those proteins involved in DNA-DSB pathways including HR, NHEJ 
repair, and SUMO). This will include assessment of expression, subcellular localisation and 
interaction, using immunohistochemistry (IHC) and tissue microarray (TMA) utilising 
primary invasive early stage sporadic BC. In addition, a subset of hereditary BC cases will be 
used as a control group for BRCA1 deficiency. Reverse Phase Protein Microarray (RPPA) 
Chapter 1                                                                                               General Introduction 
54 
 
will be used to perform a comprehensive profiling of DDR pathways in cell lines 
corresponding to the main molecular classes of BC. This will determine associations with 
clinico-pathological characteristics, assess the impact of DDR protein expression and 
determine their impact on the response to therapy (long-term follow-up and treatment 
information were available). This is the first large study to investigate the expression of 
different proteins in different DDR pathway and their subcellular localisation in BC.  
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Chapter 2 
 
2.1 Materials and Methods 
 
2.1.1 Patient Cohorts  
 
The study cohort comprised of three groups: A) 1904 unselected cases of female 
primary operable invasive tumours between 1986 and 1998, B) 386 cases selected from a 
consecutive series of primary operable ER negative tumours between 1998 and 2007 and C) 
24 well-characterised series of breast tumours from patients with known BRCA1 gene 
mutations. However, High Resolution Melting Analysis (HRMA) with employing PCR was 
used for BRCA1 mutation detection in group C (this was performed by Dr Ahmed 
Benhasouna). All cases were obtained from the well-characterised Nottingham Tenovus 
primary breast carcinoma series. All patients were measured in a standardised manner, in 
terms of clinical history and characteristics of tumour. This was based on age, menopause 
status, tumour size, tumour type, histological grade, nodal status, lymphovascular invasion 
and the NPI. In 1988, tumour characteristics considered in the management of patients were 
13,DQG(5VWDWXV&DVHVZLWKDVFRUHRI13,UHFHLYHGQRDGMXYDQW WKHUDS\, but those 
patients with NPI> 3.4 received Tamoxifen if they expressed ER+ (+/-Zoladex in pre-
menopausal patients or ovarian irradiation) [268]. Classical cyclophosphamide, methotrexate 
and 5-flurouracil were used if the patients were ER- and were fit enough to receive 
FKHPRWKHUDS\,QHDUO\¶VWKHVDPHSURWRFROZDVDSSOLHGLQDGGLWLRQSDWients who were 
grade II, or III, and node positive have been given prophylactic irradiation to the axilla 
following surgery. However, It was clear that not all patients required radiotherapy, because 
most of un-irradiated patients did not suffer local recurrence [154]. 
 
Survival data were collected using a prospective method and included BC specific 
survival (BCSS), defined as the interval from the date of primary treatment to the time of 
death due to BC, in addition to any disease-free interval (DFI), identified as the interval from 
the date of primary treatment to the first loco-regional recurrence. Additionally, Metastasis-
Free Interval (MFI) is defined as the duration from the date of primary surgery to the 
appearance of distant metastasis. All these parameters were measured in months. 
 
The sporadic patients cohort (n=2290FRPSULVHGRIFDVHV\HDUVROG
and 1495 (65.7%) patients >50 years old. Characteristics of disease differed between the 
cohorts; at primary diagnosis, 346 (15.2%) were grade I, 670 (29.5%) were grade II and 1257 
(55.3%) were grade III. The majority of the cohort 1486 (65.8%) demonstrated a tumour size 
greater than 1.5cm and 580 (35.1%) had definite vascular invasion. Data relating to follow-
ups were collected initially at 3 monthly intervals, followed by intervals of 6 months and, 
subsequently, 12 months (median 116 months; range from 2 to 247 months for BCSS). 
Within this period, recurrence and distant metastases occurred in 809 (36.4%) and 642 
(28.5%) patients respectively. A total of 564 (29.3%) cases died from BC. Data of some cases 
was missing, due to patients lost to follow up.  
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Table 2.1, Table 2.2, and Table 2.3 summarise the frequencies of clinico-pathological 
features, treatment plan for the patients, and pDWLHQW¶VRXWFRPH UHVSHFWLYHO\ LQ the different 
cohorts, which are classified based on ER and BRCA1 protein expression in sporadic and 
hereditary BCs.  
 
Nottingham Research Ethics Committee 2 approved this study. 
 
Table 2.1 Frequency of Clinico-Pathological Features in the Different Cohorts of Breast 
Cancer. 
Parameters Sporadic  ER- &BRCA1- 
Sporadic ER+&  
BRCA1+ 
Hereditary 
ER- 
Hereditary 
ER+ 
Menopause 
Status 
Pre-menopausal 247(47.6) 255(36.8) ND* Post-menopausal 272(52.4) 437(63.2) 
Age (years) <50 241(45.8) 217(31.4) 13(76.5) 5(83.3)  285(54.2) 475(68.6) 4(23.5) 1(16.7) 
Tumour Size 
(cm) 
 124(24.2) 279(40.3) 3(20) 2(33.3) 
>1.5 388(75.8) 414(59.7) 12(80) 4(66.7) 
Stage 
1 329 (62.8) 448(64.6) 
ND* 2 142(27.1) 199(28.7) 
3 53(10.1) 46(6.6) 
Grade 
1 3 (0.6) 176(25.4) 0 0 
2 44 (8.4) 335(48.3) 1(6.3) 1(16.7) 
3 479 (91.1) 182(26.3) 15(93.8) 5(83.3) 
Tubule 
Formation 
1 2(0.4) 50(7.4) 0 0 
2 70(13.5) 279(41.4) 3(20) 1(16.7) 
3 445(86.1) 345(51.2) 12(80) 5(83.3) 
Pleomorphism 
1 1(0.2) 21(3.1) 0 0 
2 11(2.1) 400(59.4) 0 0 
3 504(97.7) 252(37.4) 15(100) 6(100) 
Mitosis 
1 27(5.2) 365(54.1) 0 0 
2 71(13.7) 148(22) 2(13.3) 2(33.3) 
3 419(81.0) 
 
161(23.9) 13(86.7) 4(66.7) 
Vascular 
Invasion 
No 129(61.4) 397(67.3) 6(35.3) 2(33.3) 
Yes 81(38.6) 193(32.7) 11(64.7) 4(66.7) 
Tumour Type 
Medullary 24(4.6) 1(0.1) 1(5.9) 0 
Invasive Ductal/No Special 
Type 
463(89) 281(41) 5(88.2) 5(83.1) 
lobular 5(1) 89(13) 0 0 
Mixed** 16(3.1) 256(38.7) 0 0 
other*** 12(2.3) 49(7.2) 1(5.9) 1(16.7) 
ND*= no data available. Four cohorts are classified based on the protein expression of nuclear ER and BRCA1 in hereditary and 
sporadic BCs. ** Lobular or tubular mixed BCs. *** Mucinous, Alveolar Lobular, Miscellaneous including Metaplastic, Adenoid 
Cystic, Spindle, and Tubulolobular. Hereditary= Known BRCA1 germline mutation. 
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Table 2.2 Frequency of Treatment Received in the Different Cohorts of Breast Cancer. 
Treatment Sporadic ER
-
 & 
BRCA1- 
Sporadic ER+& 
BRCA1+ Hereditary ER
-
 Hereditary ER+ 
Chemotherapy No 170(35.4) 612(91.2) 
ND* 
Yes 310(64.6) 59(8.8) 
Endocrine 
Treatment 
No 432(89.6) 400(59.6) 
Yes 50(10.4) 271(40.4) 
Radiotherapy 
local 
No 58(27.8) 314(46.9) 
Yes 151(72.2) 356(53.1) 
Radiotherapy 
nodes 
No 151(72.2) 561(83.6) 
Yes 58(27.8) 110(16.4) 
Four cohorts are classified based on the protein expression of nuclear ER and BRCA1 in hereditary and sporadic BCs. 
Although some cases are ER positive tumours, they did not receive endocrine therapy, because the treatment plan for those 
FDVHVZLWKDVFRUHRI13, and therefore received no adjuvant therapy. In addition, even if the cases were scored as ER 
negative, if they showed any positivity (very weak expression of ER), then they received endocrine therapy. ND*= no data 
available. Hereditary= Known BRCA1 germline mutation. 
 
 
 
Table 2.3 3DWLHQWV¶RXWFRPHV in the Different Cohorts of Breast Cancer. 
Status Sporadic ER
-
 & 
BRCA1- 
Sporadic ER+& 
BRCA1+ Hereditary ER
-
 Hereditary ER+ 
Survival from BC* Alive 362(76.1) 426(75.9) 
ND++ 
Dead 114(23.9) 135(24.1) 
Disease 
Recurrence** 
No 377(73.8) 431(63.3) 
Yes 134(26.2) 250(36.7) 
Distance 
Metastasis*** 
No 391(75.3) 522(75.4) 
Yes 128(24.7) 170(24.6) 
NPI+ 
Excellent 2(0.4) 127(18.5) 0 0 
Good 25(4.8) 182(26.5) 0 1(16.7) 
Moderate 1 202(38.9) 196(28.5) 3(20) 2 (33.3) 
Moderate2 171(32.9) 113(16.4) 5(33.3) 1(16.7) 
Poor 85(16.4) 57(8.3) 7(46.7) 2(33.3) 
Very poor 34(6.6) 12(1.7) 0 0 
Four cohorts are classified based on the protein expression of nuclear ER and BRCA1 in hereditary and sporadic BCs. Breast 
cancer specific survival*, defined as the interval from the date of primary treatment to the time of death due to BC. Only 
patients who died from BC were considered.  
Disease free interval**, identified as the interval from the date of primary treatment to the first loco-regional recurrence. 
Metastasis free interval*** is defined as the duration from the date of primary surgery to the appearance of distant metastasis. 
NPI+= Nottingham Prognostic Index: an excellent prognostic group; NPI range of 2.08±2.4, a good prognostic group; NPI 
range of 2.42 to င3.4, a moderate prognostic I group; NPI range of 3.42 to င4.4, a moderate prognostic II group; NPI range 
of 4.42 to င5.4, a poor prognostic group; NPI range of 5.42 to င6.4, and a very poor prognostic group; NPI range of 6.5±
6.8. ND++= no data available. Hereditary= Known BRCA1 germline mutation. 
 
2.1.1.1 Available Biomarkers' Data 
 
Data on a wide range of biomarkers of known clinical and biological relevance to BC 
were accessible and saved on a web-based interface (Distiller; Slidepath Ltd, Dublin, 
Ireland). These include, ER, PgR, HER-2 [269], CK5, CK17, CK14 [198], tumour suppressor 
proteins (P53 and PTEN), [270-272] cell proliferative marker (Ki-67), cell cycle 
progression/arrest regulator markers (P21, P27) [273-275], down regulator proteins for 
BRCA1; ID4 and MTA1. All markers were stained on TMA except Ki-67 which was 
performed on full face sections. 
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2.1.2 Tissue Microarray Construction  
 
TMA can be a time-consuming, labour-intensive, and economically costly technique. 
However, there are some advantages to using this high-throughput technique for 
immunohistochemistry, particularly as all tissue samples are exposed to the same conditions 
of the experiment, leading to more consistent and rigorous results. In addition, TMA provides 
efficient management of tissue archives as large number of tumour samples could be 
screened together allowing preservation of tissue resources for further research [276, 277].  
Paraffin-embedded formalin-fixed specimens of BC were identified from the Nottingham-
Tenovus primary breast carcinoma series (the three groups in section 2.1.1). Table 2.4 
summarises the details of the TMA construction. TMAs for the ER negative series and 
previous primary series as described previously [278]. However, TMAs for the new primary 
series and BRCA1 tumours were constructed as follows: 
 
 
2.1.2.1 Preparation of the Donor Blocks and Their Corresponding Slides 
 
Sampling the representative site from the donor block is very critical for construction 
of TMAs. Full-face sections were prepared from each donor block and stained with 
haematoxylin and eosin and assessed using light microscopy to identify the most 
representative areas in the tumour, this step was achieved by a pathologist (Dr Dena Jerjees). 
Only invasive tumour was considered and avoiding in-situ lesions and necrotic or 
haemorrhagic tumour zones. However, priority was given to blocks that contain enough 
tumour tissue that had not been frequently sectioned for previous studies. These tumour areas 
were marked on top of the slide and then transferred to the corresponding donor paraffin 
block for future sampling using the tissue arrayer needle.  
 
 
2.1.2.2 Designing the Array 
 
Tumours were arrayed where each block contained up to 150 cores (10x15 layouts). 
The cores orientation on the array slide is very crucial mainly because uncertainty regarding 
their orientation can certainly threaten the experiment's evaluation. Therefore, in each array 
block three normal kidney tissue cores were used at the beginning of the first row, and three 
normal liver tissue cores at the end of the last row to identify the start and the end of the array 
as well as to guarantee correct orientation.  
 
 
2.1.2.3 Construction of the Array  
 
An automated GrandMaster TMA arrayer (3DHISTECH Ltd, UK) was used with a 
0.6mm core needle. It is a simultaneous loading, imaging, drilling and punching 
microarrayer. In addition, it automatically measures the block height measurement to ensure 
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the embedded cores are in alignment with the recipient block surface, and label image capture 
for reference. TMA construction was performed by: Alaa Alshareeda, Dr Rezvan Feysal, Dr 
Dena Akram, and Mr Glynn Donovan. Copies of the TMA were made with 1 core per patient 
included on each donor block. A total of eight copies were made with 4 from peripheral and 4 
from central zones of the tumour. For this study, those TMAs with cores sampled from the 
periphery were used.  
 
 
2.1.2.4 Sectioning of the TMA Blocks 
 
Prior to sectioning for the first time after construction, the TMA blocks were 
incubated at 37°C for 15min; to allow both the surrounding paraffin and cores to hybridise. 
For immunohistochemistry, 4 µm tissue sections were cut from each TMA block using a 
microtome and placed onto Xtra slides (Surgipath Ltd) by Mr Christopher Nolan. 
 
 
Table 2.4 The Details of TMA Construction Used in This Study 
TMA Method Markers Acknowledgments 
TMA of ER-
negative tumours 
(386 cases). 
TMAs were prepared by a manual TMA 
arrayer as described previously [278-280]. 
Briefly, cores of 0.6 mm thickness were 
obtained from the most representative areas of 
the tumours then re-embedded in microarray 
blocks. Each case was represented once on 
each TMA; TMAs of 150 cases per block were 
made. 
All markers used in 
this study Ahmed Benhasouna. 
Previous TMA of 
unselected 
primary series  
(1,944 cases) 
Rad51, BRCA1, 
PIAS4,  PIAS1, 
CHK1, and ATM. 
Ahmed Benhasouna, 
Mohammed 
Aleskandarany, and 
Claire Paish. 
New TMA of 
Unselected 
Primary series  
(1,904 cases) 
As described in Sections 2.1.2.1 to 2.1.2.4 
ATR,CHK2, Ȗ+$;
BARD1, SMC6L1, 
DNA-PK, 
KU70/KU80, UBC9, 
KPNA2, and NPM 
Alaa Alshareeda, 
Rezvan Feysal, Dena 
Akram, and Glynn 
Donovan. 
TMA of breast 
tumours from 
patients with 
known BRCA1 
gene mutations (24 
cases). 
All markers used in 
this study Woolston Caroline. 
For unselected primary series, 2 different sets were used, because the previous one was exhausted and lost the tissue so, a 
new set on the same cases was made. The new TMA was fewer than the previous because some of donor blocks were 
exhausted. Only the matched cases were considered in this study and excluded missing one. Although manual and 
automated methods were used to construct the TMA, this has no effect on the step of selecting the tumour area, since in 
both methods this step was done manually by pathologists.  In this study, TMA from periphery area of the tumour was used 
mainly in the new, the previous unselected primary series and also used for ER-negative tumours, whereas, central TMA 
was used for known BRCA1 gene mutation TMA. 
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2.1.3 Immunohistochemistry  
 
Immunohistochemistry has become an established tool for both research and 
diagnostic purposes. It represents the process of detecting antigens (in the present study; 
proteins) in a tissue's cells by exploiting the principle of antibodies binding specifically to 
antigens in biological tissues.  IHC offers fast results (within 1-2 days), fairly inexpensive, 
allows co-localisation of an antigen and the lesion it has produced, leading to increase 
diagnostic accuracy [281]. In this study, 16 antibodies were investigated; ATM, ATR, CHK1, 
&+.Ȗ+$;5DG BRCA1, BARD1, SMC6L1, KU70/KU80, DNA-PK, UBC9, PIAS1, 
PIAS4, KPNA2, and NPM (Table 2.5). 
 
 
2.1.3.1 Immunohistochemical Antibody Labelling Using the Novolink Detection Method  
 
The slides were placed on a 60oC hotplate for 10 minutes, in order to ensure that the 
TMA cores adhered firmly to the slides. They were then allowed to cool and were de-waxed, 
in two xylene baths (Genta Medica, York, UK), for 5 minutes each, followed by rehydration 
in alcohol baths for 3x 2 minutes each. The slides were then washed under running water for 
5 minutes (this step was performed by IHC autostainer machine, ©Leica Biosystems). 
 
 Antigen retrieval was performed by microwaving the slides at 800W for 20 minutes 
in citrate buffer (1M sodium citrate at pH6.0) and then cooling the slides under running tap 
water. Slides then were loaded into Shandon Sequenza coverplates (Thermo Scientific), 
making sure that there were no air bubbles present (this was done in tap water bath under 
water surface), and subsequently placed into Sequenza trays. Slides were rinsed with TBS 
(Tris Buffered Saline pH7.6). Endogenous peroxidise activity was blocked by applying 
+\GURJHQ 3HUR[LGLVH 1RYR/LQN 'HWHFWLRQ 6\VWHP /HLFD 5(-K)) for 5 minutes, 
IROORZHG E\ ULQVLQJ ZLWK 7%6 IRU [  PLQXWHV 3URWHLQ EORFN 1RYR/LQN 'HWHFWLRQ
System (Leica, RE7150-K)) was then applied for 5 minutes. After the slides were washed 
with TBS for 2x 5 minutes, the primary antibody for each target (optimally diluted in Leica 
antibody diluent) was applied and incubated for 60 minutes at room temperature or overnight 
at 4 oC depend on the antibody used. The slides were rinsed with TBS for 2x 5 minutes and 
were then incubated with post primary block 1RYR/LQN Detection System (Leica, RE7150-
K) for 30 minutes, before being rinsed again with TBS for 2x 5 minutes. Novolink polymer 
was then added for 30 minutes. The washing step, using TBS, was repeated and followed by 
freshly-prepared Diaminobenzidine tetrahydrochloride (DAB) working solution (1:20 DAB 
chromogen in DAB substrate) 1RYR/LQN 'HWHFWLRQ 6\VWHP /HLFD 5(-K) being 
added to the slides for 5 minutes; the slides were then once again washed with TBS for 2x 5 
minutes. Slides were counter-stained with haHPDWR[\OLQ 1RYR/LQN 'HWHFWLRQ 6\VWHP
(Leica, RE7150-K) for 6 minutes, therefore, the slides were removed from the coverplates.  
Slides were then rinsed under running water for 5 minutes. Finally, the slides were 
dehydrated by immersing them in IMS alcohol for 3x 2 minutes. They were then cleared in 
xylene (Genta Medica, York, UK) for 2x 5 minutes (again these steps were performed by 
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autostainer machine, ©Leica Biosystems), followed by mounting, with a glass cover slip, in 
DPX (BDH, Poole, UK).  
 
 
2.1.3.2 Optimisation of Antibodies Used for IHC 
 
All the antibodies were optimised on TMA before the staining on the whole series, by 
changing different variables in the protocol of the staining until the optimum result was 
obtained; such as no/less background staining, and high degree of expression heterogeneity, 
VWDUWLQJ ZLWK WKH GLOXWLRQ UHFRPPHQGHG E\ WKH VXSSOLHU¶V GDWDVKHHW LQ DGGLWLRQ WR WKUHH RU
more dilutions above and below the recommended dilution. In addition antigen retrieval 
solutions were used, all the antibodies used in this study were subsequently pre-treated in 
0.1M citrate buffer at pH 6.0.   
 
In addition to Western blotting, negative controls (with omission of the primary 
antibody) were used in each experiment to ensure the specificity of the antibodies. In 
addition, specific positive controls, as advised by the antibody manufacturer or choosing a 
specific tissue from the human protein atlas (http://www.proteinatlas.org/) to observe the 
pattern and intensity of the protein expressions on TMA were included in the IHC 
experiments. However, all negative controls used in this study were applied on BC tissue. 
Positive controls used for each antibody is presented in the specific results Chapters.  
 
All the markers used in this study have been previously stained on TMA, reference 
for each antibody is represented in the specific chapter. Moreover, some control TMA slides 
containing a variety of BC cases with some containing cores from different areas of the same 
cases in addition to normal parenchymal elements were used during optimisation to assess the 
degree of expression heterogeneity.  
 
 
2.1.3.3 Immunohistochemical Scoring 
 
Stained TMA slides were scanned using high-resolution digital images (Nanozoomer; 
Hamamatsu Photonics, Welwyn Garden City, UK) at x20 magnification and were scored 
visually on high-resolution monitors, using a web-based interface (Distiller, Slidepath Ltd., 
Dublin, Ireland). However, the following markers were scored using light microscopy: ATM, 
ATR, CHK1, CHK2, Rad51, PIAS4, KU70/KU80 and BRCA1.  
 
Only staining of invasive cancer cells within the tissue cores was considered taking 
care not to score any in-situ components. The pattern of expression was visually recorded and 
considered any cellular localisation (e.g. nucleus or cytoplasm). For evaluation of IHC, a 
modified Histochemical-score (H-score) was used  [282]. For H-score, both the intensity of 
staining and the percentage of stained cells were considered within each tissue core. Staining 
intensity was scored as 0, 1, 2 or 3 for negative, weak, moderate and strong, respectively. The 
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percentage of positive cells for each intensity was subjectively estimated. Multiplication of 
the two indices (intensity and percentage positive cells) provided final scores that ranged 
IURPWR$OOFDVHVZHUHVFRUHGZLWKRXWSULRUNQRZOHGJHRIWKHSDWLHQWV¶SDWKRORJLFDORU
outcome data.  
 
The author re-scored each marker with at least 30% of a randomly chosen subset of 
cases (details are summarised in each chapter). A statistical agreement test was performed 
(Kappa value) for each marker, where there was good agreement , and an average was 
taken. If there were discrepancies, the highest scoring was taken. However, if only one core 
was informative (because of either loss or absence of tumour tissues), then the score applied 
was that of the remaining core.  
 
2.1.4 Cell Line and Culture Media 
 
Cell lines and reagent were taken from the group of Dr Madhusudan Srinivasan as 
collaborative project. BRCA1 deficient HeLaSilenciX® cells and control BRCA1 proficient 
HeLaSilenciX® cells (Cervical carcinoma cell line) were obtained from Tebu-Bio 
(www.tebu-bio.com). Cells of SilenciX were grown in DMEM medium (with 580mg/L of L-
Glutamine, 4500 mg/L D- Glucose with 110mg/L Sodium Pyruvate) supplemented with 10% 
)HWDO%RYLQH6HUXP)%6SHQLFLOOLQVWUHSWRP\FLQDQGȝJPO+\JURP\FLQ%/LIH
Technologies). BC cell line MDA-MB-436 (BRCA1 deficient) was grown in DMEM (Sigma, 
UK), while MCF-7 (BRCA1 proficient and ER+) and MDA-MB-231 (ER- and EGFR+) were 
grown in RPMI1640 (Sigma, UK). All of the media applied to culture cell lines were 
supplemented with 10% FBS (PAA, UK) and 1% Penicillin/Streptomycin. MCF-7 and 
MDA-MB-231 were purchased from ATCC and MDA-MB-436 cell line was purchased from 
CLS.   
 
2.1.4.1 Preparation of Cell Lysates 
 
Thawing and freezing procedures were carried out by Nada Albarakati. Cells were 
grown to 80% confluency and were washed with sterile Phosphate Buffer Saline (PBS). The 
cell monolayer was disrupted by a 5-minute incubation with 2mL 10% trypsin/EDTA in PBS, 
pre-warmed to 37ºC. Flasks were gently shaken to help disrupt the cell monolayer. Cells were 
suspended in fresh media, at a concentration of 1x106 cells per ml. They were then pelletted 
through centrifugation at 500g for 5 minutes. 1 mL of cell suspension was pipetted and 
washed once with PBS. Therefore, lysis of the cells was performed by adding RIPA buffer 
(25mM Tris, 150mM NaCl, 1% Nonidet P-40, 1% sodium deoxycholate and 0.1% Sodium 
Dodecyl Sulfate  (SDS)) to a phosphatase and protease inhibitor cocktail (Pierce, Thermo 
Fisher Scientific, UK), therefore, the lysate was incubated on ice for 10 minutes, with 
frequent shaking. Lysates were centrifuged for 20 minutes at 4qC at 13000g, in order to 
remove cell debris. Finally, the supernatant was stored at -20 °C, until use. 
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2.1.4.2 Cell Passage Procedure 
 
The first part of this procedure was identical to that described in section 2.1.4.1. 
Following the centrifugation step, the supernatant was discarded and the cell pellet re-
suspended in 10 mL fresh growth medium (pre-warmed to 37ºC). A small amount (10 µL) of 
the resulting suspension was pipetted into each chamber of a Neubauer haemocytometer, 
which has 25 central squares, and allowed to settle for 1 min before counting. All cells within 
the 5 x 5 division grids of both chambers were counted. The mean count was calculated and 
the numbers of cells were calculated using the following equation: Number of cells/mL = 
Mean cell count x dilution factor (10) x 104. The suspension was diluted with fresh growth 
medium and poured into cell culture plates or cell culture flasks. The passages number used 
in this study were as follows: for HeLa BRCA1; between passage 21 and 30, HeLa BRCA1 
control; between passage 15 and 20, MCF-7; between passage 25 and 32, MDA-MB-231; 
passage 15 and 24, finally for MDA-MB-436; between passage 12 and 20.  
 
 
2.1.4.3 Cell Lysate Protein Quantification (Bradford Assay) 
 
The concentration of cell lysate protein was calculated using the BioRad Bradford 
assay, using bovine serum albumin (BSA) as a standard.  10PL of a protein was mixed with 
250mL of diluted and filtered assay solution in a 96-well plate leading to a differential colour 
change occurs in response to the protein concentration. Consequently, OD595nm was 
established using microplate reader; FLUOstar OPTIMA from BMG LABTECH Ltd., 
Aylesbury, UK, to determine the absorbance value.  Therefore, a standard curve was created 
using BSA diluted in lysis buffer by plotting the values of absorbance against concentrations 
of corresponding protein. The absorbance of unknown protein lysates was plotted on the 
standard curve to evaluate the concentration of the proteins in each cell lysate, and, this step 
was performed in triplicate. The determination of the concentration of the protein, in 
individual cell lysates, was performed to help load equal amount of protein. 
 
 
2.1.4.4 Specificity of Antibodies by Western Blot (W.B) 
 
The specificity of the following antibodies was achieved through Western blot (Table 
2.5) with the exception of PIAS4, ATR, BRCA1, and BARD1. These markers were stained 
EHIRUH VWDUWLQJ FHOO FXOWXUH¶V ZRUN GHWDLOV DUH JLYHQ LQ HDFK FKDSWHU Western blotting 
validated the specificity of some antibodies, however, this was deemed to be validated by a 
single band at the correct protein size. The pre-VWDLQHGPDUNHU µIXOO UDQJH UDLQERZPDUNHU¶
(Invitrogen Life Technologies) was used as a molecular weight standard.   
 
A mixture of different cell lysates to detect the specificity of an antibody has 
previously been applied in different studies and showed its reliability [283-285]. In this study, 
KU70/KU80, and Rad51 were tested by W.B on MCF-7 cell lines, whereas, the remaining 
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DQWLERGLHV $70 &+. &+. Ȗ+$; 60&/ 3,$6 8%& .31$ DQG 130
were detected in a mixture of different lysates (MCF-7, MDA-MB-231 and HeLa BRCA1 
and its control). All the antibodies tested in this study shared the same positive controls which 
were MCF-7, HeLa BRCA1 cell lines. http://www.proteinatlas.org/ provides profile data for 
positive controls of all the markers used in this study. 
 
 
2.1.4.5 Denaturing Polyacrylamide Gel Electrophoresis 
 
The separation of proteins was achieved by SDS-PAGE, in accordance with the 
Laemmli method. Proteins were solubilised in SDS loading buffer. One part of the 2X SDS 
buffer (1x50mM Tris-HCl, pH 6.8, 10% (v/v) glycerol, 2% (w/v) SDS, 0.01% (w/v) 
bromophenol blue and 1% (v/v) b-mercaptoethanol) was added to the same volume of the 
VDPSOHDQGZDVKHDWHGIRUPLQXWHVDW&(TXDODPRXQWVRISURWHLQȝJZHUHORDGHG
into each well of a precast 10-15% Tris Glycine Gel (Bio-Rad). Gels were run at 150V for 90 
minutes in Tris/Glycine/SDS running buffer (Bio-5DG XVLQJ µ&ULWHULRQ¶ %LR-Rad) gel 
equipment. The pre-VWDLQHG PDUNHU µIXOO UDQJH UDLQERZ PDUNHU¶ ,QYLWURJHQ /LIH
Technologies) was used as a molecular weight standard.  
 
After electrophoresis, proteins were transferred to nitrocellulose membranes 
(Hybond-C extra, Amersham Pharmacia Biotech) by wet transfer, using a Bio-Rad trans-Blot 
cell. Electro-blotting was performed at 25V for 90 minutes in transfer buffer (20% (v/v) 
methanol, 50mM Tris-HCl and 380mM glycine). Membranes were blocked in 10mL of 
blocking buffer (PBS contained 0.1% Tween-20 and 5% non-fat dry milk) for 1 hour at room 
temperature. The blot was washed 3 times (for duration of 5 minutes per wash) in TBS-
Tween-20 and was incubated with primary antibodies at 4°C overnight, or at room 
temperature for a period of 1 hour.  After washing three times with TBS-Tween-20 detection 
of the transferred proteins were obtained by Enhanced Chemiluminescence (ECL). The 
secondary antibody (Anti-rabbit or anti mouse monoclonal horseradish peroxidase conjugate, 
Dako, Carpinteria, CA, USA), diluted 1:2000 in blocking buffer, was added for 1 hour at 
room temperature. Following an additional wash, the membrane was incubated with ECL 
detection reagent (GE Healthcare, UK) for 1 minute and then removed from the solution and 
wrapped in cling film. The membrane was put into a film case and brought to the dark room. 
A sheet of Kodak film (Kodak Bio Max Film) was overlaid on the blot for different exposure 
times: 2 minutes, except KU70/KU80 which was for 20 seconds. The film was soaked in 
developer (Sigma Aldrich, UK) for 2 minutes, fixed in fixing solution (Sigma Aldrich, UK) 
for 2 minutes, then washed in water for 2 minutes and allowed to dry. Details of the dilution 
of primary antibodies are given in Table 2.6 
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Table 2.5 List of Antibody Tested by Western Blot on Different Cell Lines. 
Antibody Cell lines used Specific positive cell lines* 
Rad51 Single cell line MCF-7 MCF-7 or  HeLa BRCA1 cell lines 
KU70/KU80 Single cell line MCF-7 MCF-7 or  HeLa BRCA1 cell lines 
SMC6L1 A mixture of MCF-7, MDA-MB-231, HeLa BRCA1 and its control MCF-7 or  HeLa BRCA1 cell lines 
DNA-PK A mixture of MCF-7, MDA-MB-231, HeLa BRCA1 and its control MCF-7 or  HeLa BRCA1 cell lines 
ATM A mixture of MCF-7, MDA-MB-231, HeLa BRCA1 and its control MCF-7 or  HeLa BRCA1 cell lines 
CHK1 A mixture of MCF-7, MDA-MB-231, HeLa BRCA1 and its control MCF-7 or  HeLa BRCA1 cell lines 
CHK2 A mixture of MCF-7, MDA-MB-231, HeLa BRCA1 and its control MCF-7 or  HeLa BRCA1 cell lines 
Ȗ+$; A mixture of MCF-7, MDA-MB-231, HeLa BRCA1 and its control MCF-7 or  HeLa BRCA1 cell lines 
PIAS1 A mixture of MCF-7, MDA-MB-231, HeLa BRCA1 and its control MCF-7 or  HeLa BRCA1 cell lines 
UBC9 A mixture of MCF-7, MDA-MB-231, HeLa BRCA1 and its control MCF-7 or  HeLa BRCA1 cell lines 
KPNA2 A mixture of MCF-7, MDA-MB-231, HeLa BRCA1 and its control MCF-7 or  HeLa BRCA1 cell lines 
NPM A mixture of MCF-7, MDA-MB-231, HeLa BRCA1 and its control MCF-7 or  HeLa BRCA1 cell lines 
Passages, Bradford assay and gel electrophoresis were done by the author. Passages used in W.B. were as follows; HeLa 
BRCA1; passages 29&30, HeLa BRCA1 control; passage 15&16, MCF-7; passages 25&26, MDA-MB-231; passage 
15&16. * Available at http://www.proteinatlas.org/. 
 
2.1.5 Reverse Phase Protein Microarray (RPPA) 
 
Cell lines preparation and protein extraction and interpretation of the results were 
carried out by the author. However, the RPPA and analysis was carried out by Dr Ola Nejm 
(Immunology, School of Life Sciences, University Hospital, Nottingham, UK) as a 
collaborative project.      
 
Three different passages were used in RPPA per experiment, and each run was 
duplicated. The passages numbers used were as follows: for HeLa BRCA1; between passage 
21and 30, HeLa BRCA1 control; between passage 15and 20, MCF-7; between passage 25and 
32, finally for MDA-MB-436; between passage 12 and 20. Cell line lysates were solubilised 
in a 4x SDS sample buffer, with a ratio of 1:3 respectively, and were boiled for 5 minutes at 
95°C. Samples were loaded onto a 384-well plate (Genetix, UK), where each sample was 
serially diluted 5 times in 1x SDS buffer. Samples were robotically spotted, in duplicate, onto 
nitrocellulose-coated glass slides (GraceBiolab, USA), using a microarrayer (MicroGridII). 
Slides were incubated overnight in blocking solution (0.2% I-block (Tropix, Bedford, MA, 
USA) and 0.1% Tween-20 in PBS) at 4qC, with shaking. After washing three times for 5 
minutes each (TBS-Tween-20), the slides were incubated overnight with the primary 
antibodies (details of the dilution of primary antibodies are given in Table 2.6) and optimally 
diluted in antibody diluents, in order to reduce background (DAKO). In addition, mouse anti- 
Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) antibody (BioLegend, UK), diluted 
1:250 in the same diluent was used as house-keeping protein, in terms of control for protein 
loading. Slides were incubated overnight at 4°C, with shaking. Following washing, as 
described before, the slides were incubated with diluted infrared (1:5000 in washing buffer) 
secondary antibodies ((800CW anti-rabbit and 700CW anti-mouse antibodies) Dako, 
Carpinteria, CA, USA) for 30 minutes at room temperature in the dark, with shaking. The 
slides were washed as before and were dried through centrifugation at 500g for 5 minutes, 
before being scanned with a /LFRU2G\VVH\VFDQQHUDWȝPUHVROXWLRQDWQPJUHHQDQG
700nm (red). The resultant TIFF images were processed with Axon Genepix Pro-6 
Microarray Image Analysis software (Molecular Services Inc.), in order to obtain 
fluorescence data for each feature and to generate gpr files. Protein signals were finally 
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determined, with background subtraction and normalisation to the internal housekeeping 
targets, using RPPanalyzer, a module within the statistical language on the CRAN 
(http://cran.r-project.org/). Finally, a heat map was created using Multi Experiment Viewer 
(MEV) software.  
 
All the antibodies were tested by RPPA, except PIAS4, this marker was previously 
stained by the author before starting the collaboration with Dr Ola Nejm, the aim was to 
YDOLGDWH533$RQWKHFHOOOLQHVDQGFRPSDUHLWZLWK,+&¶VILQGLQJVDQGWKLVZDVDFKLHYHGRQ
WKH RWKHU  DQWLERGLHV $70 $75 &+. &+. Ȗ+$; 5DG %5&$ %$5'
SMC6L1, KU70/KU80, DNA-PK, UBC9, PIAS1, KPNA2, and NPM).  
 
 
2.1.6 Statistical Analyses 
 
All statistical analyses were carried out using IBM SPSS statistic 21.0 software. All 
statistical analysis was carried out by Alaa Alshareeda except the RPPA results which were 
performed by Dr Ola Nejm. Mohammad Albanghali and Dr Jenna Reps provided advice 
regarding selecting the most suitable statistics tests.  For all statistical tests, a two-sided P-
value of <0.01 was considered statistically significant. 
 
 
2.1.6.1 The Determination of the Optimal Cut-offs  
 
Cut-off values for the positivity of biomarkers were individually assessed and 
determined based on previous publications [273]. Table 2.6 shows the details of primary 
antibodies; such as source, cut off and pre-treatment, used in this study. The cut-off of the 
biomarkers were dichotomised and obtained using different approaches: a) using the mean or 
median of the H-score of the staining according to distribution pattern whether normally or 
not normally distributed, or b) using x-tile software (version 3.6.1, 2003-2005, Yale 
University, USA http://x-tile.software.informer.com) (Table 2.6). x-tile plot shows the 
presence of significant tumour classes and illustrates the robustness of the relationship 
between a biomarker and outcome by construction of a two dimensional projection of every 
possible subpopulation. x-tile software randomly splits the total cohort of the patient into two 
VHSDUDWH LGHQWLFDO WUDLQLQJ DQG YDOLGDWLRQ VHWV E\ FUHDWLQJ VHSDUDWH GDWD RI ³FHQVRUHG´ DQG
³XQFHQVRUHG´REVHUYDWLons, ranked by follow up time of the patients. However, those patients 
who died from BC were considered as an event (uncensored), whereas patients died from 
other causes or lost to follow-up during this study were censored during the analysis at that 
event time. Therefore, the optimal cut-points were identified by locating the brightest pixel 
on the diagram of x-tile plot of the training set. Statistical significance was investigated by 
validating the obtained cut-point to the validation set. 
  
In the present study, x-tile was used if the value of mean or median was very high (e.g 
H-score >200). In the present study, it was XVHG IRU 5DG &+. Ȗ+$; $70 $75 
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[286], PIAS1, PIAS4 [285], KU70/KU80 [287], BARD1, DNA-PK, and NPM. However, for 
the reaming markers (CHK2, BRCA1, SMC6L1, UBC9 and KPNA2), regardless of cellular 
localisation, the cut-offs were based on the frequency distribution.   
 
The following statistical methods were used: 
 
2.1.6.2 Univariate Analysis with Clinico-Pathological al Parameters and Tumour 
Markers  
 
All statistical analyses were performed using IBM SPSS 21.0. Analysis of continuous 
variables was performed using the appropriate statLVWLFDO WHVWHJ3HDUVRQ¶VFRUUHODWLRQDQG
ANOVA test [administered at 1% level of significance]). One way ANOVA test was used to 
find out which of different BC classes ( by IHC or cell lines) were significantly different from 
each other (post hoc test; Tukey). 
 
The differences between all categorical markers, with regards to clinico-pathological 
features, or with other tumour markers were analysed using the Pearson Chi-Squared test (x2). 
Consequently, x2 was also used in order to examine the inter-relations between markers 
themselves.  
 
 
2.1.6.3 Univariate Analysis with 3DWLHQWV¶Outcome  
 
Patients still alive or those that died for any reason other than BC were censored. The 
Kaplan-Meier method (IBM SPSS 21.0) was used to generate a univariate survival curve and 
the differences in survival among the biomarkers were evaluated using the log-rank test.  
 
 
2.1.6.4 Multivariate Analysis with PDWLHQWV¶Outcome  
 
,IDPDUNHULQXQLYDULDWHDQDO\VLVZDVVWDWLVWLFDOO\VLJQLILFDQWZLWKSDWLHQW¶VRXWFRPH
then Cox regression (IBM SPSS 21.0) was applied for multivariate analyses to test for 
confounders and prognostic or predictive independency of the investigated biomarker from 
standard prognostic/predictive factors including tumour grade, tumour stage, and tumour size. 
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Table 2.6 Sources, Dilution, Cut-offs Point and Pre-treatment Conditions Used of the 
Primary Antibodies Used in this Study. 
Antibody Clone Source Dilution IHC 
Dilution 
W.B 
RPPA 
Distribution* Cut-offs IHC kit 
DNA Damage Sensors and Signal Transducers 
ATM Ab 32420 Abcam 1:100 
overnight 
1:1,000 
1:500 Nuclear [-tile Novolink 
ATR 1E9 Novus Biologicals 
1:20 
overnight 
NT 
1:500 Nuclear +-score, x-tile[286] Novolink 
CHK1(Phospho 
S345) Ab58567 Abcam 1:150 1h 
1:1,000 
1:6,000 Nuclear/cytoplasmic 
+-score nuclear, 
H-score cytoplasmic 
, x-tile. 
Novolink 
CHK2 Ab 47433 Abcam 1:100 1h 1:500 1:6,000 Nuclear +-score, median. Novolink 
Ȗ+$; 
(phospho S139) 
 
Ab22551 Abcam 1:600 1h 1:2,000 1:1000 Nuclear/cytoplasmic 
+-score nuclear, 
H-score cytoplasmic, x-tile. Novolink 
Homologous Recombination Repair 
BARD1 NBP1-19636 
Novus 
Biologicals 1:50 1h 
NT 
1:200 Nuclear/cytoplasmic 
+-score cytoplasmic, 
>0 H-score nuclear, x-tile. Novolink 
BRCA1 Ab-1 (MS110) Calbiochem 1:150 1h 
NT 
1:200 Nuclear/cytoplasmic 
3 H-VFRUHQXFOHDU
H-score cytoplasmic, 
means 
ABC[288] 
Rad51 Ab88572 Abcam 1:70 1h 1:1,000 1:100 Nuclear/cytoplasmic 
+-VFRUHQXFOHDU+-
score cytoplasmic, x-tile. Novolink 
SMC6L1 AB57759 Abcam 1:100 1h 1:1,000 1:250 Nuclear/cytoplasmic 
>240 H-score nuclear, 
mean230 H-score 
cytoplasmic, median. 
Novolink 
Non Homologous End Joining Repair 
KU70/KU80 Ab3108 Abcam 1:2500 1h 
1:1,000 
1:500 Nuclear +-score, x-tile. Novolink 
DNA-PK 3H6 Cell 
signaling 1:28 1h 
1:2,000 
1:150 Nuclear +-score, x-tile. Novolink 
Basal Cytokeratins 
Ck5 5Ab-1xM26 TBC 1:50 1h 
NT 
NT Cytoplasmic  [198, 273]. Novolink 
CK17 VPC-413 Vector laboratories 1:100 1h 
NT 
NT Cytoplasmic [198, 273]. Novolink 
CK14 LL002 Novocastra 1:100 1h NT NT Cytoplasmic  [198, 273]. Novolink 
Epidermal Growth Factor Receptor Family Members 
HER-2 Polyclonal Dako-Cytomation 1:100 1h 
NT 
NT Membranous  [273]. ABC[268]. 
Hormone Receptors 
ER 1D5 Dako-Cytomation 1:200 1h 
NT 
NT Nuclear [273]. ABC[268]. 
PgR PgR Dako-Cytomation 1:150 1h 
NT 
NT Nuclear [273]. ABC[268]. 
BRCA1 Down Regulators Proteins 
MTA1 Ab84136 Abcam 1:200 1h NT NT Nuclear/cytoplasmic 
1XFOHDU+-score& 
&\WRSODVP+-score, 
x-tile. 
Novolink 
ID4 Ab77345 Abcam 1:100 1h NT NT Nuclear/cytoplasmic 
1XFOHDU+-score, 
PHDQ	&\WRSODVP
H-score, median. 
Novolink 
Proliferative Marker 
Ki-67** MIB1 M7240 
Dako-
Cytomation 1:100 1h 
NT 
NT Nuclear >34% mean. ABC[268]. 
NT= not tested. IHC= immunohistochemistry. W.B= western blot. RPPA= Reverse Phase Protein Microarray. *Cellular localisation. **Ki-67 
Performed on full face formalin fixed, paraffin embedded tissue sections (FFPE, ȝPWKLFN, whereas all other antibodies were stained on 
TMA.MTA1, ID4, Ki-67, ER, PgR, HER-2, basal CKs were accessible and saved on a web-based interface (Distiller; Slidepath Ltd, Dublin, 
Ireland). 
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Table 2.6 Sources, Dilution, Cut-offs Point and Pre-treatment Conditions Used of The 
Antibodies Used in This Study Continued. 
Antibody Clone Source Dilution IHC 
Dilution 
W.B 
RPPA 
Distribution* Cut-offs IHC kit 
Cell Cycle Progression/arrest Regulator Markers 
P21 EA10 Abcam 1:25 1h NT NT Nuclear [273]. ABC[268]. 
P27 SX53G8 
Dako-
Cytomati
on 
1:10 1h NT NT Nuclear 
+-score 
[273]. ABC[268]. 
SUMO Markers 
PIAS4 NBP1-31215 Novus Biologicals 
1:250 
1h 
NT 
NT Nuclear 
+-score, 
x-tile Novolink 
PIAS1 Ab32219 Abcam 1:425 1h 
1:1,000 
1:1,000 Nuclear/cytoplasmic 
1XFOHDU+-
score 
Cytoplasm 
+-score, x-
tile 
Novolink 
UBC9 Ep2938Y Novus Biologicals 
1:225 
1h 
1:500 
1:250 Nuclear/cytoplasmic 
Nuclear 
+-score, 
median 
Cytoplasm 
+-score, 
mean. 
Novolink 
Tumour Suppressor Markers 
P53 DO7 Novocastra 1:50 1h NT NT Nuclear [273]. ABC[268]. 
PTEN 
MMAC1 Ab-
4 (Clone 
17.A) 
Thermo 1:501h NT 1:500 Nuclear  
37(1+-
score, mean. 
Novolink 
Nucleocytoplasmic Transport Markers 
Nucleophosmin Ab55708 Abcam 1:400 1h 1:5,000 1:500 Nuclear 
+-score, 
x-tile. Novolink 
KPNA2 Ab84440 Abcam 1:400 1h 1:1,000 1:500 Nuclear 
+-score, 
median. Novolink 
All the antibodies were pre-treated in citrate antigen retrieval pH=6.0 in microwave for 20 minutes and stained on TMA. NT= not tested. 
IHC= immunohistochemistry. W.B= western blot. RPPA= Reverse Phase Protein Microarray. *Cellular localisation.  P53, PTEN, P21 and 
P27 were accessible and saved on a web-based interface (Distiller; Slidepath Ltd, Dublin, Ireland). 
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Chapter 3 
 
3.1 Introduction  
 
3.1.1 DNA Damage Response in Relation to Cell Cycle Control Checkpoints 
 
The majority of human cells do not usually actively progress through a cell cycle; 
WKH\ JHQHUDOO\ UHPDLQ LQ DQ µRXW-of-F\FOH¶ VWDWH $PLQRULW\RI FHOOVGR WHQG WREH DFWLYHO\
proliferating (cycling) and these are largely found in the stem-transit amplifying 
compartments of self-renewing tissues; for example, the epithelia and bone marrow [289]. 
The majority of functional cells are irreversibly withdrawn from the cell-division cycle 
directly into terminally differentiated states, such as the surface epithelial cells of 
skin/mucosa, or have reversibly withdrawn into a quiescent (G0) state, such as hepatocytes 
[290, 291]. 
 
The cell cycle has four distinct phases and the most essential phases are the synthesis 
(S) phase, when replication of the DNA commences, and the M (mitosis) phase, when the cell 
splits into two daughter cells. Two gap phases, referred to as G1 and G2, separate the S and 
M phases. G1 is the very first phase within the interphase, beginning from the end of the M 
phase and right up until DNA synthesis begins; this is a time when the cell becomes sensitive 
to positive and negative discriminative stimulus from networks of growth signalling. G2 
refers to the gap immediately after the S phase and ensures that the cell is ready to enter the 
M phase and divide. G0 represents a state where cells possess reversibly reclusive rights from 
the cell division cycle in response to cells of high density, or maybe deprivation of mitogen 
[292]. However, cells may irreversibly recede from the cell cycle into terminally 
differentiated or senescent out-of-cycle states. Progression and transition from one phase to 
another through the cell cycle is monitored by sensor mechanisms, referred to as checkpoints, 
which usually manage the appropriate order of events [293]. If the sensor systems recognise 
aberrant or even incomplete cell cycle events, such as DNA damage, checkpoint pathways 
carry the signal directly to effectors, leading to the induced arrest of the cell cycle until it is 
repaired [294, 295]. Effector proteins comprise of Cyclin-Dependent Kinases inhibitors 
(CDKIs), which can often reversibly stop the progression of the cell cycle. Cell cycle engine 
deregulation underlies uncontrolled cell proliferation, which will subsequently characterise 
the phenotype of cancer [296, 297]. 
 
Following the detection of DNA lesions, DDR organises the repair of DNA, the 
control of the cell-cycle checkpoint and specific programmes, such as apoptosis and 
senescence, in order to increase genomic integrity and thus suppress tumorigenesis [298]. The 
decision as to which system of repair to use is dependent upon type of lesion and phase of the 
cell cycle. 
 
As outlined in Chapter 1, the DNA-DSB lesion is the most lethal: it may be cytotoxic 
or cytostatic and produces oncogenic translocations [299, 300]. In the cell, this lesion is 
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usually repaired by two major pathways, the NHEJ and HR pathways. HR is cell-cycle 
dependent: it is controlled by Cyclin-Dependent Kinases (CDK) activity and, sometimes, 
simply by the expression of cell cycle-dependent or the stability of the required factors [301]. 
HR readily repairs DNA-DSB in cells in the S and G2 phases, whereas repair by NHEJ 
occurs during the G1 phase [302]. As cells develop directly into G2±M, the chromosomes are 
condensed into a highly-ordered structure of chromatin, which would make a homology 
search by sister chromatid difficult [302].  
 
Checkpoints consist of cellular monitoring, in addition to signalling pathways that 
organise the repair of DNA, the metabolism of chromosomes and transitions of the cell-cycle 
[303, 304]. Checkpoint proteins tend to be recruited to DNA lesions through repair 
complexes that create the intermediate structures of DNA, which act as signals to trigger the 
response of checkpoints. For instance, in mammals, the MRE11±RAD50±Nbs1 (MRN) 
complex processes DSBs to create long single-stranded (ss) DNA regions, which stimulates 
the response of checkpoints [305, 306]. Following activation, the transducers of checkpoints 
transmit and enhance the signal of checkpoints to downstream targets; for example, the DNA-
repair apparatus and the machinery of the cell-cycle [303]. The signal transmission or 
activation of these targets can often be completed by distinct phosphorylation events: this 
influence the level of transcription or activity of repair genes, in addition to regulating the 
cell-cycle transitions by affecting the stability of the activity of other proteins involved in the 
maintenance of checkpoints or progression of the cell-cycle. A major factor in the machinery 
of checkpoints are the phosphoinositide 3-kinase related kinases; Ataxia Telangiectaxia 
mutation (ATM), ATM-Rad3-related (ATR) and DNA- dependent Protein Kinase (DNA-
PK). ATM and DNA-PK largely act in response to DSBs, whereas ssDNA activates ATR 
[304]. The activation and recruitment of these kinases to DNA lesions are the result of direct 
interactions with Nijmegen Breakage Syndrom1 (NBS1) (for ATM), ATRIP (for ATR) and 
KU80 (for DNA-PK) [307, 308]. The resection of DSBs, which can be much less effective in 
G1 and are restricted by CDK activity [305, 306, 309], additionally results in the activation of 
ATR13. Despite the fact that ATM and ATR respond to distinct lesions, recent evidence 
indicates that ATR is also stimulated by IR-induced DSBs, in a cell-cycle regulated manner 
[306]. The activation of ATR by DSBs requires ATM as well as MRN±CtIP (CtBP-
interacting protein); thus, it only arises throughout the S and G2 phases and is eliminated by 
the inhibition of CDK [306, 310]. These findings are in-line with previous results 
demonstrating, in terms of IR-induced foci formation, that the HR protein (Rad51), in both 
yeast and human cells, is restricted to the S and G2 phases and is dependent on checkpoint 
activity [311-313]. The relevant CDK targets in this pathway, in addition to CtIP [310], 
remain to be determined. 
 
As soon as ATM and ATR are recruited to damaged sites, they target many different 
substrates, such as checkpoint kinase-1 (CHK1) and CHK2 [314]. It is demonstrated that 
these signalling modules play a role in the organisation of the response of checkpoints to the 
repair of DNA [304, 314]. Generally, in terms of response to the DNA-DSB, ATM is 
recruited to damaged sites by the MRN sensor complex. Thus, CHK2 is activated at the 
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damage site after phosphorylation by ATM, which, with other ATM substrates, subsequently 
activate a cascade of proteins including histone H2AX, mediator of DNA damage checkpoint 
1 (MDC1), 53BP1 and BRCA1 [315, 316]. In terms of short sequences of single-strand 
breaks created by DSBs, the Replication Protein A (RPA)-coated DNA recruits ATR and its 
interacting protein, ATRIP, with assistance at the site of the lesion from Rad17, Rad9, Rad1 
and complexes of Hus1 [317, 318]. Subsequent ATR phosphorylation stimulates the mediator 
DNA Topoisomerase 2-Binding Protein 1 (TopBP1), leading to interaction  and the 
phosphorylation of additional mediator proteins, such as H2AX, claspin and BRCA1, which 
eventually induces the activation of CHK1 [319].  
 
CHK1 phosphorylation of Rad51 is required for HR in mammalian cells; in addition, 
CHK1 affects the replacement of RPA on ssDNA, together with Rad51 and Rad52, in a 
process that triggers the formation of Rad51 presynaptic filaments and HR-mediated (DSB 
repair) initiation [320]. The ATM-dependent phosphorylation of the Nbs1 subunit forms a 
complex of MRN and Fanconi Anemia group D2 protein (FANCD2) [321] from the 
crosslink-repair pathway of Fanconi Anaemia (FA), which is believed to enhance the repair 
of HR during the S phase [322]. A common response to DSBs, chromatin relaxation is 
promoted by ATM phosphorylation of KRAB-associated protein 1 (KAP1) [323]. The ATM-
dependent phosphorylation of histone H2AX is an early event that is essential in the efficient 
repair of DSBs and potentially plays a role in repair recruitment, cohesion and checkpoint 
factors [324]. 
 
H2AX is a key component in DNA repair, which is readily phosphorylated on serine 
four residues from the carboxyl terminus (serine c- IRUPLQJ Ȗ+$; DW QDVFHQW VLWHV RI
'6%:LWKLQPLQXWHVRI WKHIRUPDWLRQRID'6%YDVWTXDQWLWLHVRIȖ+$;IRUPLQ WKH 
chromatin located around the break site, developing a focus on where proteins participated in 
the repair of DNA and on the accumulation of chromatin remodelling [325]. The HR 
functions of H2AX aUHPHGLDWHGE\Ȗ+$;LQWHUDFWLRQDORQJZLWKWKHFKURPDWLQ-associated 
adaptor protein MDC1. H2AX is most likely susceptible to further post-translational 
modifications related to the response of DNA damage, along with additional functions of 
chromatin [326] Ȗ+$; LV HVVHQWLDO IRU VLVWHU-chromatid homologous recombination, most 
likely in assisting the connections between sister chromatids [327]. A summary of the most 
common markers in response to DNA damage is shown in Figure 3.1. 
 
 
3.2 Hypothesis 
 
Cellular response to any genotoxic stress is a highly complex process, and it usually 
EHJLQVZLWKRQHRIWZRV\VWHPVWKH³VHQVLQJ´RU³GHWHFWLRQ´RIWKe damage of DNA, then a 
number of events that include signal transduction and transcription factors activation. The 
activated transcription factors stimulate expressions of several genes which usually have roles 
in different cellular functions such as DNA repair, cell cycle arrest, and apoptosis. The 
response to DNA damage enhances genomic integrity and the ability for replication and thus 
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suppresses tumuorigenesis. Correct genetic information transmission from one cell to its 
progeny is based mostly on processes within the cell to check any defects within its genome 
as well as to repair these deficiencies in order not to pass them to following generations. 
These processes are mainly controlled through an array of DNA damage response proteins 
such as DNA damage sensors, signal transducers and effectors. Sensors, such as ATM and 
ATR, have the ability to identify damage areas and trigger signal transducers, which either 
activate or inactivate effectors. Effector proteins trigger checkpoints of cell cycle such as; 
CHK1 and CHK2, and then the cell may efficiently repair the damage or carry on towards 
apoptosis if these types of damages are irreparable. However, these molecules are not only 
essential for surveillance of occasional non-lethal DNA damage, yet are likewise necessary 
for the cell survival as well as the organism [328]. It is thus hypothesised that alterations of 
the DNA damage sensors may contribute to the development and progression of at least a 
proportion of sporadic breast carcinoma particularly those associated with features similar to 
breast carcinoma arising in patients with BRCA1 germline mutations [329, 330]. Despite the 
fact that the previous studies have described the sequence of events associated with DNA 
damage sensing, signalling transduction and repair in cells, the whole process appears to be 
complex and its characterisation in BC remains to be explored. 
 
 
3.3 Aim  
 
This chapter aims to underline the importance of the DNA damage sensors (ATM and 
ATR) signal transducers (CHK1 and CHK2)  and DNA damage repair  factor protein such as 
Ȗ+$;LQBC by using IHC; TMA in the context of specific, well-defined patient subgroups 
and RPPA in different cell lines. In addition, the association between cell-cycle markers, 
pathological features, expression of tumour biomarkers and clinical outcome will be 
determined.  
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3.4 Materials and Methods 
 
A previously described in Chapter 2 
 
 
3.4.1 Patient Samples  
 
All data are as previously described in Chapter 2 Section 2.1.1.  Three cohorts were 
used: A) 1904 unselected cases of female primary operable invasive tumours between 1986 
and 1998, B) 386 cases selected from a consecutive series of primary operable ER negative 
tumours between 1998 and 2007 and C) 24 well-characterised series of breast tumours from 
patients with known BRCA1 germline mutations. However, HRMA with employing PCR was 
used for BRCA1 mutation detection in group C (this was performed by Dr Ahmed 
Benhasouna). All cases were obtained from the well-characterised Nottingham Tenovus 
primary breast carcinoma series. 
 
 
 
Figure 3.1 The roles of CHK1 and CHK 2 in cell cycle and DNA repair. In response to DNA damage, ATM (usually targets 
DNA- DSB), and/or ATR (usually targets ssDNA) trigger the activation of checkpoint CHK2 and CHK1 respectively that 
leads to cell cycle arrest or delay. Checkpoints pathways are characterised by cascade of protein phosphorylation events 
(indicated with P) that alter the activity, and even localisation of modified proteins. This leads to one of two reactions either 
apoptosis or DNA repair.  
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3.4.2 Available Biomarkers' Data 
 
Data on a wide range of biomarkers of known clinical and biological relevance to BC 
were accessible and saved on a web-based interface (Distiller; Slidepath Ltd, Dublin, 
Ireland). These include, ER, PgR, HER-2, CK5, CK17, CK14, tumour suppressor proteins 
(P53 and PTEN), and cell proliferative marker (Ki-67) [270-272, 331]. 
 
 
3.4.3 Immunohistochemistry  
 
As previously described in Chapter 2 Section 2.1.3. Five markers of DNA damage 
sensors and signal transducers, and a repair factor protein (ATM, ATR, CHK1, CHK2 and 
Ȗ+$;ZHUHLQYHVWLJDWHGLQWKLVFKDSWHU 
 
 
3.4.3.1 Immunohistochemical Antibody Labelling Using the Novolink Detection Method 
 
As previously described in Chapter2 Section 2.1.3.1. In this chapter, CHK1 and 
Ȗ+$; ZHUH stained by the author as data on CHK2, ATR, and ATM expression were 
already available (Acknowledgement: Mr Paul Moseley). All these markers have already 
been previously successfully stained on TMA [332-337].   
 
 
3.4.3.2 Optimisation of Antibodies Used for IHC 
 
As previously described in Chapter 2 Section 2.1.3.2. In addition to Western blotting, 
specificity of staining was confirmed by application of negative (with omission of the 
primary antibody) and positive controls. Positive controls were used according to the 
PDQXIDFWXUHU¶V GDWDVKHHW DQGRU IURP WKH KXPDQ SURWHLQ DWODV DYDLOable at 
http://www.proteinatlas.org/. This helped not only to test the specificity of staining but also to 
assess the pattern and intensity of protein expressions in the appropriate tissue.  Details of the 
negative and positive controls used are summarised in Table 3.1.  Moreover, some control 
TMA slides containing a variety of BC cases with some containing cores from different areas 
of the same cases in addition to normal parenchymal elements were used during optimisation 
to assess the degree of expression heterogeneity.  
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Table 3.1 Immunohistochemistry Positive and Negative Controls of Antibodies Used in this 
Chapter. 
Antibody Positive control Negative control Reference 
ATR Ovarian cancer BC tissue Novus Biologicals/ human protein atlas available 
at  http://www.proteinatlas.org/ 
ATM BC tissue BC tissue Abcam/ human protein atlas available at  http://www.proteinatlas.org/ 
CHK1 BC tissue BC tissue [332] 
CHK2 BC tissue BC tissue Abcam/ human protein atlas available at  http://www.proteinatlas.org/ 
ȖH2AX BC tissue BC tissue Abcam/ human protein atlas available at  http://www.proteinatlas.org/ 
Stating of positive and negative controls was performed together in the same run. Negative staining was performed 
without adding the antibody which showed no staining. All were performed on TMA. All these markers have already 
been previously successfully stained on TMA [332-337]. 
 
    
 
3.4.3.3 Immunohistochemistry Scoring   
 
As previously described in Chapter 2 Section 2.1.3.3.  For evaluation of IHC of the 
TMA, a modified histochemical score (H-score) was used [282]. For H-score, both the 
intensity of staining and the percentage of stained cells were considered within each tissue 
core. Staining intensity was scored as 0, 1, 2 or 3 for negative, weak, moderate and strong, 
respectively. The proportion (percentage) of positive cells for each intensity was subjectively 
estimated. Multiplication of the two indices (intensity and percentage positive cells) provided 
final scores that range from 0 to 300.  
 
The author re-scored each marker with at least 30% of a randomly chosen subset of 
cases. A statistical agreement test was performed (Kappa value) for each marker, where there 
was good agreement , and an average was taken. If there were discrepancies, the 
highest scoring was taken. Kappa values are summarised in Table 3.2. ATM, ATR, CHK2, 
and CHK1 were scored using light microscopyZKHUHDVȖ+$;were scored visually using 
high-resolution digital images using a web-based interface (Distiller, Slidepath Ltd., Dublin, 
Ireland).  
 
Scoring of ATM, ATR and CHK2 was carried out by Dr Tarek Abdel-Fatah, which 
30% were rescored by the author+RZHYHU&+.DQGȖ+$;ZHUHVFRUHGDQGUH-scored 
by the author (100%, 30% of the cases were rescored respectively). 
 
Table 3.2 The Statistical Agreement between Different Scoring of Antibodies Used in this 
Chapter. 
Markers Percentage of re-scoring Kappa value 
Ȗ+$;Q 30% 0.83 
Ȗ+$;F 30% 0.86 
CHK1.n 100% 0.69 
CHK1.c 100% 0.6 
CHK2 30% 0.72 
ATR 30% 0.70 
ATM 30% 0.63 
Kappa test was performed on IBM SPSS 21.0 software. An average was taken after re-scoring. 
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3.4.4 Specificity of the Antibodies by Western Blot 
 
As previously described in Chapter 2 Section 2.1.4.4. Western blot was used on all 
markers except ATR. ATR marker was previously stained by a collaborative group who used 
IHC negative and positive controls for this marker (Acknowledgement: Mr Paul Moseley). A 
mixture of different cell lysates to detect only the specificity of an antibody has been applied 
in different studies and showed its reliability [283, 284]. In the present study, ATM, CHK1, 
&+.DQGȖ+$;ZHUHGHWHFWHGLQDPL[WXUHRIGLIIHUHQW lysates (MCF-7, MDA-MB-231, 
HeLa BRCA1 and its control). All the antibodies tested in this chapter share the same 
positive controls which were MCF-7 and HeLa BRCA1 cell lines. The pre-stained marker 
µIXOOUDQJHUDLQERZPDUNHU¶,QYLWURJHQ/LIH7HFKQRORJLHVZDVXVHGDVDPROHFXODUZHLJKW
standard. http://www.proteinatlas.org/ provides profile data for positive controls of all the 
markers used in this study. Table 3.3 summarises the details of W.B for each marker.  
 
Table 3.3 List of Antibodies Tested by Western Blot on a Mixture of Different Cell Lines. 
Antibody Cell lines Specific positive cell lines* 
ATM A mixture of MCF-7, MDA-MB-231, HeLa BRCA1 and its control MCF-7 or  HeLa BRCA1 cell lines 
CHK1 A mixture of MCF-7, MDA-MB-231, HeLa BRCA1 and its control MCF-7 or  HeLa BRCA1 cell lines 
CHK2 A mixture of MCF-7, MDA-MB-231, HeLa BRCA1 and its control MCF-7 or  HeLa BRCA1 cell lines 
Ȗ+$; A mixture of MCF-7, MDA-MB-231, HeLa BRCA1 and its control MCF-7 or  HeLa BRCA1 cell lines 
Cell lines and reagent were obtained from the group of Dr Madhusudan Srinivasan. Thawing and freezing procedures were 
done by Nada Albarakati. Passages, Bradford assay and gel electrophoresis were done by the author. Passages used in W.B 
were as follows; HeLa BRCA1; passages 29&30, HeLa BRCA1 control; passages 15&16, MCF-7; passages 25&26, MDA-
MB-231; passages 15&16. *Data available at  http://www.proteinatlas.org/ 
 
 
3.4.5 Reverse Phase Protein Microarray  
 
RPPA was carried out as previously described in Chapter 2 Section 2.1.5. Cell line 
preparation and protein extraction and interpretation of the results were carried out by the 
author. However, RPPA run and analysis was carried out by Dr Ola Nejm (Immunology, 
School of Life Sciences, University Hospital, Nottingham, UK) as a collaborative project.       
                                                      
 
3.5 Statistical Analysis  
 
All statistical analyses were done by the author using IBM SPSS 21.0 software. For 
all statistical tests, a two-sided P-value of <0.01 was considered statistically significant. 
  
 
3.5.1 The Determination of the Optimal Cut-offs  
 
As described previously in Chapter 2 Section 2.1.6.1. Biomarker expression were 
dichotomised using different approaches: a) using the mean or median of the H-score of the 
staining according to distribution pattern whether normally or not normally distributed, or b) 
using x-tile software (version 3.6.1, 2003-2005, Yale University, USA). If the cut-off by 
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mean or median was very high (e.g H-score >200) then x-tile was considered such as in, 
CHK1, Ȗ+$;$70[286] and ATR. The median for CHK2 was used as cut off. Table 3.4 
shows the details of the antibodies used in this chapter. Details of H-score histograms are 
presented in Appendix 1.  
 
Table 3.4 Sources, Dilution, Cut-offs Point and Pre-Treatment Conditions of the Antibodies 
Used in this Chapter. 
Antibody Clone Source Dilution 
IHC 
Dilution 
W.B 
RPPA 
+Distribution Cut-offs IHC kit 
ATM Ab 
32420 Abcam 
1:100 
overnight 
1:1,000 
1:500 Nuclear [-tile.  Novolink 
ATR 
1E9 Novus Biologicals 
1:20 
overnight 
NT 
1:500 Nuclear 
+-score, 
x-tile. [286] Novolink 
CHK1(Phospho 
S345) 
Ab58567 Abcam 1:150 1h 1:1,000 1:6,000 Nuclear/cytoplasmic 
1XFOHDU0 
H-score, 
Cytoplasm 
+-score, 
x-tile. 
Novolink 
CHK2 
Ab 
47433 Abcam 1:100 1h 
1:500 
1:6,000 Nuclear 
+-
score, 
median. 
Novolink 
Ȗ+$; 
(phospho S139) 
 Ab22551 Abcam 1:600 1h 1:2,000 1:1,000 Nuclear/cytoplasmic 
1XFOHDU
H-score 
Cytoplasm 
+-
score, x-tile. 
Novolink 
IHC= immunohistochemistry. W.B= western blotting. NT= not tested. All the antibodies were pre-treated in citrate antigen 
retrieval pH=6.0 in microwave for 20 minutes and stained on TMA. CHK1, CHK2, DQGȖ+$;ZHUHLQFXEDWHGDWURRP
temperature for 1 hour, whereas ATR and ATR were incubated at 4oC overnight. + Cellular localisation.  
 
 
3.5.2 Univariate Analysis with Clinico-Pathological al Parameters and Tumour Markers  
 
The differences between all markers, with regards to clinico-pathological features, or 
with other tumour markers were analysed using the Pearson Chi-Squared test (x2). 
Consequently, x2 was also used in order to examine the inter-relations between markers 
themselves. In addition analysis of continuous variables was performed using the appropriate 
statistical test 3HDUVRQ¶V FRUUHODWLRQ and ANOVA. One way ANOVA was used to find out 
which of different BC classes (by IHC or RPPA) were significantly different from each other 
(post hoc test; Tukey).  
 
 
3.5.3 Univariate Analysis with 3DWLHQWV¶Outcome  
 
Patients who were alive or those who died for any reason other than BC were not 
included. The Kaplan-Meier method was used to generate a univariate survival curve and the 
differences in survival among the biomarkers were evaluated using the log-rank test.  
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3.5.4 Multivariate Analysis with PDWLHQWV¶Outcome  
 
If a marker in XQLYDULDWHDQDO\VLVZDVVWDWLVWLFDOO\VLJQLILFDQWZLWKSDWLHQW¶VRXWFRPH
then Cox regression was applied for multivariate analyses to test for confounders and 
prognostic or predictive independency of the investigated biomarker from standard 
prognostic/predictive factors such as tumour grade, tumour stage, and tumour size.    
 
 
3.6 Results 
 
3.6.1 Expression of DNA Damage Sensors and Signal Transducers Proteins in Invasive 
Breast Cancer  
 
Western blotting validated the specificity of some antibodies in the DNA damage 
sensors pathway, this was deemed to be validated by a single band at the correct protein size 
(see Figure 3.2).  In invasive tumours, CHK2, ATM and ATR showed nuclear (n) staining, 
whereas Ȗ+$; DQG &+. VKRZHG ERWK QXFOHDU DQG F\WRSODVPLF (c) staining. Although 
&+. DQG Ȗ+$; DUH mainly localised in the nucleus, cytoplasm expression has been 
mentioned previously [338-340]. Figures 3.3 and 3.4 show the immunostaining expression of 
DNA damage sensors and signal transducers proteins. Table 3.5 outlines the frequencies of 
DNA damage sensors and signal transducers proteins in sporadic and known BRCA1 
germline mutations BCs (hereditary), while Figure 3.5 represents the distribution (mean) of 
these proteins in the different classes of BC by IHC. The 4 classes included were classified 
based on BRCA1 and ER proteins expression. Class 1; sporadic BRCA1 negative and ER 
negative, class 2; sporadic BRCA1 positive and ER positive, class 3; known BRCA1 germline 
mutation BC that showing ER negativity and finally class 4; known BRCA1 germline 
mutation BC and showing ER positivity.  
 
$70 &+. &+.Q DQG Ȗ+$;Q VWDLQLQJ VKRZHG VWURQJHU H[SUHVVLRQ LQ
sporadic ER+ cancers than sporadic ER- or known BRCA1 germline mutations showing ER-. 
In contrast, ATR protein was higher in known BRCA1 germline mutations regardless of ER 
status than sporadic BRCA1/ER tumours. In contrast, CHK1.c showed lower expression in 
sporadic ER/BRCA1 tumours (regardless of ER status) than sporadic BC Ȗ+$;F
expression was almost similar among the classes (Figure 3.5). There was a strong difference 
between sporadic BRCA1-/ER- and sporadic BRCA1+/ER+ among CHK2, CHK1.n, ATM, 
DQGȖ+$;QDOO3<0.0001, Figure 3.5). In addition a strong statistical difference was seen 
between sporadic BRCA1-/ER- and hereditary BC showing ER- among CHK1.c and ATR ( 
P<0.0001, and P=0.006 respectively, Figure 3.5).  However, only CHK1.c showed a 
statistical difference between sporadic ER-/ BRCA1- and hereditary BC showing ER+ 
(P<0.0001, Figure 3.5). Sporadic ER+/ BRCA1+ vs. Hereditary ER- was significantly different 
among CHK1.n (P<0.0001, Figure 3.5), CHK1.c (P<0.0001), ATM (P<0.0001), ATR 
3 &+.3 DQGȖ+$;Q3  (all Figure 3.5). Only CHK1.c showed 
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a significant association between sporadic ER+ BRCA1+ vs. hereditary BC showing ER+ 
(P=0.0003). 
 
The large error bars of Figure 3.5 is expected, the mean of H-score does not explain 
repeated observation, it shows the distribution of different cases share ER and BRCA1 status 
but with  other factors such as grade, stage and size of the tumour which may have some 
effects on the expression of the markers. 
 
 
 
 
 
 
  
Figure 3.2 Detection of DNA damage sensors and signal transducers proteins level by Western blot in a 
mixture of cell lines, MDA-MB-231, MCF-7, HeLa BRCA1 and its control. The predicted size of each 
protein is labelled on the band. Passages used in W.B were as follows; HeLa BRCA1; passages29&30, 
HeLa BRCA1 control; passages 15&16, MCF-7; passages 25&26, and MDA-MB-231; passages 15&16. 
     CHK1    CHK2    ATM   Ȗ+$; 
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Figure 3.3 Expressions of ATR and ATM on TMA. a; a negative control for ATR in invasive ductal carcinoma of 
no special type stage 1 and grade 3 breast cancer. b; a positive control for ATR (nuclear expression) in ovarian 
cancer. c;  nuclear expression of ATR in  known BRCA1 germline mutation, (stage data is missing) grade 3 ductal 
invasive carcinoma of no special type breast cancer. d; a negative control for ATM in invasive ductal carcinoma of 
no special type; stage 1 and grade 2. e; nuclear expression of ATM in lobular mixed breast cancer; stage 2 and 
grade 2 which is also a positive control for ATM. Magnification x20. 
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Table 3.5 Frequencies of DNA Damage Sensors and Signal Transducers Proteins Expression 
in Breast Cancer. 
Markers Sporadic BC Known BRCA1 germline mutation BC (%) Frequency (%) Frequency 
CHK1  
Nuclear 26.9 355/1322 5.3 1/19 
Cytoplasmic 89.6 1183/1322 63.2 17/19 
CHK2 50.9 543/1066 0 0/24 
ATM 45.7 636/1392 8.3 2/24 
ATR 44 566/1285 73.9 17/23 
Ȗ+$;  
Nuclear 87.6 1137/1299 89.5 17/19 
Cytoplasmic 88.9 1155/1299 84.2 16/19 
Sporadic BC includes both unselected and ER-negative BC cases.  The number of cases may be reduced due to loss of cases during 
preparation of tissue for staining (TMA sectioning or IHC procedure). 
Figure 3.4 ([SUHVVLRQRIȖ+$;&+.DQG&+.SURWHLQVE\,+&:KHUHDDQHJDWLYHFRQWUROIRUȖ+$;LQ
LQYDVLYH GXFWDO EUHDVW FDUFLQRPD RI QR VSHFLDO W\SH JUDGH DQG VWDJH  E Ȗ+$; QXFOHDU DQG F\WRSODVPLF
expression in invasive ductal carcinoma of no special type; grade 1 and stage 1. c; a negative control for CHK1 in 
invasive ductal breast carcinoma of no special type; grade 2 and stage 1. d; CHK1 nuclear and cytoplasmic 
expression in invasive ductal carcinoma of no special type;  grade 2 and stage 1. e; a negative control for CHK2 in 
invasive ductal breast carcinoma of no special type; grade3 and stage 1.f; nuclear expression of CHK2 in  known 
BRCA1 germline mutation, invasive ductal breast carcinoma of no special type; grade 3 (data for stage is missing). 
Ȗ+AX, CHK1, and CHK2 used breast cancer as a positive control. Magnification x20. 
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Figure 3.5 DNA damage sensor and signal transducers protein levels detected by IHC on TMA. Each bar represents 
different class based on hereditary or sporadic BRCA1 and ER status. Where n. is nuclear expression and c. is 
cytoplasmic expression. Error bars represent Mean (SD) and was created on H-score (ranges 0-300).  A= sporadic cases 
[ER- & BRCA1-] vs. sporadic cases [ER+ & BRCA1+], B= sporadic cases [ER- & BRCA1-] vs. Hereditary cases [ER-], 
C= sporadic cases [ER- & BRCA1-]vs. Hereditary cases [ER+], D= sporadic cases [ER+ & BRCA1+]vs. Hereditary cases 
[ER-], E= sporadic cases [ER+ & BRCA1+] vs. Hereditary cases [ER+], and F= Hereditary cases [ER-] vs. Hereditary 
cases [ER+].  One way ANOVA test was used for each marker within the classes. 
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  3.6.2 Correlation of DNA Damage Sensors and Signal Transducers Proteins 
 
The associations between co-expression of cellular localisation of DNA damage 
sensors and signal transducers proteins are summarised in Table 3.6 (Pearson X2). 
Ȗ+$;Q+.c+ showed a high negative association with CHK1.n and positive associations with 
CHK1.c and CHK2 (all P<0.0001). CHK1n-.c+ had an association with both ATM and ATR; 
3 DQG 3  UHVSHFWLYHO\  $75 VKRZHG D QHJDWLYH DVVRFLDWLRQ ZLWK Ȗ+$;Q
(P=0.007). CHK2 showed a direct association with ATM (P=0.002), and ATR (P=0.004). 
Significant and non-significant correlations of DNA-damage sensors and signal transducers 
proteins are detailed in Appendix1.  
 
Table 3.6 The Correlation between Co-expression of Cellular Localisation of DNA Damage 
Sensors and Signal Transducers Proteins. 
Ȗ+$; 
Parameters 
 
c- n- 
N (%) 
c+ n+ 
N (%) 
c+ n- 
N (%) 
c- n+ 
N (%) X
2
 
P 
CHK1.n Negative 11(84.6) 496(76.5) 83(84.7) 47(58) 19 <0.0001 Positive 2(15.4) 152(23.5) 15(15.3) 34(42) 
CHK1.c Negative 6(46.2) 47(7.3) 10(10.2) 16(19.8) 34 <0.0001 Positive 7(53.8) 600(92.7) 88(89.8) 65(80.2) 
CHK2 Negative 7(63.6) 274(45.4) 63(84) 35(50) 41 <0.0001 Positive 4(36.4) 330(54.6) 12(16) 35(50) 
CHK1 
Parameters 
 
c- n- 
N (%) 
c+ n+ 
N (%) 
c+ n- 
N (%) 
c- n+ 
N (%) X
2
 
P 
ATM Negative 26(66.7) 80 (40.4) 368 (59.8) 19 (47.5) 26 <0.0001 Positive 13(33.3) 118 (59.6) 247 (40.2) 21 (52.5) 
ATR Negative 26 (45.6) 109(67.3) 264(50.6) 19(51.4) 16 0.001 
 Positive 31(54.4) 53(32.7) 258(49.4) 18(48.6) 
ATR 
Parameters 
 
Negative 
N (%) 
Positive 
N (%) X
2
 
P 
Ȗ+$;Q Negative 66(13.4) 37(8) 7 0.007 Positive 427(86.6) 425(92) 
CHK2 
Parameters 
 
Negative 
N (%) 
Positive 
N (%) X
2 P 
ATM Negative 203(59.9) 147(47.6) 10 0.002 Positive 136(40.1) 162(52.4) 
ATR Negative 257(57.1) 219(47.6) 8 0.004 Positive 193(42.9) 241(52.4) 
N= number of cases. c. = cytoplasmic, n. = nuclear expression. The FXWRIISRLQWVRISRVLWLYLW\ZHUHDVIROORZV+-score for CHK1.n 
DQG+-VFRUHIRU&+.F+-VFRUHIRU&+.IRU$70+-score or ATR. This table shows the co-expression of 
FHOOXODUORFDOLVDWLRQRIȖ+$;DQG&+. 
 
3.6.3 Correlation of DNA Damage Sensors and Signal Transducers Proteins with Other 
Tumour Markers 
 
The correlations between categorical (Pearson X2) DNA damage sensors and signal 
transducers proteins and other tumour biomarkers (regarding co-expression of cellular 
localisDWLRQRI&+.DQGȖ+$;DUe summarised in Tables 3.7a-b. In addition, Table 3.8 
showed similar correlation but using FRQWLQXRXV GDWD 3HDUVRQ¶V FRUUHODWLRQ). Some 
correlations between categorical and continuous data were different therefore, only these 
categorical correlations were re-analysed, but regardless co-expression of cellular 
localisation, in order to compare each cellular localisation separately (Table 3.9).  
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In regards to hormone receptors, there was a highly significant association between 
ER- with; ATM-, CHK1n-.c+ DQGȖ+$;n+.c+; all P<0.0001 and CHK2; P=0.007, in addition 
PgR- ZLWK$70&+.DQGȖ+$;DOO3, Tables 3.7a-b) and finally TN tumours 
with; ATM, &+. DQG Ȗ+$; DOO 3, Tables 3.7a-b. Only CHK1 showed a 
significant negative association with HER-2 (P=0.005, Tables 3.7b).  
 
There was a highly significant association between the DNA damage sensors and 
signal transducers proteins (except CHK2) and at least one of the basal cytokeratins (CK5 or 
CK17) or with BLBC, as defined by the negative expression of ER, PgR and HER-2 in 
addition to the positive expression of the basal CKs (CK5, CK17, and CK14).  CHK1 and 
Ȗ+$;ZLWK%/%&both P<0.0001 and ATM; P=0.002, (Tables 3.7a-b).  ATR with CK17; 
P=0.001, CHK1 with CK5; P=0.001 DQGȖ+$;ZLWK&.3, Tables 3.7a-b). There 
ZDV D KLJK VLJQLILFDQW DVVRFLDWLRQ EHWZHHQ Ȗ+$;Q+.c+ (P=0.001), CHK1n-.c+ (P=0.001), 
and CHK2- (P<0.0001) with PTEN- (Tables 3.7a-b), but not with ATM or ATR. Significant 
and non-significant correlations of DNA-damage sensors and signal transducers proteins are 
detailed in Appendix1.  
 
Table 3.8 (3HDUVRQ¶V FRUUHODWLRQ) shows the correlation on continuous data of DNA 
damage sensors and signal transducers proteins with other tumour markers. Regression 
analysis of continuous data (Table 3.8) confirmed the categorical data (Tables 3.7 and 3.9). 
However, when Ȗ+$;.c was analysed as a continuous variable, some correlations showed 
different results. Ȗ+$;F KDG D significant correlation with CHK1.n, PgR and ER in 
categorical data, P=0.001, P=0.001 and P<0.0001 respectively, Table 3.9), while the 
correlation lost significance in continuous data (P=0.2, P=0.5 and P=0.1 respectively, Table 
3.8). Similarly was seen between CHK1.c and PgR (categorical; P<0.0001, and continuous; 
P=0.26, Tables 3.9 and 3.8 respectively), whereas, continuous analysis increased the 
significance of the correlation between CHK1.n and CK5 (categorical; P=0.2, and 
continuous; P=0.008, Tables 3.9 and 3.8). 
 
Table 3.7a The Correlation between Co-expression of Cellular Localisation RIȖ+$;ZLWK
other Tumour Markers. 
Ȗ+$; 
Parameters 
 
c- n- 
N (%) 
c+ n+ 
N (%) 
c+ n- 
N (%) 
c- n+ 
N (%) X
2
 
P 
ER Negative 9(52.9) 426(43) 91(67.4) 30(24.8) 49 <0.0001 Positive 8(47.1) 564(57) 44(32.6) 91(75.2) 
PgR Negative 14(73.7) 509(54.1) 101(75.4) 41(35.7) 43 <0.0001 Positive 5(26.3) 432(45.9) 33(24.6) 74(64.3) 
TN Negative 10(55.6) 690(72) 61(45.9) 97(84.3) 52 <0.0001 Positive 8(44.4) 268(28) 72(54.1) 18(15.7) 
CK5 Negative 9(75) 560(76) 62(55.4) 74(83.1) 26 <0.0001 Positive 3(25) 117(24) 50(44.6) 15(16.9) 
BLBC Negative 9(64.3) 674(78) 63(53.4) 95(86.4) 42.5 <0.0001 Positive 5(35.7) 190(22) 55(46.6) 15(13.6) 
Ki-67 Negative 6(40) 287(32.8) 21(17.4) 56(52.8) 32.5 <0.0001 Positive 9(60) 588(67.2) 100(82.6) 50(47.2) 
PTEN Negative 10 (100) 423 (79.7) 64 (94.1) 43 (69.4) 15.6 
 
0.001 Positive 0 108 (20.3) 4 (5.9) 19 (30.6) 
N= number of cases. c. = cytoplasmic, n. = nuclear expression. The cut off points are presented in the next table. This table shows the co-
H[SUHVVLRQRIFHOOXODUORFDOLVDWLRQRIȖ+$; 
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Table 3.7b The Correlation between DNA Damage Sensors and Signal Transducers Proteins 
with other Tumour Markers. 
CHK1 
 
Markers c
- n- 
N (%) 
c+ n+ 
N (%) 
c+ n- 
N (%) 
c- n+ 
N (%) X
2
 
P 
ER 
Negative 16(21.9) 100(35.6
) 
397(46) 11(18.6) 
35 <0.0001 
Positive 57(78.1) 181(64.4
) 
466(54) 48(81.4) 
PgR 
Negative 28(73.3) 119(44.9
) 
467(56.3) 19(33.3) 
26 <0.0001 
Positive 47(62.7) 146(55.1
) 
362(43.7) 38(66.7) 
TN 
Negative 62(86.1) 213(78.6
) 
581(69.2) 49(84.5) 
20 <0.0001 
Positive 10(13.9) 58(21.4) 258(30.8) 9(15.5) 
HER-2 
Negative 66(93) 241(86.1
) 
703(82) 55(94.8) 
13 0.005 
Positive 5(7) 39(13.9) 154(18) 3(5.2) 
CK5 Negative 
48(92.3) 159(75.4
) 
543(72.7) 39(92.9) 
17.5 0.001 
Positive 4(7.7) 52(24.6) 204(27.3) 3(7.1) 
BLBC Negative 
56(90.3) 207(81.2
) 
582(74.8) 51(96.2) 
22 <0.0001 
Positive 6(9.7) 48(18.8) 196(25.2) 2(3.8) 
P53 Negative 
58(81.7) 175(63.6
) 
516(61) 46(79.3) 
19 <0.0001 
Positive 13(18.3) 100(36.4
) 
330(39) 12(20.7) 
Ki-67 
Negative 32(51.6) 95(39.4) 240(31.9) 29(55.8) 
22 <0.0001 
Positive 30(48.4) 146(60.6
) 
513(68.1) 23(44.2) 
PTEN 
Negative 36 (83.7) 99 (79.8) 359 (82.7) 11 (47.8) 
17.5 0.001 
Positive 7 (16.3) 25 (20.2) 75 (17.3) 12 (52.2) 
ATM 
Markers Negative N (%) 
Positive 
N (%) X
2 P 
ER 
Negative 362 (49.3) 221 (34.9) 
29 <0.0001 
Positive 372 (50.7) 413 (65.1) 
PgR 
Negative 415 (58.7) 265 (44.1) 
27.7 <0.0001 
Positive 292 (41.3) 336 (55.9) 
TN 
Negative 475 (66.5) 485 (78.9) 
25 <0.0001 
Positive 239 (33.5) 130 (21.1) 
BLBC Negative 
478 (74.9) 456 (82.2) 
9 0.002 
Positive 160 (25.1) 99 (17.8) 
Ki-67 
Negative 221 (34.7) 233 (43.8) 
10 0.001 
Positive 416 (65.3) 299(56.2) 
ATR 
Markers Negative N (%) 
Positive 
N (%) X
2
 
P 
CK17 
 
Negative 425(89.9) 314(81.8) 
12 0.001 
Positive 48(10.1) 70(18.2) 
Ki-67 
Negative 278(51.1) 151(31.8) 
39 <0.0001 
Positive 266(48.9) 324(68.2) 
CHK2 
Markers Negative N (%) 
Positive 
N (%) X
2
 
P 
ER Negative 169(33.6) 135(25.9) 7 0.007 Positive 334(66.4) 386(74.1) 
PTEN Negative 328 (89.1) 226 (72.4) 31 <0.0001 Positive 40 (10.9) 86 (27.6) 
N= number of cases. c = cytoplasmic, n = nuclear expression. The cut off points of positivity were the same as previously published [273], 
DQGZHUHDVIROORZVIRU(5DQG35RI+HUFHS7HVWIRU+(5IRU&.!IRUKi-67+-score for CHK1.n and 
+-VFRUH IRU &+.F DQG  IRU 3 71  7ULSOH QHJDWLYH (5 3J5 DQG +(5-2). Basal Like BC (BLBC) as defined by Triple 
QHJDWLYHSRVLWLYHH[SUHVVLRQRI&.DQG&.DQG&.37(1+-score. This table shows the co-expression of cellular localisation 
of CHK1. 
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Table 3.8 3HDUVRQ¶V FRUUHODWLRQV EHWZHHQ '1$ 'DPDJH 6HQVRUs and Signal Transducers 
Proteins with other Tumour Markers. 
Markers CHK1.c CHK1.n CHK2 ATR ATM Ȗ+$;F Ȗ+$;Q 
CHK1.n 
 
R -0.100 
* 
0.171 -0.053 0.125 -0.042 0.155 
P <0.0001 <0.0001 0.138 <0.0001 0.222 <0.0001 
N 1321 665 779 892 839 839 
CHK2 
 
R 0.053 0.171 
* 
0.112 0.107 0.016 0.354 
P 0.171 <0.0001 0.001 0.006 0.665 <0.0001 
N 665 665 912 648 760 760 
ATR 
 
R -0.016 -0.053 0.112 
* 
-0.021 0.084 0.116 
P 0.654 0.138 0.001 0.549 0.009 <0.0001 
N 779 779 912 789 955 955 
ATM 
 
R 0.013 0.125 0.107 -0.021 
* 
0.039 0.180 
P 0.700 <0.0001 0.006 0.549 0.257 <0.0001 
N 892 892 648 789 866 866 
Ȗ+$;F 
 
R 0.195 -0.042 0.016 0.084 0.039 
* 
0.250 
P <0.0001 0.222 0.665 0.009 0.257 <0.0001 
N 839 839 760 955 866 1298 
Ȗ+$;Q 
 
R 0.114 0.155 0.354 0.116 0.180 0.250 
* P 0.001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
N 839 839 760 955 866 1298 
PgR 
 
R -0.035 0.088 0.139 -0.016 0.125 -0.021 0.173 
P 0.260 0.005 <0.0001 0.571 <0.0001 0.515 <0.0001 
N 1015 1015 1003 1197 1059 959 959 
ER 
 
R -0.087 0.133 0.168 0.040 0.156 -0.049 0.239 
P 0.005 <0.0001 <0.0001 0.164 <0.0001 0.127 <0.0001 
N 1025 1025 1019 1218 1079 967 967 
Ki-67 
 
R 0.119 -0.128 -0.098 0.191 -0.077 0.105 -0.249 
P <0.0001 <0.0001 0.004 <0.0001 0.009 <0.0001 <0.0001 
N 1108 1108 860 1019 1169 1117 1117 
P53 
 
R 0.095 -0.054 -0.016 0.019 -0.053 -0.023 -0.117 
P 0.002 0.083 0.623 0.508 0.079 0.466 <0.0001 
N 1014 1014 1005 1203 1087 965 965 
CK5 
 
R 0.114 -0.090 -0.045 -0.011 -0.048 0.054 -0.131 
P 0.001 0.008 0.200 0.744 0.169 0.134 <0.0001 
N 858 858 805 939 809 768 768 
CK17 
 
R 0.077 -0.060 -0.011 0.112 0.008 0.031 0.003 
P 0.013 0.056 0.768 0.001 0.806 0.336 0.926 
N 1026 1026 748 857 979 952 952 
PTEN 
R -0.105 0.201 0.249 -0.016 0.003 -0.048 0.240 
P 0.008 <0.0001 <0.0001 0.641 0.944 0.214 <0.0001 
N 624 624 680 816 588 671 671 
7KH WDEOH UHSUHVHQWV FRQWLQXRXV GDWD IRU DOO WKH PDUNHUV 1  QXPEHU RI FDVHV 5  3HDUVRQ¶V FRUUHODWLRQ P=Probability value. c. = 
cytoplasmic, n. = nuclear expression. * Analysis between the marker itself. 
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Table 3.9 Correlation between DNA Damage Sensors and Signal Transducers Proteins with 
other Tumour Markers Regardless Co-expression of Cellular Localisation. 
ȖH2AX.c 
Markers Negative N (%) 
Positive 
N (%) 
P-value 
X2 
 
CHK1.n Negative 
58 (61.7) 580 (77.6) 0.001 
11.5 Positive 36 (38.3) 167 (22.4) 
CHK1.c Negative 
22 (23.4) 57 (7.6) <0.0001 
24 Positive 72 (76.6) 689 (92.4) 
PgR 
Markers Negative N (%) 
Positive 
N (%) 
P-value 
X2 
 
CHK1.c 
Negative 47 (7.4) 85 (14.3) <0.0001 
15 Positive 586 (92.6) 508 (85.7) 
CHK1.n Negative 
495 (78.1) 409 (69) <0.0001 
13 Positive 139 (21.9) 184 (31) 
ȖH2AX.c Negative 55 (8.3) 79 (14.5) 0.001 12 Positive 611 (91.7) 465 (85.5) 
ȖH2AX.n Negative 115 (17.3) 38(7) <0.0001 28.7 Positive 550(82.7) 506 (93) 
P53 
Markers Negative N (%) 
Positive 
N (%) 
P-value 
X2 
 
CHK1.n Negative 
574 (72.1) 343 (75.4) 0.2 
1.5 Positive 222 (27.9) 112 (24.6) 
CHK1.c 
Negative 104 (13.1) 25 (5.5) <0.0001 
18 Positive 691 (86.9) 430 (94.5) 
ER 
Markers Negative N (%) 
Positive 
N (%) 
P-value 
X2 
 ȖH2AX.n Negative 100(18) 52 (7.4) <0.0001 33 Positive 456 (82) 655 (92.6) 
ȖH2AX.c Negative 39 (7) 99 (14) <0.0001 15.7 Positive 518 (93) 608 (86) 
CK5 
Markers Negative N (%) 
Positive 
N (%) 
P-value 
X2 
 
ȖH2AX.c Negative 83 (11.8) 18 (7.3) 0.05 4 Positive 622 (88.2) 228 (92.7) 
ȖH2AX.n Negative 71 (10.1) 53 (21.6) <0.0001 21 Positive 634 (89.9) 192 (78.4) 
CHK1.n Negative 
591 (74.9) 208 (78.8) 0.2 
1.6 
 
Positive 198 (25.1) 56 (21.2) 
CHK1.c 
Negative 87 (11) 7 (2.7) <0.0001 
17 Positive 702 (89) 256 (97.3) 
PTEN 
 
Markers Negative N (%) 
Positive 
N (%) 
P-value 
X2 
 ȖH2AX.n Negative 74 (13.7) 4 (3.1) 0.001 11.6 Positive 466 (86.3) 127 (96.9) 
ȖH2AX.c Negative 53 (9.8) 19 (14.5) 
 
0.1 
2 Positive 487 (90.2) 112 (85.5) 
N= number of cases. c. = cytoplasmic, n. = nuclear expression.  This tabled does not consider co-expression of subcellular localisation. 
Because there was a difference in the correlations between Table 3.7 (co-expression of cellular localisation; categorical data) and Table 
3.8 (continuous data), therefore, these correlations were re-analysed but regardless co-expression of nuclear and cytoplasmic expression, 
in order to compare each cellular localisation separately.  
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3.6.4 Correlation of DNA Damage Sensors and Signal Transducers Proteins with 
Clinico-Pathological Features 
 
Table 3.10 summarises the association between the DNA damage sensors and signal 
transducers proteins &+. &+. $70 $75 DQG Ȗ+$; DQG WKH YDULRXV FOLQLFR-
pathological features (Pearson X2). The majority of tumours with poor prognostic features, 
such as high tumour grade, tubule formation, large tumour size, high mitotic frequency and 
higher nuclear pleomorphism, were associated with low levels of ATM (all P<0.0001, except 
tumour size P=0.002), ATR (all P<0.0001, except tubular formation;  P=0.002 and tumour 
size; P=0.005) and CHK1.n-.c+ (P<0.0001, P=0.01, P=0.008, P<0.0001, and P<0.0001 
respectively). In contrast, CHK2 was not associated with any of the clinico-pathological 
features.  
 
  7KH GRXEOH SRVLWLYH H[SUHVVLRQ RI Ȗ+$; LUUHVSHFWLYH RI FHOOXODU ORFDOLVDWLRQ
showed a significant positive association with all these poor clinico-pathological features (all 
P<0.0001 except tumour size P=0.002). All DNA damage sensors and signal transducers 
proteins except CHK2 were highly associated with the moderate I NPI (all P<0.0001). Only 
ATM- (P=0.002) and ATR- (P<0.0001) showed a significant association with stage 1 
WXPRXUVȖ+$;&+.$TM, and ATR, were highly associated with tumour type (invasive 
ductal/ no special type P<0.0001 all). Details for significant and non-signification 
correlations are detailed in Appendix 1.  
 
The high value of X 2 can be referred to, a) a bias in the patients¶SRSXODWLRQ, b) after 
statistical advise and checking the data, it does not seem to have any assumption issues, the 
main problem is generally when one of the values of expectation is five or less, but however, 
in the results presented here a large chi squared value is resulted when the expectations are 
not less than five.  However, the data just seem to show that it is very likely that the 
association is not due to chance. 
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Table 3.10 Relationship between DNA Damage Sensors and Signal Transducers Proteins 
with Clinico-Pathological Features. 
Parameters 
Ȗ+$; 
c- n- 
N (%) 
c+ n+ 
N (%) 
c+ n- 
N (%) 
c- n+ 
N (%) X
2
 
P 
Size FP 4(22.2) 292(29.1) 25(18.2) 48(39.3) 14 0.002 
>1.5cm 14(77.8) 713(70.9) 112(81.8) 74(60.7) 
Grade 
1 1(5) 118(11.7) 4(2.9) 13(10.6) 
 
58 
 
<0.0001 2 4(20) 267(26.4) 14(10) 54(43.9) 
3 15(75) 626(61.9) 122(87.1) 56(45.5) 
Tubules 
1 0 39(3.9) 0 6(4.9) 
 
27.5 
 
<0.0001 2 4(21.1) 305(30.5) 19(13.9) 29(23.8) 
3 15(78.9) 657(65.5) 118(86.1) 87(71.3) 
Pleomorphism 
1 0 15(1.5) 1(0.7) 2(1.6) 
 
48 
 
<0.0001 2 7(36.8) 270(27) 13(9.5) 57(46.7) 
3 12(63.2) 715(71.5) 123(89.8) 63(51.6) 
Mitosis 
1 1(5.3) 264(26.4) 7(5.1) 49(40.2) 
 
64.5 
 
<0.0001 2 5(26.3) 180(18) 16(11.7) 25(20.5) 
3 13(68.4) 557(55.6) 114(83.2) 48(39.3) 
NPI 
Excellent 1(6.7) 72(7.2) 2(1.4) 9(7.3) 
 
 
47.5 
 
 
<0.0001 
Good 1(6.7) 152(15.2) 4(2.9) 30(24.4) 
Moderate I 8(53.3) 319(31.8) 50(35.7) 44(35.8) 
Moderate II 3(20) 276(27.5) 47(33.6) 26(21.1) 
Poor 1(6.7) 131(13.1) 31(22.1) 11(8.9) 
Very Poor 1(6.7) 52(5.2) 6(4.3) 3(2.4) 
Tumour Type 
Invasive Ductal/NST 15(78.9) 699(69.8) 106(76.8) 69(58) 
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<0.0001 
lobular 1(5.3) 24(2.4) 4(2.9) 20(16.8) 
Atypical Medullary 0 22(2.2) 12(8.7) 2(1.7) 
*Mixed 3(15.8) 221(22.1) 14(10.1) 25(21) 
**other 0 35(3.5) 2(1.4) 3(2.5) 
N= number of cases. c. = cytoplasmic, n. = nuclear expression. *Lobular or tubular mixed BCs. **Mucinous, Alveolar Lobular, Miscellaneous 
including Metaplastic, Adenoid Cystic, Spindle, and Tubulolobular. NST= no special type. NPI= Nottingham Prognostic Index. Excellent NPI (2.08±
2.4), good NPI (2.42 to င3.4), a moderate prognostic I NPI (3.42 to င4.4), moderate prognostic II NPI (4.42 to င5.4), poor NPI (5.42 to င6.4), and a 
very poor NPI (6.5±6.8). Co-expression of cellular localisation RIȖ+$; was considered in this table. 
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Table 3.10 Relationship between DNA Damage Sensors and Signal Transducers Proteins 
with Clinico-Pathological Features Continued. 
CHK1 
Parameters c
- n- 
N (%) 
c+ n+ 
N (%) 
c+ n- 
N (%) 
c- n+ 
N (%) X
2
 P 
Size FP 31(40.3) 111(37.9) 257(29.3) 24(40.7) 12 0.008 
>1.5cm 46(59.7) 182(62.1) 620(70.7) 35(59.3) 
Grade 
1 14(18.2) 60(20.4) 84(9.5) 12(20.3) 
59 <0.0001 2 33(42.9) 83(28.2) 237(26.8) 29(49.2) 
3 30(39) 151(51.4) 563(63.7) 18(30.5) 
Tubules 
1 3(4.1) 19(6.8) 27(3.1) 3(5.1) 
16 0.01 2 28(38.4) 97(34.5) 241(28) 18(30.5) 
3 42(57.5) 165(58.7) 593(68.9) 38(64.4) 
Pleomorphism 
1 2(2.7) 9(3.2) 5(0.6) 3(5.1) 
77 <0.0001 2 40(54.8) 112(40) 214(24.9) 30(50.8) 
3 31(42.5) 159(56.8) 641(74.5) 26(44.1) 
Mitosis 
1 28(38.4) 90(32) 214(24.9) 34(57.6) 
39 <0.0001 2 14(19.2) 58(20.6) 156(18.1) 6(10.2) 
3 31(42.5) 133(47.3) 491(57) 19(32.2) 
NPI 
Excellent 8(10.5) 42(14.4) 55(6.3) 9(15.3) 
57 <0.0001 
Good 18(23.7) 57(19.6) 119(13.6) 15(25.4) 
Moderate I 27(35.5) 95(32.6) 276(31.4) 18(30.5) 
Moderate II 10(13.2) 59(20.3) 262(29.8) 10(16.9) 
Poor 11(14.5) 24(8.2) 122(13.9) 7(11.9) 
Very Poor 2(2.6) 14(4.8) 44(5) 0 
Tumour Type 
Invasive Ductal/NST 39(52) 165(57.1) 630(72) 17(29.3) 
85 <0.0001 
lobular 7(9.3) 15(5.2) 40(4.6) 12(20.7) 
Atypical Medullary 2(2.7) 7(2.4) 21(2.4) 2(3.4) 
*Mixed 22(29.3) 84(29.1) 165(18.9) 25(43.1) 
**other 5(6.7) 18(6.2) 19(2.2) 2(3.4) 
Parameters 
ATM ATR 
Negative 
N (%) 
Positive 
N (%) X
2
 
P Negative N (%) 
Positive 
N (%) X
2 P 
Size FP 222(29.9) 241 (38) 10 0.002 245(34.2) 151(26.9) 8 0.005 
>1.5cm 520(70.1) 393 (62) 471(65.8) 410(73.1) 
Stage 
1 444(59.7) 441(68.7) 
12.5 0.002 
479(66.9) 314(56) 
17 <0.0001 2 224(30.1) 155(24.1) 185(25.8) 185(33) 
3 76 (10.2) 46 (7.2) 52(7.3) 62(11.1) 
Grade 
1 61 (8.2) 135 (21) 
55.3 <0.0001 
152(21.2) 56(10) 
40 <0.0001 2 195(26.2) 186(28.9) 235(32.8) 163(29.1) 
3 489(65.6) 322(50.1) 329(45.9) 342(61) 
Tubules 
1 32 (4.4) 37 (5.9) 
30 <0.0001 
56(8.2) 19(3.4) 
13 0.002 2 170(23.2) 225(35.7) 216(31.7) 185(33) 
3 532(72.5) 369(58.5) 410(60.1) 357(63.6) 
Pleomorphism 
1 11 (1.5) 20(3.2) 
31 <0.0001 
24(3.5) 4(0.7) 
29 <0.0001 2 187(25.5) 239(38) 281(41.5) 174(31) 
3 535 (73) 370(58.8) 372(54.9) 383(68.3) 
Mitosis 
1 168(22.9) 240 (38) 
40.5 <0.0001 
269(39.4) 144(25.7) 
28 <0.0001 2 129(17.6) 110(17.4) 119(17.4) 103(18.4) 
3 437(59.5) 281(44.5) 294(43.1) 314(56) 
NPI 
Excellent 49(6.6) 95(15) 
56 <0.0001 
105(14.7) 35(6.4) 
57 <0.0001 
Good 101(13.7) 114(18) 139(19.5) 88(16) 
Moderate I 241(32.7) 213(33.6) 229(32.1) 143(26) 
Moderate II 200(27.1) 155(24.4) 161(22.6) 159(28.9) 
Poor 112(15.2) 39(6.2) 63(8.8) 96(17.5) 
Very Poor 34(4.6) 18(2.8) 16(2.2) 29(5.3) 
Vascular 
Invasion 
Negative 297(59.6) 330(70.2) 11.8 0.001 429(67.5) 269(55.6) 16 <0.0001 Positive 201(40.4) 140(29.8) 207(32.5) 215(44.4) 
Tumour Type 
Invasive Ductal/NST 525(71) 383(60.3) 
30 <0.0001 
397(56.6) 367(66.2) 
 
 
 
21 
<0.0001 
lobular 44(6) 33(5.2) 41(5.8) 27(4.9) 
Atypical Medullary 25(3.4) 15(2.4) 25(3.6) 10(1.8) 
*Mixed 114(15.4) 170(26.8) 190(27.1) 136(24.5) 
**other 31(4.2) 34(5.4) 48(6.8) 14(2.5) 
N= number of cases. c. = cytoplasmic, n. = nuclear expression. * Lobular or tubular mixed BCs. ** Mucinous, Alveolar Lobular, Miscellaneous 
including Metaplastic, Adenoid Cystic, Spindle, and Tubulolobular. NST= no special type. NPI= Nottingham Prognostic Index. Excellent NPI 
(2.08±2.4), good NPI (2.42 to င3.4), a moderate prognostic I NPI (3.42 to င4.4), moderate prognostic II NPI (4.42 to င5.4), poor NPI (5.42 to င6.4), and a very poor NPI (6.5±6.8). Co-expression of cellular localisation of CHK1 was considered here. 
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3.6.5 Relationship between DNA Damage Sensors and Signal Transducers Proteins and 
PatientV¶ Outcome by Univariate Analysis  
 
Figures 3.6 to 3.12 show the association between the expression of DNA damage 
sensors and signal transducers proteins and patientV¶ outcomes. 
 
Positive nuclear (n) expression of CHK1 showed a longer BCSS (P=0.017, Figure 
3.6a) than negative expression, although it was not of statistical significant, whereas the 
positive cytoplasmic (c) expression of CHK1 showed poorer BCSS than negative one 
(P=0.028, Figure 3.6b. finally, the co-expression of nuclear- and cytoplasmic+ CHK1 had the 
worst outcome, while nuclear+/cytoplasmic- CHK1 had the best BCSS (P=0.025, Figure 
3.6c). Interestingly, cases showing CHK1.n- treated with chemotherapy (unselected cases) 
(P=0.007, Figure 3.7a) or endocrine therapy (among ER+ patients) (P=0.008, Figure 3.7c) 
demonstrated worse BCSS than those who did not receive these treatments. In addition, cases 
of CHK1.c- treated with endocrine therapy (amongst them ER+ patients) (P=0.04, Figure 
3.7d) showed a trend for increased BCSS over the other groups, yet patients treated with 
chemotherapy and demonstrating a low cytoplasmic expression of CHK1 had worse survival 
rates than those patients who did not receive this treatment, although it was not of statistical 
significant (P=0.018, Figure 3.7b).  
 
CHK2 demonstrated no effect on patient survival (P=0.4, Figure 3.8a); however, 
similar to nuclear CHK1, tumours having CHK2- and received chemotherapy (unselected 
cases) or treated with endocrine therapy in patients with tumours expressing ER+ 
demonstrated poor BCSS, when compared to untreated cases  ( P=0.08; Figure 3.8b, P=0.002, 
Figure 3.8c respectively).  
 
Positive ATM conferred an improved BCSS (P<0.0001, Figure 3.9a) or longer time to 
induce distant metastasis (P<0.0001, Figure 3.9b) over ATM negativity. Interestingly, low 
ATM expression levels in patients that received chemotherapy had worse BCSS than those 
who did not receive it (unselected cases; (P<0.0001, Figure 3.9c). Furthermore, patients 
receiving endocrine treatment (amongst ER+ patients) had worse BCSS than patients who did 
not receive the treatment (P<0.0001, Figure 3.9d). 
 
Unlike ATM, patients with positive ATR tumours demonstrated a trend for poorer 
BCSS (P=0.01, Figure 3.10a) than ATR negative tumours. In contrast, high expression levels 
of ATR demonstrated worse BCSS in those patients who received chemotherapy (unselected 
cases) (P=0.01, Figure 3.10b) or endocrine treatment (amongst ER+ patients) (P=0.001, 
Figure 3.10c) than those who did not. 
 
Although the co-H[SUHVVLRQ RI Ȗ+$;Q-.c- demonstrated the shortest BCSS, it was 
not of statistical significance (P=0.097, Figure 3.11a). Nuclear or cytoplasmic expression of 
Ȗ+$;VKRZHGQRVLJQLILFDQWDVVRFLDWLRQZLWKSDWLHQW¶VRXWFRPH)LJXUHE-3.11d). 
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Interestingly, patients who were treated with chemotherapy and expressed nuclear 
3  )LJXUH D RU F\WRSODVPLF Ȗ+$; 3 )LJXUH E GHPRQVWUDWHG
worse BCSS than those who did not receive the treatment. A similar effect was seen with 
endocrine treated ER-positive patients Figure 3.12c for nuclear (P<0.0001) and 3.12d for 
F\WRSODVPLFȖ+$; (P=0.029).    
 
 
 
 
  
Figure 3.6 The associations between CHK1 with BCSS. 0= negative and 1= positive expression of CHK1.  Where 
n= nuclear expression and c= cytoplasmic expression of CHK1 and N; number of cases. Only patients who died 
from breast cancer were considered. a; shows association between nuclear expression of CHK1 and BCSS, whereas 
b; shows cytoplasmic expression. c; co-expression of nuclear and cytoplasmic expression of CHK1 and its 
association with BCSS.  P<0.01 was considered significant. 
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Figure 3.7 The associationVEHWZHHQ&+.ZLWK%&66DQGWKHHIIHFWRIWUHDWPHQWRQSDWLHQW¶VRXWFRPH1QXPEHU
of cases. n= nuclear expression and c= cytoplasmic expression. Only patients who died from breast cancer were 
considered. a; association between nuclear expression of CHK1 and BCSS based on chemotherapy in unselected cases 
and b; cytoplasmic expression of CHK1 and BCSS based on chemotherapy in unselected cases. c;  nuclear expression 
of CHK1 and BCSS based on receiving/or not endocrine therapy  in only ER-positive cases. d; cytoplasmic expression 
of CHK1 and BCSS based on receiving/or not endocrine therapy  in only ER-positive cases. P<0.01 was considered 
significant. Some ER-positive tumours did not receive endocrine therapy, because the treatment plans for those cases 
was DVSDWLHQWVZLWKDVFRUHRI13,UHFHLYHGQRDGMXYDQWWKHUDS\  
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Figure 3.8 7KHDVVRFLDWLRQVEHWZHHQ&+.ZLWK%&66DQGWKHHIIHFWRIWUHDWPHQWRQSDWLHQW¶VRXWFRPH1QXPEHURI
cases. Only patients who died from breast cancer were considered. a; shows association between CHK2 and BCSS , 
where 0= negative and 1= positive expression.  b; expression of CHK2 and BCSS based on chemotherapy in unselected 
cases. c; expression of CHK2 and BCSS based on receiving/or not endocrine therapy  in only ER-positive cases. 
P<0.01 was considered significant. Some ER-positive tumours did not receive endocrine therapy, because the treatment 
SODQVIRUWKRVHFDVHVZDVDVSDWLHQWVZLWKDVFRUHRI13,UHFHLYHGQRDGMXYDQWWKHUDS\  
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Figure 3.9 The associations between ATM with BCSS or distant metastasis and the effect of treatment on 
SDWLHQW¶s outcome. N; number of cases. Only patients who died from breast cancer were considered. a; shows 
association between ATM and BCSS, and b; with distant metastasis, where 0= negative and 1= positive 
expression.  c; expression of ATM and BCSS based on chemotherapy in unselected cases. d; expression of ATM 
and BCSS based on receiving/or not endocrine therapy in only ER-positive cases. P<0.01 was considered 
significant. Some ER-positive tumours did not receive endocrine therapy, because the treatment plans for those 
FDVHVZLWKDVFRUHRI13,UHFHLYHGQRDGMXYDQWWKHUDS\  
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Figure 3.10 7KHDVVRFLDWLRQVEHWZHHQ$75ZLWK%&66DQG WKHHIIHFWRI WUHDWPHQWRQSDWLHQW¶VRXWFRPH1QXPEHURI
cases. Only patients who died from breast cancer were considered. a; shows association between ATR and BCSS, where 
0= negative and 1= positive expression.  b; expression of ATR and BCSS based on chemotherapy in unselected cases. c; 
expression of ATR and BCSS based on receiving/or not endocrine therapy  in only ER-positive cases.  P<0.01 was 
considered significant. Some ER-positive tumours did not receive endocrine therapy, because the treatment plans for those 
FDVHVZLWKDVFRUHRI13,UHFHLYHGQRDGMXYDQWWKHUDS\  
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Figure 3.11 7KH DVVRFLDWLRQV EHWZHHQ Ȗ+$; ZLWK %&66 RU GLVWDQW PHWDVWDVLV   QHJDWLYH DQG   SRVLWLYH
H[SUHVVLRQ RI Ȗ+$; :KHUH Q  QXFOHDU H[SUHVVLRQ DQG F  F\WRSODVPLF H[SUHVVLRQ RI Ȗ+$; DQG 1 QXPEHU RI
cases. Only patients who died from breast cancer were considered. a; co-expression of nuclear and cytoplasmic 
H[SUHVVLRQRIȖ+$;DQGLWVDVVRFLDWLRQZLWK%&66EVKRZVDVVRFLDWLRQEHWZHHQQXFOHDUH[SUHVVLRQRIȖ+$;DQG
GLVWDQWPHWDVWDVLVDQGFZLWK%&66GVKRZVF\WRSODVPLFH[SUHVVLRQRIȖ+$;ZLWK%&6630.01 was considered 
significant. 
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Figure 3.12 7KH DVVRFLDWLRQV EHWZHHQ Ȗ+$; ZLWK %&66 DQG WKH HIIHFW RI WUHDWPHQW RQ SDWLHQW¶V RXWFRPH 1
number of cases. Only patients who died from breast cancer were considered. a; shows association between nuclear 
H[SUHVVLRQRIȖ+$;DQG%&66EDVHGRQFKHPRWKHUDS\LQXQVHOHFWHGFDVHVDQGEF\WRSODVPLFH[SUHVVLRQRIȖ+$;
DQG %&66 EDVHG RQ FKHPRWKHUDS\ LQ XQVHOHFWHG FDVHV F QXFOHDU H[SUHVVLRQ RI Ȗ+$; DQG %&66 EDVHG RQ
receiving/or not endocrine therapy  in only ER-SRVLWLYHFDVHVGF\WRSODVPLFH[SUHVVLRQRIȖ+$;DQG%&66EDVHG
on receiving/or not endocrine therapy  in only ER-positive cases. P<0.01 was considered significant. Some ER-
positive tumours did not receive endocrine therapy, because the treatment plan for those cases was as patients with a 
VFRUHRI13,UHFHLYHGQRDGMXYDQWWKHUDS\ 
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3.6.6 Relationship between DNA Damage Sensors and Signal Transducers Proteins and 
3DWLHQWV¶Outcomes by Multivariate Analysis  
 
Table 3.11 and Figure 3.13 show Cox-regression analyses for predictors of BCSS for 
ATM and ATR. Only markers showed significant association in univariate analysis were 
considered. It seems that ATM, but not ATR is independent prognostic marker for breast 
cancer.  
 
Multivariate analysis for combinations (such as ATM with chemotherapy or ATM 
with endocrine therapy) does not usually perform, multivariate analysis applies for the main 
marker results (+ vs. -) as combination effect may be biased by the other factors and not by 
the target marker. 
     
Table 3.11Cox-Regression Analyses for Predictors of BCSS 
Parameters P-value 
95.0% CI 
Parameters P-value 
 
95.0% CI 
Lower Upper Lower Upper 
ATM 0.007 0.529 0.906 ATR 0.7 0.744 1.234 
NPI 0.963 0.659 1.549 NPI 0.264 0.885 1.559 
Tumour Size <0.0001 1.373 2.956 Tumour Size 0.033 1.035 2.186 
Tumour Stage <0.0001 1.331 2.345 Tumour Stage 0.001 1.246 2.533 
Tumour Grade 0.014 1.091 2.190 Tumour Grade 0.019 1.081 2.360 
BLBC 0.208 0.588 1.123 BLBC 0.289 0.584 1.174 
Ki-67 0.009 1.116 2.184 Ki-67 0.040 1.015 1.965 
NPI=Nottingham prognostic index. Basal Like BC (BLBC) as defined by Triple negative +positive expression of CK5 and CK14 and 
CK17. Only markers in univariate analysis that were statistically significant with SDWLHQWV¶RXWFRPHV were applied for Cox regression (IBM 
SPSS 21.0) for multivariate analyses. ATR showed a trend for poor BCSS in univariate analysis. 
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 3.13 Multivariate Cox-regression analysis for ATM and ATR. In order to test for confounders 
and prognostic or predictive independency of the investigated biomarker from standard 
prognostic/predictive factors; tumour grade, stage and size, NPI, BLBC, and Ki-67 were included. 0= 
negative expression, and 1=positive expression.  
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3.6.7 Expression of DNA Damage Sensors and Signal Transducers Proteins in Cell 
Lines by Reverse Phase Protein Microarray 
 
RPPA was used to evaluate the expression level of DNA damage sensors and signal 
transducers markers in different cell lines (BRCA1 deficient HeLasilenciX® cells and its 
control (proficient BRCA1)), MCF-7 (proficient BRCA1 and ER+) and MDA-MB-436 
(deficient BRCA1 and ER-) cells. Figure 3.14 shows the expression of ATM, ATR, CHK1, 
&+.DQGȖ+$;LQGLIIHUHQWFHOOOLQHV using RPPA.  
 
RPPA confirmed the IHC results (especially nuclear expression, but not cytoplasmic 
IRU &+. DQG Ȗ+$;, with the exception of ATR, and demonstrated a higher level of 
expression of DNA damage sensors and signal transducers markers in HeLa BRCA1 control 
or MCF-7 cell lines than BRCA1 deficient HeLa or MDA-MB-436 cell lines. All the markers 
showed similar expression amongst the cell lines.  
 
In regards to statistics; there was a high significant difference in the expression of 
CHK1 between; HeLa BRCA1 control vs. MDA-MB-436 (P=0.0002), HeLa BRCA1 vs. 
MDA-MB-436 (P=0.008), and finally MDA-MB-436 vs. MCF-7 (P=0.0008). For ATM; 
HeLa BRCA1 control vs. MDA-MB-436 (P=0.007). For ATR; HeLa BRCA1 vs. HeLa 
BRCA1 control (P<0.0001), HeLa BRCA1 control vs. MDA-MB-436 (P<0.0001), HeLa 
BRCA1 control vs. MCF-7 (P<0.0001) and finally MDA-MB-436 vs. MCF-7 (P=0.007). 
)LQDOO\IRUȖ+$;MDA-MB-436 vs. MCF-7 (P=0.007). 
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Figure 3.14 The DNA-damage sensors and signal transducers protein levels detected by RPPA in different cell lines 
(BRCA1 deficient HeLaSilenciX® cells and its control [BRCA1 and BRCA1.C respectively], MCF-7 and MDA-MB-
436 cells). For image of nitrocellulose slide spotted with different cell lysates; the red square represents the 700 
channel for detection of mouse antibody while green square the 800 channel for rabbit antibody. Images of scanned 
nitrocellulose slides printed with extracted protein from cell lines and probed with the antibodies against the target 
proteins. Five 2-fold dilutions of each sample were printed in duplicate. Background was subtracted and the intensity 
of each spot was normalised to its corresponding GAPDH level. Each (R) represents different passage of each sample, 
therefore, three different passages of each sample were used. Error bars represent Mean (SD). HeLa BRCA1; between 
passage21 and 30, HeLa BRCA1 control; between passage 15 and 20, MCF-7; between passage 25 and 32, and 
MDA-MB-436; between passage 12 and 20. A= BRCA1 vs. BRCA1.C, B= BRCA1 vs. MDA-MB-436, C= BRCA1 
vs. MCF-7, D= BRCA1.C vs. MDA-MB-436, E= BRCA1.C vs. MCF-7, and F= MDA-MB-436 vs. MCF-7. One way 
ANOVA test was used. 
Chapter 3                                        DNA Damage Sensors and Signal Transducers in BC 
103 
 
3.7 Discussion   
 
Cellular response to any genotoxic stress is a highly complex process, and it usually 
EHJLQVZLWKRQHRIWZRV\VWHPVWKH³VHQVLQJ´RU³GHWHFWLRQ´RIWKHGDPDJHRI'1$WKHQD
number of events that include signal transduction and activation of transcription factors. The 
activated transcription factors stimulate expressions of several genes which usually have roles 
in different cellular functions such as DNA repair, cell cycle arrest, and apoptosis[328]. 
Focusing on how the repair of DNA is modulated in accordance with the responding to the 
damage provides important applications in the treatment of cancer [341].  
 
In this Chapter, the expression of DNA damage sensors and signal transducers 
proteins $70 $75 &+. &+. DQG Ȗ+$; ZDV H[DPLQHG LQ EUHDVW WXPRXUV XVLQJ
IHC, TMA) and in different cell lines (using RPPA). These markers were correlated with 
clinical outcome, tumour pathological features and the expression of other tumour 
biomarkers, in order to demonstrate their expression patterns in BC cases or the cell lines. 
Figure 3.15 summarises the finding in this chapter and pathway involved in DNA damage 
sensors and signal transducers in BC.   
  
All the findings by IHC, particularly nuclear expression, were similar to those 
observed with RPPA in different cell lines, with the exception of ATR. In RPPA, the HeLa 
BRCA1 or MDA-MB-436 cell lines ($70 &+. &+. DQG Ȗ+$; or, in the case of 
IHC, BRCA1 hereditary [known germline mutation cases], or sporadic BRCA1-/ER- cases) 
showed lower levels of all DNA damage sensors and signal transducers proteins (than the 
HeLa BRCA1control cell line or MCF-7 (ER+ and BRCA1+) and for IHC; sporadic 
BRCA1+/ER+ cases. Current progress in identifying the function of BRCA1 suggests that this 
gene has an important role in a common pathway that is involved in response to DNA- 
damage or even cell-cycle control and repair of DNA-damage [341, 342]. It is therefore 
expected that any defect of BRCA1 will have an impact on response to DNA-damage [341, 
342]. Wiltshire et al have used BC cell line HCC1937 and found that BRCA1 deficiency 
results in increased chromosome damage and was involved in controlling both G2/M 
checkpoints [342]. In this study the influence of BRCA1 deficiency as in HeLa BRCA1/ 
MDA-MB-436 cell lines or a mutation as in hereditary BRCA1 BC tissue turns out to 
respond to DNA-damage. This is illustrated by observing the low level of the basic markers 
of DNA-damage such as ATM, ATR and signal transducer such as CHK1, and CHK2, in 
addition to WKH '1$ GDPDJH UHSDLU IDFWRU SURWHLQ Ȗ+$;. However, further studies are 
warranted to observe the functional behaviour of the cells, and to investigate the effect of 
%5&$ RQ WKH OHYHO RI WKHVH PDUNHUV $70 $75 &+. &+. DQG Ȗ+$;. The 
quantitative assessment of DNA damage can performed by Comet assay through single gel 
electrophoresis and analysed by fluorescent microscope. In addition, cell cycle analysis 
employing flow cytometry would help to distinguish cells in different phases of the cell cycle 
[343]. 
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   In IHC, the expression of ATR in known BRCA1 germline mutations cases was higher 
than in sporadic cases, unlike the findings in regards to the cell line, which showed the 
opposite effect. Interestingly, this finding is in agreement with the cytoplasmic expression of 
ERWK&+.DQGȖ+$;$OWKRXJKWKH533$UHVXOWVUHIOHFt most of the findings pertaining to 
IHC, the assessment of the markers presented here highlights the variations in using cellular 
pathways to investigate the use of in vivo tumour cells and cancer cell lines. Other reports 
confirm the variations between cell lines and tissue by studying the function of different 
genes, such as cell-cycle progression genes, protein processing and protein turnover, and 
have stated that cell lines differed most significantly from tumours based on meta-analysis 
using Gene Ontology [344, 345]. Such behaviour, however, may possibly have arisen as a 
result of different factors relating to the cell culture environment [345]. The noticeable 
difference between IHC and RPPA used for the study of ATR expression could be due to the 
difference in the samples used, for example using cervical cell lines (HeLa-BRCA1 cell 
lines). In addition, the composition of the cell culture medium may be precisely why patterns 
of protein expression differentiate cancer cell lines from breast tumour tissue. However, 
variations in environmental selection pressures may also clarify the differential patterns of the 
expression of protein in tumour tissue and the cell lines. Compounds may have a significant 
and diverse effect on the altered pathways between cell lines and tumour tissue. In addition, 
the result of the IHC was considered both nuclear and cytoplasmic expression of the marker, 
whereas in cell lines the expression was investigated regardless cellular localisation. 
 
$70$75 DFWLYDWLRQ DQG ³VHQVRU´ SURWHLQV UHFUXLW &+.&+. DW GDPDJH VLWHV
where the latter are activated [346, 347]. DSBs activate ATM, leading to the phosphorylation 
of both P53 and CHK2: this step then leads to the accumulation of P53 and the activation of 
its downstream target genes [348, 349]. Transcriptional activation will direct into two 
mechanisms, whether it is apoptosis or G1-cell cycle arrest, and enforce the S- and G2- cell 
cycle arrests regulated by CHK1. ATR (predominantly) or ATM (to a lesser extent) 
phosphorylates CHK1 [346, 347]. Interestingly, the existence of crosstalk between these 
pathways is expected, as stalled replication forks can cause DSB leading to ATM activation 
and DSB repair can produce RPA- coated ssDNA, which triggers the pathway of ATR [350]. 
A number of siRNA studies have investigated the importance of CHK1 and CHK2 and these 
showed that CHK1 is essential for both S and G2 arrest within damaged cells, whereas CHK2 
is not able to influence arrest [351-355]. It is expected that the arrest of the S phase will halt 
overt DNA damage, but if cells are not able to arrest in this phase, due to the absence of 
CHK1, more DNA breaks will arise. This increased damage may stimulate another 
checkpoint mechanism, which helps prevent progression through the G2 phase [355]. A study 
of the MDA-MB-231 cell line, by Zhang et al showed that suppression of CHK2 had no 
effect on the arrest of the cell cycle, while cells simultaneously suppressed for both CHK1 
and CHK2 continued to be arrested, mainly in the G2 phase [355]. Based on the finding by 
Zhang et al [355]LW¶VH[SHFWHGWKDWKLJK&+.DQG&+.VKRXOGOHDGWRFHOOF\FOHDUUHVWLQ
order to induce repair or cell death. In the present study, CHK2, CHK1.n, ATR and ATM 
were rarely exprHVVHGZKHUHDV&+.FDQGȖ+$;QFZHUHKLJKO\H[SUHVVHG ,WPD\WKXV
be suggested that the high cytoplasmic expression of CHK1 may have an adverse effect of 
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cell cycle arrest of the DNA damaged cancerous cell and the active cellular localisation is in 
the nucleus for repair. As both ATM and ATR were rarely expressed, it is possible that the 
repair may induce by an alternate incorrect checkpoint regulator, and could not sensors the 
damage correctly. In addition, the cytoplasmic expression of CHK1 may play some role in 
tumorigenesis through the DNA damage sensors and signal transducers pathway and takes 
this action as a survival pathway for the tumour cell [356, 357]. However this hypothesis 
needs further studies to be confirmed, cell fractionation and cell cycle analysis with 
employing flow cytometry may help here.  
 
In cervical cancer cell line, inhibition of ATM severely decreased clonogenic 
survival, suggesting that cervical cancer cells seriously rely on signalling axis of ATM for 
survival after irradiation, whereas the high level of ATM increased the survival [358]. In 
addition, Bueno et al [359] have showed that low protein expression of ATM was associated 
with distant metastasis and reduced DFI in BC. The present study supports these findings 
where the low protein expression of ATM was highly associated with poor BCSS and shorter 
time to induce distant metastasis. In addition, ATM protein expression was an independent 
prognostic marker in sporadic BC. Therefore, the results can lead to suggest that ATM may 
be a clinically applicable marker of BC outcome.  
 
The subcellular localisation of phosphorylated CHK1 at S345 (used in the present 
study) was mainly observed in the cytoplasmic fraction, indicating that this particular site of 
phosphorylation promoted the cytoplasmic localisation of CHK1. In terms of phosphorylation 
at S317, CHK1 was detected in the nucleus towards the late S phase. It is thus possible that 
CHK1 de-phosphorylation at S345 induced the movement of CHK1 from the cytoplasm, in 
addition to its accumulation in the nucleus. According to this concept, the mobility shift in 
CHK1, upon damage of DNA, was observed only in the cytoplasm [339]. The 
phosphorylations might be critical for transducing signals to downstream targets [339]. Thus, 
it would help to address these two phosphorylation sites and to clarify the mechanisms related 
to how these different phosphorylation sites regulate function of CHK1. Mass spectrometry 
offers a rapid and highly sensitive method to mapping different phosphorylation sites [360]. 
The subcellular localisation of CHK1 and the aggressive feature (such as high histologic 
grade, high nuclear pleomorphism and tumour size more than 1.5cm) of cytoplasmic CHK1 
in this study may be explained by a defect of CHK1 in BC. Puc et al [361] studied the effect 
of cytoplasmic CHK1 on genomic instability using a mouse mammary tumour model. They 
found that at the G2 phase of the cell cycle, endogenous CHK1 could be observed leaving 
from the nucleus at the time of peak AKT kinase phosphorylation. The reduction of nuclear 
CHK1 may possibly explain the raise of Cdc25A protein noticed in G2/M phases [362]. In 
addition, the PTEN reduction in U2OS cells with RNA interference (RNAi) resulted in 
increased cytoplasmic expression of CHK1, and then serine 280 phosphorylation seems to be 
a trigger for CHK1 monoubiquitination, which have been proved affect CHK1 cellular 
localisation. In general, their study suggests that increased serine 280 phosphorylation and 
ubiquitination of CHK1 in PTENíí cells improved cytoplasmic localisation, therefore 
inhibiting its checkpoint function [361]. This study in some points may help to explain the 
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high association between PTEN and high cytoplasmic/low nuclear CHK1 noticed in the 
present study. Further studies regarding the effect of PTEN on cytoplasmic CHK1 are 
warranted. Introducing a CHK1-null allele into mice with mammary epithelium-specific 
inactivation of PTEN, in order to investigate the effect of PTEN disruption on genetic 
instability and if it has a role in inactivation of nuclear/cytoplasmic CHK1 that lead to tumour 
formation. Southern-blot analysis can be used for detecting the amount of PTEN. 
 
In this Chapter, the expression of the DNA damage sensors and signal transducers 
proteins CHK2-Ȗ+$;Q+.c+, CHK1.n-c+, ATM- and ATR+ were associated with aggressive 
clinicpathological features. However, low or high levels of CHK1 have been reported in 
certain human or mouse tumours [363-369] and mutation of the CHK2 or ATM has also been 
associated with an increased risk of BC [370, 371]. Heikkinen et al have hypothesised that 
germline mutations in ATR may account for some BC families [372]. In the present study, 
although few cases showed primary nuclear localisation, a high amount of CHK1 was 
detected in the cytoplasm of the cells. I can hypothesise that the cytoplasmic localisation of 
CHK1 may make it inaccessible, in terms of beginning its role by ATM/ATR, in response to 
DNA damage. The absence of the expression of CHK1 from the nuclei and high expression 
in the cytoplasm enhanced the aggressive characteristics of BC, such as high histologic grade 
3 tumours, larger tumour size and the occurrence of TN and BLBC. Ganzinelli et al 
supported the findings here, highlighting a low expression of nuclear , but not cytoplasmic 
CHK1 in TNBCs [373]. Further study is warranted to confirm the importance of CHK1 in 
BLBC or TNBC. HRM analysis with employing real-time PCR will help in mutation 
detection. This will help in investigating CHK1 inhibitors for treatment in TNBC or BLBC, 
where strategies of treatment are limited at present.  
 
In BC, a strong correlation has been found between the positive Ki-67 and tumour 
grade, age, and rate of mitotic indices [374-376]. In the present study, there was a strong 
positive association between the protein expression levels of CHK1n-.c+, and the proliferation 
marker, Ki-67, [377] and the tumour suppressor P53. This finding is consistent with the data 
of Lundgren [332], suggesting that CHK1 is a marker for tumour aggressiveness and 
proliferative activities in addition,  Gottifredi et al stated that P53 and CHK1 play 
interdependent and complementary roles in regulating both the arrest and resumption of 
G2 after DNA damage [378] ,Q DGGLWLRQ Ȗ+$;Q+.c+, ATM-, and ATR+ showed similar 
association with Ki-67, thus, these markers may possibly influence the aggressive nature of 
breast tumours.  
 
Histone H2AX is phosphorylated on Ser-139, in response to DNA damage after 
exposure to genetic agents. In addition, histone H2AX is phosphorylated in untreated normal 
cells as well as tumour cells; this occurs throughout the cell cycle and, predominantly, in the 
S and G2/M phases [379]. In the present study, the observed significant negative correlation 
EHWZHHQȖ+$;QDQGWKHSURWHLQ3PD\WKXVLQGLFDWHWKDWWKHWXPRXUSURWHLQ3KDVDQ
important role in facilitating phosphorylation of histone H2AX, an essential step in the 
mobilisation of the DNA repair machinery at the site of a DNA-DSB [379]. Further studies 
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DUHZDUUDQWHG WR LQYHVWLJDWH WKHHIIHFWRI3RQSKRVSKRU\ODWLRQRIȖ+$;+RZHYHU WKH
NQRZQ FHOOXODU ORFDOLVDWLRQ IRU Ȗ+$; LV WKH QXFOHXV DQG FKURPRVRPH [380-382] and the 
mislocalisation of protein to the cytoplasm has been reported in different studies [383, 
384]. Overexpression of Tyrosine Kinase receptor type 1(TrkA), (cell differentiation kinase), 
FDXVHV DFFXPXODWLRQ RI Ȗ+2AX proteins in the cytoplasm, leading to considerable cell 
death in U2OS cells [385]. In addition, Jung et al [386] suggested that cytoplasmic expression 
of Ȗ+$; could be an important factor in TrkA-mediated cell death by 
controlling TrkA upon the damage of DNA. Ȗ+$;LVa marker of activated DNA damage 
and its overexpression in cancer indicating a role in oncogenic transformation [387]. 
Although Ȗ+$;ZDVRYHUH[SUHVVHGLQWKLVVWXG\WKHUHLVQRHYLGHQFHVKRZLQJWKLVZDVGXH
to DNA damage, therefore, genetics- and genomics-based methods that have confirmed 
functions for conserved DNA damage response and DNA repair proteins will help to discover 
novel components of these response pathways. Comet assay or FLARETM Assay (Fragment 
Length Analysis using Repair Enzymes) will provide the ability to detect DNA damage in 
cells.  
 
The Development of DSB is subsequently followed by H2AX phosphorylation, 
OHDGLQJWRWKHIRUPDWLRQRIȖ+$;ZKLFKLVWKHILUVWVWHSLQUHFUXLWLQJDQGORFDOLVLQJ'1$
repair proteins [388]. The inhibition or depletion of CHK1 in cells activates the immediate 
phosphorylation of ATR targets and H2AX induction and thus DNA breaks accumulate 
[389]7KHUHVXOWVKHUHVKRZWKDWȖ+$;Q+.c+ is negatively associated with ATR and ATM. 
However, ATR- had a significant association with CHK1n-.c+ and CHK2-. It can be 
hypothesised that tKHKLJKOHYHORIȖ+$;FRXOGEHWKHUHVXOWRIGHIHFWDQGXQFKHFNHGFHOO
cycles or a defect in DNA damage sensors pathway. Banath et al have demonstrated that the 
H2AX gene is frequently altered in cervical cancer cell lines, which can induce a 3-fold 
LQFUHDVHLQWKHIRUPDWLRQRIȖ+$;[390]. Other studies have also demonstrated a high level 
RIȖ+$;LQYDULRXVW\SHVRIFDQFHUVVXFKDVOXQJEUHDVWFRORQDQGRYDULDQFDUFLQRPDV[2, 
391].  
 
Regardless of significant developments in cancer therapy in recent years, resistance 
towards chemotherapy remains the most important challenge to address amongst patients 
suffering from solid tumours [392]. Endocrine resistance is also commonly found in BC 
therapies, with around one-third of ER-Įpositive BC resistant to targeted drugs [332]. For 
this reason, clarification of the resistance mechanisms may prove vital in enhancing strategies 
of treatment. In general, all the markers in this chapter, which were associated with poor 
IHDWXUHV DQG UHFHLYHG HQGRFULQH WKHUDS\ KDG ZRUVH SDWLHQW¶V RXWFRPH WKDQ ZKR GLG QRW
receive the treatment. Endocrine responsiveness mechanisms in BC are controlled by 
sophisticated interactions between steroid hormones and several signalling pathways, which 
are more than likely influenced by various genetic changes [393]. The identification of the 
genes responsible for playing some role in resistance to Tamoxifen is one strategy in 
understanding the main mechanisms within this complex series of events. A small number of 
studies have dealt with genetic alterations and resistance to anti-oestrogen; it may therefore 
be of great benefit to continue the investigation into potential markers associated with 
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resistance. Lundgren et al and other studies are in some way in agreement with the findings 
of this study, in highlighting that CHK1 is associated with an impaired Tamoxifen response 
[332, 394]. However, it is too early to suggest the impact of CHK1 or any marker in this 
study on response to chemotherapy or endocrine therapy, therefore further studies are 
warranted to investigate it. Genome /exome sequencing can be performed on BC patients 
who received treatment, and then evaluate the response to the therapy. After sequencing, the 
data can be analysed and compared with the clinical data for each patient (object response to 
therapy). 
 
%DVHGRQWKHILQGLQJVKHUHWKHVXEFHOOXODUORFDOLVDWLRQRIȖ+$;RU&+.PD\KDYH
some roles in poor SDWLHQWV¶ RXWFRPHV even after receiving chemotherapy or endocrine 
treatment; it would have been interesting to have assessed the cellular fractionation in the 
current cohort ± this could be carried out through further work/investigations by others 
continuing the study. The cytotoxicity of DNA-damaging agents, which normally produce 
cell-cycle arrest in tumour cells, may be improved by combining them with checkpoint 
inhibitors. In addition, any mutation or defect in the pathways of the DNA damage sensors 
proteins may cause mislocalisation in the cytoplasm and thus affect the function of treatment. 
Nuclear and cytoplasmic fractions of the targeted proteins sucKDV&+.DQGȖ+$;FDQEH
used and treated separately with Tamoxifen or with chemotherapy such as CMF, therefore 
flow cytometry will help to observe how the different compounds affected 
Tamoxifen/chemotherapy-induced cell cycle arrest and apoptosis. However, nuclear and 
F\WRSODVPLF IUDFWLRQV FDQ EH XVHG WR GHWHFW &+. RU Ȗ+$; E\ :HVWHUQ EORWWLQJ $QG
finally Immunofluorescence may help to visualise CHK1+ RU Ȗ+$;+ cells upon 
Tamoxifen/chemotherapy stimulation.  
 
7KHPDUNHUV&+.FDQGȖ+$;FZKHQWKH\ZHUHDQDO\VHGDVFRQWLQXRXVYDULDEOHV
some correlations lost the significance in comparison to categorical data. It is more logic to 
consider the continuous variable as correlation is biological and certainly the cut-off points 
will reflect these correlations, but it can be argued that from a clinical point of view, using 
markers as a dichotomised data may be more helpful for patient management such as HER-2, 
ER and Ki67 status in BC which are used as positive/ negative and not as continuous 
variables. 
 
Knowing the subcellular location of a protein is important for understanding its 
functions [395]. However, regardless co-expression of cellular localisation, CHK1.n 
(regardless cytoplasmic expression) showed no correlation with P53, but was statistically 
significant with cytoplasmic CHK1 without considering the nuclear expression, similarly was 
VHHQ ZLWK &. 7DEOHV  DQG  ,Q DGGLWLRQ 3HDUVRQ¶V FRUUHODWLRQ Fontinuous data 
DQDO\VLV RI Ȗ+$;F KDG QR FRUUHODWLRQ ZLWK (5 RU 3J5 DQG &+.F ZLWK 3J5 EXW ZDV
highly significant with their nuclear expression. Therefore, it can be hypothesised that 
cytoplasmic, but not nuclear, expression of CHK1 may have the main role in association with 
P53 in BC. In contrast, QXFOHDUH[SUHVVLRQRIȖ+$;may have the main role with ER and 
PgR and similarly nuclear expression may be the main localisation in the association between 
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CHK1 and PgR.  Further studies are warranted to investigate the effect of cellular localisation 
RI&+.DQGȖ+$;RQWKHLUIXQFWLRQ+RZHYHU$PLQRDFLGFRPSRVLWLRQ-based methods, 
these methods use machine learning approaches, which include neural networks [396]and 
support vector machines (SVM), is usually used to predict subcellular localisation of a 
protein. Improvement in understanding the molecular details in the cytoplasmic/nuclear 
DFWLRQV RI &+. RU Ȗ+$; PD\ KHOS WR ILQG D WDUJHW IRUBC, especially the two cellular 
compartments showed different features of BC.  
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Figure 3.15 A summary of the finding in this chapter and pathway involved in DNA damage sensors and signal 
transducers in breast cancer. X represents a defect in the response to DNA damage by showing low level expression of 
ATM. As response to DNA-damage the level of ATM should be increased. Here the low level of ATM may explain a 
defect in the response to the damage or the cancer itself has other causes than a defect in DNA repair.  
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Chapter 4 
 
4.1 Introduction 
 
4.1.1 DNA Double Strand Break Repair 
 
Increasing evidence proposes that BRCA1 plays a role in many essential functions, 
such as DNA repair, transcription and control of the cell cycle. Of the various types of DNA 
damage that can occur within a mammalian cell, the DSB is understood to be the most lethal 
[262, 397]. Many studies have indicated a link between DSB, genomic instability and cancer 
and this relationship is based upon the fact that syndromes representing a predisposition to 
cancer are characterised by genome instability and arise from a mutation in DSB-responsive 
genes [262, 398]. DSB induction in the early stage of tumorigenesis, in addition to 
concomitant activation of damage responsive proteins, gives rise to cellular apoptosis. In the 
continuous presence of DSB and in the advanced stages of cancer, proteins that respond to 
the breaks, such as P53, became mutated, leading to a defect in apoptosis or senescence: this 
will result in the development of carcinogenesis [2, 399].  
 
DSB can be generated by extrinsic sources, such as IR or radiomimetic drugs used for 
chemotherapy; additionally, intrinsic sources, such as ROS, are believed to induce DSB 
[400]. Unlike single strand nicks or base modification, DSB can initiate gross chromosomal 
aberrations, if not repaired quickly. However, the repair process may be error-prone or, in 
some cases, may be detrimental to the organism. It is recognised that mammalian cells have 
the ability to quickly transfer the damage signal to the cell cycle arrest or machineries of 
apoptosis and DNA repair mechanisms [399]. Damaged cells require time for repair and this 
is achieved by the action of cell cycle arrest. Occasionally, apoptosis may be more prudent 
for cells where the DNA remains unrepaired or has excessive damage. Both these 
mechanisms are strongly believed to work as barriers to carcinogenesis [399]. It has been 
determined that the molecular mechanisms of DSBR can be divided into two pathways of 
repair: HR and NHEJ [341].  
 
 
4.1.1.1 Homologous Recombination 
 
Figure 4.1A outlines the mechanisms of the HR pathway. The main difference 
between the HR and NHEJ pathways lies in their requirement for a homologous DNA 
template during the repair process [262]. The HR pathway is a more accurate method of 
repair: the sister chromatid is used as a template, in order to copy the missing information 
into the broken locus; however, as sister chromatids are identical to each other, the repair 
process for damaged DNA can be initiated without genetic sequence [401]. Thus, this 
pathway only functions in the S/G2 phases of the cell cycle [402].  
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BRCA1 has a role in DSB: it initiates the response to DNA damage, thereby 
maintaining genomic integrity [403, 404]. BARD1 is known as the main protein-binding 
partner to BRCA1. BARD1 and BRCA1 are co-ordinately expressed; however, BARD1 is 
apparently expressed independently of BRCA1 in some tissues that respond to hormonal 
regulation, particularly in the uterus [405] and testis [406]. BARD1 and BRCA1 develop a 
constant heterodimer via their respective RING domains. The heterodimer, which is more 
resistant to proteolysis than the respective homodimers, is the efficient domain for ligase 
activity of ubiquitin, the repair of DNA and transcriptional regulation [407-410]. A tumour-
associated mutation of BRCA1, C61G within the RING finger domain, can interrupt the 
interaction of BRCA1/BARD1 [410], which implies that the heterodimer of BARD1/BRCA1 
has a significant function in BRCA1-mediated tumour suppression. Genomic integrity is 
maintained by the suppressor gene BRCA1 by protecting cells from the harmful effects of 
DSBs and primarily stimulates HR, which is typically known to be an error-free repair 
method [341].  
 
In HR, BRCA1 co-localises with Rad51 to form a complex [403, 404]. A single 
strand of DNA is coated by Rad51 to form a nucleoprotein filament that penetrates and 
makes pairs with a homologous region in duplex DNA, leading to the activation of strand 
exchange and the creation of a crossover between the juxtaposed DNA [411, 412]. This 
action suggests that BRCA1 has a role in the detection and repair of DSBs [403]. The 
formation of Rad51 is decreased after treatment with DNA-damaging agents and during HR 
in BRCA1-deficient cells [413] and thus HR is defective in BRCA1-deficient cells [414]. It 
remains unclear whether Rad51 and BRCA1 can bind directly [413]. Rad51 is not the only 
protein that interacts with BRCA1 to modulate DNA repair; Rad50, with its partners Mer11 
and NBS1, has a similar function [415, 416].  
 
Bau et al proposed that Rad51 may be required for NHEJ for DSB repair [417]. In 
terms of an in-vitro end-joining assay, some studies have shown that cells from mice or 
humans that expressed deficient BRCA1 had more reduced end-joining activity than BRCA1 
proficient cells [36, 418]. Additionally, in vivo BRCA1 increases precise end-joining activity 
[36] (the ATM/CHK2 mediated signalling pathway is also necessary for precise NHEJ [419, 
420]). BRCA1 also plays a role in NHEJ, as it is able to protect DNA ends from excess 
trimming by exonucleases (e.g., Mer11-dependent nucleolytic activity). This was confirmed 
by Paull et al who demonstrated the strong binding of BRCA1 to the ends of DNA and the 
inhibition of Mer11 activity of the MRN complex [421]. Thus, it is suggested that BRCA1 
prevents familial BC; not only by stimulating HR, but also by decreasing error-prone NHEJ 
and promoting error-free NHEJ methods [413].  
 
In eukaryotes, there are six conserved structural maintenance of chromosome (SMC) 
protein family members, SMC1±6. These participate in different functions, including 
condensation of chromosomes, the cohesion of sister-chromatids and the repair of DNA 
damage [422]. The precise mechanisms of how these proteins enhance such distinct functions 
have not yet been determined. Insights directly into the mode-of-action of the SMC family 
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proteins are suggested by their unique organisation, in addition to their pattern of association 
with various other proteins. As they develop their particular mature configuration, SMC 
proteins fold into highly elongated structures containing an asymmetrically-localised ATPase 
activity [423, 424]. SMC6L1 is a key component of the SMC5-SMC6 complex, which is 
involved in DNA-DSB through HR [425, 426]. It has been suggested that this complex may 
possibly enhance the homologous recombination of sister chromatids, simply by enrolling the 
complex of SMC1-SMC3 to DSBs. The association between precatenanes (intertwined 
replicated DNA duplexes) and the linkages of sister chromatid that accumulate in SMC6 
mutants within the existence of DNA damage remains to be identified [427].  
 
 
4.1.1.2 Non Homologous End Joining 
 
Figure 4.1B highlights the mechanisms of the NHEJ pathway. Unlike HR, NHEJ 
combines the two broken DNA strand ends with little or no homology sequence, leading to 
the deletion or insertion of filler DNA, which is operative in all phases of the cell cycle [399, 
428]. Genetic studies featuring radiosensitive mammalian cell lines defective in the re-joining 
of DSBs and also mutations in the genes that encode the components of NHEJ have been 
helpful in identifying a variety of proteins involved in the DSBR process [429, 430]. The 
main two proteins that mediate NHEJ are KU70/KU80 and DNA-PK. The DNA binding 
subunit of DNA-PK, KU, is a heterodimer that includes 70 and 80 kDa subunits (KU70 and 
KU80 respectively). The first step in NHEJ is the detection of DSB by the KU70/KU80 
heterodimer. Cells defective in either KU70 or KU80 are IR-sensitive and do not complete 
V(D)J recombination (combines Variable, Diverse, and Joining gene). Although NHEJ is 
considered the predominant repair pathway in mammalian cells, it is an error-prone method, 
due to the fact that it does not base repair on an intact homologous template (sister chromatid) 
[399, 428].  
 
It has been demonstrated that the XRCC5, XRCC6 and XRCC7 genes encode the 
DNA-PK; XRCC5 and XRCC6 encode the KU70/KU80 heterodimer (the DNA-binding 
subunit of DNA-PK), while XRCC7 encodes the 470 kDa DNA-catalytic subunit of protein 
kinase DNA-PK [431-433]. Despite the fact that the actual role of these proteins in the DSBR 
process remains to be identified, three possible steps have already been indicated in the repair 
of DSBs via NHEJ: (a) end-binding and bridging, (b) terminal processing and, finally, (c) 
ligation. In the first step, KU binds the ends of the DNA (the activity of the end-binding of 
KU indicates that it could be the initial detector of damage in NHEJ), aligns them and 
prepares for ligation; additionally, it protects from degradation [434]. DNA-PK is recruited 
towards DSBs by KU, leading to the activation of its kinase function [435]. Even though the 
target proteins of DNA-PK remain unidentified, many experts have proposed that DNA-PK is 
able to (a) phosphorylate XRCC4 and eliminate or transfer the ligase IV/XRCC4 complex 
from KU-bound DNA ends and thus enable essential processing actions to occur [436, 437], 
(b) manage the accessibility of DNA ends to processing in its inactivation through auto-
phosphorylation and/or by means of enabling the translocation of KU away from the DSB 
and, finally, [438] (c) phosphorylate both KU70 and KU80, with as-yet-undetermined effects.  
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In mammals, DNA polymerases assist in increasing the efficiency of NHEJ by 
enabling gaps to be filled throughout the re-joining of the two non-complementary ends. A 
physical interaction between KU, XRCC4 and the ligase IV±polymerase complex has also 
been documented [439]. Finally, throughout the final step of NHEJ, the DNA ligase IV tight 
complex and XRCC4, which has been demonstrated to form a tetramer, are recruited to ligate 
the DSBs [440, 441]. Several studies have aimed to identify other factors involved in NHEJ. 
Recent studies using human radiosensitive SCID (severe combined immunodeficiency) cells 
determined mutations in a novel protein of DNA-DSBR , known as Artemis, and revealed the 
value of this protein in lymphoid differentiation in bone marrow [264, 442]. Artemis is 
involved in DNA end processing, as a result of the 5¶ exonuclease activity [443]. 
 
 
4.2 Hypothesis  
 
Of the various types of DNA damage that can occur within a mammalian cell, DSB is 
understood to be the most lethal [262, 397]. Many studies have indicated a link between 
DSB, genomic instability and cancer and this relationship is based upon the fact that 
syndromes representing a predisposition to cancer are characterised by genome instability 
and arise from a mutation in DSB-responsive genes [262, 398]. Women with reduced or 
aberrant BRCA1 and show defect in DNA-DSBR pathway are generally TNBC and basal 
phenotype, with aggressive features [444]. It is thus hypothesised that alterations of the repair 
pathways of DNA-DSBs may also contribute to the development and progression of at least a 
proportion of sporadic breast carcinoma particularly those associated with features similar to 
breast carcinoma arising in patients with BRCA1 germline mutations and particularly with 
respect to development of forms of ER- negative BC.  
 
 
4.3 Aim  
 
The aim of this chapter is to investigate the roles of DNA-DSBR pathways using 
different markers in the repair pathways of HR and NHEJ in BC series using IHC in TMAs 
and RPPA, in order to determine the association between the DNA-DSBR markers, 
pathological features, tumour phenotypes and clinical outcomes.    
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Figure 4.1 Outline of DNA-DSB repair:  A: HR, B: NHEJ. In HR; Nbs1, Mer11 and Rad51 form complex 
which is called MRN. Homology search is started by Rad51 and BRCA1. Holliday junction is a mobile 
junction between 4 strands of DNA and it is importance in maintaining genomic integrity. In NHEJ; 
KU70/KU80 binds to the DNA ends, align, and protect them from degradation.  
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4.4 Materials and Methods 
 
A previously described in Chapter 2 
 
 
4.4.1 Patient Samples  
 
All data are as previously described in Chapter 2 Section 2.1.1.  Three cohorts were 
used: A) 1904 unselected cases of female primary operable invasive tumours between 1986 
and 1998, B) 386 cases selected from a consecutive series of primary operable ER negative 
tumours between 1998 and 2007 and C) 24 well-characterised series of breast tumours from 
patients with known BRCA1 germline mutations. However, High Resolution Melting 
Analysis (HRMA) with employing PCR was used for BRCA1 mutation detection in group C 
(this was performed by Dr Ahmed Benhasouna). All cases were obtained from the well-
characterised Nottingham Tenovus primary breast carcinoma series. 
 
 
 
4.4.2 Available Biomarkers' Data 
 
Data on a wide range of biomarkers of known clinical and biological relevance to BC 
were accessible and saved on a web-based interface (Distiller; Slidepath Ltd, Dublin, 
Ireland). These include, ER, PgR, HER2, CK5, CK17, CK14, tumour suppressor proteins 
(P53 and PTEN), BRCA1 down regulators proteins such as and MTA1 and ID4 and cell 
proliferative marker (Ki-67) [270-274, 331].  
 
 
4.4.3 Immunohistochemistry  
 
As previously described in Chapter 2 Section 2.1.3. Six markers from HR and NHEJ 
repair pathways were investigated in this chapter; BRCA1, BARD1, Rad51, SMC6L1, 
KU70/KU80 and DNA-PK.  
 
 
4.4.3.1 Immunohistochemical Antibody Labelling Using the Novolink Detection Method 
 
As previously described in Chapter 2 Section 2.1.3.1. All the markers were stained by 
the author except BRCA1 which was previously stained by our research group (with thanks 
to Dr Ahmed Benhasouna). All these markers have already been previously successfully 
stained on TMA [287, 335, 336, 445-448].  
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4.4.3.2 Optimisation of Antibodies used for IHC 
 
As previously described in Chapter 2 Section 2.1.3.2. In addition to Western blotting, 
specificity of staining was confirmed by application of negative (with omission of the 
primary antibody) and positive controls. Positive controls were used according to the 
PDQXIDFWXUHU¶V GDWDVKHHW DQGRU IURP WKH KXPDQ SURWHLQ DWODV DYDLODEOH DW
http://www.proteinatlas.org/. This helped not only to test the specificity of staining but also to 
assess the pattern and intensity of protein expressions in the appropriate tissue.  Details of the 
negative and positive controls used are summarised in Table 4.1.  Moreover, some control 
TMA slides containing a variety of BC cases with some containing cores from different areas 
of the same cases in addition to normal parenchymal elements were used during optimisation 
to assess the degree of expression heterogeneity.  
 
 
Table 4.1 Immunohistochemistry Positive and Negative Controls of Antibodies Used in this 
Chapter. 
Antibody Positive control Negative control Reference 
Homologous Recombination Repair Markers 
Rad51 Normal kidney or BC tissue. BC tissue Abcam/ human protein atlas available at  http://www.proteinatlas.org/ 
BRCA1 Normal kidney or BC tissues BC tissue Calbiochem / human protein atlas 
available at  http://www.proteinatlas.org/ 
BARD1 Normal liver or BC tissue. BC tissue Novus Biologicals/ human protein atlas 
available at  http://www.proteinatlas.org/ 
SMC6L1 Normal kidney or BC tissue. BC tissue Abcam/ human protein atlas available at  http://www.proteinatlas.org/ 
Non Homologous End Joining Repair Markers 
DNA-PK BC tissue BC tissue Cell signalling/ human protein atlas 
available at  http://www.proteinatlas.org/ 
KU70/KU80 BC tissue BC tissue Abcam/ human protein atlas available at  http://www.proteinatlas.org/ 
Staining of positive and negative controls was performed together in the same run. Negative staining was performed without 
adding the antibody and showed no staining.  All were stained on TMA. All these markers have already been previously 
successfully stained on TMA [287, 335, 336, 445-448].  
 
    
 
4.4.3.3 Immunohistochemistry Scoring   
 
As previously described in Chapter 2 Section 2.1.3.3.  For evaluation of IHC of the 
TMA, a modified H-score was used [282]. For H-score, both the intensity of staining and the 
percentage of stained cells were considered within each tissue core. Staining intensity was 
scored as 0, 1, 2 or 3 for negative, weak, moderate and strong, respectively. The proportion 
(percentage) of positive cells for each intensity was subjectively estimated.  Multiplication of 
the two indices (intensity and percentage positive cells) provided final scores that range from 
0 to 300.  
 
The author re-scored each marker with at least 30% of a randomly chosen subset of 
cases. A statistical agreement test was performed (Kappa value) for each marker, where there 
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was good agreement , and an average was taken. If there were discrepancies, the 
highest scoring was taken. Kappa values are summarised in Table 4.2. Rad51, KU70/KU80 
and BRCA1 were scored using light microscopy, whereas the others were scored visually on 
high-resolution monitors using a web-based interface (Distiller, Slidepath Ltd., Dublin, 
Ireland). Scoring of all markers was performed by the author except BRCA1 was performed 
by Dr Ahmed Benhasouna and rescored by the author. 
 
4.4.4 Specificity of the Antibodies by Western Blot (W.B) 
 
As previously described in Chapter 2 Section 2.1.4.4. Western blot was used on all 
markers except BRCA1 and BARD1, because these markers were stained before applying 
W.B. A mixture of different cell lysates to detect only the specificity of an antibody has been 
applied in different studies and showed its reliability [283, 284]. In the present study, all the 
markers were detected in a mixture of different lysates (MCF-7, MDA-MB-231, HeLa 
BRCA1 and its control), in addition, Rad51 and KU70/KU80 was done on single cell line 
(MCF-7) and showed similar finding to the mixture cell lines (data in Appendix 2). All the 
antibodies tested in this chapter share the same positive controls which were MCF-7, HeLa 
BRCA1 cell lines. The pre-VWDLQHG PDUNHU µIXOO UDQJH UDLQERZ PDUNHU¶ ,QYLWURJHQ /LIH
Technologies) was used as a molecular weight standard.  http://www.proteinatlas.org/ 
provides profile data for positive controls of all the markers used in this study. Table 4.3 
summarises the details of W.B for each marker.  
 
Table 4.3 List of Antibodies Tested by Western Blot on Different Cell Lines. 
Antibody Cell lines Specific positive cell lines* 
Homologous Recombination Repair Markers 
Rad51 MCF-7 MCF-7 or  HeLa BRCA1 cell lines 
SMC6L1 A mixture of MCF-7, MDA-MB-231, HeLa BRCA1 and its control MCF-7 or  HeLa BRCA1 cell lines 
Non Homologous End Joining Repair Markers 
KU70/KU80 MCF-7 MCF-7 or  HeLa BRCA1 cell lines 
DNA-PK A mixture of MCF-7, MDA-MB-231, HeLa BRCA1 and its control MCF-7 or  HeLa BRCA1 cell lines 
Cell lines and reagents were obtained from the group of Dr Madhusudan Srinivasan, thawing and freezing procedures were 
done by Nada Albarakati. Passages, Bradford assay and gel electrophoresis were done by the author. Passages used in W.B 
were as follows; HeLa BRCA1; passages 29&30, HeLa BRCA1 control; passages 15&16, MCF-7; passages 25&26, MDA-
MB-231; passages 15&16. *Data available at http://www.proteinatlas.org/. 
Table 4.2 The Statistical Agreement between Different Scoring of Antibodies Used 
in this Chapter. 
 
Markers Percentage of re-scoring Kappa value 
Homologous Recombination repair Markers 
BRCA1.n 30% 0.57 
BRCA1.c 30% 0.69 
BARD1.c 30% 0.97 
BARD1.n 30% 1 
SMC6L1.n 30% 0.62 
SMC6L1.c 30% 0.75 
Rad51.n 30% 0.8 
Rad51.c 30% 0.6 
Non Homologous End Joining repair Markers 
 
KU70/KU80 100% 0.98 
DNA-PK 30% 0.7 
Kappa test was performed on IBM SPSS 21.0. An average was taken after re-scoring.  
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4.4.5 Reverse Phase Protein Microarray  
 
RPPA was carried out as previously described in Chapter 2 Section 2.1.5. Cell lines 
preparation and protein extraction and interpretation of the results were carried out by the 
author. However, RPPA run and analysis was carried out by Dr Ola Nejm (Immunology, 
School of Life Sciences, University Hospital, Nottingham, UK) as a collaborative project.  
 
In addition to HR and NHEJ repair markers, PTEN was analysed using RPPA (details 
of the antibody dilution is presented in Chapter 2, Table 2.6).                                                
 
 
4.5 Statistical Analysis  
 
All statistical analyses were done by the author using IBM SPSS statistic 21.0 
software.  For all statistical tests, a two-sided P-value of <0.01 was considered statistically 
significant. 
 
 
4.5.1 The Determination of the Optimal Cut-offs  
 
As described previously in Chapter 2 Section 2.1.6.1. The expression of the 
biomarkers investigate in this study were dichotomised using two different approaches: a) 
using the mean or median of the H-score of the staining according to distribution pattern 
whether normally or not normally distributed, or b) using x-tile software (version 3.6.1, 2003-
2005, Yale University, USA). If the cut-off by mean or median was very high (e.g H-score 
>200) then x-tile was considered, all the markers in this study used x-tile except SMC6L1 
and BRCA1. However, for SMC6L1, regardless cellular localisation, both x-tile cut-points 
and mean or/median were high so a more reasonable cut-off based on frequency distribution, 
therefore, mean was for nuclear and median for cytoplasmic expression of SMC6L1. Some 
markers showed similar cut-off by x-tile and mean/median such as BARD1.n, and BRCA1.n. 
The means of DNA-PK and Rad51 were high so x-tile was considered. If the mean/median of 
Rad51 was taken then more than three quarter of the cases will be considered negative 
  
 
Table 4.4 shows the details of the antibodies used in this chapter. Details of H-score 
histograms of all markers are presented in Appendix 2.  
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Table 4.4 Sources, Dilution, Cut-offs Point and Pre-Treatment Conditions of the Antibodies 
Used in this Chapter. 
Antibody Clone Source Dilution IHC 
Dilution 
W.B 
RPPA 
+Distribution Cut-offs IHC kit 
Homologous Recombination Repair 
 
BARD1 NBP1-19636 Novus Biologicals 1:50 1h 
NT 
1:200 Nuclear/cytoplasmic 
+-score 
cytoplasm, >0 H-
score *nuclear, x-tile. 
Novolink 
BRCA1 Ab-1 (MS110) Calbiochem 1:150 1h 
NT 
1:200 Nuclear/cytoplasmic 
 H-score *nuclear, 
H-score 
cytoplasmic, means. 
ABC 
Rad51 Ab88572 Abcam 1:70 1h 1:1,000 1:100 Nuclear/cytoplasmic 
1XFOHDU+-score 
&\WRSODVP+-
score, x-tile. 
Novolink 
SMC6L1 AB57759 Abcam 1:100 1h 1:1,000 1:250 Nuclear/cytoplasmic 
Nuclear >240 H-
score, mean 
Cytoplasm +-
score, median. 
Novolink 
Non Homologous End Joining Repair 
 
KU70/KU80 Ab3108 Abcam 1:2500 1h 
1:1,000 
1:500 Nuclear +-score, x-tile. Novolink 
DNA-PK 3H6 Cell 
signalling 1:28 1h 
1:2,000 
1:150 Nuclear 
1XFOHDU+-
score, x-tile. Novolink 
All the antibodies were pre-treated in citrate antigen retrieval pH=6.0 in microwave for 20 minutes and stained on TMA using IHC. + 
Cellular localisation. BRCA1 was stained/scored by Dr Ahmed Benhasouna. All the antibodies were incubated at room temperature for 1 
hour. *BARD1.n and BRCA1.n showed similar cut-off by x-tile and mean/median. IHC= Immunohistochemistry. W.B= western blotting. 
NT= not tested. W.B was not run on BRCA1 and BARD1, because these markers were stained before applying W.B. 1h= 1 hour incubation 
with the primary antibody at room temperature. 
 
 
4.5.2 Univariate Analysis with Clinico-Pathological Parameters and Tumour Markers  
 
The differences between all markers, with regards to clinico-pathological features, or 
with other tumour markers were analysed using the Pearson Chi-Squared test (X2). 
Consequently, X2 was also used in order to examine the inter-relations between markers 
themselves. In addition analysis of continuous variables was performed using 3HDUVRQ¶V
correlation and ANOVA. One way ANOVA was used to find out which of different BC 
classes (by IHC or RPPA) were significantly different from each other (post hoc test; Tukey).  
 
 
4.5.3 Univariate Analysis with 3DWLHQWV¶Outcome  
 
Patients who were alive or those who died for any reason other than BC were not 
included. The Kaplan-Meier method was used to generate a univariate survival curve and the 
differences in survival among the biomarkers were evaluated using the log-rank test.  
 
 
4.5.4 Multivariate Analysis with PDWLHQWV¶Outcome  
 
,IDPDUNHULQXQLYDULDWHDQDO\VLVZDVVWDWLVWLFDOO\VLJQLILFDQWZLWKSDWLHQW¶VRXWFRPH
then Cox regression was applied for multivariate analyses to test for confounders and 
prognostic or predictive independency of the investigated biomarker from standard 
prognostic/predictive factors such as tumour grade, tumour stage, and tumour size.    
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4.6 Results  
 
4.6.1 Expression of DNA-DSB Repair Markers in Invasive Breast Cancer  
 
Western blotting validated the specificity of antibodies in DNA-DSB repair, which 
was deemed validated by a single band at the correct protein size (see Figure 4.2). However, 
some antibodies, such as BARD1 and BRCA1, were stained previously before applying W.B, 
however, positive and negative tissue controls were used to validate the specificity of the 
antibodies. Normal liver tissue was used as positive control of BARD1 (Figure 4.3), and 
normal kidney tissue for BRCA1 (Figure 4.4) (http://www.proteinatlas.org/). However 
BRCA1 was stained previously by Dr Ahmed Benhasouna [449] and BARD1 by the author.  
 
In invasive tumours, the markers for HR repair (Rad51, BRCA1, BARD1 and 
SMC6L1) showed both nuclear and cytoplasmic staining (see Figures 4.3-4.6), whereas, the 
markers of NHEJ repair pathway (DNA-PK and KU70/KU80) demonstrated only nuclear 
staining, with no cytoplasmic or membranous staining observed (Figure 4.7). Although 
BRCA1 and Rad51 are localised in the nucleus, cytoplasmic expression has been mentioned 
previously (in breast and human soft tissue sarcoma cells) [450-452]. In addition, BARD1 
and is expected to express in cytoplasm of the cell [453, 454] as well as SMC6L1,  from 
Human Protein-Protein Interaction Mining Tool available at (http://liweilab.genetics.ac.cn/). 
 
Table 4.5 displays the frequencies of HR and NHEJ repair proteins in sporadic and 
known BRCA1 germline mutations BCs (hereditary), while Figure 4.8 represents the 
distribution of DNA-DSB repair markers (mean) in different classes of BC by IHC. The four 
classes included were classified based on BRCA1 and ER proteins status. Class 1; sporadic 
BRCA1 negative and ER negative, class 2; sporadic BRCA1 positive and ER positive, class 
3; known BRCA1 germline mutations BC that showing ER negativity, and finally; known 
BRCA1 germline mutations BC and showing ER positivity.  
 
There was a strong expression of nuclear BRCA1, nuclear Rad51, or BARD1.c 
(Figure 4.8) in sporadic BRCA1+/ER+ cancers, compared to sporadic BRCA1-/ER- (for all  
P<0.0001) or in comparison to known BRCA1 germline mutations that showing ER 
negativity (BRCA1.n and BARD1.c; P<0.0001 and for Rad51.n; P=0.0001). In contrast, 
cytoplasmic expression of BRCA1 or SMC6L1 in terms of sporadic BRCA1+/ER+ cancers 
was the weakest amongst the other classes.  
 
The expression of the NHEJ markers (KU70/KU80 and DNA-PK) showed similar 
levels in sporadic classes, however, DNA-PK showed a significant difference between  
known BRCA1 germline mutations tumours that expressing ER- and sporadic BRCA1+/ER+ 
(P=0.009).  
 
The large error bars of Figure 4.8 are expected, the mean of H-score does not explain 
repeated observation, it shows the distribution of different cases share ER and BRCA1 status 
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but with other factors such as grade, stage, and size of the tumour which may have some 
effects on the expression of the markers. 
 
Figure 4.2 Detection of different DNA-DSB repair proteins level by Western blot. Detection of DNA-PK and 
SMC6L1 levels by Western blot in a mixture of cell lines, MDA-MB-231, MCF-7, HeLa BRCA1 and its control, 
whereas KU70/KU80 and Rad51 by Western blot in MCF-7 cell line. The predicted size of each protein is labelled 
on the band. Passages used in W.B were as follows; HeLa BRCA1; passages29&30, HeLa BRCA1 control; 
passages 15&16, MCF-7; passages 25&26, and MDA-MB-231; passages 15&16. 
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Figure 4.3 Expression of BARD1 on TMA. Where a; positive control in normal liver tissue, b; negative 
control in invasive ductal/NST breast cancer; stage 2 and grade 3, and c; cytoplasmic expression of BARD1 in 
invasive ductal carcinoma/NST; stage 1, and grade 3. Magnification x20.  
 
Figure 4.4 Expression of BRCA1 on TMA. Where a; positive control in normal kidney tissue, b; negative control in 
invasive ductal/NST breast cancer; stage 1 and grade 3, and c; expression of nuclear and cytoplasmic BRCA1 in 
invasive ductal carcinoma/NST; stage 1 and grade 3. Magnification x20 
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Figure 4.5 Expression of Rad51 on TMA. Where a; positive control in normal kidney tissue, b; negative control in 
invasive ductal /NST breast cancer; grade 3 and stage 1, and c; expression of nuclear and cytoplasmic Rad51 in 
invasive ductal carcinoma /NST; grade 3 and stage 1. Magnification x20 
 
Figure 4.6 Expression of SMC6L1 on TMA. a; negative control for SMC6L1 in breast cancer tissue, b; positive 
control in normal kidney tissue and c; SMC6L1.nuclear and cytoplasmic expression in breast cancer tissue. a and 
c are invasive ductal carcinoma/NST; stage 1, and grade 3. Magnification x20 
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Table 4.5 Frequency of DNA-DSB Repair proteins Expression in Breast Cancer 
Markers 
Sporadic BC known BRCA1 germline mutations BC 
% Frequency % Frequency 
Non Homologous End Joining Repair 
KU70/KU80 86.9% 1130/1301 100% 22/22 
DNA-PK 85.2% 1142/1341 78.9% 15/19 
Homologous Recombination Repair 
Rad51 
Cytoplasmic 89.2% 1051/1184 100% 18/18 
Nuclear 34.7% 411/1184 0% 0/18 
BRCA1 
Cytoplasmic 41.8% 732/1758 0% 0/23 
Nuclear 72.8% 1280/1758 13% 3/23 
BARD1 
Cytoplasmic 79.8% 1179/1477 26.3% 5/19 
Nuclear 9.1% 135/1477 5.3% 1/19 
SMC6L1 
Cytoplasmic 67.9% 942/1387 65% 13/20 
Nuclear 65.9% 914/1387 75% 15/20 
Sporadic BC includes both unselected and ER-negative BC cases. The number of cases may be reduced due to loss cases 
during preparation of tissue for staining (TMA sectioning or IHC procedure). 
 
     
 
  
Figure 4.7 Expression of DNA-PK and KU70/KU80 on TMA. a; negative control for both markers in breast cancer 
tissue, b; DNA-PK. nuclear, and c; KU70/KU80.nuclear. All are invasive ductal carcinoma/NST; stage 1, and grade 
3. Positive control for these two proteins is breast cancer tissue. Magnification x20 
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Figure 4.8 DNA-DSB repair protein levels detected by IHC in breast cancer on TMA. Each bar represents different class 
based on hereditary or sporadic BRCA1 and ER status. n= nuclear and c= cytoplasmic expression. Error bars represent 
Mean (SD) and was created on H-score (ranges 0-300). A= sporadic cases [ER- & BRCA1-] vs. sporadic cases [ER+ & 
BRCA1+], B= sporadic cases [ER- & BRCA1-] vs. Hereditary cases [ER-], C= sporadic cases [ER- & BRCA1-]vs. 
Hereditary cases [ER+], D= sporadic cases [ER+ & BRCA1+]vs. Hereditary cases [ER-], E= sporadic cases [ER+ & 
BRCA1+] vs. Hereditary cases [ER+], and F= Hereditary cases [ER-] vs. Hereditary cases [ER+].  ANOVA test was used 
for each marker within the classes.     Very few cases showed nuclear staining of BARD1.  
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4.6.2 Correlation of DNA-DSB Repair Markers  
 
Table 4.6a summarises the associations between the DNA-DSB repair markers 
(Pearson X2). There was a high association between both the HR and NHEJ markers. 
Rad51.n-.c+ showed a strong association with KU70/KU80+ (P<0.0001), DNA-PK+ 
(P=0.002), SMC6L1.c+ and BARD1.c+ (both P<0.0001). In addition, BRCA1.n-.c+ had a 
significant association with KU70/KU80+ and DNA-PK+, Rad51.c+, Rad51.n-, and 
BARD1.c+ (all P<0.0001). SMC6L1.n+.c+ was highly associated with KU70/KU80+, DNA-
PK+, BRCA1.n- (all P<0.0001), BRCA1.c- and BARD1.c+ (both P=0.006). In terms of NHEJ 
markers, KU70/KU80 and DNA-PK were positively associated with each other (P<0.0001). 
DNA-PK+ was highly associated with BARD1.c (P<0.0001), and however, BARD1nuclear 
and its cytoplasmic expression showed a negative association with each other (P<0.0001).  
 
BRCA1 is combined with BARD 1 as they form a complex in the process of DNA 
repair. Thus the functional component should demonstrate double nuclear positivity while 
other combinations may not be fully functional [455]. Table 4.6b shows complex of 
BRCA1/BARD1 and their subcellular localisation. BARD1n-c+ and BRCA1n+c- were mainly 
expressed in the complex. In addition, Table 4.6c shows a high correlation between 
BRCA1.n+/BARD1.c+ complex and the apoptotic marker P53- (P<0.0001). Details of 
significant and non-significant associations are summarised in Appendix 2. 
 
The high value of X 2 of all the results in this section can be referred to, i) a bias in the 
population of patients, ii) based on the data here, it does not seem to have any assumption 
issues, the main problem is normally when one of the expectation values is 5 or less, but in 
the results presented here a large chi squared value is resulted when the expectations are not 
less than 5. However, the data just seem to show that it is very likely that the association is 
not due to chance.  
 
Table 4.6a Correlation between DNA -DSB Repair Markers. 
SMC6L1 
Parameters 
 
c- n- 
N (%) 
c+ n+ 
N (%) 
c+ n- 
N (%) 
c- n+ 
N (%) X
2 P 
KU70/KU80 Negative 38(26.8) 41(8.9) 18(12.3) 18(15.3) 31 <0.0001 Positive 104(73.2) 422(91.1) 128(87.7) 100(84.7) 
DNA-PK Negative 66 (34.6) 34 (5.5) 48 (24) 23 (15.2) 114 <0.0001 Positive 125 (65.4) 580 (94.5) 152 (76) 128 (84.8) 
BARD1.c 
 
Negative 58(28.3) 114(17.5) 39(18.6) 40(23.4) 13 0.006 Positive 147(71.7) 537(82.5) 171(81.4) 131(76.6) 
BRCA1.c 
 
Negative 110 (61.8) 292 (51) 115 (57.8) 100 (64.1) 12.5 0.006 Positive 68 (38.2) 280 (49) 84 (42.2) 56 (35.9) 
BRCA1.n 
 
Negative 86 (48.3) 344 (59.9) 133 (66.8) 72 (46.2) 22.8 <0.0001 Positive 92 (51.7) 230 (40.1) 66 (33.2) 84 (53.8) 
Rad51 
Parameters c
- n- 
N (%) 
c+ n+ 
N (%) 
c+ n- 
N (%) 
c- n+ 
N (%) X
2 P 
KU70/KU80 Negative 24(36.9) 24(7.5) 58(9.7) 11(23.4) 55 <0.0001 Positive 41(63.1) 294(92.5) 542(90.3) 36(76.6) 
DNA-PK Negative 13(31) 24(10.5) 82(16.5) 1(4) 15 0.002 Positive 29(69) 205(89.5) 414(83.5) 24(96) 
SMC6L1.c Negative 26(55.3) 84(34.7) 131(26.4) 8(28.6) 19.5 <0.0001 Positive 21(44.7) 158(65.3) 365(73.6) 20(71.4) 
BARD1.c Negative 12(26.7) 23(9.5) 148(27.9) 3(8.8) 37 <0.0001 Positive 33(73.3) 218(90.5) 383(72.1) 31(91.2) 
N= number of cases. c. = cytoplasmic, and n. = nuclear expression. . The cut off points of positivity are presented in the next tables. 
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Table 4.6a Correlation between DNA -DSB Repair Markers Continued.  
 
Markers  
BRCA1 
c- n- 
N (%) 
c+ n+ 
N (%) 
c+ n- 
N (%) 
c- n+ 
N (%) 
X2 
 
P 
Rad51.c 
Negative 20 (7.3) 16 (11.7) 11 (4.2) 47 (16.8) 
27 <0.0001 
Positive 253 (92.7) 121 (88.3) 252 (95.8) 233 (83.2) 
Rad51.n 
Negative 228 (83.2) 75 (54) 210 (79.5) 120 (42.6) 
135.8 <0.0001 
Positive 46 (16.8) 64 (46) 54 (20.5) 162 (57.4) 
KU70/KU80 
Negative 32 (10.1) 29 (18.6) 6 (2.3) 58 (18.4) 
43.7 <0.0001 
Positive 284 (89.9) 127 (81.4) 259 (97.7) 258 (81.6) 
DNA-PK 
Negative 68 (20.9) 22 (13.8) 22 (7.1) 37 (12.6) 
25.7 <0.0001 
Positive 258 (79.1) 137 (86.2) 287 (92.9) 257 (87.4) 
BARD1.c 
Negative 97 (28.5) 22 (11.9) 83 (25.3) 36 (11.1) 
44 <0.0001 
Positive 243 (71.5) 163 (88.1) 245 (74.7) 287 (88.9) 
BARD1.c 
Markers Negative N (%) 
positive 
N (%) X
2
 
P 
BARD1.n 
 
Negative 297(99.7) 1043(88.6) 35 <0.0001 
Positive 1(0.3) 134(11.4) 
Rad51.n 
Negative 160(85.6) 417(62.2) 36 <0.0001 
Positive 27(14.4) 253(37.8) 
DNA-PK 
Markers Negative N (%) 
positive 
N (%)   
BARD1.c 
Negative 67(36.2) 176(16.9) 
37 <0.0001 
Positive 118(63.8) 864(83.1) 
KU70/KU80 
Negative 37(28.2) 68(9.5) 
35.5 <0.0001 
Positive 94(71.8) 645(90.5) 
N= number of cases. c. = cytoplasmic, n. = nuclear expression. The cut off points of SRVLWLYLW\ZHUHDVIROORZV 40 H-VFRUHIRU%5&$FDQG 
IRU%5&$Q130  H-score for BARD1.c  and  > 0 H-VFRUHIRU%$5'Q+-VFRUHIRU5DGQDQG+-score for Rad51.c, >240 H-score 
IRU60&/QDQG+-VFRUHIRU60&/FH-VFRUHIRU.8.8DQG+-score for DNA-PK. 
 
Table 4.6b BRCA1/BARD1 and their Subcellular Localisation. 
Markers 
BRCA1/BARD1 complex any localisation 
Negative 
N (%) 
positive 
N (%) 
P 
X2 
BARD1 
BARD1n-c- 96 (100) 141(10.7) 
<0.0001 
 
512 
BARD1n+c+ 0 134(10.2) 
BARD1n-c+ 0 1043(79.1) 
BARD1n+c- 0 1(0.1) 
BRCA1 
BRCA1n-c- 96 (100) 244(16) 
<0.0001 
 
384 
BRCA1n+c+ 0 283(18.6) 
BRCA1n+c- 0 566(37.2) 
BRCA1n-c+ 0 430(28.2) 
BRCA1 is combined with BARD 1 as they form a complex in the process of DNA repair. Thus the functional component should 
demonstrate double nuclear positivity while other combinations may not be fully functional. N= number of cases. c. = cytoplasmic, n. = 
nuclear expression. The cut off points of positivity; +-score for %5&$FDQG IRU%5&$Q130 H-score for BARD1.c and > 0 H-
score for BARD1.n. 
 
Table 4.6c Correlation between BRCA1/BARD1 Complex and the Apoptotic Marker P53. 
BRCA1.n/BARD1.c 
P53 
Negative 
N (%) 
positive 
N (%) 
P 
X2 
BRCA1.n- BARD1.c- 72 (10.1) 107 (23.7) 
<0.0001 
 
89 
BRCA1.n+ BARD1.c+ 334 (46.8) 112 (24.8) 
BRCA1.n- BARD1.c+ 261 (36.6) 222 (49.2) 
BRCA1.n+ BARD1.c- 46 (6.5) 10(2.2) 
BARD1 location in the cell cytoplasm correlates with its apoptotic function. N= number of cases. c. = cytoplasmic, n. = nuclear expression. 
+-VFRUHIRU%5&$FDQG3 for BRCA1.n, 130 H-score for BARD1.c and > 0 H-score for BARD1.n, DQGIRU3.  
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4.6.3 Correlation of DNA-DSB Repair Markers with Other Tumour Biomarkers 
 
The association between categorical (X2) DNA-DSB repair markers (regarding 
subcellular localisation) and other tumour biomarkers are summarised in Table 4.7a-d.  
 
Hormone receptors; ER-, PgR- and TN tumours showed high significant associations 
with Rad51.n-.c+ (all P<0.0001, Table 4.7a), BRCA1.n-.c+ (all P<0.0001, Table 4.7b), and 
BARD1.c+ (all P<0.0001, Table 4.7c), but SMC6L1.n+.c+ was only significant with TN 
(P<0.0001, Table 4.7c) and KU70/KU80 with ER (P=0.005, Table 4.7d). 
 
There was a highly significant association between the HR markers, but not the NHEJ 
markers, with at least one of the basal cytokeratins (CK5, CK14 and/or CK17) or BLBC 
(Tables4.7a-c).  
 
There was a high significant association between negative PTEN and all HR repair 
markers; Rad51n-.c+ (P<0.0001, Table 4.7a), BRCA1n+.c- (P<0.0001, Table 4.7b), 
SMC6L1n+.c+ (P=0.001, Table 4.7c), and finally BARD1.c+ (P=0.005, Table 4.7c). However, 
regarding NHEJ repair markers; only DNA-PK showed such an association with PTEN 
(P<0.0001, Table 4.7d).   
 
Two markers that acted as down regulators for BRCA1 were investigated here: these 
were ID4 and MTA1 (data for these markers are saved on a web-based interface (Distiller; 
Slidepath Ltd, Dublin, Ireland))). All HR and NHEJ markers were significantly associated 
with at least one of BRCA1 down regulators (ID4 or MTA1), regardless of cellular 
localisation (Tables4.7a-d). 
 
P53- was significantly associated with HR, but not NHEJ repair markers or SMC6L1, 
(for both Rad51 and BRCA1; P<0.0001, and for BARD1; P=0.0001, Tables 4.7a-c). There 
was a high significant association with all HR/NHEJ repair proteins with at least one of 
DNA-damage sensors and signal transducers proteins such as CHK1, CHK2, ATM, ATR, 
DQG Ȗ+$;  )RU +5 UHSDLU 5DG &+.Q &+.F &+. $70 Ȗ+$;Q DOO
3H[FHSWȖ+$;F3 7DEOHD%5&$&+.Q&+.F&+.$70
ATR Ȗ+$;Q DQG Ȗ+$;F; all P<0.0001, Table 4.7b), SMC6L1 (CHK1.c; P=0.001, 
Ȗ+$;Q Ȗ+$;F, ATR DQG &+. 3 7DEOH F %$5'F Ȗ+$X.n; 
3 Ȗ+$;F 3  7DEOH F IRU 1+(- UHSDLU PDUNHUV a high significant 
association was seen between KU70/KU80 and DNA-damage sensors and signal transducer 
such as (CHK1.c; P<0.0001, and ATR; P=0.007, Table 4.7d), in addition DNA-PK had a 
significant association with &+.F &+. $75 Ȗ+$;F DQG Ȗ+$;Q DOO 3
(Table 4.7d).    
 
Cell cycle progression/arrest regulator marker P27- showed a significant association 
with Rad51, BRCA1, BARD1.c (all P<0.0001, Tables 4.7a-c), and KU70/KU80 (P=0.002, 
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Table 4.7d). Details of significant and non-significant associations are summarised in 
Appendix 2.  
 
Table 4.8 shows the correlation on continuous data of DNA- DSB repair proteins with 
other tumour markers (Pearson¶V correlation). Some correlations between categorical and 
continuous data were different therefore, only these categorical correlations were re-analysed, 
but regardless co-expression of cellular localisation, in order to compare each cellular 
localisation separately. Therefore, Table 4.9 shows the association between categorical (X2) 
DNA-DSB repair markers and other tumour biomarkers but regardless co-expression of 
VXEFHOOXODUORFDOLVDWLRQWRPDNHWKHFRPSDULVRQZLWKFRQWLQXRXVGDWD3HDUVRQ¶VFRUUHODWLRQ
Table 4.8) easier.  
  
Table 4.8 is confirming the categorical data (Tables 4.7 and 4.9) in the area of 
statistical significant and direction of the correlation. However, when Rad51.n was analysed 
as a continuous variable, some correlations showed different results. A trend for significant 
correlation was observed with DNA-PK (P=0.031, continuous data, Table 4.8) while a 
significant correlation was found with categorical data (P=0.004, Table 4.9). Similarly was 
seen in the correlation between BRCA1.c and P27 (P=0.2, continuous data; Table 4.8 and 
P=0.005, categorical data; Table 4.9), PgR (P=0.37, continuous data; Table 4.8 and P=0.001, 
categorical data; Table 4.9) ER (P=0.759, continuous data; Table 4.8 and P<0.0001, 
categorical data; Table 4.9), Rad51.n where the correlation lost significance in continuous 
data(P=0.047, continuous data; Table 4.8 and P=0.009, categorical data; Table 4.9), but the 
correlation was changed to significant with SMC6L1.n (P=0.002, continuous data; Table 4.8 
and P=0.06, categorical data; Table 4.9). 
 
The high value of X 2 of all the results in this section can be referred to, i) a bias in the 
population of patients, ii) based on the data here, it does not seem to have any assumption 
issues, the main problem is normally when one of the expectation values is 5 or less, but in 
the results presented here a large chi squared value is resulted when the expectations are not 
less than 5. However, the data just seem to show that it is very likely that the association is 
not due to chance.  
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Table 4.7a Correlation between Rad51 with other Tumour Markers. 
 
Markers 
Rad51 
c- n- 
N (%) 
c+ n+ 
N (%) 
c+ n- 
N (%) 
c- n+ 
N (%) X
2 P 
ER Negative 23(33.3) 81(24.4) 387(56.7) 5(9.4) 126 <0.0001 Positive 46(66.7) 251(75.6) 295(43.3) 48(90.6) 
PgR Negative 30(46.9) 127(38.7) 426(65.4) 6(12.5) 100 <0.0001 Positive 34(53.1) 201(61.3) 225(34.6) 42(87.5) 
Triple Negative Negative 52(78.8) 284(86.3) 397(60.5) 49(94.2) 88 <0.0001 Positive 14(21.2) 45(13.7) 259(39.5) 3(5.8) 
CK5 Negative 46(86.8) 235(83.9) 376(67.5) 41(95.3) 42 <0.0001 Positive 7(13.2) 45(16.1) 181(32.5) 2(4.7) 
CK17 Negative 51(94.4) 215(84.6) 463(79.3) 36(90) 11.5 0.009 Positive 3(5.6) 39(15.4) 121(20.7) 4(10) 
BLBC Negative 49(87.5) 278(88) 406(68.1) 45(93.8) 58 <0.0001 Positive 7(12.5) 38(12) 190(31.9) 3(6.2) 
P53 Negative 47(75.8) 233(71) 370(55.1) 40(80) 37 <0.0001 Positive 15(24.2) 95(29) 302(44.9) 10(20) 
ID4.c Negative 41(57.7) 113(32.3) 236(34.3) 24(43.6) 19 <0.0001 Positive 30(42.3) 237(67.7) 452(65.7) 31(56.4) 
PTEN Negative 27 (69.2) 151 (76.3) 250 (89) 14 (53.8) 31 <0.0001 Positive 12 (30.8) 47 (23.7) 31 (11) 12 (46.2) 
CHK1.n Negative 50(73.5) 190(60.5) 518(85.6) 18(35.3) 114 <0.0001 Positive 18(26.5) 124(39.5) 87(14.4) 33(64.7) 
CHK1.c Negative 18(26.5) 21(6.7) 37(6.1) 15(29.4) 61 <0.0001 Positive 50(73.5) 292(93.3) 568(93.9) 36(70.6) 
CHK2 Negative 20 (52.6) 88 (43.3) 191 (60.8) 8 (32) 20 <0.0001 Positive 18 (47.4) 115 (56.7) 123 (39.2) 17 (68) 
Ki-67 Negative 32(55.2) 139(50) 149(24.1) 22(53.7) 77 <0.0001 Positive 26(44.8) 139(50) 469(75.9) 19(46.3) 
ATM Negative 20 (64.5) 98 (44.7) 311 (62.8) 13 (37.1) 26.5 <0.0001 Positive 11 (35.5) 121 (55.3) 184 (37.2) 22 (62.9) 
Ȗ+$;.n 
 
Negative 4(11.1) 8(3.6) 93(19.2) 1(3.7) 34 <0.0001 Positive 32(88.9) 217(96.4) 392(80.8) 26(96.3) 
Ȗ+$;.c Negative 8(22.2) 24(10.7) 37(7.6) 7(25.9) 17 0.001 Positive 28(77.8) 201(89.3) 448(92.4) 20(74.1) 
P27 
 
Negative 12(44.4) 34(28.6) 203(59.2) 8(34.8) 36 <0.0001 Positive 15(55.6) 85(71.4) 140(40.8) 15(65.2) 
MTA1.n 
 
Negative 19(46.3) 82(34) 250(48.2) 10(30.3) 16 0.001 Positive 22(53.7) 159(66) 269(51.8) 23(69.7) 
MTA1.c Negative 15(35.7) 26(10.8) 63(12.1) 9(27.3) 25 <0.0001 Positive 27(64.3) 215(89.2) 456(87.9) 24(72.7) 
N= number of cases. c. = cytoplasmic, n. = nuclear expression. The cut off points of positivity were the same as previously published [273], 
and were as follRZVIRU(5 3J5+-score for PTEN,  IRU$70IRU&.!34% for Ki-67DQG+-score for P27, 
+-score for MTA1.c, +-VFRUHIRU07$Q+-VFRUHIRU&+.QDQG+-VFRUHIRU&+.F+-VFRUHIRU&+.
DQG+-score for Ȗ+$; nuclear and cytoplasmic respectivelyDQG+-score for Rad51 nuclear and cytoplasmic respectively. 
+-score for ID4.c. Triple negative (ER, PgR and HER-2). BLBC= Triple negative +positive expression of CK5 and CK14 and CK17 
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Table 4.7b Correlation between Co-expression of Cellular Localisation of BRCA1 with other 
Tumour Markers. 
 
Markers  
BRCA1 
c- n- 
N (%) 
c+ n+ 
N (%) 
c- n+ 
N (%) 
c+ n- 
N (%) 
X2 
 
P 
ER 
Negative 253 (53.9) 68 (24.2) 76 (13.7) 270 (63.2) 325 <0.0001 
Positive 216 (46.1) 213 (75.8) 478 (86.3) 157 (36.8) 
PgR 
Negative 301 (65.6) 96 (34.3) 155 (28) 269 (67.1) 
225 <0.0001 
Positive 158 (34.4) 184 (65.7) 399 (72) 132 (32.9) 
Triple Negative 
Negative 276 (60) 239 (84.8) 498 (90.2) 240 (60) 
179.8 <0.0001 
Positive 184 (40) 43 (15.2) 54 (9.8) 160 (40) 
HER-2 
Negative 391 (84.6) 237 (85.3) 515 (92.1) 307 (75.2) 52.6 <0.0001 
Positive 71 (15.4) 41 (14.7) 44 (7.9) 101 (24.8) 
CK5 Negative 
247 (67.5) 194 (87.4) 363 (90.1) 190 (65.3) 
95 <0.0001 
Positive 119 (32.5) 28 (12.6) 40 (9.9) 101 (34.7) 
CK17 Negative 
292 (78.5) 171 (85.9) 319 (91.1) 265 (78.4) 
28 <0.0001 
Positive 80 (21.5) 28 (14.1) 31 (8.9) 73 (21.6) 
CK14 Negative 
396 (86.8) 249 (89.2) 498 (92.1) 330 (81.7) 
24 <0.0001 
Positive 60 (13.2) 30 (10.8) 43 (7.9) 74 (18.3) 
BLBC Negative 
277 (67.7) 232 (88.5) 491 (94.6) 237 (67.7) 
154 <0.0001 
Positive 132 (32.3) 30 (11.5) 28 (5.4) 113 (32.3) 
P53 
Negative 277 (59.1) 185 (66.1) 449 (81.3) 204 (47.8) 
126.9 <0.0001 
Positive 192 (40.9) 95 (33.9) 103 (18.7) 223 (52.2) 
ID4.n 
Negative 354 (83.3) 194 (85.1) 419 (90.3) 308 (80.8) 
16 0.0001 
Positive 71 (16.7) 34 (14.9) 45 (9.7) 73 (19.2) 
PTEN 
Negative 186 (90.3) 126 (81.3) 198 (71.5) 102 (79.7) 
26 <0.0001 
Positive 20 (9.7) 29 (18.7) 79 (28.5) 26 (20.3) 
CHK1.n Negative 
259 (80.9) 111 (67.3) 214 (65.6) 210 (78.1) 
25.5 <0.0001 
Positive 61 (19.1) 54 (32.7) 112 (34.4) 59 (21.9) 
CHK1.c Negative 
32 (10) 12 (7.3) 53 (16.3) 7 (2.6) 
33 <0.0001 
Positive 288 (90) 153 (92.7) 272 (83.7) 262 (97.4) 
CHK2 
Negative 159 (62.6) 69 (40.8) 117 (41.5) 90 (58.8) 
34.5 <0.0001 
Positive 95 (37.4) 100 (59.2) 165 (58.5) 63 (41.2) 
Ki-67 
Negative 109 (26.2) 93 (41.7) 255 (57.7) 102 (25.6) 
125 <0.0001 
Positive 307 (73.8) 130 (58.3) 187 (42.3) 297 (74.4) 
ATR 
Negative 150 (55.8) 97 (51.1) 213 (57.6) 66 (38.8) 
17.8 <0.0001 
Positive 119 (44.2) 93 (48.9) 157 (42.4) 104 (61.2) 
ATM 
Negative 233 (71) 72 (38.3) 159 (47.5) 168 (55.3) 62.8 <0.0001 
Positive 95 (29) 116 (61.7) 176 (52.5) 136 (44.7) 
MTA1.n 
 
Negative 159 (48.2) 64 (36.8) 108 (34.7) 126 (39.7) 
13 0.004 
Positive 171 (51.8) 110 (63.2) 203 (65.3) 191 (60.3) 
MTA1.c 
Negative 41 (12.4) 25 (14.3) 68 (21.8) 26 (8.2) 
25 <0.0001 
Positive 289 (87.6) 150 (85.7) 244 (78.2) 291 (91.8) 
P27 
 
Negative 103 (57.5) 21 (27.6) 45 (25.4) 131 (61.5) 
70 <0.0001 
Positive 76 (42.5) 55 (72.4) 132 (74.6) 82 (38.5) 
Ȗ+$;.n 
 
Negative 74 (23.4) 7 (4.5) 17 (6.2) 40 (13.2) 51 <0.0001 
Positive 242 (76.6) 148 (95.5) 258 (93.8) 264 (86.8) 
Ȗ+$;.c 
 
Negative 33 (10.4) 20 (12.9) 46 (16.7) 15 (4.9) 
21.6 <0.0001 
Positive 283 (89.6) 135 (87.1) 229 (83.3) 290 (95.1) 
N= number of cases. c. = cytoplasmic, n. = nuclear expression. The cut off points of positivity were the same as previously published [273], 
DQGZHUHDVIROORZVIRU(53J5DQG&.RI+HUFHS7HVWIRU+(5IRU&.DQG&.!34% for Ki-67H-score for 
P27, DQG5% for P53. PTE1+-score, .IRU07$QDQG+-VFRUHIRUF\WRSODVPLF+-VFRUHIRU&+.QDQG+-score 
IRU&+.F+-VFRUHIRU&+.DQG+-VFRUHIRUȖ+$;QXFOHDUDQGF\WRSODVPLFUHVSHFWLYHO\IRU$70+-
score for ATR. ID4.n 12 H-score. +-VFRUHIRU%5&$FDQG3 for BRCA1.n. Triple negative (ER, PgR and HER-2). BLBC= Triple 
negative +positive expression of CK5 and CK14 and CK17 
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Table 4.7c Correlation between HR Repair Markers with other Tumour Markers. 
 
Markers 
SMC6L1 
c- n- 
N (%) 
c+ n+ 
N (%) 
c+ n- 
N (%) 
c-n+ 
N (%) X
2 P 
TN Negative 169(75.4) 498(74.2) 128(59) 132(72.1) 21 <0.0001 Positive 55(24.6) 173(25.8) 89(41) 51(27.9) 
CK5 Negative 128(77.1) 397(75.5) 107(63.3) 114(83.8) 18 <0.0001 Positive 38(22.9) 129(24.5) 62(36.7) 22(16.2) 
CK17 Negative 146(86.4) 422(80.2) 129(72.9) 113(86.9) 14 0.003 Positive 23(13.6) 104(19.8) 48(27.1) 17(13.1) 
BLBC Negative 160(82.5) 476(79.2) 127(62.6) 135(80.8) 30 <0.0001 Positive 34(17.5) 125(20.8) 76(37.4) 32(19.2) 
PTEN Negative 120 (81.6) 284 (79.8) 111 (91) 78 (70.3) 16 0.001 Positive 27 (18.4) 72 (20.2) 11 (9) 33 (29.7) 
CHK1.c Negative 27(18.4) 31(6.6) 16(10.5) 13(10.5) 18 0.001 Positive 120(81.6) 436(93.4) 136(89.5) 111(89.5) 
CHK2 Negative 93 (60) 160 (40.2) 84 (64.6) 51 (47.7) 32.6 <0.0001 Positive 62 (40) 238 (59.8) 46 (35.4) 56 (52.3) 
ATR Negative 132 (67.7) 207 (42.2) 79 (49.1) 106 (73.6) 65 <0.0001 Positive 63 (32.3) 283 (57.8) 82 (50.9) 38 (26.4) 
Ki-67 Negative 83(40.5) 194(31.3) 52(27.4) 73(45.6) 19 <0.0001 Positive 122(59.5) 426(68.7) 138(72.6) 87(54.4) 
MTA1.n 
 
Negative 126(58.1) 181(27.3) 150(68.8) 40(23.4) 170 <0.0001 Positive 91(41.9) 482(72.7) 68(31.2) 131(76.6) 
MTA1.c 
 
Negative 78(35.9) 34(5.1) 18(8.3) 59(34.5) 185 <0.0001 Positive 139(64.1) 630(94.9) 200(91.7) 112(65.5) 
Ȗ+$;Q 
 
Negative 47(25.3) 28(4.4) 71(37.8) 6(3.7) 180 <0.0001 Positive 139(74.7) 603(95.6) 117(62.2) 156(96.3) 
Ȗ+$;F 
 
Negative 36(19.3) 29(4.6) 7(3.7) 44(27.2) 100 <0.0001 Positive 151(80.7) 602(95.4) 181(96.3) 118(72.8) 
 
Markers 
BARD1.c 
Negative 
N (%) 
Positive 
N (%) X
2
 
P 
ER Negative 188(65.7) 437(38.6) 68 <0.0001 Positive 98(34.3) 696(61.4) 
PgR Negative 180(69) 552(50.7) 28 <0.0001 Positive 81(31) 536(49.3) 
TN Negative 137(52.7) 830(75.2) 52 <0.0001 Positive 123(47.3) 273(24.8) 
CK5 Negative 132(60.3) 676(78.5) 31 <0.0001 Positive 87(39.7) 185(21.5) 
BLBC Negative 138(59.5) 799(80.3) 45 <0.0001 Positive 94(40.5) 196(19.7) 
P53 Negative 149(53.4) 706(64.2) 11 0.0001 Positive 130(46.6) 394(35.8) 
ID4.n Negative 214(77) 882(85.9) 13 <0.0001 Positive 64(23) 145(14.1) 
ID4.c Negative 147(51.9) 389(33.4) 33 <0.0001 Positive 136(48.1) 774(66.6) 
MTA1.n Negative 141(54) 365(35.9) 28 
 
<0.0001 Positive 120(46) 651(64.1) 
MTA1.c Negative 74(28.4) 111(10.9) 51 <0.0001 Positive 187(71.6) 906(89.1) 
PTEN Negative 87 (91.6) 558 (79.5) 8 0.005 Positive 8 (8.4) 144 (20.5) 
P27 Negative 114(68.3) 170(39.8) 39 <0.0001 Positive 53(31.7) 257(60.2) 
CHK2 Negative 62 (60.8) 333 (47.2) 6.6 0.01 Positive 40 (39.2) 373 (52.8) 
Ȗ+$;Q 
 
Negative 59(24.5) 90(9.9) 35.5 <0.0001 Positive 182(75.5) 815(90.1) 
Ȗ+$;F 
 
Negative 38(15.8) 76(8.4) 11.6 0.001 Positive 203(84.2) 830(91.6) 
N= number of cases. c. = cytoplasmic and n. = nuclear expression. Co-expression of cellular localisation of SMC6L1 is considered. BARD1 
shows very few cases of nuclear expression 5.3% so, only cytoplasmic was considered. The cut off points of positivity were the same as 
Tables 4.7a-b. >240 H-VFRUH IRU60&/Q DQG  +-VFRUH IRU60&/F+-score for BARD1.c .Triple negative (ER, PgR and 
HER-2). BLBC= Triple negative +positive expression of CK5 and CK14 and CK17 
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Table 4.7d Correlation between NHEJ Repair Markers with other Tumour Markers. 
 
Markers  
KU70/KU80 
Negative 
N (%) 
Positive 
N (%) X
2 P 
ER 
Negative 51(32.7) 489(44.6) 8 0.005 
Positive 105(67.3) 607(55.4) 
P53 Negative 
114(74.5) 653(60.9) 
11 0.001 
Positive 39(25.5) 420(39.1) 
ID4.c 
Negative 82(48) 402(36.2) 9 0.003 
Positive 89(52) 709(63.8) 
CHK1.c 
Negative 40(26) 83(8.1) 
45 <0.0001 
Positive 114(74) 936(91.9) 
ATR 
Negative 84 (65.1) 325 (52.2) 
7 0.007 
Positive 45 (34.9) 298 (47.8) 
MTA1.c 
Negative 37(33) 88(11.3) 38 <0.0001 
Positive 75(67) 689(88.7) 
P27 
Negative 24(32) 233(51.2) 9.5 0.002 
Positive 51(68) 222(48.8) 
 
Markers  
DNA-PK 
Negative 
N (%) 
Positive 
N (%) X
2
 
P 
PTEN 
Negative 124 (93.9) 469 (78.7) 
16.6 <0.0001 
Positive 8 (6.1) 127 (21.3) 
CHK1.c Negative 
26(20.2) 53(7.2) 
22 <0.0001 
Positive 103(79.8) 685(92.8) 
CHK2 Negative 
104 (77.6) 274 (43.9) 50 <0.0001 
Positive 30 (22.4) 350 (56.1) 
ATR 
Negative 106 (67.9) 360 (45.7) 
25.8 <0.0001 
Positive 50 (32.1) 428 (54.3) 
MTA1.n 
Negative 129(69) 340(33.8) 
82 <0.0001 
Positive 58(31) 667(66.2) 
MTA1.c 
Negative 73(39) 88(8.7) 
124 <0.0001 
Positive 114(61) 920(91.3) 
Ȗ+$;Q Negative 53(32.9) 92(9.8) 64 <0.0001 
Positive 108(67.1) 843(90.2) 
Ȗ+$;F Negative 29(18) 76(8.1) 15.5 <0.0001 
Positive 132(82) 860(91.9) 
N= number of cases. c. = cytoplasmic, n. = nuclear expression. The cut off points of positivity were the same as previously published [273], 
and were as follows: IRU.8.8IRU'1$-PK, IRU ER+-score for P27, and IRU337(1+-score, 
 IRU 07$Q DQG  +-VFRUH IRU F\WRSODVPLF  +-VFRUH IRU &+.F  +-VFRUH IRU &+.   DQG   +-score for  
Ȗ+$;QXFOHDUDQGF\WRSOasmic respectively. +-score for ATR. ,'QDQG,'FH-score. Triple negative (ER, PgR and 
HER-2). NHEJ repair markers only expressed in the nucleus with no cytoplasmic expression.  
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Table 4.8 3HDUVRQ¶V&RUUHODWLRQVEHWZHHQ'1$-DSB Repair Markers with other Tumour Markers. 
Markers BRCA1 
.c 
BRCA1 
.n 
BARD1
.n 
BARD1 
.c 
Rad51 
.c 
Rad51 
.n 
SMC6L1
.c 
SMC6L1 
.n 
KU70/ 
KU80 DNA/PK 
BRCA1.c 
R 
* 
-0.129 -0.009 0.009 0.174 -0.064 0.090 0.093 0.119 0.140 
P <0.0001 0.764 0.748 <0.0001 0.047 0.003 0.002 <0.0001 <0.0001 
N 1756 1178 1178 955 955 1106 1106 1055 1090 
BRCA1.n 
R -0.129 
* 
0.044 0.218 -0.088 0.449 -0.122 0.002 -0.108 0.070 
P <0.0001 0.129 <0.0001 0.007 <0.0001 <0.0001 0.953 <0.0001 0.020 
N 1756 1178 1178 955 955 1106 1106 1055 1090 
BARD1.n 
R -0.009 0.044 
* 
0.169 0.052 -0.024 0.037 0.051 0.011 0.054 
P 0.764 0.129 <0.0001 0.132 0.493 0.195 0.072 0.734 0.061 
N 1178 1178 1477 851 851 1237 1237 918 1225 
BARD1.c 
R 
* 
0.085 0.131 0.212 0.201 0.063 0.280 
P 0.014 <0.0001 <0.0001 <0.0001 0.058 <0.0001 
N 851 851 1237 1237 918 1225 
Rad51.c 
R 
* 
0.031 0.119 -0.027 0.164 0.021 
P 0.283 0.001 0.436 <0.0001 0.551 
N 1178 813 813 1030 792 
Rad51.n 
R 
* 
0.159 0.077 
P <0.0001 0.031 
N 1030 792 
SMC6L1.c 
R -0.084 
* 
0.416 0.143 0.208 
P 0.016 <0.0001 <0.0001 <0.0001 
N 813 1387 869 1156 
SMC6L1.n 
R 0.031 
* 
0.280 0.504 
P 0.382 <0.0001 <0.0001 
N 813 869 1156 
P53 
R 0.099 -0.172 0.044 0.059 0.111 -0.113 0.037 0.013 0.004 0.043 
P <0.0001 <0.0001 0.149 0.054 0.001 0.001 0.228 0.685 0.904 0.175 
N 1433 1433 1088 1088 865 865 1042 1042 978 999 
PgR 
R 0.024 0.251 -0.004 0.021 -0.081 0.192 0.009 0.052 0.080 0.037 
P 0.372 <0.0001 0.906 0.481 0.017 <0.0001 0.771 0.094 0.013 0.239 
N 1433 1433 1085 1085 865 865 1039 1039 971 999 
ER 
R -0.008 0.300 -0.021 -0.035 -0.109 0.231 -0.048 0.090 0.119 0.048 
P 0.759 <0.0001 0.482 0.244 0.001 <0.0001 0.123 0.003 <0.0001 0.130 
N 1440 1440 1103 1103 875 875 1052 1052 982 1015 
Ki-67 
R 0.049 -0.279 0.007 -0.008 0.175 -0.226 0.132 -0.052 -0.095 0.045 
P 0.061 <0.0001 0.815 0.768 <0.0001 <0.0001 <0.0001 0.077 0.002 0.131 
N 1483 1483 1248 1248 995 995 1175 1175 1075 1144 
CHK1.c 
R 0.240 -0.052 0.019 0.202 0.300 0.011 0.125 0.194 0.161 0.205 
P <0.0001 0.090 0.558 <0.0001 <0.0001 0.722 <0.0001 <0.0001 <0.0001 <0.0001 
N 1081 1081 939 939 1037 1037 890 890 1173 867 
CHK1.n 
R 0.010 0.352 -0.007 0.071 -0.150 0.457 -0.135 -0.004 -0.039 0.078 
P 0.747 <0.0001 0.841 0.030 <0.0001 <0.0001 <0.0001 0.900 0.181 0.021 
N 1081 1081 939 939 1037 1037 890 890 1173 867 
CHK2 
R 0.013 0.317 0.116 0.124 -0.081 0.208 0.129 0.256 0.027 0.340 
P 0.701 <0.0001 0.001 <0.0001 0.051 <0.0001 <0.0001 <0.0001 0.485 <0.0001 
N 858 858 808 808 580 580 790 790 650 758 
ATR 
R 0.091 -0.085 -0.032 0.055 -0.011 -0.042 0.235 0.098 0.076 0.202 
P 0.004 0.007 0.304 0.078 0.783 0.272 <0.0001 0.002 0.037 <0.0001 
N 1000 1000 1011 1011 673 673 991 991 753 946 
ATM 
R 0.119 0.234 0.016 0.038 0.022 0.157 -0.028 0.044 0.026 0.051 
P <0.0001 <0.0001 0.616 0.250 0.535 <0.0001 0.394 0.187 0.446 0.134 
N 1158 1158 940 940 780 780 906 906 863 871 
*Repeated analysis or aQDO\VLVEHWZHHQWKHPDUNHULWVHOI1 QXPEHURIFDVHV5 3HDUVRQ¶VFRUUHODWLRQ3 3UREDELOLW\YDOXH7KLVWDEOHVKRZVWKHForrelation 
on continuous data of DNA- DSB repair proteins with other tumour markers. The cut off points of positivity were the same as Tables 4.7. 
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Table 4.8 3HDUVRQ¶V&RUUHODWLRQVEHWZHHQ'1$-DSB Repair Markers with other Tumour Markers 
Continued. 
Markers BRCA1 
.c 
BRCA1 
.n 
BARD1 
.n 
BARD1 
.c 
Rad51  
.c 
Rad51 
.n 
SMC6L1 
.c 
SMC6L1 
.n 
KU70/ 
KU80 DNA/PK 
P27 
R -0.049 0.251 -0.043 0.181 0.044 0.187 -0.066 -0.030 -0.058 0.022 
P 0.215 <0.0001 0.293 <0.0001 0.322 <0.0001 0.125 0.489 0.179 0.607 
N 647 647 594 594 512 512 538 538 530 527 
 
Ȗ+$;c 
R 0.103 -0.033 -0.020 0.250 0.224 0.027 0.391 0.202 0.072 0.167 
P 0.001 0.281 0.500 <0.0001 <0.0001 0.459 <0.0001 <0.0001 0.039 <0.0001 
N 1052 1052 1146 1146 773 773 1167 1167 818 1096 
Ȗ+$;n 
 
R 0.018 0.293 0.068 0.284 -0.038 0.263 0.042 0.439 0.173 0.376 
P 0.561 <0.0001 0.021 <0.0001 0.298 <0.0001 0.151 <0.0001 <0.0001 <0.0001 
N 1052 1052 1146 1146 773 773 1167 1167 818 1096 
MTA1.n 
R 0.016 0.187 0.085 0.280 -0.061 0.132 0.095 0.388 0.146 0.366 
P 0.600 <0.0001 0.002 <0.0001 0.076 <0.0001 0.001 <0.0001 <0.0001 <0.0001 
N 1135 1135 1277 1277 834 834 1269 1269 888 1194 
MTA1.c 
R 0.093 -0.069 0.061 0.415 0.209 -0.016 0.454 0.308 0.161 0.428 
P 0.002 0.021 0.030 <0.0001 <0.0001 0.644 <0.0001 <0.0001 <0.0001 <0.0001 
N 1135 1135 1277 1277 834 834 1269 1269 888 1194 
ID4.n 
R 0.073 -0.063 0 -0.099 -0.059 -0.068 -0.036 -0.005 -0.034 -0.052 
P 0.005 0.015 0.994 <0.0001 0.055 0.026 0.217 0.866 0.241 0.072 
N 1501 1501 1305 1305 1074 1074 1209 1209 1170 1181 
ID4.c 
R 0.074 -0.003 0.061 0.336 0.145 0.017 0.116 0.087 0.039 0.153 
P 0.004 0.910 0.030 <0.0001 <0.0001 0.587 <0.0001 0.003 0.189 <0.0001 
N 1496 1496 1274 1274 1060 1060 1185 1185 1151 1159 
CK17 
R 0.067 -0.137 0.017 -0.024 0.071 -0.070 0.072 0.013 0.028 0.025 
P 0.018 <0.0001 0.583 0.433 0.030 0.034 0.023 0.680 0.365 0.427 
N 1261 1261 1073 1073 932 932 1002 1002 1026 983 
CK5 
R -0.004 -0.174 0.008 0.003 0.134 -0.128 0.020 -0.116 -0.042 -0.029 
P 0.887 <0.0001 0.801 0.926 <0.0001 <0.0001 0.563 0.001 0.224 0.409 
N 1081 1081 882 882 756 756 817 817 848 803 
PTEN 
R -0.035 0.214 0.150 0.094 -0.195 0.158 -0.134 0.104 0.054 0.161 
P 0.332 <0.0001 <0.0001 0.008 <.0001 <0.0001 <0.0001 0.005 0.184 <0.0001 
N 766 766 797 797 544 544 736 736 606 728 
5HSHDWHGDQDO\VLVRUDQDO\VLVEHWZHHQWKHPDUNHULWVHOI1 QXPEHURIFDVHV5 3HDUVRQ¶VFRUUHODWLRQ3 3UREDELOLW\YDOXH This table shows the correlation 
on continuous data of DNA- DSB repair proteins with other tumour markers. The cut off points of positivity were the same as Tables 4.7. 
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Table 4.9 Correlation between HR Repair Proteins with other Tumour Markers Regardless 
Co-expression of Cellular Localisation 
Markers 
BRCA1.n BRCA1.c 
Negative 
N (%) 
Positive 
N (%) 
P 
X2 
Negative 
N (%) 
Positive 
N (%) 
P 
X2 
ER 
Negative 526(58.5) 144 (17.2) <0.0001 
312 
329(32.2) 338(47.7) <0.0001 
43 Positive 373(41.5) 693 (82.8) 694(67.8) 370(52.3) 
PgR 
Negative 572(66.4) 252 (30.1) <0.0001 
223 
456(45) 365(53.6) 0.001 
12 Positive 290(33.6) 584 (69.9) 557 (55) 316(46.4) 
CK5 
Negative 438(66.5) 559 (89.2) <0.0001 
95 
610(79.3) 384(74.9) 0.06 
3 Positive 221(33.5) 68 (10.8) 159(20.7) 129(25.1) 
P27 
Negative 235(59.6) 66(26.1) <0.0001 
70 
148(41.6) 152(52.6) 0.005 
7.9 Positive 159(40.4) 187 (73.9) 20 (58.4) 137(47.4) 
SMC6L1.n 
Negative 219(34.5) 158 (33.5) 0.7 
0.1 
225(36.5) 152(31.1) 0.06 
3 Positive 416(65.5) 314 (66.5) 392(63.5) 336(68.9) 
MTA1.n 
Negative 286(44.1) 172 (35.4) 0.003 
8.6 
267(41.7) 190(38.7) 0.3 
1 Positive 363(55.9) 314 (64.6) 374(58.3) 301(61.3) 
CHK1.c 
Negative 40 (6.8) 65 (13.2) <0.0001 
12.7 
85 (13.2) 19 (4.4) <0.0001 
23 Positive 551(93.2) 427 (86.8) 560(86.8) 415(95.6) 
CHK1.n 
Negative 470(79.5) 326 (66.1) <0.0001 
24.7 
473(73.2) 321(74) 0.8 
0.07 Positive 121(20.5) 167 (33.9) 173(26.8) 113 (26) 
CHK2 
Negative 249(61.2) 186 (41.2) <0.0001 
34 
276(51.5) 159(49.4) 0.5 
0.4 Positive 158(38.8) 266 (58.8) 260(48.5) 163(50.6) 
Ȗ+$;Q Negative 114(18.3) 24 (5.6) <0.0001 36 
91(15.4) 47(10.2) 0.014 
6 Positive 508 (81.7) 407(94.4) 500(84.6) 412(89.8) 
Ȗ+$;F Negative 49 (7.9) 66(15.3) <0.0001 14.5 
79(13.4) 35(7.6) 0.003 
9 Positive 574(92.1) 365 (84.7) 512 (86.6) 425(92.4) 
Rad51.n 
Negative 440(81.5) 195(46.2) <0.0001 
131 
348(62.6) 285(70.7) 0.009 
6.9 Positive 100(18.5) 227(53.8) 208 (37.4) 118(29.3) 
BARD1.c 
Negative 181 (27) 58(11.4) <0.0001 
43.8 
133 (20.1) 105(20.5) 0.8 
0.03 Positive 489 (73) 452 (88.6) 530(79.9) 408(79.5) 
Markers 
Rad51.n Rad51.c 
Negative 
N (%) 
Positive 
N (%) 
P 
X2 
Negative 
N (%) 
Positive 
N (%) 
P 
X2 
CK17 
Negative 514(80.4) 255 (85.3) 0.07 
3 
87 (92.6) 678(80.9) 0.005 
7.8 Positive 125(19.6) 44(14.7) 7 (7.4) 160(19.1) 
P27 
Negative 216(58.2) 42 (29.6) <0.0001 
33.7 
20 (40) 237(51.3) 0.1 
2 Positive 155(41.8) 100 (70.4) 30 (60) 225(48.7) 
SMC6L1.n 
Negative 188(34.6) 83 (30.3) 0.2 
1.5 
22 (29.3) 246(33.3) 0.5 
0.5 Positive 356(65.4) 191 (69.7) 53 (70.7) 492(66.7) 
N= number of cases. c. = cytoplasmic, n. = nuclear expression. This table was created to make the comparison between the continuous and 
categorical data much easier, since this table does not consider co-expression of subcellular localisation, leading to compare each cellular 
localisation separately. The cut off points of positivity were the same as Tables 4.7. 
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Table 4.9 Correlation between HR Repair Proteins with other Tumour Markers Regardless 
Co-expression of Cellular Localisation Continued. 
Markers 
Rad51.n Rad51.c 
Negative 
N (%) 
Positive 
N (%) 
P 
 
X2 
Negative 
N (%) 
Positive 
N (%) 
P 
 
X2 
ID4.c 
Negative 277(36.4) 139 (33.9) 0.4 
0.7 
65 (51.6) 349(33.6) <0.0001 
16 Positive 483(63.6) 271 (66.1) 61 (48.4) 689(66.4) 
MTA1.n 
Negative 269 (48) 93 (33.5) <0.0001 
16 
29 (39.2) 332(43.7) 0.4 
0.5 Positive 292 (52) 185 (66.5) 45 (60.8) 428(56.3) 
CHK1.c 
Negative 56 (8.3) 37 (10.1) 0.3 
0.9 
33 (27.7) 58 (6.3) <0.0001 
60 Positive 618(91.7) 331 (89.9) 86 (72.3) 860(93.7) 
CHK2 
Negative 212(60.1) 97 (41.8) <0.0001 
18.7 
28 (44.4) 279 (54) 0.1 
2 Positive 141(39.9) 135 (58.2) 35 (55.6) 238 (46) 
ATM 
Negative 332 (63) 112 (43.8) <0.0001 
26 
33 (50) 409(57.3) 0.2 
1.3 Positive 195 (37) 144 (56.2) 33 (50) 305(42.7) 
MTA1.c 
Negative 78 (13.9) 36 (12.9) 0.7 
0.1 
24 (32) 89 (11.7) <0.0001 
24 Positive 484(86.1) 242 (87.1) 51 (68) 671(88.3) 
Ȗ+$;Q Negative 97 (18.6) 9 (3.5) <0.0001 33 
5 (7.9) 101(14.2) 0.2 
2 Positive 425(81.4) 248 (96.5) 58 (92.1) 609(85.8) 
Ȗ+$;F Negative 45 (8.6) 33 (12.8) 0.06 3 
15 (23.8) 61(8.6) <0.0001 
15 Positive 477(91.4) 224 (87.2) 48 (76.2) 649(91.4) 
BRCA1.c 
Negative 348 (55) 208 (63.8) 0.009 
7 
67 (71.3) 486(56.6) 0.006 
7.5 Positive 285 (45) 118 (36.2) 27 (28.7) 373(43.4) 
DNA-PK 
Negative 95 (17.6) 25 (9.8) 0.004 
8 
14 (20.9) 106(14.6) 0.2 
1.8 Positive 444 (82.4) 231 (90.2) 53 (79.1) 619(85.4) 
Markers 
SMC6L1.n SMC6L1.c 
Negative 
N (%) 
Positive 
N (%) 
P 
 
X2 
Negative 
N (%) 
Positive 
N (%) 
P 
 
X2 
CK5 
Negative 235 (70.1) 511 (77.2) 0.01 
5.8 
242 (80.1) 504 (72.5) 0.01 
6.5 Positive 100 (29.9) 151 (22.8) 60 (19.9) 191 (27.5) 
CK17 
Negative 275 (79.5) 535 (81.6) 0.4 
0.6 
259 (86.6) 551 (78.4) 0.002 
9 Positive 71 (20.5) 121 (18.4) 40 (13.4) 152 (21.6) 
Ȗ+$;Q Negative 118 (31.6) 34 (4.3) <0.0001 166 
53 (15.2) 99 (12.1) 0.1 
2 Positive 256 (68.4) 759(95.7) 295 (84.8) 720 (87.9) 
BRCA1.n 
Negative 219 (58.1) 416 (57) 0.7 
0.12 
158 (47.3) 477 (61.7) <0.0001 
20 Positive 158 (41.9) 314(43) 176 (52.7) 296 (38.3) 
Ki-67 
Negative 135 (34.2) 267 (34.2) 0.098 
0 
156 (42.7) 246 (30.4) <0.0001 
17 Positive 260 (65.8) 513 (65.8) 209 (57.3) 564 (69.6) 
N= number of cases. c. = cytoplasmic, n. = nuclear expression. This table was created to make the comparison between the continuous and 
categorical data much easier, since this table does not consider co-expression of subcellular localisation, leading to compare each cellular 
localisation separately. The cut off points of positivity were the same as Tables 4.7. 
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4.6.4 Correlation of DNA-DSB Repair Markers with Clinico-Pathological Features 
 
Tables 4.10a to 4.10c summarise the association between DNA-DSB repair markers 
(BRCA1, BARD1, Rad51, SMC6L1, KU70/KU80 and DNA-PK) and the various clinico-
pathological features (Pearson X2). HR repair markers showed a significant association with 
poor features such as higher tumour grade (grade III), higher nuclear pleomorphism, and 
higher mitotic frequency, for HR repair markers (Tables 4.10a-c): BRCA1.n-.c+ (all 
P<0.0001), Rad51.n-.c+ (all P<0.0001), BARD1.c+ (P<0.0001, 0.007, and <0.0001 
respectively) and SMC6L1n+.c+ (P=0.001, P<0.0001 and P<0.0001 respectively).  
 
In terms of NHEJ markers (Table 4.10c): KU70/KU80+ was highly associated with 
higher tubular formation (P=0.008) and vascular invasion (P<0.0001). DNA-PK showed no 
significant association with any of clinico-pathological features. Details of significant and 
non-significant associations are summarised in Appendix 2.  
 
As previously discussed, the high value of X 2 can be referred to, i) a bias in the 
population of patients, ii) based on the data here, it does not seem to have any assumption 
issues, the main problem is normally when one of the expectation values is 5 or less, but in 
the results presented here a large chi squared value is resulted when the expectations are not 
less than 5. However, the data just seem to show that it is very likely that the association is 
not due to chance.  
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Table 4.10a Relationship between Rad51 with Clinico-Pathological Parameters 
Parameters 
Rad51 
c- n- 
N (%) 
c+ n+ 
N (%) 
c+ n- 
N (%) 
c- n+ 
N (%) X
2
 
P 
Size 
FP 30(41.7) 138(39.8) 177(25.7) 19(34.5) 
25.5 <0.0001 
>1.5cm 42(58.3) 209(60.2) 512(74.3) 36(65.5) 
Grade 
1 14(19.4) 67(19.3) 47(6.7) 9(16.4) 
140 <0.0001 2 31(43.1) 129(37.1) 139(19.9) 32(58.2) 
3 27(37.5) 152(43.7) 513(73.4) 14(25.5) 
Tubules 
1 3(4.5) 21(6.2) 14(2) 1(1.9) 
44.5 <0.0001 2 29(43.3) 117(34.6) 160(23.4) 24(44.4) 
3 35(52.2) 200(59.2) 509(74.5) 29(53.7) 
Pleomorphism 
1 1(1.5) 9(2.7) 1(0.1) 0 
104.5 <0.0001 2 32(47.8) 142(42.1) 139(20.4) 32(59.3) 
3 34(50.7) 186(55.2) 541(79.4) 22(40.7) 
Mitosis 
1 28(41.8) 135(39.9) 117(17.1) 25(46.3) 
104 <0.0001 2 16(23.9) 65(19.2) 120(17.6) 16(29.6) 
3 23(34.3) 138(40.8) 446(65.3) 13(24.1) 
NPI 
Excellent 9(12.5) 45(13.1) 28(4) 7(12.7) 
111 <0.0001 
Good 22(30.6) 80(23.3) 61(8.8) 14(25.5) 
Moderate1 16(22.2) 94(27.3) 250(36) 17(30.9) 
Moderae2 16(22.2) 83(24.1) 205(29.5) 16(29.1) 
Poor 6(8.3) 33(9.6) 109(15.7) 1(1.8) 
Very poor 3(4.2) 9(2.6) 41(5.9) 0 
Tumour Type 
Invasive Ductal/NST 35 (49.3) 188 (54.7) 535 (77.3) 17 (31.5) 
137 <0.0001 
lobular 8 (11.3) 24 (7) 20 (2.9) 13 (24.1) 
Atypical Medullary 1 (1.4) 5 (1.5) 21 (3) 0 
Mixed+ 21 (29.6) 109 (31.7) 98 (14.2) 22 (40.7) 
Other++ 6 (8.5) 18 (5.2) 18 (2.6) 2 (3.7) 
N= number of cases. c. = cytoplasmic, n. = nuclear expression. + Lobular or tubular mixed BCs. ++ Mucinous, Alveolar Lobular, 
Miscellaneous including Metaplastic, Adenoid Cystic, Spindle, and Tubulolobular. NST= No Special Type. NPI= Nottingham Prognostic 
Index. Excellent NPI (2.08±2.4), good NPI (2.42 to င3.4), a moderate prognostic I NPI (3.42 to င4.4), moderate prognostic II NPI (4.42 to င5.4), poor NPI (5.42 to င6.4), and a very poor NPI (6.5±6.8). The cut-off was as follows+-VFRUHIRU5DGQDQG+-score for Rad51.c 
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Table 4.10b Relationship between BRCA1 with Clinico-Pathological Parameters 
Parameters 
BRCA1 
c- n- 
N (%) 
c+ n+ 
N (%) 
c- n+ 
N (%) 
c+ n- 
N (%) X
2 P 
Size 
FP 128 (27.1) 88 (31.1) 229 (40.5) 108 (25.9) 
31 <0.0001 
>1.5cm 345 (72.9) 195 (68.9) 337 (59.5) 309 (74.1) 
Grade 
1 41 (8.6) 57 (20.1) 128 (22.6) 24 (5.6) 
285 <0.0001 2 91 (19.2) 93 (32.9) 255 (45.1) 66 (15.3) 
3 342 (72.2) 133 (47) 183 (32.3) 340 (79.1) 
Tubules 
1 18 (3.9) 16 (5.8) 38 (6.9) 12 (2.8) 
51 <0.0001 2 108 (23.5) 105 (37.9) 198 (35.8) 99 (23.4) 
3 334 (72.6) 156(56.3) 317 (57.3) 312 (73.8) 
Pleomorphism 
1 3 (0.7) 9 (3.2) 14 (2.5) 2 (0.5) 
319 <0.0001 2 97 (21.1) 99 (35.7) 322 (58.4) 42 (10) 
3 359 (78.2) 169 (61) 215 (39) 378 (89.6) 
Mitosis 
1 82 (17.8) 103 (37.2) 276 (49.9) 58 (13.7) 
228.6  
<0.0001 2 78 (17) 57 (20.6) 106 (19.2) 76 (18) 
3 300 (65.2) 117 (42.2) 171 (30.9) 289 (68.3) 
NPI 
Excellent 28 (6) 37 (13.2) 93 (16.6) 16 (3.8) 
148 <0.0001 
Good 50 (10.7) 62 (22.1) 131 (23.4) 38 (9) 
Moderate1 151 (32.2) 75 (26.8) 171 (30.5) 146 (34.5) 
Moderae2 137 (29.2) 69 (24.6) 104 (18.6) 134 (31.7) 
Poor 76 (16.2) 26 (9.3) 50 (8.9) 63 (14.9) 
Very poor 27 (5.8) 11 (3.9) 11 (2) 26 (6.1) 
Tumour Type 
Invasive Ductal/NST 355 (75.4) 167 (60.1) 236 (42.1) 353 (83.3) 
286 <0.0001 
lobular 10 (2.1) 7 (2.5) 87 (15.5) 6 (1.4) 
Atypical Medullary 18 (3.8) 8 (2.9) 6 (1.1) 10 (2.4) 
Mixed+ 70 (14.9) 80 (28.8) 195 (34.8) 46 (10.8) 
Other++ 18 (3.8) 16 (5.8) 36 (6.4) 9 (2.1) 
N= number of cases. c. = cytoplasmic, n. = nuclear expression. +Lobular or tubular mixed BCs. ++ Mucinous, Alveolar Lobular, 
Miscellaneous Including Metaplastic, Adenoid Cystic, Spindle, and Tubulolobular. NST= No Special Type. NPI= Nottingham Prognostic 
Index. Excellent NPI (2.08±2.4), good NPI (2.42 to င3.4), a moderate prognostic I NPI (3.42 to င4.4), moderate prognostic II NPI (4.42 to င5.4), poor NPI (5.42 to င6.4), and a very poor NPI (6.5±6.8). The cut-off was as follows; +-score for BRCA1.c, DQG for BRCA1.n. 
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Table 4.10c Relationship between DNA-DSB Repair Markers with Clinico-Pathological 
Parameters. 
BARD1 
 
Parameters Negative N (%) 
Positive 
N (%) X
2
 
P 
Grade 
1 27(9.1) 148(12.6) 
28 <0.0001 2 50(16.8) 350(29.8) 
3 220(74.1) 676(57.6) 
Tubules 
1 12(4.1) 45(3.9) 
33 <0.0001 2 43(14.8) 366(31.9) 
3 235(81) 738(64.2) 
Pleomorphism 
1 5(1.7) 16(1.4) 
10 0.007 2 61(21) 348(30.4) 
3 224(77.2) 780(68.2) 
Mitosis 
1 57(19.7) 328(28.5) 
16 <0.0001 2 43(14.8) 215(18.7) 
3 190(65.5) 606(52.7) 
Tumour Type 
Invasive Ductal/NST 211 (72.5) 782 (67.4) 
22 <0.0001 
lobular 19 (6.5) 50 (4.3) 
Atypical Medullary 7 (2.4) 29 (2.5) 
Mixed+ 36 (12.4) 265 (22.8) 
Other++ 18 (6.2) 34 (2.9) 
SMC6L1 
 
Parameters c
- n- 
N (%) 
c+ n+ 
N (%) 
c+ n- 
N (%) 
c- n+ 
N (%) X
2 P 
Stage 
1 161(65.4) 384(53.9) 147(65.9) 129(65.8) 
24 0.001 2 68(27.6) 240(33.7) 61(27.4) 61(27.4) 
3 17(6.9) 89(12.5) 15(6.7) 15(6.7) 
Grade 
1 34(13.8) 70(9.8) 21(9.3) 26(13.3) 
22 0.001 2 72(29.3) 189(26.5) 40(17.8) 65(33.2) 
3 140(56.9) 455(63.7) 164(72.9) 105(53.6) 
Pleomorphism 
1 8(3.4) 6(0.8) 1(0.5) 4(2.1) 
44 <0.0001 2 83(35.2) 169(23.9) 40(18.5) 72(38.3) 
3 145(61.4) 531(75.2) 175(81) 112(59.6) 
Mitosis 
1 61(25.7) 172(24.3) 38(17.5) 68(36.2) 
27 <0.0001 2 48(20.3) 138(19.5) 30(13.8) 27(14.4) 
3 128(54) 398(56.2) 149(68.7) 93(49.5) 
Vascular 
Invasion 
Negative 126(66) 241(51.6) 109(66.9) 93(66) 
21 <0.0001 
Positive 65(34) 226(48.4) 54(33.1) 48(34) 
Tumour Type 
Invasive Ductal/NST 160 (66.7) 506 (71.8) 165 (75.3) 111 (57.2) 
49 <0.0001 
lobular 14 (5.8) 22 (3.1) 2 (0.9) 19 (9.8) 
Atypical Medullary 11 (4.6) 13 (1.8) 9 (4.1) 3 (1.5) 
Mixed+ 45 (18.8) 151(21.4) 37 (16.9) 52 (26.8) 
Other++ 10 (4.2) 13 (1.8) 6 (2.7) 9 (4.6) 
KU70/KU80 
 
Parameters Negative N (%) 
Positive 
N (%) X
2
 
P 
Grade 
1 26(15.5) 139(12.4) 
8 0.01 2 60(35.7) 30(27.1) 
3 82(48.8) 681(60.5) 
Tubules 
1 6(3.7) 44(4) 
9.5 0.008 2 63(38.7) 295(26.9) 
3 94(57.7) 756(69) 
Vascular 
Invasion 
Negative 168(100) 935(83.7) 32 <0.0001 
Positive 0 182(16.3) 
N= number of cases. c. = cytoplasmic, n. = nuclear expression. +Lobular or tubular mixed BCs. ++ Mucinous, Alveolar Lobular, 
Miscellaneous Including Metaplastic, Adenoid Cystic, Spindle, and Tubulolobular. NSP=no special type. The cut-off were as follows;  
for KU70/KU80, >240 H-VFRUHIRU60&/QDQG+-VFRUHIRU60&/F+-score for BARD1.c. 
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4.6.5 Relationship between DNA-DSB Repair Markers and 3DWLHQWV¶Outcomes by 
Univariate Analysis  
 
For HR markers, positive BRCA1.n (but not BRCA1.c) expression was significantly 
associated with longer BCSS and a longer amount of time to distant metastasis (Figures 4.9a-
b; P=<0.0001 for both). BRCA1.n+.c- had the best BCSS (P<0.0001, Figure 4.9c), however 
cytoplasmic expression of BRCA1 had no effect of BCSS (P=0.6, Figure 4.9d).  
 
&KHPRWKHUDS\ LPSURYHG SDWLHQW¶V %&66 VKRZLQJ %5&$Q- , but not cytoplasmic 
(P<0.0001, and P=0.027, Figures 4.10a-b), however this was not seen after receiving 
endocrine treatment in ER-positive tumours (P<0.0001 for both nuclear and cytoplasmic 
expressions, Figures 4.10c-d). BARD1, irrespective of subcellular localisation, was not 
significantly associated with BCSS (Figure 4.11). However, endocrine therapy improved 
SDWLHQW¶V %&66 VKRZLQJ %$5'Q- (P=0.001, Figure 4.12c). The negative expression of 
Rad51.n demonstrated shorter BCSS than the positive expression of Rad51.n (P<0.0001, 
Figures 4.13a). Rad51.c+ showed a trend for shorter BCSS than Rad51.c- (P=0.02, Figure 
4.13b). However, the co-expression of nuclear and cytoplasmic Rad51 highlighted that 
Rad51n-.c+ indicates a worse BCSS, in comparison with other subcellular combinations 
(Rad51n+.c+, Rad51n-.c- and Rad51n+.c-) (P<0.0001, Figure 4.13c). In regards to 
chemotherapy, patients showing Rad51.n+ who did not receive chemotherapy showed the 
best BCSS, whereas the other groups showed no difference ((Rad51.n-/received/not received 
chemotherapy, and Rad51.n+ received chemotherapy), P=0.002, Figure 4.14a). SMC6L1 
showed no effect on BCSS (Figures 4.15a-c), however, regarding to receiving chemotherapy, 
SMC6L1.n- showed better BCSS than SMC6L1+ (P=0.002, Figure 4.16a).   
 
With regards to NHEJ, both markers DNA-PK and KU70/KU80 had no effect on 
SDWLHQWV¶ RXWFRPHV (Figures 4.17a-b). However, endocrine treatment improved BCSS of 
patients showing DNA-PK+ (P=0.008, Figure 4.17f).  
 
The co-expression of KU70/KU80- and DNA-PK+ in TN tumours demonstrated the 
worst BCSS (P=0.001, Figure 4.18a), but showed no effect on non-TN cases (P=0.97, Figure 
4.18b). In addition, in TN+ cases, negative expression of KU70/KU80 and BRCA1.n 
represented better  BCCS than KU70/KU80+ and BRCA1+, whereas in non-TN tumours that 
were also negative for KU70/KU80 and BRCA1.n demonstrated the worst survival (BCSS) 
rates (P=0.017 and P<0.0001 respectively; Figures 4.18c-d respectively). Finally, the double 
negative expression of SMC6L1.n and Rad51.n in unselected cases, showed shorter BCSS 
than the double positive expression of SMC6L1.n and Rad51.n (P=0.003, Figure 4.18e).  
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Figure 4.9 7KH DVVRFLDWLRQV EHWZHHQ %5&$ ZLWK SDWLHQWV¶ RXWFRPHV   QHJDWLYH DQG   SRVLWLYH H[SUHVVLRQ RI
BRCA1. Where n= nuclear expression and c= cytoplasmic expression of BRCA1 and N; number of cases. Only 
patients who died from breast cancer were considered. a; the association between nuclear expression of BRCA1 and 
BCSS, in addition b; the association between nuclear expression of BRCA1 and distant metastasis. c; co-expression 
of nuclear and cytoplasmic BRCA1 and its association with BCSS. d; the association between cytoplasmic expression 
of BRCA1 and BCSS. P<0.01 was considered significant. 
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Figure 4.10 7KH DVVRFLDWLRQVEHWZHHQ%5&$ ZLWK%&66DQG WKH HIIHFW RI WUHDWPHQWRQSDWLHQW¶V RXWFRPH1
number of cases. Only patients who died from breast cancer were considered. a; association between nuclear 
expression of BRCA1 and BCSS based on chemotherapy in unselected cases and b; cytoplasmic expression of 
BRCA1 and BCSS based on chemotherapy in unselected cases. c; nuclear expression of BRCA1 and BCSS based 
on receiving/or not endocrine therapy  in only ER-positive cases. d;  cytoplasmic expression of BRCA1 and BCSS 
based on receiving/or not endocrine therapy  in only ER-positive cases. P<0.01 was considered significant. Some of 
ER-positive tumours did not receive endocrine therapy, because the treatment plan for those cases was as patients 
ZLWKDVFRUHRI13,UHFHLYHGQRDGMXYDQWWKHUDS\  
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Figure 4.11 The associations between BARD1 with BCSS. 0= negative and 1= positive expression of BARD1. Where 
n= nuclear expression and c= cytoplasmic expression of BARD1 and N; number of cases. Only patients who died from 
breast cancer were considered. a; shows association between nuclear expression of BARD1 and BCSS, whereas b; 
shows association between cytoplasmic BARD1 and BCSS. c; co-expression of nuclear and cytoplasmic BARD1and its 
association with BCSS.  P<0.01 was considered significant.  
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Figure 4.12 7KH DVVRFLDWLRQV EHWZHHQ %$5' ZLWK %&66 DQG WKH HIIHFW RI WUHDWPHQW RQ SDWLHQW¶V RXWFRPH 1
number of cases. Only patients who died from breast cancer were considered. a; association between nuclear 
expression of BARD1 and BCSS based on chemotherapy in unselected cases and b; cytoplasmic expression of 
BARD1 and BCSS based on chemotherapy in unselected cases. c;  nuclear expression of BARD1 and BCSS based on 
receiving/or not endocrine therapy  in only ER-positive cases. d; cytoplasmic expression of BARD1 and BCSS based 
on receiving/or not endocrine therapy in only ER-positive cases. P<0.01 was considered significant. Some of ER-
positive tumours did not receive endocrine therapy, because the treatment plan for those cases was as patients with a 
VFRUHRI13,UHFHLYHGQRDGMXYDQWWKHUDS\ 
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Figure 4.13 The associations between Rad51 with BCSS. 0= negative and 1= positive expression of Rad51. Where n= 
nuclear expression and c= cytoplasmic expression of Rad51 and N; number of cases. Only patients who died from breast 
cancer were considered. a; association between nuclear expression of Rad51 and BCSS, whereas b; association between 
cytoplasmic Rad51 and BCSS. c; co-expression of nuclear and cytoplasmic of Rad51and its association with BCSS. 
P<0.01 was considered significant.   
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Figure 4.14 The DVVRFLDWLRQVEHWZHHQ5DGZLWK%&66DQG WKHHIIHFWRI WUHDWPHQWRQSDWLHQW¶VRXWFRPH1QXPEHURI
cases. Only patients who died from breast cancer were considered. a; association between nuclear expression of Rad51 and 
BCSS based on chemotherapy in unselected cases and b; cytoplasmic expression of Rad51 and BCSS based on 
chemotherapy in unselected cases. c; nuclear expression of Rad51 and BCSS based on receiving/or not endocrine therapy  in 
only ER-positive cases. d; cytoplasmic expression of Rad51 and BCSS based on receiving/or not endocrine therapy  in only 
ER-positive cases. P<0.01 was considered significant. Some of ER-positive tumours did not receive endocrine therapy, 
EHFDXVHWKHWUHDWPHQWSODQIRUWKRVHFDVHVZDVDVSDWLHQWVZLWKDVFRUHRI13, received no adjuvant therapy.  
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Figure 4.15 The associations between SMC6L1 with BCSS. 0= negative and 1= positive expression of SMC6L1. Where n= 
nuclear expression and c= cytoplasmic expression of SMC6L1 and N; number of cases. Only patients who died from breast 
cancer were considered. a; association between nuclear expression of SMC6L1 and BCSS, whereas b; shows association 
between cytoplasmic SMC6L1 and BCSS. c; co-expression of nuclear and cytoplasmic SMC6L1 and its association with 
BCSS. P<0.01 was considered significant. 
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Figure 4.16 TKHDVVRFLDWLRQVEHWZHHQ60&/ZLWK%&66DQGWKHHIIHFWRIWUHDWPHQWRQSDWLHQW¶VRXWFRPH1QXPEHURI
cases. Only patients who died from breast cancer were considered. a; association between nuclear expression of SMC6L1 
and BCSS based on chemotherapy in unselected cases and b; cytoplasmic expression of SMC6L1 and BCSS based on 
chemotherapy in unselected cases. c; nuclear expression of SMC6L1 and BCSS based on receiving/or not endocrine therapy 
in only ER-positive cases. d; cytoplasmic expression of SMC6L1 and BCSS based on receiving/or not endocrine therapy  in 
only ER-positive cases. P<0.01 was considered significant. Some of ER-positive tumours did not receive endocrine therapy, 
because the treatment plan for those cases was as patients with a score of N3,UHFHLYHGQRDGMXYDQWWKHUDS\ 
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Figure 4.17 7KHDVVRFLDWLRQVEHWZHHQ1+(-UHSDLUPDUNHUVZLWK%&66DQGWKHHIIHFWRIWUHDWPHQWRQSDWLHQW¶VRXWFRPH 
negative and 1= positive expression.  N; number of cases. Only patients who died from breast cancer were considered. a,b 
&g; show the  association between KU70/KU80&DNA-PK and DFI/BCSS. c&d; show the association between 
KU70/KU80&DNA-PK and BCSS based on chemotherapy in unselected cases, respectively. e&f; show the expression of 
KU70/KU80& DNA-PK and BCSS based on receiving/or not endocrine therapy in only ER-positive cases, respectively. 
P<0.01 was significant. Some of ER-positive tumours did not receive endocrine therapy, because the treatment plan for 
those cases was as patients with a scRUHRI13,UHFHLYHGQRDGMXYDQWWKHUDSy. 
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TN Non-TN 
Non-TN TN 
Figure 4.18 The association between co-expression of NHEJ and HR repair markers and BCSS in TN and Non-TN or unselected 
breast cancer.  TN= triple negative breast cancer. a; shows BCSS of co-expression of KU70/KU80 and DNA-PK in TN. b, BCSS 
of co-expression of KU70/KU80 and DNA-PK in non-TN. c; BCSS of co-expression of KU70/KU80 and BRCA1 in TN breast 
cancer. d; BCSS of co-expression of KU70/KU80 and BRCA1 in non-TN. e; BCSS of co-expression of HR markers SMC6L1 and 
Rad51 in unselected breast cancer.  All shows nuclear expression. P<0.01 was considered significant. The aim of these figures is to 
LQYHVWLJDWHWKHHIIHFWRIDFRPSOH[RIGLIIHUHQWUHSDLUSDWKZD\VRQSDWLHQW¶VRXWFRPH 
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4.6.6 Expression of HR and NHEJ Repair Proteins and 3DWLHQWV¶Outcomes by 
Multivariate Analysis  
 
Table 4.11 and Figure 4.19 show Cox-regression analyses for predictors of BCSS and 
distant metastasis for HR and complexes of HR/NHEJ. Only markers that showed significant 
association in univariate analysis were considered. It shows that Rad51.n, co-expression of 
Rad51.n.c, KU70/KU80 &BRCA1 complex and KU70/KU80&DNA-PK complex are 
independent prognostic markers for BC.  
 
Multivariate analysis for combinations (such as BRCA1 with chemotherapy or 
BRCA1 with endocrine therapy) does not usually perform, multivariate analysis applies for 
the main marker results (+ vs -) as combination effect may be biased by the other factor and 
not by the target marker. 
 
 
Table 4.11 Cox-regression Analyses for Predictors of BCSS and Distant Metastasis. 
Parameters 
 
P-value 
 
95.0% CI Parameters 
 
P-value 
 
95.0% CI 
Lower Upper Lower Upper 
BRCA1.n BRCA1.n.c 
Tumour Stage <0.000
1 
1.510 2.375 Tumour Stage <0.0001 1.511 2.377 
Tumour Grade <0.000
1 
1.429 2.374 Tumour Grade <0.0001 1.495 2.472 
Tumour  Size 0.002 1.184 2.134 Tumour  Size 0.002 1.181 2.129 
NPI 0.5 0.812 1.583 NPI 0.540 0.795 1.550 
BLBC 0.2 0.638 1.116 BLBC 0.2 0.640 1.118 
BRCA1.n 0.1 0.668 1.037 BRCA1.n.c 0.04 0.827 0.996 
BRCA1.n* SMC6L1&Rad51 
Tumour Stage <0.0001 1.594 2.431 Tumour Stage 0.001 1.255 2.327 
Tumour Grade <0.0001 1.213 1.914 Tumour Grade 0.004 1.189 2.483 
Tumour Size 0.002 1.181 2.036 Tumour Size 0.3 0.840 1.799 
BLBC 0.1 0.618 1.058 BLBC 0.050 0.473 1.000 
NPI 0.2 0.890 1.647 NPI 0.366 0.781 1.952 
BRCA1.n 0.05 0.667 1.004 SMC6L1&Rad51 0.120 0.975 1.246 
Rad51.n Rad51.n.c 
Tumour Stage <0.000
1 
1.512 2.584 Tumour Stage 0.000 1.537 2.639 
Tumour Grade <0.000
1 
1.378 2.559 Tumour Grade 0.000 1.402 2.620 
Tumour Size 0.04 1.024 2.001 Tumour Size 0.026 1.045 2.045 
BLBC 0.004 0.434 0.855 BLBC 0.003 0.425 0.839 
NPI 0.94 0.661 1.466 NPI 0.748 0.624 1.403 
Rad51.n 0.004 0.507 0.881 Rad51.n.c 0.01 0.557 1.991 
KU70/KU80& DNA-PK+ BRCA1&KU70/KU80^ 
Tumour Stage 0.26 0.8 2.658 Tumour Stage <0.0001 1.589 3.182 
Tumour Grade 0.2 0.5 34.307 Tumour Grade 0.001 1.257 2.588 
Tumour Size 0.08 0.9 4.904 Tumour Size 0.09 0.9 2.288 
BLBC 0.6 0.4 1.666 BLBC 0.96 0.7 1.527 
NPI 0.5 0.5 3.798 NPI 0.9 0.6 1.591 
KU70/KU80& DNA-PK 0.004 1.18 2.396 BRCA1&KU70/KU80 0.001 0.16 0.610 
BLBC= as defined by TN+ positivity of CK5 and CK14 and CK17. NPI=Nottingham Prognostic Index. BCSS was considered in the 
analysis, except for BRCA1.n* distant metastasis was considered. Cellular localisation used for all the markers was nucleus. Only 
markers in univariate analysis that were statistically significant with SDWLHQWV¶RXWFRPHV were applied for Cox regression (IBM SPSS 
21.0) for multivariate analyses. + In TNBC, whereas ^ in non- TNBC. 
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Figure 4.19 Multivariate Cox-regression analyses for HR and NHEJ markers. In order to test for confounders and 
prognostic or predictive independency of the investigated biomarker from standard prognostic/predictive factors; 
tumour grade, stage and size, NPI, and BLBC, were included. 0= negative expression, and 1=positive expression. 
c=cytoplasmic and n=nuclear expressions. 
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4.6.7 Expression of DNA-DSB Repair Markers in Cell Lines by Reverse Phase Protein 
Microarray 
 
RPPA was used to evaluate the expression levels of DNA-DSB repair markers in 
different cell lines (BRCA1 deficient HeLaSilenciX® cells and its control, (proficient 
BRCA1), MCF-7, and MDA-MB-436 cells). Figure 4.20 shows the expression of HR and 
NHEJ repair markers in different cell lines using RPPA. 
 
RPPA confirmed the IHC results and demonstrated a higher level of expression of 
DNA-DSB repair markers (Rad51, BRCA1, BARD1, SMC6L1 and DNA-PK) in the HeLa 
BRCA1 control or MCF-7 cell lines (ER+, BRCA1+), when compared with the BRCA1 
deficient HeLa, or MDA-MB-436 (ER- & BRCA1-) cell lines. In contrast, the NHEJ marker 
KU70/KU80 was highly expressed in BRCA1 deficient HeLa cell lines, in comparison to its 
control. However, only SMC6L1and KU70/KU80 showed statistical significant differences 
between BRCA1 deficient HeLa and MCF-7 (P=0.004 and P=0.01 respectively). 
  
Expression of PTEN in different cell lines using RPPA is presented in Appendix 2. 
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Figure 4.20 The DNA-DSB repair protein levels detected by reverse phase protein microarray in different cell lines 
(BRCA1 deficient HeLaSilenciX® cells and its control [BRCA1 and BRCA1.C respectively], MCF-7 and MDA-MB-
436 (436) cells).  For image of nitrocellulose slide spotted with different cell lysates; the red square represents the 700 
channel for detection of mouse antibody while green square the 800 channel for rabbit antibody. Images of scanned 
nitrocellulose slides printed with extracted protein from cell lines and probed with the antibodies against the target 
proteins. Five 2-fold dilutions of each sample were printed in duplicate. Background was subtracted and the intensity 
of each spot was normalised to its corresponding GAPDH level. Each (R) represents different passage of each sample, 
therefore, three different passages of each sample were used. Error bars represent Mean (SD). HeLa BRCA1; between 
passage21 and 30, HeLa BRCA1 control; between passage 15 and 20, MCF-7; between passage 25 and 32, and MDA-
MB-436; between passage 12 and 20. A= BRCA1 vs. BRCA1.C, B= BRCA1 vs. MDA-MB-436, C= BRCA1 vs. 
MCF-7, D= BRCA1.C vs. MDA-MB-436, E= BRCA1.C vs. MCF-7, and F= MDA-MB-436 vs. MCF-7. One way 
ANOVA test was used.  
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4.7 Discussion 
 
The mechanisms of DNA repair play a significant role in the maintenance of the 
integrity of DNA, in addition to protecting against DNA damage. Any deregulation of these 
mechanisms is related to the development of cancer, as observed in BCs, particularly in terms 
of BRCA1 and BRCA2 mutations. DNA-DSB leads to the death of cells or the loss of genetic 
material and is thus lethal to cells. HR and NHEJ are two distinct pathways in the repair of 
DSBs in mammalian cells [262, 397]. However, deficiencies in HR and NHEJ have already 
been associated with chromosome instability, sensitivity of DNA damage and predisposition 
to cancer, reflecting the threats presented by DSBs [4].  
 
DNA-DSB repair proteins Rad51, BRCA1, BARD1, SMC6L1, KU70/KU80 and 
DNA-PK in a series of unselected (ER- and ER+) cases, in addition to known BRCA1 
germline mutations BC cases, were investigated, in order to further understand the 
involvement of BRCA1/DSB repair pathways in BC using IHC, and in different cell lines 
(using RPPA). The results of DNA-DSB repair markers were correlated with clinical 
outcomes and the expression of other biomarkers, in order to demonstrate their role in BC.  
 
It is well known that DNA damage induces an increase in the nuclear levels of the 
cells [456]; thus, the markers investigated were initially expected to be expressed primarily 
within the nucleus of a cell. Interestingly, the main markers in the HR pathway (Rad51 and 
BRCA1) and other markers of HR (BARD1 and SMC6L1) (but not the NHEJ pathway 
markers (KU70/KU80 and DNA-PK)) were expressed in both the nucleus and cytoplasm of 
the cells. It is important to be aware of the characteristics of false positive staining by IHC, 
especially in terms of cytoplasmic expression. However, false staining can be easily 
recognised by the observer. If the staining is false, then it would often be somewhat 
indistinct, showing a lack of cell-to-FHOO KHWHURJHQHLW\ DQG KDYLQJ D ¶PXGG\¶ DSSHDUDQFH
However, these features were not observed in the antibodies investigated in this study and 
intensity varied amongst the cases; thus, staining of cytoplasmic expression does not appear 
to represent an artefact. The results of cytoplasmic expression were constant in almost all the 
antibodies tested in this study, showing an association with poor features more than nuclear 
expression. This is not the first study showing the cytoplasmic expression of these markers 
(BRCA1, Rad51, SMC6L1, and BARD1), although different antibody clones were used [450, 
453, 454, 457, 458]. However, it would be better if blocking peptides was used to confirm 
antibody specificity and eliminating concerns about non-specific binding.  
 
In the present study, low levels of nuclear HR proteins such as BRCA1 protein was 
correlated with poor survival, which is similar to a previously reported study investigating 
mRNA levels in lung cancer [459]. In addition, a low level of nuclear Rad51 was correlated 
with established poor prognostic factors, such as high histological grade, TN phenotype and 
poor predictor of patient survival: Graeser et al supports these findings [460]. Cancer cell 
lines with a HR defect, as an example of those that have BRCA1 or BRCA2 loss, tend to be 
unable to stimulate foci of Rad51 following DNA damage  [55, 460]. The inability to make 
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Rad51 after DNA damage shows a functional readout of a defect in HR. In the present study, 
the HeLa BRCA1 cell line (deficient BRCA1), or BRCA1 known mutation BC cases/ ER- 
BC, showed lower levels of Rad51 (or any HR marker) than the control HeLa BRCA1 cell 
line (proficient BRCA1) or sporadic BC showing positive BRCA1 and ER. This finding 
proposes a defect in the HR pathway in BRCA1 known mutation cases/ or ER negativity 
sporadic BC. In line with a previous study [461],  the immunostaining of Rad51 in primary 
BC confirmed a direct relationship between high cytoplasmic Rad51 expression and TN 
status, but an inverse relationship was observed with nuclear expression. This observation 
suggests the possible role of steroid hormone receptors in the regulation of Rad51 [462]. 
Pedram et al investigated the effect of oestradiol (E2)/ER on the HR pathway, where E2 
inhibition of ATR signalling produced a delay in the formation of Rad51 nuclear foci: this 
was observed after UV-irradiation [463]. It is thus possible to hypothesise that the absence of 
steroid hormone receptors may be a surrogate marker of E2/ER signalling, which may 
directly influence the DNA-DSB repair pathway [464, 465]. In the results presented in this 
chapter, a comparison of the Rad51 nuclei and cytoplasmic expression arising within mutated 
BRCA1 carriers showed a high level of cytoplasmic Rad51, supporting the hypothesis that 
nuclear levels may be lower due to the mutation of BRCA1, which might inhibit the transfer 
of Rad51 into the nucleus of the cell. Mitra et al supported these findings in prostate cancer 
[466]. The level of DNA damage required to induce the cytoplasmic to nuclear transport of 
Rad51 has not yet been established. Gildemeister et al have investigated subcellular fractions 
of HeLa and HCT116 (colon cancer cell line) cells and have identified a considerable 
improvement in levels of nuclear Rad51, upon exposure to a moderate dose of IR. In 
addition, they have detected an increase in DNA damage induced (IR/using Western blot) in 
nuclear Rad51 in BRCA2-defective cell line Capan-1, providing further evidence that Rad51 
nuclear transport is an essential aspect of the cellular response to DNA damage [457]. 
 
The HR pathway marker SMC6L1 [467] is correlated with the expression of BRCA1 
[468]. In common with the other investigated HR markers, SMC6L1 was expressed in both 
the nucleus and cytoplasm of cancer cells. In gene-level analyses, SMC6L1 was associated 
with overall and high-grade risk of BC [469]. Roy et al has proposed that SMC6(alternative 
term for SMC6L1) plays a role in the repair of DNA in vivo aimed towards the complex of 
SMC5±6 to ssDNA substrates developed throughout the HR processes and/or replication of 
DNA [467]. Interestingly, unlike the other HR markers, double positive nuclear and 
cytoplasmic expression of SMC6LI was associated with poor prognostic factors, such as TN, 
CK5+, high histological grade, nuclear pleomorphism and mitosis. SMC6L1 showed no effect 
on patient survival, unless when co-expressed with another HR marker; for example, Rad51, 
where double positive SMC6L1.n and Rad51.n cancers were significantly associated with a 
longer BCSS. However, significance was lost in Multivariate analysis, as combination effect 
may be biased by other factors and not by the investigated marker, leading to loss the 
significant of the target markers. This is the first large study of clinico-pathological 
significance, in terms of the survival of SMC6L1 in BC. The findings in this study uncover 
the association of SMC6L1 in linking recognition of DNA damage repair pathways in BC.  
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DSBs that arise throughout replication, if allowed to remain unfixed by the end of the 
S phase, should be repaired prior to mitosis. For HR to occur during both the S and G2 
phases, applying sister chromatids as a template, it is necessary that the sister chromatids are 
produced in closeness to each other. This is most likely initiated by cohesion, which offers an 
actual physical linkage of the sister chromatids from the S phase, until their eventual 
separation during the anaphase. Cohesion is required throughout the S phase. Cohesion is 
triggered by DSB, following completion of DNA replication, and this function is essential for 
the repair of sister-chromatid in cells in the G2 phase [470, 471]. Unsurprisingly, anything 
affecting the cohesion complex or its components through mutation or loading seriously 
affects DSB repair [472, 473]. In the present study, SMC6L1.n (HR marker and may promote 
sister chromatid homologous recombination by recruiting the SMC1-SMC3 cohesin complex 
to DSB [474]) showed a positive association with cytoplasmic CHK1, nuclear or cytoplasmic 
Ȗ+$;&+.+ and ATR. Interestingly, it showed no association with ATM. However, it is 
well known that the first activated kinase by DSB is ATM, and ATR was proven to work as 
downstream of ATM in DSB-induced checkpoint signalling in both phases; S/G2 [306]. 
SMC6L1 has been stated as an important target of ATM for the DSB-induced checkpoint of 
S phase [475]. Therefore, it is interesting that DSB damage-induced sister chromatid 
cohesion requires ATR more than ATM. The result here suggests that ATM may not be 
activated by SMC6L1 and the other DNA damage sensors proteins have roles in cohesion 
complex leading to a defect in DNA repair. However, it is unclear at this point, whether 
SMC6L1 is a direct target of ATR. Further studies should certainly provide interesting 
observation into the roles of ATR in DSB-responsive sister chromatid cohesion. However, 
real time PCR can be used in the future to detect the accumulation of ATR or any markers at 
the damage site by using fluorescent proteins against the target markers. 
 
The major protein-binding partner to BRCA1 is BARD1. BARD1 was initially 
identified as being a nuclear protein and a tumour suppressor gene that has a role in DNA 
repair [476] by localising to nuclear dots of BRCA1 through the S phase and right after DNA 
damage [407, 408]. Rodriguez et al have showed that BARD1 is a nuclear±cytoplasmic 
shuttling protein. It has an N-terminal nuclear export sequence (NES), which assists the 
export to the nucleus through the chromosome region maintenance 1 (CRM1) transport 
receptor pathway. Analogous to the BRCA1 NES [477], the BARD1 NES can also be 
positioned directly inside the binding domain of BARD1-BRCA1; its export activity is 
obstructed upon interaction with BRCA1, leading to the nuclear anchorage of BARD1. 
Rodriguez et al described a unique case study of protein regulation, wherein BRCA1 and 
BARD1 control the subcellular localisation of each other through the reciprocal masking of 
their particular nuclear export signals [477]. In the present study, the co-expression of any 
BARD1/BRCA1 implies that there is a cytoplasmic shift in cellular BARD1. Considering 
that BARD1 and BRCA1 stabilise the expression of each other, [478] the expression of 
BARD1 and BRCA1 were compared in this study. BRCA1.c was co-expressed with 
BARD1.c in some but not all cases. Additionally, the protein BARD1 was localised to the 
cytoplasm (very few cases showed nuclear expression), while BRCA1 was more frequently 
expressed in the nucleus. The expression of BARD1.c was higher than that of BRCA1.n; 
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BRCA1 was localised to the cytoplasm and, in the majority of cases, to the nucleus. In 
addition, there was a high positive correlation between BRCA1.n and BARD1.c. These 
findings propose that the form of BARD1 expressed in breast tumours may not be able to 
directly interact with BRCA1. Wu et al using real time-PCR and cloned and sequenced 
BARD1 cDNAs, showed that the BARD1 overexpressed in ovarian cancer cells and localised 
to the cytoplasm is most probably an aberrant form of BARD1 [479]. Fabbro et al observed 
that BARD1 can increase the nuclear import of BRCA1, in addition to preventing the nuclear 
export of BRCA1 by masking its nuclear export signal [480] 7KLV µFKDSHURQH¶ SURFHVV
requires a direct interaction between the two proteins and BARD1 promotes BRCA1 
recruitment to DNA repair-associated nuclear foci, upon damage of DNA [480, 481].  
 
A recent study has further demonstrated that BARD1 shuttles between the nucleus 
and the cytoplasm: its location in the cell cytoplasm correlates with its apoptotic function, 
which is significantly decreased by BRCA1 [453, 454]. In contrast, Wu et al mirror the 
finding of this study by showing short DFI of cytoplasmic BARD1 with higher tumour grade 
in both ovarian and sporadic BCs [482]. BARD1 stimulates BRCA1-independent apoptosis 
through the P53 pathway after DNA damage [454]. In the present study, the expression of 
BARD1 and P53 was compared, although there was no correlation between their expressions. 
An excess of BARD1 over BRCA1 in known BRCA1 germline mutations cases is expected to 
produce BARD1-induced P53-dependent apoptosis. It is assumed that it is likely that cancer 
cells would inactivate either BARD1 or P53 to avoid apoptosis; however, the tendency 
regarding mutations or epigenetic alterations may be tissue specific. It has been stated that 
BARD1 demonstrates pro-apoptotic activity and is associated with activated expression in 
mice cells immediately after genotoxic stress [483]. This activity is influenced by P53 and, to 
some extent, is suppressed by BRCA1 co-expression in mouse TAC-2 mammary epithelial 
cell lines and embryo stem cells. Interestingly, in this study, BARD1 showed no association 
with P53, but complex BRCA1.n+/BARD1.c+ showed a strong negative association with P53: 
this may show the effect of BRCA1 on BARD1 subcellular localisation and apoptosis by 
P53. Leading however, further studies showing the effect of P53 on complex 
BRCA1/BARD1 are warranted. To investigate the probability that BARD1, like its main 
binding partner BRCA1 has the ability to shuttle in and out of the nucleus, in cell lines for 
example MCF-7 or HeLa BRCA1 control (since both showed the highest expression of 
BRCA1 and BARD1 in this study), the CRM1 nuclear export receptor can be overexpressed 
and evaluated its influence on subcellular localisation of BARD1. In addition, to determine 
the subcellular distribution of endogenous BARD1, fractionated cell lysates from the cell 
lines can be prepared, and analysed for BARD1 using Western blotting. In addition, to 
determine whether the expression of BARD1 in cancers with mutations of BRCA1 is 
correlated with P53 mutation status, real time-PCR can be performed, and cDNA of P53 can 
be cloned and sequenced [453, 454]. 
 
It has been suggested that loss of the expression of PTEN may possibly result in a 
defect in HR. In terms of the phenotype of genomic instability in PTEN-deleted cells, Shen et 
al revealed that cells deficient in PTEN have defective DNA-DSB repair, quite possibly due 
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to loss or downregulation of Rad51, in addition to loss of PTEN at centromeres [484]. PTEN 
works on chromatin and controls the expression of Rad51, which usually decreases the 
incidence of spontaneous DSBs [484]. In the present study, all HR repair markers such as 
Rad51n-.c+, and SMC6L1.n+.c+, and only DNA-PK- from NHEJ pathway were associated 
with loss of PTEN. In addition, RPPA showed that a low expression of PTEN was mainly 
seen in the HeLa BRCA1 cells (deficient BRCA1) (Appendix 2). These findings may explain 
the involvement of PTEN in HR repair. However, when BRCA1.c, but not BRCA1.n, was 
analysed as a continuous variable, correlations showed no significant with PTEN. It is more 
logic to consider the continuous variable as correlation is biological and certainly the cut-off 
points will reflect these correlations, but it can argue that from a clinical point of view, using 
categorical markers may be more helpful for patient management such as ER status in BC 
which is used as positive/ negative and not as continuous variables.   
  
Cells that lack BRCA1 are known to lack the repair of DSBs through the conservative 
mechanism of HR; thus, they apply a substitute repair pathway, primarily NHEJ. Despite the 
fact that NHEJ has a significant role in the repair of DSBs [262], this pathway had no 
consideration for homology (sister chromatid) in repairing breaks and it is therefore 
considered an error-prone repair, ultimately causing elevated instability of the genome [399, 
428, 485]. In this study, as the BRCA1 is extensively discussed, verifying the relationship 
between BRCA1 and NHEJ markers in identifying the risk of BC would probably offer a 
further perception of NHEJ, with regards to the role of HR in tumorigenesis of the breast 
[486]. This study reviews such an investigation, based on (a) using cases of known BRCA1 
germline mutations as a control group (b) a large and well-characterised series of clinically 
annotated, sporadic early-stage BC and, finally, (c) cell lines of BC with varying BRCA1 
statuses. The findings here demonstrate that the expression of KU70/KU80 and DNA-PK was 
higher in tumours showing aggressive characteristics, such as high histologic grade, TN, 
basal-like phenotype and negative expression of BRCA1. Importantly, the expression of 
KU70/KU80 or DNA-PK was associated with the absence of the expression of protein in 
nuclear and positive cytoplasmic BRCA1. RPPA also confirmed this in the cell lines, 
demonstrating a high expression of KU70/KU80 in BRCA1 deficient cell lines (HeLa 
BRCA1), when compared with BRCA1 proficient cell lines (HeLa BRCA1 control). Ghezzi 
et al supported this observation in their research into colorectal cancer [487]. Unlike 
KU70/KU80, DNA-PK was higher in BRCA1 proficient cell lines than in the BRCA1 
deficient cell line (HeLa), again this supports the finding by IHC.  
 
The prognostic significance of the expression of KU70/KU80 and DNA-PK in the 
literature is inconsistent. In this study, KU70/KU80+ showed a trend for longer DFI in 
unselected tumours. This outcome is in line with the research of Pavon et al which 
highlighted a significant relationship between high tumour KU70 mRNA and better overall 
survival in head and neck cancers [488]. However, in colorectal carcinomas, KU70/KU80 
does not predict survival [489]. It may thus be suggested that the prognostic value of 
KU70/KU80 could possibly be organ specific. However, the present study showed that 
KU70/KU80- and DNA-PK+ in TN cases had the worst BCSS. Thus, there is a possibility that 
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complexes of NHEJ markers could possibly differentiate between distinct tumour classes, 
such as ER+ and ER-. Herein, the variation between KU70/KU80 and DNA-PK may possibly 
be a chance result, since they are in the same pathway and thus are expected to show similar 
results; however, it is also possible that their particular features and functions may reveal this 
variation. DNA-PK is apparently limited to higher eukaryotes, whereas KU70/KU80 is 
expressed in the majority of organisms from yeast to man [490]. The function of Ligase IV is 
entirely reliant on KU70/KU80 but not on DNA-PK, highlighting that the components of the 
DNA-PK complex have several functions [491].  
 
The tumour suppressor P53 is phosphorylated and activated by DNA-PK, which is 
dependent on the presence of DNA breaks for its activity [492]. It is widely acknowledged 
that P53 is mutated or deleted in several cancers, including BC [493], and is essential in the 
cellular response to IR by managing cell-cycle checkpoint control, inducing apoptosis, and, 
quite possibly, modulating DNA repair. In the present study, dichotomised, but not 
continuous; (lost significant), KU70/KU80 was positively associated with P53. It appears 
that, in addition to their function in the repair of DNA, DNA-PK and KU70/KU80 may play a 
role in apoptosis as a response to IR, at least in cells with functioning P53. Leading however, 
further studies showing the effect of P53 on NHEJ repair pathway are warranted. Determine 
whether the expression of NHEJ markers in BC (e.g in BRCA HeLa and MCF-7 cells, which 
showed high level of KU70/KU80 and DNA-PK respectively) is correlated with P53 
mutation status, real time-PCR can be performed, and cDNA of P53 can be cloned and 
sequenced.   
 
As outlined above, HR markers show a possible interaction with NHEJ, particularly in 
TN tumours, which could possibly have an impact on their ability to repair DSBs. In TN 
cases, as opposed to non-TN cases, the co-expression of KU70/KU80- and BRCA1.n+ had an 
inverse effect on survival; thus, it appears acceptable to anticipate that HR markers may 
contribute to NHEJ activity and play a pivotal role in the outcome or development and 
progression of BC, particularly in TN tumours. Despite the fact that this demonstrates the co-
expression of HR and NHEJ markers, several questions remain, in terms of which pathway is 
the driver and which marker actually regulates the repair of DSBs. Further functional studies 
are warranted, such as utilising the Comet assay to detect the main markers responds to 
DNA-DSB.  
 
After receiving chemotherapy, cases showing high levels of Rad51.n or BRCA1.n 
protein demonstrated a shorter BCSS, in comparison to cases that received no chemotherapy. 
In contrast, the formation of Rad51 foci in response to DNA damage was recently 
demonstrated to be related to response to neoadjuvant anthracycline-based chemotherapy in 
BC [460]. As chemotherapy toxicity is associated with the ability of a compound to bind 
DNA and develop cross-links, in addition to triggering the death of cells through the 
induction of DSBs [494], it can suggest that a defect in the HR pathway may be responsible 
for failure to repair damage caused by these agents, leading to activate a backup error prone 
pathways such as NHEJ to induce the repair [399, 428, 485].  It is proposed that BRCA1 helps 
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prevent familial BC; not only by stimulating the HR pathway, but also by possibly 
eliminating error-prone NHEJ and promoting error-free NHEJ methods [30]. In this study, 
BRCA1 germline mutated BCs demonstrated a high level of an NHEJ protein (KU70/KU80) 
(but not DNA-PK), in addition to the negative expression of nuclear, not cytoplasmic, HR 
proteins (Rad51 & BRCA1): this may indicate that NHEJ (as an error-prone pathway) is the 
active pathway in the repair of DNA-DSBs in this class of BC. It is important to understand 
whether defects in this particular pathway may engage in the development of BC by studying 
the entire pathway and any overlap markers; thus, the potential effect that one selective 
marker from the distinct repair pathways of DNA-DSB has on SDWLHQWV¶RXWFRPHV must be 
considered. Unfortunately, in this study, BCs containing a BRCA1 mutation are relatively 
infrequent to comment on this group alone. Based on the present study, the cytoplasmic 
expression of HR markers showed a similar effect to NHEJ markers in BC patients, whereas 
the nuclear expression of HR had diverse effects. These findings confirm the diverse role of 
DNA-DSB repair proteins and emphasise the role of subcellular localisation, providing 
further evidence of the complexity of DNA damage response mechanisms.  
 
The results of this study combine the power of IHC with the parallel analytic 
capability of protein microarray RPPA. RPPA was achieved using whole cell extracts and, 
interestingly, the nuclear (rather than the cytoplasmic) expressions of Rad51, BRCA1 and 
SMC6L1 were in-line with the RPPA findings, as was cytoplasmic BARD1 by IHC. This 
confirms the importance of subcellular localisation when investigating any protein (shows 
both localisations) and validates the assertion that nuclear or even cytoplasmic expression 
does not occur by chance. The subcellular localisation of HR markers suggests that the traffic 
of proteins between the nucleus and cytoplasm might play a role in the development of BC. 
Based on the present findings, it can hypothesis that tumours deficient in HR proteins, such 
as Rad51 and BRCA1, may activate a back-up HR pathway for the repair of DSBs, such as 
NHEJ (KU70/KU80 and DNA-PK), this was concluded based on the high level of NHEJ 
proteins.  
 
Knowing the subcellular location of a protein is important for understanding its 
functions [395]. However, regardless co-expression of cellular localisation, BRCA1.c 
UHJDUGOHVVQXFOHDUH[SUHVVLRQVKRZHGQRFRUUHODWLRQZLWK&.07$QȖ+$;.n, CHK2, 
CHK1.n, Rad51.n, BARD1.c, but all these markers were statistically significant with nuclear 
BRCA1 (without consLGHULQJWKHF\WRSODVPLFH[SUHVVLRQ,QDGGLWLRQ3HDUVRQ¶VFRUUHODWLRQ
(continuous data analysis) confirm these finding, leading to hypothesis that the nuclear but 
not cytoplasmic BRCA1 may have the main role in association with these markers in BC. 
Additionally, the association between Rad51.n (regardless cytoplasmic expression) showed 
no correlation with MTA1.c, CHK1.c, and ID4.c, but all these markers were statistically 
significant with cytoplasmic Rad51 (regardless of nuclear expression). Again this may help to 
suggest that the cytoplasmic expression of Rad51 may have the main role in association with 
these markers in BC. Further studies are warranted to investigate the effect of cellular 
localisation of HR repair markers on their function. Improvement in understanding the 
molecular details in the cytoplasmic/nuclear actions of HR repair markers may help to find a 
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target for BC, especially the two cellular compartments showed different features of BC. In 
addition, to determine the subcellular distribution of any marker, fractionated cell lysates 
from cell lines can be prepared, and analysed for target marker using Western blotting. 
 
Although HR and NHEJ proteins may be valuable markers in clinical studies of novel 
therapeutics that target the repair of DNA damage based on the hypothesis of synthetic 
lethality, such as PARP inhibitors, investigating the different proteins plays a role in the 
various repair pathways may offer valuable information, given the complexity of the DNA 
repair processes. Thus, studying further markers of HR and NHEJ repair would improve our 
understanding of the repair of DNA in BC. 
 
Figure 4.21 summarises the key findings in this chapter and pathways involved in 
DNA-DSB in BC.   
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Figure 4.21 A summary of the key findings in this chapter and pathway involved in DNA-DSB repair in breast cancer. 
The cytoplasmic expression was mainly detected in HR markers and was associated with poor survival such as Rad51, 
whereas nuclear expression showed favourable outcome. However, NHEJ markers (KU70/KU80 and DNA-PK) were 
only expressed in the nucleus of cancer cells, and were highly associated with poor features in breast cancer. 
Chapter 5                                                                                                  SUMOylation in BC 
167 
 
Chapter 5 
 
5.1 Introduction  
 
5.1.1 SUMOylation and Association with DSB Repair in Breast Cancer 
 
There are various essential standards in protecting the balance of the genetic 
information of any cell [495]; for example, the independence functions of genome 
maintenance and the immediate reaction to any kind of genomic injury, which in any other 
case would certainly result in disorder within important cellular functions by interfering with 
gene expression. There is also a reversible reaction to the physiological condition associated 
with the cell. In addition, the mechanism for the protection associated with the stability of the 
genome needs to clearly show a flexible reaction to distinct kinds of harmful agents, to which 
a cell may often be exposed [496]. Post-translational modifications, along with ubiquitin on 
its own and a small ubiquitin-related modifier (SUMO), have already been determined as 
major factors in the maintenance of the genome. SUMO is an ubiquitin-like protein that is 
covalently attached to a number of target proteins, in order to modify their function. In 
contrast to ubiquitination, SUMO does not target proteins for proteolytic breakdown; rather, 
it is involved in controlling a number of different protein functional properties, such as 
protein-protein interactions, as well as subcellular targeting [6].  
 
In humans, there are three well-characterised SUMO isoforms: SUMO-2 and SUMO-
3, which share a high level of similarity, and SUMO-1. SUMO follows a similar enzyme 
structural pattern as ubiquitin modification, requiring an E1-activating enzyme, an E2-
conjugating enzyme (only one of these, Ubiquitin-Conjugating Enzyme 9 (UBC9), is 
recognised) and E3-ligating enzymes, including PIAS1-4 (protein inhibitor of activated 
STAT1-STAT4 (signal transducer and activator of transcription)) [497].   
 
Apart from their DNA and protein binding ability, which can be mediated by the 
conserved region of (scaffold attachment factor-A/B/acinus/PIAS (SAP), PIAS proteins 
consist of a really interesting new gene (RING), a finger-like zinc-binding domain, in 
addition to a SUMO interaction motif: as a result, they function as SUMO-E3 ligases (E3) 
[498]. PIAS is thus able to interact with and even modulate a variety of protein activity, in 
addition to signalling cascades [499].   
 
Similar to ubiquitin conjugation, SUMO requires an E1-activating enzyme and an E2 
conjugase [500]. Despite the fact that this action can take place without an E3 ligase, it would 
not be efficient. The presence of mammalian E3 ligases was identified by a couple of 
independent studies employing yeast two-hybrid approaches, which indicated that family 
members of PIAS were SUMO ligases [501, 502]. These studies showed that both PIAS1 and 
3,$6Ȗ 3,$6 in vivo and in vitro offered P53 and LEF1 (Lymphoid Enhancer-binding 
Factor 1) SUMO respectively [501-503]. In contrast to ubiquitin conjugation, SUMO appears 
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to modify the function of protein; not through degradation, but rather by changing function, 
localisation or even the extent of ubiquitylation. PIAS stimulated SUMO involves the motif 
of the RING finger of PIAS, largely because deletion or modification of this motif removes 
the SUMO of PIAS-binding partners [501, 502]. The functional effects of PIAS association 
and PIAS-induced SUMO appear to be different; for example, the removal of SUMO sites in 
LEF1 failed to change its targeting to nuclear bodies, while, in contrast, the deletion of the 
RING motif in PIAS4 blocked this targeting [502]. The loss of the RING finger domain from 
PIAS1 failed to block P53-mediated transcription [504], despite the fact that a study proposed 
that this impact could possibly be cell-type specific [501].  
 
The modification of proteins by SUMO possesses several functions,  including protein 
stability, apoptosis, response to stress, progression throughout the cell cycle, nuclear cystolic 
transport and transcriptional regulation [505, 506]. Thus, SUMO can easily, rapidly and 
reversibly adjust the properties of proteins and also negate the requirement for de novo 
protein synthesis. This  makes such proteins suitable regulators for fine-tuning the repair of 
DNA, in addition to the pathways of damage response [507]. The contribution of ubiquitin, 
along with SUMO, in terms of the key pathways of genome maintenance, has been 
previously reviewed [7, 508]. It has been determined that the proteins of SUMO E3 increase 
the effectiveness of SUMO attachment simply by binding with both UBC9 (the E2 enzyme) 
and the substrate, consequently behaving as bridging factors. SUMO is simply triggered by 
the E1 enzyme and is directed to the E2 SUMO conjugate enzyme (UBC9) [509].  
 
PIAS has been observed to have much wider functions in the transcriptional and 
cellular regulation of tissue development, in addition to carcinogenesis. It interacts with 
various other nuclear proteins; for example, nuclear hormone receptors, such as the androgen 
receptor (AR) [510] ER [511], P53 [512], MDM2 [513], BRCA1 [514] and MTA1 [515]. The 
exact roles of these proteins in BC are still unclear.  
 
The declaration that SUMO of several replications and repair proteins enhance 
immediately after DNA damage delivers the attractive hypothesis that this response aids 
replication, in addition to facilitating repair. The recruitment of PIAS SUMO E3s (homologs 
of yeast Siz1 and Siz2) to DSB sites in human cells, as well as the impairment of HR, once 
SUMO is defective, helps support this hypothesis. It also offers powerful proof that SUMO 
has a functional role in the damage response to DSBs [7, 516-518]. 
 
The PIAS family plays a significant part in proficient DNA repair [7, 516]. 
Immediately upon damage to DNA, PIAS1 and PIAS4 are required, in order to finish the 
accretion of the necessary proteins for DNA repair, such as BRCA1, to the DNA damage site 
[7, 516]. The in vitro modification of SUMO of the BRCA1/BARD1-associated RING 
domain 1 heterodimer dramatically enhances its ligase activity, identifying it as a SUMO-
regulated ubiquitin ligase [516]. PIAS1 has been recognised as a cofactor that prevents the 
transcriptional activation potential of STAT1, in addition to augmenting the transcriptional 
activity of nuclear hormone receptors, whereas PIAS4 represses STAT1 and AR without the 
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need to interfere with DNA binding. PIAS1 is required for complete BRCA1 recruitment 
towards a damaged DNA site, quite possibly throughout BRCA1 and RAP80 interaction, 
while PIAS4 is needed earlier in the DNA damage repair cascade, in order to recruit other 
DNA repair proteins [519]. Depletion of PIAS1 and PIAS4 induces sensitivity to irradiation 
and cisplatin in U2OS cells (human osteosarcoma cell line expressing wild type P53) [7, 497, 
516].  
 
PIAS1 highly promotes ER SUMO in the occurrence of E2 ligands as well as 
Tamoxifen. As a result, the SUMO of ER is ligand dependent: this indicates that hormone 
binding, in addition to its receptor configuration alteration, is essential for its interaction with 
the modification machinery of SUMO [511]. Despite the fact that PIAS1 provides E3 ligase 
activity, it is not necessary for the regulation of ER. PIAS1 has also been suggested as a 
factor in the regulation of innate immunity through epigenetic mechanisms [520]. It has been 
proposed that PIAS1 could possibly control oncogenic networks, through its ability to inhibit 
the tumour suppressor of P53, STAT proteins or BRCA1 [7, 501, 521]. However, the roles of 
PIAS1 in cancer cells seem to be specific. In prostate cancer, a high expression of PIAS1 
increases proliferation by P21 inhibition [522], whereas a decrease in its expression 
stimulates the development of colon cancer [523].  
 
In terms of the observation that SUMO usually targets various proteins appearing at 
the same stage of DSB repair, or perhaps many different subunits of a complex [517, 524], 
the influences of SUMO may be accomplished through the simultaneous modification of an 
array of functionally related proteins. These factors allow for difficulty in dissecting the 
functions of the SUMO of each substrate, as well as determining those substrates whose 
SUMO attributes the most to the survival of cells under specific circumstances.  After the 
formation of a DSB, cells stimulate protein kinases of DDR, such as ATM, ATR and DNA-
PK. Protein kinases then trigger phosphorylation of histone H2AX, in addition to the 
accumulation of proteins such as MDC1, BRCA1, CtIP and RNF8 into IR-induced foci 
(IRIF), which enhance the signalling of DSB and promote DSB repair [525, 526].  
 
 
5.2 Hypothesis  
 
The attachment of SUMO to target proteins in response to DNA-DSB regulates 
various cellular functions [509, 527]. Galanty et al [7] demonstrated that SUMO1, SUMO2 
and SUMO3 accumulate at DSB sites in mammalian cells, together with the accrual of 
SUMO1 and SUMO2/3 in need of the E3 ligase enzymes PIAS4 and PIAS1. PIAS1 and 
PIAS4 are recruited to damage sites through mechanisms requiring their SAP domains; they 
are also essential for the effective association with BRCA1 in such regions. PIAS1 and 
PIAS4 promote DSB repair and confer the resistance of IR. These results thus present PIAS1 
and PIAS4 as DDR factors and demonstrate how coordinated SUMO and ubiquitylation 
manipulate the recruitment of proteins to DSB sites [505, 506]. It is thus hypothesised that 
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SUMO contributes to the aggressive nature of BC particularly those associated with features 
similar to breast carcinoma arising in patients with BRCA1 germline mutations.  
 
 
5.3 Aim  
 
The aim of this chapter is to investigate the roles of SUMO markers; PIAS1, PIAS4 
and UBC9 in BC, using IHC, TMA and RPPA to determine the association between the 
SUMO markers, pathological features, expression of tumour biomarkers and clinical 
outcomes.    
 
 
5.4 Materials and Methods 
 
A previously described in Chapter 2 
 
 
5.4.1 Patient Samples  
 
All data are as previously described in Chapter 2 Section 2.1.1.  Three cohorts were 
used: A) 1904 unselected cases of female primary operable invasive tumours between 1986 
and 1998, B) 386 cases selected from a consecutive series of primary operable ER negative 
tumours between 1998 and 2007 and C) 24 well-characterised series of breast tumours from 
patients with known BRCA1 germline mutations. However, HRMA with employing PCR was 
used for BRCA1 mutation detection in group C (this was performed by Dr Ahmed 
Benhasouna). All cases were obtained from the well-characterised Nottingham Tenovus 
primary breast carcinoma series. 
 
 
5.4.2 Available Biomarkers' Data 
 
Data on a wide range of biomarkers of known clinical and biological relevance to BC 
were accessible and saved on a web-based interface (Distiller; Slidepath Ltd, Dublin, 
Ireland). These include, ER, PgR, HER2, CK5, CK17, CK14, tumour suppressor proteins 
(P53 and PTEN), and cell proliferative marker (Ki-67) [270-272, 331]. 
 
5.4.3 Immunohistochemistry  
 
As previously described in Chapter 2 Section 2.1.3.Three markers of SUMO (PIAS1, 
PIAS4 and UBC9) were investigated in this chapter.  
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5.4.3.1 Immunohistochemical Antibody Labelling using the Novolink Detection Method 
 
As previously described in Chapter 2 Section 2.1.3.1. In this chapter all the markers 
were stained by the author. All these markers have already been previously successfully 
stained on TMA [528, 529].  
 
 
5.4.3.2 Optimization of Antibodies used for IHC 
 
As previously described in Chapter 2 Section 2.1.3.2. In addition to Western blotting, 
specificity of staining was confirmed by application of negative (with omission of the 
primary antibody) and positive controls. Positive controls were used according to the 
PDQXIDFWXUHU¶V GDWDVKHHW DQGRU IURP WKH KXPDQ SURWHLQ DWODV DYDLODEOH DW 
http://www.proteinatlas.org/. This helped not only to test the specificity of staining but also to 
assess the pattern and intensity of protein expressions in the appropriate tissue.  Details of the 
negative and positive controls used are summarised in Table 5.1 Moreover, some control 
TMA slides containing a variety of BC cases with some containing cores from different areas 
of the same cases in addition to normal parenchymal elements were used during optimisation 
to assess the degree of expression heterogeneity.  
 
 
Table 5.1 Immunohistochemistry Positive and Negative Controls of Antibodies Used in this 
Chapter 
Antibody Positive control Negative control Reference 
PIAS1 BC tissue BC tissue Abcam/ human protein atlas available at  http://www.proteinatlas.org/ 
PIAS4 BC tissue BC tissue Novus Biologicals/ human protein atlas available 
at  http://www.proteinatlas.org/ 
UBC9 Normal liver tissue or BC tissue BC tissue 
Novus Biologicals/ human protein atlas available 
at  http://www.proteinatlas.org/ 
Stating of positive and negative controls was performed together in the same run. Negative staining was performed 
without adding the antibody and showed no staining.  All were performed on TMA. All these markers have already been 
previously successfully stained on TMA [528, 529] 
    
 
5.4.3.3 Immunohistochemistry Scoring   
 
As previously described in Chapter 2 Section 2.1.3.3.  For evaluation of IHC of the 
TMA, a modified H-score was used [282]. For H-score, both the intensity of staining and the 
percentage of stained cells were considered within each tissue core. Staining intensity was 
scored as 0, 1, 2 or 3 for negative, weak, moderate and strong, respectively. The proportion 
(percentage) of positive cells for each intensity was subjectively estimated.  Multiplication of 
the two indices (intensity and percentage positive cells) provided final scores that range from 
0 to 300.  
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All the markers were scored by the author and re-scored each marker with at least 
30% of a randomly chosen subset of cases. A statistical agreement test was performed 
.DSSDYDOXHIRUHDFKPDUNHUZKHUHWKHUHZDVJRRGDJUHHPHQWDQG an average was 
taken. If there were discrepancies, the highest scoring was taken. Kappa values are 
summarised in Table 5.2.  
 
PIAS4 were scored using light microscopy, whereas PIAS1 and UBC9 were scored 
visually using high-resolution digital images, using a web-based interface (Distiller, Slidepath 
Ltd., Dublin, Ireland).  
 
Table 5.2 The Statistical Agreement between Different Scoring of Antibodies Used in this 
Chapter. 
Markers Percentage of re-scoring Kappa value 
PIAS1.n 30% 0.7 
PIAS1.c 30% 0.9 
PIAS4 100% 0.69 
UBC9.n 30% 0.59 
UBC9.c 30% 0.68 
Kappa test was performed on IBM SPSS 21.0. An average was taken after re-scoring 
 
 
5.4.4 Specificity of the Antibodies by Western Blot 
 
As previously described in Chapter 2 Section 2.1.4.4. Western blot was used on all 
markers except PIAS4. PIAS4 marker was previously stained by the author before starting 
cell culture work. A mixture of different cell lysates to detect only the specificity of an 
antibody has been applied in different studies and showed its reliability [283, 284]. In the 
present study, PIAS1 and UBC9 were detected in a mixture of different lysates (MCF-7, 
MDA-MB-231, HeLa BRCA1 and its control). All the antibodies tested in this chapter share 
the same positive controls which are MCF-7 and HeLa BRCA1 cell lines. The pre-stained 
PDUNHUµIXOOUDQJHUDLQERZPDUNHU¶,QYLWURJHQ/LIH7HFKQRORJLHVZDVXVHGDVDPROHFXODU
weight standard. http://www.proteinatlas.org/ provides profile data for positive controls of all 
the markers used in this study. Table 5.3 summarises the details of WB for each marker.  
 
 
Table 5.3 List of Antibodies Tested by Western Blot on a Mixture of Different Cell Lines. 
Antibody Cell lines Specific positive cell lines* 
PIAS1 A mixture of MCF-7, MDA-MB-231, HeLa BRCA1 and its control MCF-7 or  HeLa BRCA1 cell lines 
UBC9 A mixture of MCF-7, MDA-MB-231, HeLa BRCA1 and its control MCF-7 or  HeLa BRCA1 cell lines 
Cell lines and reagents were obtained from the group of Dr Madhusudan Srinivasan. Thawing and freezing procedures were 
done by Nada Albarakati. Passages, Bradford assay and gel electrophoresis were done by the author. Passages used in W.B 
were as follows; HeLa BRCA1; passages 29&30, HeLa BRCA1 control; passages 15&16, MCF-7; passages 25&26, MDA-
MB-231; passages 15&16. * Data available at http://www.proteinatlas.org/. 
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5.4.5 Reverse Phase Protein Microarray 
 
RPPA was carried out as previously described in Chapter 2 Section 2.1.5. Cell lines 
preparation and protein extraction and interpretation of the results were carried out by the 
author. However, RPPA run and analysis was carried out by Dr Ola Nejm (Immunology, 
School of Life Sciences, University Hospital, Nottingham, UK) as a collaborative project.  
PIAS4, this marker was previously stained by the author before starting the collaboration 
with Dr Ola Nejm. 
                           
                            
5.5 Statistical Analysis  
 
All statistical analyses were done by the author using IBM SPSS statistic 21.0 
software. For all statistical tests, a two-sided P-value of <0.01 was considered statistically 
significant. 
 
  
5.5.1 The Determination of the Optimal Cut-offs  
 
As described previously in Chapter 2 Section 2.1.6.1, the cut-off points of the 
biomarkers were dichotomised and obtained using different approaches: a) using the mean or 
median of the H-score of the staining according to distribution pattern whether normally or 
not normally distributed, or b) using x-tile software (version 3.6.1, 2003-2005, Yale 
University, USA). x-tile was used for PIAS1 and PIAS4 (if the mean/median was taken then 
more than three quarter of the cases will be considered negative). Median and mean were 
used as cut off for UBC9 nuclear and cytoplasmic expression respectively. Table 5.4 shows 
the details of the antibodies used in this chapter. Details of H-score histograms of all markers 
are presented in Appendix 3.  
 
 
Table 5.4 Sources, Dilution, Cut-offs Point and Pre-Treatment Conditions of the Antibodies 
Used in this Chapter. 
Antibody Clone Source Dilution IHC 
Dilution 
W.B 
RPPA 
+Distribution Cut-offs IHC kit 
PIAS1 Ab32219 Abcam 1:425 1h 1:1,000 1:1,000 
Nuclear/ 
cytoplasmic 
1XFOHDU+-score 
&\WRSODVP+-
score, x-tile. 
Novolink 
PIAS4 NBP1-31215 
Novus 
Biologicals 1:250 1h 
NT 
NT Nuclear +-score, x-tile Novolink 
UBC9 Ep2938Y Novus Biologicals 1:225 1h 
1:500 
1:250 
Nuclear/ 
cytoplasmic 
1XFOHDU+-
score, median 
&\WRSODVP+-
score, mean. 
Novolink 
IHC= immunohistochemistry. W.B= Western blotting. NT= not tested. All the antibodies were pre-treated in citrate antigen 
retrieval pH=6.0 in microwave for 20 minutes and stained on TMA. + Cellular localisation. 1h= 1 hour incubation with the 
primary antibody at room temperature. 
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5.5.2 Univariate Analysis with Clinico-Pathological al Parameters and Tumour Markers  
 
The differences between all markers, with regards to clinico-pathological features, or 
with other tumour markers were analysed using the Pearson Chi-Squared test (x2). 
Consequently, x2 was also used in order to examine the inter-relations between markers 
themselves. In addition analysis of continuous variables was performed using the appropriate 
statistical test 3HDUVRQ¶V FRUUHODWLRQ and ANOVA. One way ANOVA was used to find out 
which of different BC classes (by IHC or RPPA) were significantly different from each other 
(post hoc test; Tukey).  
 
 
5.5.3 Univariate Analysis with 3DWLHQWV¶Outcome  
 
3DWLHQW¶VDOLYH or those who died for any reason other than BC were not included. The 
Kaplan-Meier method was used to generate a univariate survival curve and the differences in 
survival among the biomarkers were evaluated using the log-rank test.  
 
 
5.5.4 Multivariate Analysis with PDWLHQWV¶Outcome  
 
If a marker in univariate analysis was statistically significant with SDWLHQWV¶RXWFRPHV, 
then Cox regression was applied for multivariate analyses to test for confounders and 
prognostic or predictive independency of the investigated biomarker from standard 
prognostic/predictive factors such as tumour grade, tumour stage, and tumour size.    
 
5.6 Results  
 
5.6.1 Expression of SUMO Markers in Invasive Breast Cancer  
 
Western blotting validated the specificity of antibodies in SUMO pathway, which was 
deemed validated by a single band at the correct protein size for both PIAS1 and UBC9 (see 
Figure 5.1).  
 
PIAS4 was stained before applying W.B, however, positive and negative tissue 
controls were used to validate the specificity of the antibodies. Breast tumour tissue was used 
as a positive/negative control for PIAS4 and PIAS1 (Figure 5.2), and normal liver tissue as 
positive control and breast tumour tissue as negative control for UBC9 (Figure 5.3) 
(http://www.proteinatlas.org/). 
 
Using IHC, PIAS4 showed nuclear staining in invasive breast tumours, whereas 
PIAS1 and UBC9 showed both nuclear and cytoplasmic staining. Figures 5.2 and 5.3 outline 
the staining pattern of these markers by IHC. Table 5.5 displays the frequencies of SUMO 
proteins in sporadic and known BRCA1 germline mutations BCs, while Figure 5.4 represents 
the distribution of SUMO markers (mean) in different classes of BC by IHC. The four classes 
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included were classified based on BRCA1 and ER status (protein expression). Class 1; 
sporadic BRCA1 negative and ER negative, class 2; sporadic BRCA1 positive and ER 
positive, class 3; known BRCA1 germline mutations BC (hereditary)/ER negative, and 
finally, class 4; known BRCA1 germline mutation BC (hereditary)/ ER positive.  
 
There was a strong expression of nuclear PIAS1, nuclear UBC9, (Figure 5.4) in 
sporadic BRCA1+/ER+ cancers, compared to sporadic BRCA1-/ER- (for all  P<0.0001). 
Additionally, UBC9.n showed a significant difference between sporadic BRCA1+/ER+ 
cancers and BRCA1 hereditary BC that showing ER negativity (P<0.0001). In contrast, 
cytoplasmic expression of UBC9 in terms of BRCA1 hereditary BC that showing ER 
positivity was the weakest amongst the other classes, and was highly significant between 
sporadic BRCA1-/ER- cancers vs. BRCA1 hereditary BC that showing ER+ (P=0.002), or both 
ER+ cases in sporadic or hereditary cases (P=0.002), and finally between the two groups of 
BRCA1 hereditary BCs that showing ER- vs. ER+ (P=0.005).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Detection of SUMO proteins level by Western blot in a mixture of cell lines, MDA-
MB-231, MCF-7, HeLa BRCA1 and its control. The predicted size of each protein is labelled 
on the band. Passages used in W.B were as follows; HeLa BRCA1; passages29&30, HeLa 
BRCA1 control; passages 15&16, MCF-7; passages 25&26, and MDA-MB-231; passages 
15&16. 
Chapter 5                                                                                                  SUMOylation in BC 
176 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 The immunostaining expression of PIAS4 and PIAS1 (SUMO proteins) detected by IHC on TMA. a; 
negative control of PIAS4 in invasive ductal carcinoma/ NST, grade 3 and stage 1. b; PIAS4 nuclear expression 
in invasive lobular carcinoma, grade 3 and stage 1, also was used as positive control. c; negative control of PIAS1 
in invasive ductal carcinoma/ NST; stage 2 and grade 3. d; PIAS1 nuclear and cytoplasmic expression in invasive 
ductal carcinoma/NST; grade 2, and stage 1 which was also used as positive control. Magnification x20. 
 
Chapter 5                                                                                                  SUMOylation in BC 
177 
 
 
Table 5.5 Frequency of PIAS1, PIAS4, and UBC9 Expression in Breast Cancer. 
 
SUMO marker 
Sporadic BC  Known BRCA1 germline mutation BC 
(%) Frequency (%) Frequency 
PIAS1 
Nuclear 14.1% 
 
180/1278 0% 0/23 
Cytoplasmic 79.3% 
 
1013/1278 91.3% 21/23 
PIAS4 78.5% 
 
1154/1470 91.7% 22/24 
UBC9 
Nuclear 50.7% 
 
751/1485 5.3% 1/19 
Cytoplasmic 64.4% 
 
957/1485 52.4% 6/19 
Sporadic BC includes both unselected and ER-negative BC cases. The number of cases may be reduced due to loss cases 
during preparation of tissue for staining (TMA sectioning or IHC procedure). 
 
 
 
 
 
 
 
 
 
  
Figure 5.3 The immunostaining expression of UBC9 protein detected by IHC on TMA. a; negative control in 
invasive ductal carcinoma/NST; stage 2 and grade 3. b; normal liver tissue as positive control for UBC9. c; 
UBC9 nuclear and cytoplasmic expression in invasive ductal carcinoma/NST; grade 3 and stage 1. 
Magnification x20.  
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Figure 5.4 SUMO protein levels detected by IHC in breast cancer on TMA. Each bar represents different class 
based on hereditary or sporadic BRCA1 and ER status. n= nuclear and c= cytoplasmic expression. Error bars 
represent Mean (SD) and was created on H-score (ranges 0-300). A= sporadic cases [ER- & BRCA1-] vs. sporadic 
cases [ER+ & BRCA1+], B= sporadic cases [ER- & BRCA1-] vs. Hereditary cases [ER-], C= sporadic cases [ER- 
& BRCA1-] vs. Hereditary cases [ER+], D= sporadic cases [ER+ & BRCA1+] vs. Hereditary cases [ER-], E= 
sporadic cases [ER+ & BRCA1+] vs. Hereditary cases [ER+], and F= Hereditary cases [ER-] vs. Hereditary cases 
[ER+]. One way ANOVA test was used for each marker within the classes.  
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5.6.2 Correlation of SUMO Markers  
 
Table 5.6 summaries the associations between the SUMO markers. There was a 
strong negative association between PIAS1.n, its cytoplasmic expression and positive 
association with UBC9.n (P<0.0001). The cytoplasmic expression of PIAS1+ was highly 
associated with UBC9.c+ (P<0.0001), but not nuclear expression (P=0.5). UBC9.n was 
positively associated with its cytoplasmic expression (P<0.0001). PIAS4 showed a positive 
association with both nuclear and cytoplasmic UBC9 and PIAS1.c (all P<0.0001). 
 
Table 5.6 Correlation between SUMO Markers. 
Markers 
UBC9.n UBC9.c 
Negative 
N (%) 
Positive 
N (%) X
2 P Negative N (%) 
Positive 
N (%) X
2 P 
PIAS4 Negative 153(69.9) 395(48.1) 33 <0.0001 115(52.5) 266(32.3) 30 <0.0001 Positive 66(30.1) 426(51.9) 104(47.5) 557(67.7) 
PIAS1.n Negative 438(55.2) 35(30.4) 25 <0.0001 288(36.2) 45(39.1) 0.4 0.5 Positive 356(44.8) 80(69.6) 507(63.8) 70(60.9) 
PIAS1.c Negative 98(54.4) 377(51.5) 0.5 0.5 96(53.3) 237(32.3) 27.5 <0.0001 Positive 82(45.6) 355(48.5) 84(46.7) 496(67.7) 
UBC9.c Negative 386(52.9) 141(18.8) 188 <0.0001  Positive 344(47.1) 610(81.2) 
Markers 
PIAS1.n PIAS1.c 
Negative 
N (%) 
Positive 
N (%) X
2
 P Negative N (%) 
Positive 
N (%) X
2
 P 
PIAS4 
 
Negative 219(22.3) 36(24.4) 0.6 0.4 75(29.4) 143(16.5) 21 <0.0001 
Positive 762(77.7) 106(74.6) 180(70.6) 725(83.5) 
PIAS1.c 
 
Negative 197(18) 65(36.7) 33 <0.0001  
Positive 887(82) 112(63.3) 
1 QXPEHURIFDVHVF F\WRSODVPLFQ QXFOHDUH[SUHVVLRQ7KHFXWRIISRLQWVRISRVLWLYLW\ZHUHDVIROORZV+-score for PIAS1.n, 
DQGIRU3,$6F 160 H-score for 8%&QDQG200 H-score IRU8%&F+-score for PIAS4. 
 
 
5.6.3 Correlation of SUMO Markers with Other Tumour Markers 
 
The correlation between categorical (X2) SUMO proteins and other tumour 
biomarkers (regarding co-expression of cellular localisation of PIAS1 and UBC9) is 
summarised in Tables 5.7.  
 
Table 5.8 shows the correlation on continuous data of SUMO proteins with other 
tumour markers 3HDUVRQ¶V FRUUHODWLRQ Some correlations between categorical and 
continuous data were different therefore, only these categorical correlations were re-analysed, 
but regardless co-expression of cellular localisation, in order to compare each cellular 
localisation separately. Therefore, Table 5.9 shows the association between categorical (X2) 
SUMO markers and other tumour biomarkers but regardless co-expression of subcellular 
ORFDOLVDWLRQWRPDNHWKHFRPSDULVRQZLWKFRQWLQXRXVGDWD3HDUVRQ¶VFRUUHODWLRQ7DEOH
easier.  
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Regarding co-expression of cellular localisation (Table 5.7), there was a positive 
association between the expression of SUMO markers (PIAS1c+.n- and UBC9 c+.n+) and 
BRCA1.n (both P<0.0001), ER (both P<0.0001), PgR (P= 0.001 and P<0.0001 respectively). 
Only UBC9 c+.n+ showed an association with BLBC (P<0.0001).  
 
Regarding DNA-damage sensors and signal transducers, there was a high positive 
association between ATM and PIAS1c+.n- or UBC9 c+.n+ (P<0.0001 and P= 0.007 
respectively). In addition similar association was seen with CHK1.n- or CHK1.c+ and 
PIAS1c+.n-, PIAS4 and UBC9 c+.n+(for CHK1.n; P<0.0001, P=0.003 and P<0.0001 
respectively, for CHK1.c; all P<0.0001), CHK2+ with PIAS4 and UBC9 c+.n+ (all P<0.0001) 
(see Table 5.7). 
 
In regards to DNA-DSB repair, there was a high positive association between HR 
markers such as SMC6L1.c, Rad51.n and BRCA1.c with all SUMO markers (all P<0.0001), 
and BRCA1.n with PIAS1.n-.c+ and UBC9 c+.n+ (all P<0.0001). However, for NHEJ, there 
was a positive association between KU70/KU80 or DNA-PK and all SUMO markers (all 
P<0.0001, except KU70/KU80 with UBC9; P=0.001).  
 
Two down regulator markers for BRCA1 were investigated; MTA1 and ID4. 
MTA1.c+ showed a high association with all SUMO markers (all P<0.0001, except with 
PIAS4; P=0.001) and MTA1.n with PIAS4 and UBC9 c+.n+ (P=0.003 and P<0.0001 
respectively), however, ID4.c showed only a high association with PIAS1.n-.c+ (P<0.0001) 
(see Table 5.7). 
 
Details of significant and non-significant associations are summarised in Appendix 3. 
 
Table 5.8 shows the correlation on continuous data of SUMO proteins with other 
tumour markers. Regression analysis of continuous data confirmed the categorical data 
(Tables 5.7 and 5.9). However, when PIAS1.c was analysed as a continuous variable, some 
correlations showed different results. A significant correlation was observed with ER and Ki-
67 (P=0.003, and P<0.0001 respectively; categorical data, Table 5.9), while the correlation 
lost significance in continuous data (P=0.7, P=0.05 respectively; Table 5.8). In addition, 
some other correlations lost their significance in categorical data such as PIAS1.n with 
MTA1.n (continuous; P<0.0001 and categorical ; P=0.02, Tables 5.8 and 5.9 respectively), 
PIAS1.c with SMC6L1.n (continuous; P=0.002 and categorical ; P=0.4, Tables 5.8 and 5.9 
respectively), UBC9.c with Rad51.c (continuous; P<0.0001 and categorical ; P=0.3, Tables 
5.8 and 5.9 respectively), and with CHK1.c (continuous; P<0.0001 and categorical ; P=0.5, 
Tables 5.8 and 5.9 respectively).   
 
The high value of X 2 of all the results in this section can be referred to, i) a bias in the 
population of patients, ii) based on the data here, it does not seem to have any assumption 
issues, the main problem is normally when one of the expectation values is 5 or less, but in 
the findings presented here a large chi squared value is resulted when the expectations are not 
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less than 5. However, the data just seem to show that it is very likely that the association is 
not due to chance. 
 
Table 5.7 Correlation between SUMO Markers with other Tumour Markers. 
Parameters 
PIAS4 
Negative  
N( %) 
Positive 
N (%) X
2 P 
PgR 
Negative 175(59.7) 546(51.5) 
6 0.012 
Positive 118(40.3) 515(48.5) 
TN 
Negative 186(64.6) 783(72.6) 
7 0.008 
Positive 102(35.4) 296(27.4) 
Rad51.c 
Negative 35(16.4) 64(8.1) 
13 <0.0001 
Positive 179(83.6) 731(91.9 
Rad51.n 
Negative 159(74.3) 453(56.8) 
21.5 <0.0001 
Positive 55 (25.7) 344(43.2) 
KU70/KU80 Negative 
72(28.5) 69(7.9) 
76 <0.0001 
Positive 181(71.5) 806(92.1) 
DNA-PK 
Negative 67(35.6) 79(10.1) 
77 <0.0001 
Positive 121(64.4) 702(89.9) 
SMC6L1.n 
Negative 99(49) 236(29.9) 
26 <0.0001 
Positive 103(51) 553(70.1) 
SMC6L1.c Negative 
86(42.6) 222(28.1) 
15.6 <0.0001 
Positive 116(57.4) 567(71.9) 
CHK1.n Negative 
225(86.9) 695(78.4) 
9.5 0.003 
Positive 34(13.1) 191(21.6) 
CHK1.c Negative 
149(57.5) 352(39.8) 
14 <0.0001 
Positive 110(42.5) 533(60.2) 
CHK2 Negative 
109(64.5) 268(47.6) 
15 <0.0001 
Positive 60(35.5) 295(52.4) 
ATR 
Negative 128(66.7) 330(50.5) 
15.7 <0.0001 
Positive 64(33.3) 324(49.5) 
Ȗ+$;Q Negative 50(26.7) 85(11.3) 28.7 <0.0001 
Positive 137(73.3) 664(88.7) 
BARD1.c 
Negative 65(29.7) 168(20.3) 9 0.003 
Positive 154(70.3) 661(79.7) 
BRCA1.c Negative 
170(71.1) 534(55.9) 
18 <0.0001 
Positive 69 (28.9) 421(44.1) 
MTA1.n 
Negative 108(51.2) 318(39.9) 9 0.003 
Positive 103(48.8) 478(60.1) 
MTA1.c 
Negative 45(21.3) 99(12.4) 
11 0.001 
Positive 166(78.7) 698(87.6) 
N= number of cases. c. = cytoplasmic, n. = nuclear expression. The cut off points of positivity were the same as previously published [273], 
and were as follows: +-score for PIAS4, IRU3J5IRU07$QDQG+-score for cytoplasmic, +-score for CHK1.n 
DQG+-VFRUHIRU&+.F+-VFRUHIRU&+.+-VFRUHIRUȖ+$;QXFOHDU+-VFRUHIRU$75+-score for BRCA1.c. 
  IRU %$5'F ! +-score for SMC6L1.n DQG 230 H-score for SMC6L1.c  +-score for DNA-PK, DQG  +-score for 
KU70/KU80. Triple negative (ER, PgR and HER-2). 
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Table 5.7 Correlation between SUMO Markers with other Tumour Markers Continued. 
Parameters 
PIAS1 
c- n- 
N (%) 
c+ n+ 
N (%) 
c- n+ 
N (%) 
c+ n- 
N (%) X
2 P 
ER 
Negative 72(37.7) 28(26.7) 17(27) 408(46.9) 
26 <0.0001 
Positive 119(62.3) 77(73.3) 46(73) 462(53.1) 
PgR 
Negative 96(52.7) 41(38.3) 21(36.2) 463(55.4) 
17.6 0.001 
Positive 86(47.3) 66(6.7) 37(63.8) 373(44.6) 
P53 Negative 
130(71.4) 74(70.5) 39(72.2) 517(60.2) 
13 0.005 
Positive 52(28.6) 31(29.5) 15(27.8) 342(39.8) 
Rad51.c 
Negative 36(26.5) 13(15.9) 15(34.1) 44(5.9) 
81.5 <0.0001 
Positive 100(73.5) 69(84.1) 29(65.9) 707(94.1) 
Rad51.n 
Negative 106(77.4) 28(33.3) 18(40.9) 511(67.9) 
60 <0.0001 
Positive 31(22.6) 56(66.7) 26(59.1) 242(32.1) 
KU70/KU80 Negative 
38(22.4) 12(13.3) 15(27.3) 78(9.8) 
30 <0.0001 
Positive 132(77.6) 78(86.7) 40(72.7) 717(90.2) 
DNA-PK 
Negative 40(30.5) 7(10.6) 4(13.8) 79(12.9) 
27 <0.0001 
Positive 91(69.5) 59(89.4) 25(86.2) 533(87.1) 
SMC6L1.c Negative 
55(42) 24(32.4) 18(52.9) 157(25.2) 
25 <0.0001 
Positive 76(58) 50(67.6) 16(47.1) 467(74.8) 
ID4.c 
Negative 103(52.8) 45(40.5) 39(60.9) 264(29.7) 58 <0.0001 
Positive 92(47.2) 66(59.5) 25(39.1) 625(70.3) 
CHK1.n 
Negative 159(85) 21(20.2) 9(16.1) 699(82.6) 
302 <0.0001 
Positive 28(15) 83(79.8) 47(83.9) 147(17.4) 
CHK1.c 
Negative 54(28.9) 10(9.6) 16(28.6) 25(3) 
157 <0.0001 
Positive 133(71.1) 94(90.4) 40(71.4) 820(97) 
Ki-67 
Negative 82(47.7) 36(42.4) 29(53.7) 219(29) 34 <0.0001 
Positive 90(52.3) 49(57.6) 25(46.3) 535(71) 
ATM 
Negative 84(64.1) 30(38.5) 13(38.2) 360(57.8) 
18.4 <0.0001 
Positive 47(35.9) 48(61.5) 21(61.8) 263(42.2) 
ATR 
Negative 68(60.7) 48(70.6) 20(58.8) 259(49.9) 
13 0.004 
Positive 44(39.3) 20(29.4) 14(41.2) 260(50.1) 
Ȗ+$;Q Negative 18(14.6) 1(1.5) 1(3.4) 93(15.6) 12.6 0.006 
Positive 105(85.4) 65(98.5) 28(96.6) 503(84.4) 
Ȗ+$;F Negative 24(19.5) 11(16.7) 11(37.9) 41(6.9) 44 <0.0001 
Positive 99(80.5) 55(83.3) 18(62.1) 556(93.1) 
BARD1.c 
Negative 59(40.7) 14(19.4) 8(22.2) 119(18.2) 
35 <0.0001 
Positive 86(59.3) 58(80.6) 28(77.8) 535(81.8) 
BRCA1.c Negative 
119(73.5) 44(51.2) 32(68.1) 414(55.6) 
21 
 
<0.0001 
 
Positive 43(26.5) 42(48.8) 15(31.9) 331(44.4) 
BRCA1.n Negative 
88(54.3) 30(34.9) 13(27.1) 453(60.6) 
38 <0.0001 
Positive 74(45.7) 56(65.1) 35(72.9) 295(39.4) 
MTA1.n 
Negative 72(52.9) 22(30.1) 14(37.8) 266(42.4) 
11 0.01 
Positive 64(71.1) 51(69.9) 23(62.2) 362(57.6) 
MTA1.c 
Negative 46(33.8) 11(15.1) 9(24.3) 57(9.1) 60 <0.0001 
Positive 90(66.2) 62(84.9) 28(75.7) 572(90.9) 
N= number of cases. c. = cytoplasmic, n. = nuclear expression. The cut off points of positivity were the same as previously published [273], 
and were as follows: +-VFRUHIRU3,$6QDQGIRU3,$6FIRU PgR and  ER,  >34% for Ki-67, IRU07$QDQG
H-VFRUH IRU F\WRSODVPLF  +-VFRUH IRU &+.Q DQG  +-VFRUH IRU &+.F   +-VFRUH IRU Ȗ+$; QXFOHDU DQG  IRU
F\WRSODVPLF+-VFRUHIRU$75DQGIRU$70+-VFRUHIRU%5&$FDQG3 IRUQXFOHDUIRU%$5'F+-
VFRUHIRU60&/F+-score for DNA-3.DQG+-VFRUHIRU.8.8 for P53, +-score nuclear  and +-score 
cytoplasmic for Rad51, and  +-score for ID4.c. 
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Table 5.7 Correlation between SUMO Markers with other Tumour Markers Continued.  
Parameters 
UBC9 
c- n- 
N (%) 
c+ n+ 
N (%) 
c- n+ 
N (%) 
c+ n- 
N (%) X
2 P 
ER 
Negative 182(49.3) 217(37) 36(26.7) 183(54.8) 
48 <0.0001 
Positive 187(50.7) 369(63) 99(73.3) 151(45.2) 
PgR 
Negative 213(60.2) 268(48) 56(44.4) 205(62.7) 
28 <0.0001 
Positive 141(39.8) 290(52) 70(55.6) 122(37.3) 
TN 
Negative 231(65.3) 440(78) 114(87.7) 198(60.7) 54 <0.0001 
Positive 123(34.7) 124(22) 16(12.3) 128(39.3) 
BLBC Negative 
233(72.6) 415(80.7) 111(94.1) 196(68.8) 
38 <0.0001 
Positive 88(27.4) 99(19.3) 7(5.9) 89(31.2) 
Rad51.n 
Negative 184(76.7) 176(53.5) 44(59.5) 181(80.4) 58 <0.0001 
Positive 56(23.3) 153(46.5) 30(40.5) 44(19.6) 
KU70/KU80 Negative 
50(18.9) 32(9) 12(16.4) 21(9.4) 
17 0.001 
Positive 214(81.1) 325(91) 61(83.6) 202(90.6) 
DNA-PK 
Negative 97(31.8) 22(4.3) 7(7.3) 54(17.8) 
122 <0.0001 
Positive 208(68.2) 494(95.7) 89(92.7) 250(82.2) 
SMC6L1.n 
Negative 140(42.6) 114(22.1) 26(24.8) 151(47.9) 
74.5 <0.0001 
Positive 189(57.4) 402(77.9) 79(75.2) 164(52.1) 
SMC6L1.c 
Negative 149(45.3) 126(24.4) 60(57.1) 66(21) 
89 <0.0001 
Positive 180(54.7) 390(75.6) 45(42.9) 249(79) 
CHK1.n Negative 
205(79.5) 267(72.8) 45(55.6) 182(80.5) 
24 <0.0001 
Positive 53(20.5) 100(27.2) 36(44.4) 44(19.5) 
CHK1.c Negative 
38(14.7) 23(6.3) 13(16) 12(5.3) 
22 <0.0001 
Positive 222(85.3) 343(93.7) 68(84) 214(94.7) 
Ȗ+$;Q Negative 62(19.4) 15(2.9) 4(4.1) 77(26.4) 114 <0.0001 
Positive 257(80.6) 511(97.1) 93(95.9) 215(73.6) 
Ȗ+$;F Negative 53(16.6) 39(7.4) 22(22.7) 8(2.7) 54 <0.0001 
Positive 267(83.4) 487(92.6) 75(77.3) 284(97.3) 
CHK2 
Negative 147(70.3) 117(32.1) 27(37.5) 125(61.9) 
97 <0.0001 
Positive 62(29.7) 248(67.9) 45(62.5) 77(38.1) 
Ki-67 
Negative 122(38.7) 183(35.4) 53(45.7) 68(23.2) 
26 <0.0001 
Positive 193(61.3) 334(64.6) 63(54.3) 228(76.8) 
ATM 
Negative 151 (56.6) 201 (52.9) 37 (44) 150 (63.8) 
12 0.007 
Positive 116 (43.4) 179 (47.1) 47 (56) 85 (36.2) 
ATR 
Negative 181(69.3) 203(43.6) 56(58.3) 116(48.7) 
47 <0.0001 
Positive 80(30.7) 263(56.4) 40(41.7) 122(51.3) 
BARD1.c 
Negative 112(33.2) 77(14.3) 19(18.3) 60(18.9) 
47 <0.0001 
Positive 225(66.8) 463(85.7) 85(81.7) 258(81.1) 
BRCA1.c Negative 
196(65.1) 246(51) 74(66.7) 160(55.6) 
19.5 <0.0001 
 Positive 105(34.9) 236(49) 37 (33.3) 128(44.4) 
BRCA1.n 
Negative 202(67.1) 239(49.4) 37(33) 201(69.8) 
70 <0.0001 
Positive 99(32.9) 245(50.6) 75(67) 87(30.2) 
MTA1.n 
Negative 180(53.7) 131(24.6) 13(12) 190(59.7) 
166 <0.0001 
Positive 155(46.3) 402(75.4) 95(88) 128(40.3) 
MTA1.c 
Negative 115(34.2) 32(6) 24(22.2) 24(7.5) 
149.2 <0.0001 
Positive 221(65.8) 502(94) 84(77.8) 294(92.5) 
N= number of cases. c. = cytoplasmic, n. = nuclear expression. The cut off points of positivity were the same as previously published [273], 
and were as follows: +-VFRUHIRU8%&QDQG+-score for UBC9.c, IRU3J5DQG(5!IRUKi-67, IRU07$Q
DQG+-VFRUHIRUF\WRSODVPLF+-VFRUHIRU&+.QDQG+-VFRUHIRU&+.F+-VFRUHIRUȖ+$;QXFOHDUDQGIRU
F\WRSODVPLF+-VFRUHIRU$75DQGIRU$70+-VFRUHIRU%5&$FDQG3 IRUQXFOHDU IRU%$5'F+-
VFRUHIRU60&/FDQG!QXFOHDU+-score for DNA-3.DQG+-score for KU70/KU80,  +-VFRUHQXFOHDUDQG+-
score cytoplasmic for Rad51, and  +-score for CHK2. Triple negative (ER, PgR and HER-2).BLBC= TN + CK5 and CK14 and 
CK17. 
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Table 5.8 3HDUVRQ¶V &RUUHODWLRQV EHWZHHQ 6802 3URWHLQV ZLWK RWKHU 7XPRXU
Markers. 
Markers  PIAS1.n PIAS1.c PIAS4 UBC9.c UBC9.n 
PIAS1.n 
R 
* 
* 
* 
 
* 
0.182 
P <0.0001 
N 912 
PIAS1.c 
R -0.090 0.077 
P 0.001 0.020 
N 1278 912 
PIAS4 
R 0.047 0.207 0.246 
P 0.118 <0.0001 <0.0001 
N 1124 1124 1041 
ER 
R 0.128 0.012 0.112 -0.057 0.174 
P <0.0001 0.703 <0.0001 0.059 <0.0001 
N 975 975 1099 1109 1109 
PgR 
R 0.085 0.098 0.164 0.059 0.154 
P 0.008 0.002 <0.0001 0.051 <0.0001 
N 966 966 1085 1098 1098 
P53 
R -0.034 -0.010 0.007 0.101 -0.028 
P 0.288 0.746 0.812 0.001 0.347 
N 960 960 1084 1101 1101 
Ki-67 
R -0.140 0.060 -0.063 0.131 -0.173 
P <0.0001 0.051 0.028 <0.0001 <0.0001 
N 1072 1072 1233 1245 1245 
BRCA1.c 
R 0.004 0.157 0.113 0.110 0.046 
P 0.893 <0.0001 <0.0001 <0.0001 0.111 
N 1047 1047 1198 1184 1184 
BRCA1.n 
R 0.324 0.040 0.085 -0.013 0.287 
P <0.0001 0.197 0.003 0.665 <0.0001 
N 1047 1047 1198 1184 1184 
BARD1.c 
R 0.070 0.256 0.104 0.269 0.266 
P 0.035 <0.0001 0.001 <0.0001 <0.0001 
N 912 912 1049 1298 1298 
BARD1.n 
R -0.012 0.044 0.001 -0.032 0.061 
P 0.720 0.184 0.979 0.255 0.029 
N 912 912 1049 1298 1298 
Rad51.c 
R -0.166 0.368 0.135 0.130 -0.066 
P <0.0001 <0.0001 <0.0001 <0.0001 0.053 
N 1018 1018 1011 863 863 
Rad51.n 
R 0.422 0.138 0.195 0.028 0.248 
P <0.0001 <0.0001 <0.0001 0.420 <0.0001 
N 1018 1018 1011 863 863 
SMC6L1.c 
R -0.161 0.155 0.093 0.284 0.018 
P <0.0001 <0.0001 0.003 <0.0001 0.518 
N 868 868 992 1265 1265 
SMC6L1.n 
R -0.013 0.104 0.303 0.146 0.325 
P 0.711 0.002 <0.0001 <0.0001 <0.0001 
N 868 868 992 1265 1265 
KU70/KU80 
R -0.021 0.151 0.464 0.127 0.135 
P 0.476 <0.0001 <0.0001 <0.0001 <0.0001 
N 1116 1116 1129 917 917 
DNA-PK 
R 0.065 0.151 0.370 0.317 0.432 
P 0.061 <0.0001 <0.0001 <0.0001 <0.0001 
N 844 844 970 1221 1221 
5HSHDWHGDQDO\VLVRUDQDO\VLVEHWZHHQWKHPDUNHULWVHOI1 QXPEHURIFDVHV5 3HDUVRQ¶VFRUUHODWLRQ3 3UREDELOLW\YDOXH  
This table shows the correlation on continuous data of SUMO proteins with other tumour markers. The cut-off points as 
described in table5.7. 
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Table 5.8 3HDUVRQ¶VFRUUHODWLRQVEHWZHHQ68023URWHLQVZLWKRWKHU7XPRXU0DUNHUV
Continued. 
Markers PIAS1.n PIAS1.c PIAS4 UBC9.c UBC9.n 
CHK1.c 
R -0.100 0.426 0.228 0.207 0.095 
P 0.001 <0.0001 <0.0001 <0.0001 0.004 
N 1197 1197 1145 931 931 
CHK1.n 
R 0.794 0.008 0.136 -0.061 0.179 
P <0.0001 0.786 <0.0001 0.063 <0.0001 
N 1197 1197 1145 931 931 
CHK2 
R 0.106 0.116 0.162 0.121 0.386 
P 0.007 0.004 <0.0001 <0.0001 <0.0001 
N 631 631 732 848 848 
ATR 
R -0.077 0.066 0.078 0.173 0.101 
P 0.036 0.073 0.024 <0.0001 0.001 
N 739 739 848 1063 1063 
ATM 
R 0.108 0.045 0.073 -0.030 0.105 
P 0.001 0.181 0.022 0.356 0.001 
N 870 870 978 966 966 
Ȗ+$;F 
 
R -0.081 0.158 0.085 0.376 0.125 
P 0.021 <0.0001 0.010 <0.0001 <0.0001 
N 818 818 937 1234 1234 
Ȗ+$;Q 
R 0.171 0.039 0.259 0.085 0.530 
P <0.0001 0.268 <0.0001 0.003 <0.0001 
N 818 818 937 1234 1234 
ID4.c 
R -0.073 0.207 0.099 0.143 0.061 
P 0.014 <0.0001 <0.0001 <0.0001 0.030 
N 1153 1153 1302 1262 1262 
ID4.n 
R 0.090 -0.056 0.025 -0.069 -0.044 
P 0.002 0.055 0.358 0.013 0.114 
N 1165 1165 1325 1292 1292 
MTA1.c 
R -0.056 0.244 0.198 0.511 0.281 
P 0.094 <0.0001 <0.0001 <0.0001 <0.0001 
N 880 880 1008 1295 1295 
MTA1.n 
R 0.133 0.069 0.205 0.090 0.480 
P <0.0001 0.041 <0.0001 0.001 <0.0001 
N 880 880 1008 1295 1295 
UBC9.c 
R -0.091 0.204 0.195 
* 
0.407 
P 0.006 <0.0001 <0.0001 <0.0001 
N 912 912 1041 1481 
* Repeated analysis or analysis between the PDUNHULWVHOI1 QXPEHURIFDVHV5 3HDUVRQ¶VFRUUHODWLRQ3 3UREDELOLW\YDOXH
This table shows the correlation on continuous data SUMO proteins with other tumour markers. The cut-off points as described 
in table 5.7 
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Table 5.9 Correlation between PIAS1 and UBC9 with other Tumour Markers Regardless of 
Co-expression of Cellular Localisation. 
Markers 
PIAS1.c P 
X2 
 
PIAS1.n P 
X2 
 
Negative 
N (%) 
Positive 
N (%) 
Negative 
N (%) 
Positive 
N (%) 
ATM 
Negative 99(59.3) 391(55.6) 0.4 
0.4 
445(58.9) 44(38.6) <0.0001 
16.5 Positive 68(40.7) 312(44.4) 311(41.1) 70(61.4) 
BRCA1.c Negative 
152(72) 459(55) <0.0001 
20 
534(58.7) 78(57.8) 0.08 
0.45 Positive 59(28) 375(45) 375(41.3) 57(42.2) 
BRCA1.n 
Negative 102(48.1) 485(57.9) 0.01 
7 
542(59.4) 44(32.4) <0.0001 
35 Positive 110(51.9) 352(42.1) 370(40.6) 92(67.6) 
ER 
Negative 89(34.6) 439(44.8) 0.003 
8.6 
481(45.2) 46(26.9) <0.0001 
20 Positive 168(65.4) 540(55.2) 582(54.8) 125(73.1) 
KU70/KU80 Negative 
53(23.2) 91(10.2) <0.0001 
27 
116(12) 27(18.5) 0.03 
5 Positive 175(76.8) 797(89.8) 851(88) 119(81.5) 
Ki-67 
Negative 113(49.3) 256(30.4) <0.0001 
28.7 
302(32.5) 68(47.9) <0.0001 
13 Positive 116(50.7) 587(69.6) 626(67.5) 74(52.1) 
BARD1.c 
Negative 67(36.6) 134(18.4) <0.0001 
28 
179(22.3) 22(20.4) 0.6 
0.2 Positive 116(63.4) 595(81.6) 622(77.7) 86(79.6) 
CHK1.n Negative 
170(69.1) 722(75.8) 0.03 
5 
860(83.1) 30(18.6) <0.0001 
304 Positive 76(30.9) 230(24.2) 175(16.9) 131(81.4) 
DNA-PK 
Negative 45(27.8) 86(12.6) <0.0001 
23 
119(16) 11(11.6) 0.3 
1.2 Positive 117(72.2) 596(87.4) 625(84) 84(88.4) 
MTA1.n 
Negative 88(50) 290(41.2) 0.03 
4.5 
339(44.3) 36(32.7) 0.02 
5 Positive 88(50) 414(58.8) 427(55.7) 74(67.3) 
SMC6L1.n Negative 
61(36.3) 233(33.3) 0.4 
0.55 
262(34.6) 30(27.8) 0.2 
2 Positive 107(63.7) 467(66.7) 495(65.4) 78(72.2) 
Markers 
UBC9.n UBC9.c 
Negative 
N (%) 
Positive 
N (%) 
P 
X2 
P 
Negative 
N (%) 
Positive 
N (%) 
P 
X2 
P 
BRCA1.c Negative 
356(60.4) 320(54) 0.02 
5 
270 (65.5) 407(52.8) <0.0001 
18 Positive 233(39.6) 273(46) 142(34.5) 364(47.2) 
BRCA1.n Negative 
403(68.4) 276(46.3) <0.0001 
59 
239(57.9) 441(57.1) 0.8 
0.07 Positive 186(31.6) 320(53.7) 174(42.1) 332(42.9) 
ER 
Negative 365(51.9) 253(35.1) <0.0001 
41 
219(43.4) 400(43.4) 0.99 
0 Positive 338(48.1) 468(64.9) 286(56.6) 522(56.6) 
PgR 
Negative 418(61.4) 324(47.4) <0.0001 
27 
270(56.1) 
 
474(53.4) 0.3 
0.9 Positive 263(38.6) 360(52.6) 211(43.9) 414(46.6) 
Rad51.n 
Negative 365(78.5) 220(54.6) <0.0001 
56 
228(72.6) 358(64.4) 0.01 
6 Positive 100(21.5) 183(45.4) 86(27.4) 198(35.6) 
Rad51.c 
Negative 39(8.4) 39(9.8) 0.5 
0.45 
32(10.3) 46(8.3) 0.3 
0.9 Positive 424(91.6) 361(90.2) 280(89.7) 507(91.7) 
CHK1.c Negative 
387(80) 312(69.6) <0.0001 
13 
250(73.7) 449(75.6) 0.5 
0.4 Positive 97(20) 136(30.4) 89(26.3) 145(24.4) 
SMC6L1.c Negative 
215(33.4) 186(30) 0.2 
1.7 
210(48.3) 193(23.1) <0.0001 
83 Positive 429(66.6) 435(70) 225(51.7) 641 (76.9) 
N= number of cases. c. = cytoplasmic, n. = nuclear expression. This table was created to make the comparison between the continuous and 
categorical data much easier, since this table does not consider co-expression of subcellular localisation, leading to compare each cellular 
localisation separately. Cut-off points as Table 5.7. 
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5.6.4 Correlation of SUMO Markers with Clinico-Pathological Features 
 
Table 5.10 summarises the association between the SUMO markers (PIAS1, PIAS4, 
and UBC9) and clinico-pathological features (Pearson X2). The majority of tumours showed 
PIAS1.c+.n-, PIAS4+ or UBC9.n+.c+ were associated with poor features. Thus, PIAS1.c+.n- or 
UBC9.n+.c+ were associated with higher tumour grade (grade III), high mitotic frequency, 
higher nuclear pleomorphism and moderate NPI (all P<0.0001), in addition to a tumour size 
in excess of 1.5cm (P=0.006, and P=0.003 respectively). The expression of PIAS4+ 
(P=0.002) and UBC9.n+.c+ (P=0.005) showed a significant association with tumour stage 1. 
All markers were highly associated with invasive ductal no special type BC (P<0.0001 for 
UBC9 and PIAS1 and P=0.006 for PIAS4). Details of significant and non-significant 
associations are summarised in Appendix 3. 
 
As discussed in the previous chapters, the high value of X 2 can be referred to, i) a bias 
in the population of patients, ii) based on the data here, it does not seem to have any 
assumption issues, the main problem is normally when one of the expectation values is 5 or 
less, but in the results presented here a large chi squared value is resulted when the 
expectations are not less than 5. However, the data just seem to show that it is very likely that 
the association is not due to chance.  
  
 Table 5.10 Correlation between SUMO Markers with Clinico-Pathological Parameters. 
Parameters 
PIAS1 
c- n- 
N (%) 
c+ n+ 
N (%) 
c- n+ 
N (%) 
c+ n- 
N (%) X
2 P 
Size FP 72(36.9) 47(42.3) 24(37.5) 256(29) 12 0.006 
>1.5cm 123(63.1) 64(57.7) 40(62.5) 628(71) 
Grade 
1 38(19.5) 33(29.5) 11(17.2) 74(8.3) 
90 <0.0001 2 64(32.8) 33(29.5) 33(51.6) 228(25.5) 
3 93(47.7) 46(41.1) 20(31.3) 591(66.2) 
Tubules 
1 12(6.3) 8(7.6) 1(1.7) 25(2.9) 
24 0.001 2 49(25.9) 45(42.9) 22(37.9) 250(28.7) 
3 128(67.7) 52(49.5) 35(60.3) 595(68.4) 
Pleomorphism 
1 3(1.6) 2(1.9) 3(5.2) 5(0.6) 
84 <0.0001 2 84(44.4) 52(49.5) 29(50) 201(23.2) 
3 102(54) 51(48.6) 26(44.8) 661(76.2) 
Mitosis 
1 79(41.8) 46(43.8) 32(5.2) 178(20.5) 
85 <0.0001 2 24(12.7) 20(19) 13(22.4) 168(19.3) 
3 86(45.5) 39(37.1) 13(22.4) 524(60.2) 
Tumour Type 
Invasive Ductal/NST 106(55.2) 58(52.3) 25(39.7) 649(73.5) 
92 <0.0001 
lobular 23(12) 5(4.5) 9(14.3) 27(3.1) 
Atypical Medullary 4(2.1) 1(0.9) 1(1.6) 27(3.1) 
*Mixed 48(25) 40(36) 24(38.1) 158(17.9) 
**other 11(5.7) 7(6.3) 4(6.3) 22(2.5) 
NPI 
Excellent 28(14.4) 24(22) 9(14.1) 40(4.5) 
80 <0.0001 
Good 34(17.5) 25(22.9) 13(20.3) 126(14.2) 
Moderate 1 49(25.3) 30(27.5) 21(32.8) 304(34.3) 
Moderate 2 51(26.3) 19(17.4) 18(28.1) 252(28.4) 
Poor 24(12.4) 10(9.2) 2(3.1) 116(13.1) 
Very poor 8(4.1) 1(0.9) 1(1.6) 48(5.4) 
n. = nuclear and c. = cytoplasmic expression. N= number of cases.  *Lobular or tubular mixed BCs. **Mucinous, Alveolar Lobular, 
Miscellaneous including Metaplastic, Adenoid Cystic, Spindle, and Tubulolobular. NPI= Nottingham Prognostic Index. Excellent NPI 
(2.08±2.4), good NPI (2.42 to င3.4), a moderate prognostic I NPI (3.42 to င4.4), moderate prognostic II NPI (4.42 to င5.4), poor NPI (5.42 
to င6.4), and a very poor NPI (6.5±6.8). The cut-off points were as follows; +-VFRUHIRU3,$6QDQGIRU3,$6F 
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Table 5.10 Correlation between SUMO markers with Clinico-Pathological Parameters 
Continued. 
Parameters 
UBC9 
c- n- 
N (%) 
c+ n+ 
N (%) 
c- n+ 
N (%) 
c+ n- 
N (%) X
2 P 
Size 
FP 108(28.6) 190(31.4) 56(40) 81(23.8) 
14 0.003 
>1.5cm 270(71.4) 416(68.6) 84(60) 259(76.2) 
Stage 
1 261(68) 355(58.4) 84(59.6) 197(58.1) 
18 0.005 2 88(22.9) 188(30.9) 37(26.2) 116(34.2) 
3 35(9.1) 65(10.7) 20(14.2) 26(7.75) 
Grade 
1 47(12.2) 84(13.8) 20(14.2) 22(6.4) 
45 <0.0001 2 101(26.3) 164(27) 61(43.3) 72(21.1) 
3 236(61.5) 360(59.66) 60(42.6) 248(72.5) 
Pleomorphism 
1 4(1.1) 7(1.2) 6(4.4) 3(0.9) 
47 <0.0001 2 114(30.9) 183(30.6) 60(43.8) 62(18.3) 
3 251(68) 409(68.3) 71(51.8) 273(80.8) 
Mitosis 
1 95(25.7) 169(28.3) 60(43.8) 58(17.1) 
55 <0.0001 2 67(18.1) 115(19.2) 30(21.9) 48(14.2) 
3 208(56.2) 316(52.7) 47(34.3) 233(68.7) 
Tumour Type 
Invasive Ductal/NST 253(67.3) 418(69.6) 63(45) 253(74.9) 
97.6 <0.0001 
lobular 17(4.5) 18(3) 26(18.6) 4(1.2) 
Atypical Medullary 13(3.5) 11(1.8) 3(2.1) 11(3.3) 
*Mixed 79(21) 132(22) 42(30) 61(18) 
**other 14(3.7) 22(3.7) 6(4.3) 9(2.7) 
NPI 
Excellent 28(7.3) 48(8) 16(11.6) 16(4.7) 
43 <0.0001 
Good 62(16.2) 99(16.6) 35(25.4) 32(9.4) 
Moderate 1 139(36.4) 186(31.1) 38(27.5) 118(34.7) 
Moderate 2 98(25.7) 156(26.1) 25(18.1) 101(29.7) 
Poor 35(9.2) 87(14.5) 19(13.8) 52(15.3) 
Very poor 20(5.2) 22(3.7) 5(3.6) 21(6.2) 
PIAS4 
Parameters Negative N (%) 
Positive 
N (%) X
2 P 
Tumour stage 
1 214(68.6) 665(57.9) 
13 0.002 2 69(22.1) 367(31.9) 
3 29(9.3) 117(10.2) 
Tumour Type 
Invasive Ductal/NST 198(64.7) 774(68) 
15 0.006 
lobular 12(3.9) 63(5.5) 
Atypical Medullary 18(5.9) 23(2) 
*Mixed 65(21.2) 239(21) 
**other 13(4.2) 40(3.5) 
n. = nuclear and c. = cytoplasmic expression. N= number of cases. *Lobular or tubular mixed BCs. **Mucinous, Alveolar Lobular, 
Miscellaneous including Metaplastic, Adenoid Cystic, Spindle, and Tubulolobular. NPI= Nottingham Prognostic Index. Excellent NPI 
(2.08±2.4), good NPI (2.42 to င3.4), a moderate prognostic I NPI (3.42 to င4.4), moderate prognostic II NPI (4.42 to င5.4), poor NPI (5.42 
to င6.4), and a very poor NPI (6.5±6.8). The cut off pRLQWVRISRVLWLYLW\ZHUHDVIROORZV+-VFRUHIRU8%&QDQG+-score for 
8%&FDQG+-score for PIAS4. 
 
5.6.5 Relationship between SUMO Markers and 3DWLHQWV¶Outcomes by Univariate 
Analysis  
 
SUMO markers showed no effect on patient survival (Figures 5.5-5.9). Cases showing 
PIAS1.n- and received chemotherapy had better BCSS than those with PIAS1.n+ (P=0.006, 
Figure 5.7a). Interestingly, negative or positive expressions of UBC9.n demonstrated no 
difference in BCSS after receiving chemotherapy (P=0.003, Figure 5.9a), whereas, 
cytoplasmic expression has worse BCSS than negative one after receiving chemotherapy 
(P=0.004, Figure 5.9b). 
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Nuclear expression UBC9+, but not cytoplasmic, conferred a better BCSS after 
receiving endocrine treatment (amongst ER+ tumours) than UBC9.n- (nuclear; P=0.001, 
Figure 5.9c, cytoplasmic; P=0.006, Figure 5.9d).  
 
Multivariate analysis for combinations (such as PIAS1 with chemotherapy or PIAS1 
with endocrine therapy) does not usually perform, because multivariate analysis applies for 
the main marker results (+ vs -) as combination effect may be biased by the other factor and 
not by the target marker. 
 
 
 
Figure 5.5 7KH DVVRFLDWLRQV EHWZHHQ 3,$6 ZLWK %&66 DQG WKH HIIHFW RI WUHDWPHQW RQ SDWLHQW¶V
outcome. N; number of cases. Only patients who died from breast cancer were considered. a; shows 
association between PIAS4 and BCSS , where 0= negative and 1= positive expression.  b; expression of 
PIAS4 and BCSS based on chemotherapy in unselected cases. c;  expression of PIAS4 and BCSS based 
on receiving/or not endocrine therapy  in only ER-positive cases. P<0.01 was considered significant. 
Some of ER-positive tumours did not receive endocrine therapy, because the treatment plan for those 
FDVHVZDVDVSDWLHQWVZLWKDVFRUHRI13,UHFHLYHGQRDGMXYDQWWKHUDS\ 
 
Chapter 5                                                                                                  SUMOylation in BC 
190 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6 The associations between PIAS1 with BCSS. 0= negative and 1= positive expression of PIAS1. 
Where n= nuclear expression and c= cytoplasmic expression of PIAS1 and N; number of cases. Only 
patients who died from breast cancer were considered. a; shows association between nuclear expression of 
PIAS1 and BCSS, whereas b; shows cytoplasmic expression. c;  co-expression of nuclear and cytoplasmic 
PIAS1 and its association with BCSS. P<0.01 was considered significant.  
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Figure 5.7 7KHDVVRFLDWLRQVEHWZHHQ3,$6ZLWK%&66DQGWKHHIIHFWRIWUHDWPHQWRQSDWLHQW¶VRXWFRPH1QXPEHURIFDVHV
Only patients who died from breast cancer were considered. a; shows association between nuclear expression of PIAS1 and 
BCSS based on chemotherapy in unselected cases and b; cytoplasmic expression of PIAS1 and BCSS based on chemotherapy in 
unselected cases. c; nuclear expression of PIAS1 and BCSS based on receiving/or not endocrine therapy  in only ER-positive 
cases. d;  cytoplasmic expression of  PIAS1 and BCSS based on receiving/or not endocrine therapy  in only ER-positive cases. 
P<0.01 was considered significant. Some of ER-positive tumours did not receive endocrine therapy, because the treatment plan 
IRUWKRVHFDVHVZDVDVSDWLHQWVZLWKDVFRUHRI13,UHFHLYHGQRDGMXYDQWWKHUDS\  
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Figure 5.8 The associations between UBC9 with BCSS. 0= negative and 1= positive expression of UBC9. 
Where n= nuclear expression and c= cytoplasmic expression of UBC9 and N; number of cases. Only patients 
who died from breast cancer were considered. a; shows association between nuclear expression of UBC9 and 
BCSS, whereas b; shows cytoplasmic expression. c;  co-expression of nuclear and cytoplasmic expression of 
UBC9 and its association with BCSS.  P<0.01 was considered significant. 
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5.6.6 Expression of SUMO Markers in Cell Lines by Reverse Phase Protein Microarray 
 
RPPA was used to evaluate the expression level of SUMO markers in the four cell 
lines (BRCA1 deficient HeLaSilenciX® cells and its control cells (proficient BRCA1), MCF-
7 and MDA-MB-436 cells). RPPA confirmed the IHC results, particularly with regards to 
nuclear expression. The RPPA findings demonstrated higher levels of expression of UBC9 in 
HeLa BRCA1 control cell lines (BRCA1.C) and MCF-7, when compared to other cell lines. 
In contrast, PIAS1 was higher in BRCA1 or MDA-MB-436 than BRCA1.C or MCF7. Only 
Figure 5.9 The associations between UBC9 with BCSS and the effect of treatment on SDWLHQW¶VRXWFRPH1QXPEHU
of cases. Only patients who died from breast cancer were considered. a; shows association between nuclear 
expression of UBC9 and BCSS based on chemotherapy in unselected cases and b; cytoplasmic expression of UBC9 
and BCSS based on chemotherapy in unselected cases. c; nuclear expression of UBC9 and BCSS based on 
receiving/or not endocrine therapy  in only ER-positive cases. d; cytoplasmic expression of UBC9 and BCSS based 
on receiving/or not endocrine therapy in only ER-positive cases. P<0.01 was considered significant. Some of ER-
positive tumours did not receive endocrine therapy, because the treatment plan for those cases was as patients with a 
score of NPIUHFHLYHGQRDGMXYDQWWKHUDS\  
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expression of UBC9 in BRCA1 deficient HeLa vs. MCF-7 was of statistical significant 
(P=0.005, Figure 5.10).    
 
However, a variation of GAPDH expression was noted and was mostly likely due to 
that there is variation in the fluorescence intensity between different microarray experiments. 
Therefore the signals of each marker were normalised to the signals of GAPDH of the same 
experiment performed on the same day.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.7 Discussion 
 
SUMO is the process whereby protein function is modified, either by changing the 
extent of localisation or ubiquitylation, rather than just degradation attributable to ubiquitin 
Figure 5.10 The SUMO protein levels detected by reverse phase protein microarray in different cell lines (BRCA1 deficient 
HeLaSilenciX® cells and its control [BRCA1 and BRCA1.C respectively], MCF-7 and MDA-MB-436 cells).  For image of 
nitrocellulose slide spotted with different cell lysates; the red square represents the 700 channel for detection of mouse 
antibody while green square the 800 channel for rabbit antibody. Images of scanned nitrocellulose slides printed with extracted 
protein from cell lines and probed with the antibodies against the target proteins. Five 2-fold dilutions of each sample were 
printed in duplicate. Background was subtracted and the intensity of each spot was normalised to its corresponding GAPDH 
level. Each (R) represents different passage of each sample, therefore, three different passages of each sample were used. Error 
bars represent Mean (SD). HeLa BRCA1; between passage 21 and 30, HeLa BRCA1 control; between passage 15 and 20, 
MCF-7; between passage 25 and 32, and MDA-MB-436; between passage 12 and 20. A= BRCA1 vs. BRCA1.C, B= BRCA1 
vs. MDA-MB-436, C= BRCA1 vs. MCF-7, D= BRCA1.C vs. MDA-MB-436, E= BRCA1.C vs. MCF-7, and F= MDA-MB-
436 vs. MCF-7. One way ANOVA test was used.  
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[502, 511]. Mammalian cells express SUMO1 in addition to the highly related protein 
SUMO2 and also SUMO3 (SUMO2/3). These, to some degree, are functionally unnecessary 
proteins [530] that are structurally associated with ubiquitin and therefore covalently attach 
onto target proteins by way of a SUMO-conjugation system consisting of an E1 activating 
enzyme (SAE1/SAE2), an E2 ligase (UBC9) and various E3 ligases (PIAS) with different 
types of target-protein specificities [531]. Engagement of the SUMO pathway in areas of  
DDR was previously described [527].  
 
Investigating the characteristics of the SUMO proteins PIAS1, PIAS4 and UBC9 in a 
series of ER- and ER+ BCs, in addition to those harbouring BRCA1 germline mutations, and 
investigate correlation with other tumour markers and DNA-DSB repair markers  has allowed 
further understanding of the involvement of SUMO in repair pathways in the disease. This is 
the first characterisation of SUMO E2 and E3 ligases in a large cohort of BCs. Expression of 
PIAS1, PIAS4 and UBC9 were correlated with clinical outcome, pathological responses and 
the expression of other biomarkers, in order to demonstrate their role in different classes of 
BC. 
 
The level of SUMO expression in BC is ambiguous, despite the fact that preliminary 
findings in Clevenger¶V et al laboratory study [532] propose that the dysregulation of PIAS 
expression occurs in human BCs. The expression of SUMO markers studied in this chapter, 
using IHC, was detected in the nucleus of the cancer cells, as anticipated [523, 533], although 
cytoplasmic expression was also detected using the antibodies targeted to UBC9 and PIAS1. 
Regarding the cellular localisation (in nucleus), the frequencies of PIAS4 and UBC9 in BC 
were higher than PIAS1. This is in agreement with Coppola et al who documented that a 
significant reduction in the protein expression of PIAS1 occurs in colon cancer [534]. Chen et 
al observed a high level of UBC9 in human BCs [535], while Wei et al demonstrated a high 
expression of PIAS4 in gastric tumours [536]. The data from this study suggests that UBC9 
positivity, nuclear-/cytoplasmic+ PIAS1 and high expression of nuclear PIAS4 are associated 
with more aggressive phenotypes of BCs, such as those that are ER negative or BRCA1 
negative, and BRCA1 down regulator proteins (ID4, MTA1): this finding has been previously 
documented in other studies [535, 536]. SUMO markers also occur significantly more 
frequently amongst TN tumours, as opposed to non-TN tumours. TN tumours are usually 
highly proliferative and poorly differentiated, in addition to showing comprehensive genetic 
instability [204]. TN cancers share these and various additional features with BRCA1-
associated breast tumours, which includes high incidence of P53 mutations and poor 
prognosis. The present study shows that an increased frequency of SUMO markers may 
possibly represent an additional feature shared by tumours that occur in carriers of the 
BRCA1 mutation, in addition to TN cancers. 
 
It is well known that the trafficking of proteins in and out of the nucleus regulates 
signal transduction, gene expression, the progression of the cell-cycle and apoptosis. 
Controlled nuclear transport can also be crucial for progression and is necessary in the proper 
response to stress. Thus, in terms of SUMO markers as nuclear localised proteins, unexpected 
Chapter 5                                                                                                  SUMOylation in BC 
196 
 
cytoplasmic expression may play an important role in tumorigenesis, especially as they 
demonstrated roles other than nuclear expression. It can be hypothesised that, once SUMO 
markers are excluded from the nucleus, they are unable to work properly. In the cytoplasm, 
SUMO markers may be entirely degraded or retained: this hypothesis needs further in vitro 
studies to be confirmed.  
 
The relationship between PIAS and ERĮ has been previously described [511]. 
Mutations that halt SUMO modification damage induced transcription of ERĮwithout the 
need to influence the cellular localisation of ERĮ. Aside from highlighting PIAS1 as an E3 
ligase for ERĮ, Sentis et al [511] also determined that PIAS1 and UBC9 modulated ERĮ-
dependent transcription separately from their conjugation activity with SUMO-1. In the 
present study, the SUMO markers showed a significant positive association with ER, which 
suggests that SUMO markers may play a role in hormone receptors in BC. In addition this 
may explain the high level of UBC9 in MCF-7 cell lines or in breast tissue expressing ER+ 
and BRCA1+. The expression of SUMO biomarkers in human BC amongst BRCA1 mutation 
carriers and sporadic cases were investigated, which indicated that expression of SUMO 
proteins is aberrantly decreased more frequently amongst familial BRCA1 tumours than in 
sporadic BRCA1 tumours. The sporadic BRCA1 tumours with reduced SUMO biomarkers 
were often ER negative. The low expression of nuclear PIAS1 (where the main function is) in 
this study is further verification that the majority of SUMO markers may possibly show an 
additional feature shared by BRCA1 familial cancers, in demonstrating lack of ER (since the 
expression of PIAS1 is dependent upon the presence of ER). Thus, these results suggest that 
SUMO may modulate the ERĮ-dependent cellular response, in addition to offering a 
connection between SUMO and the pathways of oestrogen. However, in vitro studies to 
investigate the role of ER in SUMO are warranted. (5ĮGHOHWLRQPXWDQWVFDQEHFRQVWUXFWHG
by PCR however, in vitro SUMO conjugates can be separated on SDS-PAGE and analysed 
by Western blotting. 
 
The noticeable difference between IHC and RPPA used for the study of PIAS1 
expression could be due to the difference in the samples used, for example using cervical cell 
lines (HeLa BRCA1 cell lines), and it is known that cell lines express few tissue-specific 
gene/protein expression [537, 538]. In addition, the composition of the cell culture medium 
may be precisely why patterns of protein expression differentiate cancer cell lines from breast 
tumour tissue. In addition, there are common variations between the conditions of cells 
growing in vitro and that of a tissue sample. Cell lines are rapidly dividing, and general 
variations in expression of genes comprise of an up-regulation of genes related to 
proliferation [537, 538]. Compounds may have a significant and diverse effect on the altered 
pathways between cell lines and tumour tissue. Although the study focused on the protein 
expression, rather than function, determination of the cell cycle phase of the cell lines may 
help to know if this has an effect on protein expression. 
 
The role of UBC9 and PIAS4 has already been outlined as down-regulating the 
expression of BRCA1 [516, 539], in the present findings, a large number of tumours that 
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expressed UBC9 or PIAS4 showed a positive association with BRCA1 down-regulator 
proteins such as ID4 and MTA1[540], thereby provide a clue that may explain the low 
expression of BRCA1 protein in these tumours. However, these finding need further 
investigation to assess the effect of SUMO markers on BRCA1 expression.  
 
The results presented in this chapter are in-line with the hypothesis that DSBs are 
repaired by one or more alternative pathways, as well as being dependent of each other [541]. 
In the present study, tumours that expressed SUMO biomarkers showed not only a strong 
expression of KU70/KU80 (NHEJ), but also a lack of expression of the HR-associated 
markers such as Rad51 and BRCA1. This may suggest that NHEJ, the error-prone 
mechanism [542], is the effective pathway in the repair of DNA-DSBs in BC. However, real 
time PCR could be used to confirm the detection of the accumulation of KU70/KU80 or any 
markers at the damage site by using fluorescent proteins against the target markers. 
 
Markers of the cell cycle, DNA damage sensors and signal transducers such as Ki-67, 
P53, CHK1 and ATM, have been demonstrated to be good predictors of BRCA1 dysfunction 
in BC [270]. The expression of Ki-67 is related to the proliferation of abnormal cells, with 
poor outcomes [331]. It is possible that UBC9 and PIAS4 may play a role in the regulation of 
the cell cycle and however, P53 SUMO has been documented previously [503]. Park et al 
described the involvement of UBC9 in the regulation of the cell cycle, where UBC9 
negatively regulates BRCA1 via different promoters, such as P21, P27 and Gadd45 [543]. 
The association of UBC9 and PIAS4 with abnormal P53 expression in BCs suggests that 
these tumours may experience disorganised cell-cycle control and thus prompt rapid 
abnormal cell division: a hallmark of tumour aggressiveness. PIAS1 may possibly act as a 
tumour suppressor in breast tumours, as deficiency of this gene is associated with the 
proliferation of abnormal cells. Further study is required on PIAS1, in order to establish its 
potential role as a tumour suppressor. The detection of mutations and polymorphisms in 
PIAS1 as tumour suppressor genes can be achieved by single-strand conformation 
polymorphism analysis.  
 
Increasing evidence indicates that SUMO plays a role in protecting the integrity of the 
genome, in addition to modulating DNA repair [544-546]. Modification of   SUMO has also 
been involved in the maintenance of checkpoints and the modulation of cell-cycle transitions 
[547]. In addition, SUMO has an effect on the repair of DNA through the cell-cycle-specific 
modification of DNA-repair factors, or simply by aiming towards some proteins that have 
roles in cell-cycle-regulated DNA-repair pathways. It has been reported that levels of CHK1 
and CHK2 are regulated by ubiquitin-mediated proteolysis through two distinct E3 ligase 
complexes [548, 549]. In the present study, the findings show an association between at least 
one of the E3 proteins (PIAS1 and PIAS4) with DNA-damage sensors and signal transducers 
markers, indicating that these markers may be modified by SUMO, leading to a defect in the 
DNA damage sensors proteins and participation in the aggressive nature of BC.  
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ATM functions upstream as an example of BRCA1 in the same pathway, given that 
BRCA1 is directly phosphorylated by ATM kinase on serine residues S1423 and S1524, thus 
modulating BRCA1 function [550]. In the present study, SUMO markers were highly 
associated with at least one markers of the following; CHK1, ATM, Ki-67 and P53. Taking 
into account the proposition that DNA damage response is an anti-cancer barrier, the results 
in this study are consistent with a scenario where the primary cancer-predisposing defect 
(e.g., BRCA1) would probably weaken the control of genome integrity, in addition to the 
aberrantly enhanced results of unrepaired DSBs, resulting in the activation of ATM. This 
could trigger the ATM-regulated cell-cycle checkpoints and cell death pathways, which may 
lead to inactivation of ATM, if these kinds of lesions were to develop in the direction of 
malignancy. Thus, the SUMO of the BRCA1 defect, at some point, results in the improved 
inactivation frequency of ATM. It remains unknown whether the patients suffer from a defect 
in repair or that the cancer was mainly due to DNA-DSBs thus further studies are warranted 
to investigate and confirm this perhaps by using the Comet assay which is a standard 
technique for evaluation of damage or repair of DNA, biomonitoring and genotoxicity testing 
[551, 552]. Figure 5.11 summarises the main findings of this chapter. In response to DNA- 
damage the level of ATM should be increased leading to increase level of BRCA1 
expression. Here the low level of ATM may explain a defect in the response to the damage or 
the cancer itself has other causes than a defect in DNA-DSB repair.  
Knowing the subcellular location of a protein is important for understanding its 
functions [395]. However, in continuous data, PIAS1.c showed no correlation with 
BRCA1.n, but was statistically significant with nuclear PIAS1, similarly was seen with other 
nuclear markers such as ER, ATM, MTA1.n and CHK1.n. Therefore, it can be hypothesised 
that nuclear, but not cytoplasmic, PIAS1 may have the main role in association with 
BRCA1.n or any marker expressed in the nucleus (such as ATM and ER), in BC. Further 
studies are warranted to investigate the effect of cellular localisation of PIAS1 and UBC9 on 
their function.  
 
When SUMO markers were analysed as continuous variables, some correlations 
lost/improved the significance in comparison to categorical data. It is more logic to consider 
the continuous variable as correlation is biological and certainly the cut-off points will reflect 
these correlations, but it can argue that from a clinical point of view, using markers as a 
dichotomised data may be more helpful for patient management such as HER-2 status in BC 
which is used as positive/ negative and not as continuous variables.   
 
To conclude, the findings of this chapter confirm the previous results, in addition to 
revealing possible new features or roles for the high level expression of SUMO markers in 
relation to the negative/low expression of BRCA1 in BC, especially in terms of DNA-DSB 
repair pathways and DNA damage sensors and signal transducers pathways. In addition, these 
markers may be accustomed to screening for BRCA1, TN and BLBC.  
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Figure 5.11 A summary of the key findings of SUMO markers and their involvement in DNA damage 
sensors and signal transducers, and DNA-DSB repair pathways in BC. X represents a defect in the response 
to DNA damage by showing low level expression of ATM.  High expression of SUMO biomarkers showed 
not only a strong expression of KU70/KU80 (NHEJ), but also a lack of expression of the HR-associated 
markers. Increased association with MTA1 and ID4 in SUMO markers may participate in the low 
expression of BRCA1. 
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Chapter 6 
 
6.1 Introduction  
 
6.1.1 Nucleocytoplasmic Transport in B.C 
 
The mechanisms of nucleocytoplasmic transport have already been described as being 
generally associated with several cellular processes, such as gene expression, progression of 
the cell-cycle, apoptosis and transduction of signals [553]. It is accepted that modulation of 
the nuclear import of macromolecules is essential for changing cellular phenotypes 
throughout progression and malignant cell transformation [554]. The transport of 
nucleocytoplasmic proteins, such as Nucleophosmin (NPM), is important in cellular 
homeostasis, as the proper and regular response to endogenous and environmental stimuli 
depends on the communication between the nucleus and the cytoplasm [555, 556]. This 
particularly applies to kinases and phosphatases, several of which transfer to and outside of 
the nucleus in response to oxidants or various other stressors. The separation of the nucleus 
and cytoplasm arises in part signalling and various other events. However, this 
compartmentalisation may obstruct the communication of intracellular signalling in the event 
that components of the nuclear transport apparatus are influenced by ROS. This result is due 
to the fact that the factors of nuclear transport are important cellular targets for oxidants 
[557]. Nucleocytoplasmic transport arises through cylindrical structures spanning the nuclear 
envelope, often known as nuclear pore complexes (NPCs) [553]. Despite the fact that ions, 
small molecules and small proteins (less than 20 kDa) are able to easily pass through NPCs 
by diffusion, NPCs control and restrict the passage of macromolecules (more than 40 kDa) to 
those with the appropriate signals [555, 556]. The direction of transport through NPCs is 
dependent on a transmission identified as the nuclear localisation signal (NLS) [558]; in 
addition nucleocytoplasmic transport is controlled by soluble receptors that identify NLS 
within their particular cargoes. The majority of these transport receptors are members of a 
large family of homologous proteins referred to as karyopherins or importins. In human cells, 
DPLQLPXPRIȕLPSRUWLQDQGVL[ĮLPSRUWLQSURWHLQVKDYHDOUHDG\EHHQLGHQWLILHG [558, 
559]. Proteins transferred inside the nucleus carry NLS, which can be identified simply by 
LPSRUWLQ ĮLPSRUWLQ ȕ KHWHURGLPHUV 1/6 LV UHFRJQLVHG DQG ERXQG E\ ,PSRUWLQ Į ZKHUHDV
LPSRUWLQȕSHUPLWV WKHFRPSOH[SDVVDJHWKURXJK13&,QDGGLWLRQ ,PSRUWLQĮFDQIXQFWLRQ
on its own by binding to nuclear cargoes, with no need for tKHDVVLVWDQFHRILPSRUWLQȕ[560].  
 
.DU\RSKHULQĮ-2 (KPNA2) is a member of the family of proteins associated with the 
active transport of cargo proteins that contain an NLS from the cytoplasm to the nucleus. 
Despite the fact that the KPNA2 function has not been fully investigated, it mediates the 
transport of the nucleus of some tumour suppressors [561, 562]. Studies of co-transfection 
with green fluorescent protein (GFP)-CHK2 and wild type or even mutant KPNA2 
highlighted a role for KPNA2 in the nuclear import of CHK2 [561]. In BC, the nuclear 
expression of the protein KPNA2 is related to higher tumour grade and stage, positive lymph 
node status, negative ER and PgR receptors and increased proliferation [563, 564]. 
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Furthermore, the expression of KPNA2 is significantly related to poor survival and was 
shown to be an independent prognostic factor in BC [565]. These findings suggest that 
KPNA2 plays an important role in the proliferation of BC.  
 
NPM was initially identified as a highly conserved nucleolar phosphoprotein that is 
largely expressed in the granular component of the nucleolus [566]. More recently, however, 
it was asserted that NPM has a role in the regulation of cell growth; thus, proliferation, 
apoptosis, transformation, cancer pathogenesis and nuclear shuttling is expected [567]. The 
exact function of NPM in oncogenesis is controversial [568], as NPM is mutated or 
rearranged in many haematological disorders [569], including AML. The expression of NPM 
is rapidly increased in response to mitogenic stimuli, with higher protein amounts observed in 
highly proliferating and malignant cells [570]: this is due to the fact that the expression of 
NPM rises rapidly in the early G1 phase, during mitosis [571]. It has been documented that 
the NPM protein is overexpressed in different tumours and it is proposed as a marker for 
different cancers, such as gastric [567] colon [572] and breast [573] cancers.  
 
In the nucleolus, the ubiquitin ligase F-box protein (FBW7J is bound and stabilised 
by NPM, which has been suggested as a factor in the ubiquitination and degradation of the 
oncogenic transcription factor Myc [574]. Without functional NPM, FBW7J is mislocalised 
to the cytoplasm and degraded, ultimately causing enhanced Myc levels and the proliferation 
of cells. Similarly, in AML, many mutations of NPM expose a de novo nuclear export signal, 
resulting in the cytoplasmic localisation of the protein [575]. 
 
 
6.2 Hypothesis  
 
It is recognised that modulation of the nuclear import of macromolecules is essential 
for changing cellular phenotypes throughout progression and for malignant cell 
transformation as a result, it is hypothesised that the nucleocytoplasmic transport markers 
contributes to the development and progression of BC and may have some roles in the 
subcellular localisation expression of many markers. 
 
 
6.3 Aim  
 
The aim of this chapter is to investigate the roles of KPNA2 and NPM in BC in order 
to determine the association between the subcellular localised markers and nucleocytoplasmic 
transport markers. In addition, it aims to investigate the pathological features of the 
expression of KPNA2 and NPM and their association with clinical outcomes.    
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6.4 Materials and Methods 
 
As previously described in Chapter 2 
 
 
6.4.1 Patient Samples  
 
All data are as previously described in Chapter 2 Section 2.1.1.  Three cohorts were 
used: A) 1904 unselected cases of female primary operable invasive tumours between 1986 
and 1998, B) 386 cases selected from a consecutive series of primary operable ER negative 
tumours between 1998 and 2007 and C) 24 well-characterised series of breast tumours from 
patients with known BRCA1 germline mutations. However, HRMA with employing PCR was 
used for BRCA1 mutation detection in group C (this was performed by Dr Ahmed 
Benhasouna). All cases were obtained from the well-characterised Nottingham Tenovus 
primary breast carcinoma series. 
 
 
6.4.2 Available Biomarkers' Data 
 
Data on a wide range of biomarkers of known clinical and biological relevance to BC 
were accessible and saved on a web-based interface (Distiller; Slidepath Ltd, Dublin, 
Ireland). These include ER, PgR, and HER-2 [270-272, 331].  
 
 
6.4.3 Immunohistochemistry  
 
As previously described in Chapter 2 Section 2.1.3. Two markers of 
nucleocytoplasmic transport (NPM and KPNA2) were investigated in this chapter. 
 
 
6.4.3.1 Immunohistochemical Antibody Labelling Using the Novolink Detection Method 
 
As previously described in Chapter 2 Section 2.1.3.1. In this chapter both markers 
were stained by the author. Both markers have been previously successfully stained on TMA 
[576-579]. 
 
 
6.4.3.2 Optimisation of Antibodies used for IHC 
 
As previously described in Chapter  2 Section 2.1.3.2. In addition to Western blotting, 
specificity of staining was confirmed by application of negative (with omission of the 
primary antibody) and positive controls. Positive controls were used according to the 
PDQXIDFWXUHU¶V GDWDVKHHW DQGRU IURP WKH KXPDQ SURWHLQ DWODV DYDLODEOH DW 
http://www.proteinatlas.org/. This helped not only to test the specificity of staining but also to 
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assess the pattern and intensity of protein expressions in the appropriate tissue.  Details of the 
negative and positive controls used are summarised in Table 6.1. Moreover, some control 
TMA slides containing a variety of BC cases with some containing cores from different areas 
of the same cases in addition to normal parenchymal elements were used during optimisation 
to assess the degree of expression heterogeneity.  
 
 
Table 6.1 Immunohistochemistry Positive and Negative Controls of Antibodies Used in this 
Chapter. 
Antibody Positive control Negative control Reference 
KPNA2 BC tissue BC tissue Abcam/ human protein atlas available at  http://www.proteinatlas.org/ 
NPM Normal liver tissue or BC tissue BC tissue 
Abcam/ human protein atlas available at  
http://www.proteinatlas.org/ 
Stating of positive and negative controls was performed together in the same run. Negative staining was performed 
without adding the antibody and showed no staining. All were done on TMA. Both markers have been previously 
investigated on TMA [576-579]. 
    
 
6.4.3.3 Immunohistochemistry Scoring   
 
As previously described in Chapter 2 Section 2.1.3.3.  For evaluation of IHC of the 
TMA, a modified H-score was used [282]. For H-score, both the intensity of staining and the 
percentage of stained cells were considered within each tissue core. Staining intensity was 
scored as 0, 1, 2 or 3 for negative, weak, moderate and strong, respectively. The proportion 
(percentage) of positive cells for each intensity was subjectively estimated.  Multiplication of 
the two indices (intensity and percentage positive cells) provided final scores that range from 
0 to 300.  
 
$OO FDVHV ZHUH VFRUHG ZLWKRXW SULRU NQRZOHGJH RI WKH SDWLHQWV¶ SDWKRORJLFDO RU
outcome data. The author re-scored each marker with at least 30% of a randomly chosen 
subset of cases. A statistical agreement test was performed (Kappa value) for each marker, 
ZKHUH WKHUH ZDV JRRG DJUHHPHQW  DQG DQ DYHUDJH ZDV WDNHQ ,I WKHUH ZHUH
discrepancies, the highest scoring was taken. Kappa values are summarised in Table 6.2. 
Both markers were scored and re-scored by the author using high resolution digital images 
using a web-based interface (Distiller; Slidepath Ltd, Dublin, Ireland).  
 
Table 6.2 The Statistical Agreement between Different Scoring of Antibodies used in this 
Chapter. 
Markers Percentage of re-scoring Kappa value 
KPNA2 100% 0.630 
NPM 30% 0.845 
Kappa test was performed on IBM SPSS 21.0. An average was taken after re-scoring 
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6.4.4 Specificity of the Antibodies by Western Blot 
 
As previously described in Chapter 2 Section 2.1.4.4. Western blot was used on both 
markers. A mixture of different cell lysates to detect only the specificity of an antibody has 
been applied in different studies and showed its reliability [283, 284]. In the present study, 
NPM and KPNA2 were detected in a mixture of different lysates (MCF-7, MDA-MB-231, 
HeLa BRCA1 and its control). NPM and KPNA2 share the same positive controls which are 
MCF-7 and HeLa BRCA1 cell lines. The pre-VWDLQHG PDUNHU µIXOO UDQJH UDLQERZ PDUNHU¶
(Invitrogen Life Technologies) was used as a molecular weight standard.  
http://www.proteinatlas.org/ provides profile data for positive controls of NPM and KPNA2. 
Table 6.3 summarises the details of W.B for each marker.  
 
 
Table 6.3 List of Antibodies Tested by Western Blot on a Mixture of Different Cell Lines. 
Antibody Cell lines Specific positive cell lines* 
NPM A mixture of MCF-7, MDA-MB-231, HeLa BRCA1 and its control MCF-7 or HeLa BRCA1 cell lines 
KPNA2 A mixture of MCF-7, MDA-MB-231, HeLa BRCA1 and its control MCF-7 or HeLa BRCA1 cell lines 
Cell lines and reagents were obtained from the group of Dr Madhusudan Srinivasan. Thawing and freezing procedures were 
done by Nada Albarakati. Passages, Bradford assay and gel electrophoresis were done by the author. Passages used in W.B 
were as follows; HeLa BRCA1; passages 29&30, HeLa BRCA1 control; passages 15&16, MCF-7; passages 25&26, MDA-
MB-231; passages 15&16. * Data available at  http://www.proteinatlas.org/ 
 
 
6.4.5 Reverse Phase Protein Microarray 
 
RPPA was carried out as previously described in Chapter 2 Section 2.1.5.  Cell lines 
preparation and protein extraction and interpretation of the results were carried out by the 
author. However, RPPA run and analysis was carried out by Dr Ola Nejm (Immunology, 
School of Life Sciences, University Hospital, Nottingham, UK) as a collaborative project.       
                             
                          
6.5 Statistical Analysis  
 
All statistical analyses were done by the author using IBM SPSS statistic 21.0 
software. For all statistical tests, a two-sided P-value of <0.01 was considered statistically 
significant. 
 
 
6.5.1 The Determination of the Optimal Cut-offs  
 
As described previously in Chapter 2 Section 2.1.6.1. The cut-off points of the 
KPNA2 and NPM were dichotomised and obtained using different approaches: a) using the 
mean or median of the H-score of the staining according to distribution pattern whether 
normally or not normally distributed, or b) using x-tile software (http://x-
tile.software.informer.com/version 3.6.1, 2003-2005, Yale University, USA) (Table 6.4). If 
the cut-off by mean or median was very high (e.g H-score >200) then x-tile was considered, 
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however, x-tile was used for NPM because the mean of H-score was very high (mean= 226) 
and median of H-score was used for KPNA2. Table 6.4 shows the details of the antibodies 
used in this chapter. Details of H-score histograms of both markers are presented in Appendix 
4.  
 
Table 6.4 Sources, Dilution, Cut-offs Point and Pre-Treatment Conditions of the Antibodies 
used in this Chapter. 
Antibody Clone Source Dilution IHC 
Dilution 
W.B 
RPPA 
+Distribution Cut-offs IHC kit 
NPM Ab55708 Abcam 1:400 1h 1:5,000 1:500 Nuclear 
1XFOHDU+-
score, x-tile. Novolink 
KPNA2 Ab84440 Abcam 1:400 1h 1:1,000 1:500 Nuclear 
1XFOHDU+-
score, median. Novolink 
IHC= immunohistochemistry. W.B= Western blotting. All the antibodies were pre-treated in citrate antigen retrieval pH=6.0 
in microwave for 20 minutes and stained on TMA. + Cellular localisation. 1h= 1 hour incubation with the primary antibody 
at room temperature. 
 
 
6.5.2 Univariate Analysis with Clinico-Pathological Parameters and Tumour Markers  
 
The differences between all markers, with regards to clinico-pathological features, or 
with other tumour markers were analysed using the Pearson Chi-Squared test (x2). 
Consequently, x2 was also used in order to examine the inter-relations between markers 
themselves. In addition analysis of continuous variables was performed using 3HDUVRQ¶V
correlation and ANOVA. One way ANOVA was used to find out which of different BC 
classes (by IHC or RPPA) were significantly different from each other (post hoc test; Tukey).  
 
 
6.5.3 Univariate Analysis with 3DWLHQWV¶Outcome  
 
Patients who were alive or those who died for any reason other than BC were not 
included. The Kaplan-Meier method was used to generate a univariate survival curve and the 
differences in survival among the biomarkers were evaluated using the log-rank test.  
 
 
6.5.4 Multivariate Analysis with PDWLHQWV¶Outcome  
 
If a marker in univariate analysis was statistically significant with patient¶Voutcome, 
then Cox regression was applied for multivariate analyses to test for confounders and 
prognostic or predictive independency of the investigated biomarker from standard 
prognostic/predictive factors such as tumour grade, tumour stage, and tumour size.    
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6.6 Results  
 
6.6.1 Expression of Nucleocytoplasmic Transport Markers in Invasive Breast Cancer  
 
Western blotting validated the specificity of the KPNA2 and NPM antibodies 
showing a single band at the correct protein size (see Figure 6.1). In invasive tumours, 
KPNA2 and NPM demonstrated nuclear staining (see Figure 6.2). Although the majority of 
cases showed the positive nuclear expression of NPM, only (N=20/1339) cases demonstrated 
positive cytoplasmic expressions. As NPM generally functions in the nucleus, and very few 
cases showed cytoplasmic expression only nuclear staining was considered.  
 
Table 6.5 outlines the frequencies of nucleocytoplasmic transport proteins in sporadic 
and known BRCA1 germline mutations BC (hereditary), while Figure 6.3 represents the 
distribution (mean) of NPM and KPNA2 in different classes of BC by IHC. The four classes 
included were classified based on BRCA1 and ER status. Class 1; sporadic BRCA1 negative 
and ER negative, class 2; sporadic BRCA1 positive and ER positive, class 3; known BRCA1 
germline mutations BC that showing ER negativity, and finally class 4; known BRCA1 
germline mutation BC and showing ER positivity. KPNA2 showed the weakest expression in 
ER+ BC, irrespective of BRCA1 status. However, there was a high significant difference 
between sporadic ER+/BRCA1+ and known BRCA1 germline mutations BC that showing ER 
negativity (P<0.0001). In addition a highly significant difference between sporadic 
ER+/BRCA1+ and sporadic ER-/BRCA1-  BC (P<0.0001). In contrast, NPM expression was 
not significantly different between the classes. 
 
 
 
 
  
Figure 6.1 Detection of nucleocytoplasmic transport proteins level by Western blot in a mixture of cell 
lines, MDA-MB-231, MCF-7, HeLa BRCA1 and its control. The predicted size of each protein is labelled 
on the band. Passages used in W.B were as follows; HeLa BRCA1; passages29&30, HeLa BRCA1 control; 
passages 15&16, MCF-7; passages 25&26, and MDA-MB-231; passages 15&16. 
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Table 6.5 Frequency of KPNA2 and NPM expressions in Breast Cancer. 
Marker Sporadic BC known BRCA1 germline mutations BC 
(%) Frequency (%) Frequency 
KPNA2 51.3 715/1393 89.5 17/19 
NPM 81.1 1086/1339 94.7 18/19 
Sporadic BC includes both unselected and ER-negative BC cases.  The number of cases may be reduced due to loss 
cases during preparation of tissue for staining (TMA sectioning or IHC procedure). 
  
Figure 6.2 Immunostaining expression of nucleocytoplasmic transport proteins in breast cancer. Where a; negative 
control for both KPNA2 and NPM, in classical lobular breast cancer; stage 1 and grade 2. b; positive control for NPM in 
normal liver tissue. c; nuclear expression of NPM in tubular mixed breast cancer; stage 1 and grade 2. d; nuclear 
expression of KPNA2 in invasive ductal carcinoma/NST; stage 1 and grade 3 which is also a positive control. 
Magnification x20.  
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6.6.2 Correlation of Nucleocytoplasmic Transport Markers with Other Tumour 
Markers 
 
The association between the KPNA2 and NPM markers and other tumour biomarkers 
are summarised in Table 6.6 (Pearson X2). There was a highly significant association between 
KPNA2 and ER-, PgR- , and TN tumours (but not between NPM and these biomarkers) (all 
P<0.0001). At least one of nucleocytoplasmic transport markers was significantly associated 
with the subcellular localisation of the HR repair markers, including SMC6L1n+.c+ (NPM and 
KPNA2; P<0.0001), BRCA1n-.c+ (NPM and KPNA2; P=0.009 and P<0.0001 respectively), 
BARD1n-.c+ (NPM; P<0.0001), and Rad51n-.c+ (KPNA2; P<0.0001), with DNA signal 
transducers and repair markers; Ȗ+$;Q+.c+ (NPM and KPNA2; P<0.0001); CHK1n-.c+ 
(NPM and KPNA2; P=0.001 and P<0.0001 respectively), and with SUMO markers;  
UBC9n+.c+ (NPM and KPNA2; P<0.0001); PIAS1n-.c+; (KPNA2; P<0.0001). Details of 
significant and non-significant associations are summarised in Appendix 4. 
 
7DEOH  VKRZV WKH 3HDUVRQ¶V FRUUHODWLRQ using continuous data of NPM, KPNA2 
with other tumour markers that showed both nuclear and cytoplasmic expression. Continuous 
data confirmed the categorical except that continuous PIAS1.c was not associated with 
KPNA2 (continuous; P=0.26; Table 6.7, categorical P<0.0001; Table 6.6). In addition, the 
significant was improved between ER and NPM in continuous analysis (continuous; 
P<0.0001; Table 6.7, categorical P=0.5; Appendix 4).  
 
The high value of X 2 of all the results in this section can be referred to, i) a bias in the 
population of patients, ii) based on the data here, it does not seem to have any assumption 
Figure 6.3 NPM and KPNA2 protein levels detected by IHC in breast cancer on TMA. Each bar represents different class 
based on hereditary or sporadic BRCA1 and ER status. Error bars represent Mean (SD) and was created on H-score (ranges 
0-300).  A= sporadic cases [ER- & BRCA1-] vs. sporadic cases [ER+ & BRCA1+], B= sporadic cases [ER- & BRCA1-] vs. 
Hereditary cases [ER-], C= sporadic cases [ER- & BRCA1-]vs. Hereditary cases [ER+], D= sporadic cases [ER+ & 
BRCA1+]vs. Hereditary cases [ER-], E= sporadic cases [ER+ & BRCA1+] vs. Hereditary cases [ER+], and F= Hereditary 
cases [ER-] vs. Hereditary cases [ER+].  ANOVA test was used for each marker within the classes.  
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issues, the main problem is normally when one of the expectation values is 5 or less, but in 
the results presented here a large chi squared value is resulted when the expectations are not 
less than 5. However, the data just seem to show that it is very likely that the association is 
not due to chance. 
 
Table 6.6 Correlation between Nucleocytoplasmic Transport Markers with other Tumour 
Markers. 
Markers 
NPM 
Negative 
N (%) 
positive 
N (%) X
2 P 
Ȗ+$;Q Negative 62(31.3) 83(9.4) 67 <0.0001 
Positive 136(68.7) 800(90.6) 
Ȗ+$; 
n-c- 7(3.5) 9(1) 
67 <0.0001 n+c+ 
120(60.6) 720(81.5) 
n-c+ 55(27.8) 74(8.4) 
n+c- 16(8.1) 80(9.1) 
BARD1.c 
Negative 68(29.3) 180(18.1) 
14.5 <0.0001 
Positive 164(70.7) 813(81.9) 
BARD1 
n-c- 69(29.6) 179(18.1) 
19 <0.0001 n+c+ 
13(5.6) 105(10.6) 
n-c+ 151(64.8) 706(71.2) 
n+c- 0 1(0.1) 
BRCA1 
n-c- 74 (38.3) 236(26.5) 
11.5 0.009 n+c+ 26 (13.5) 137(15.4) 
n-c+ 44 (22.8) 267 (30) 
n+c- 49 (25.4) 251(28.2) 
SMC6L1.n 
Negative 120(54.8) 278(29.5) 
50.5 <0.0001 
Positive 99(45.2) 665(70.5) 
SMC6L1.c 
Negative 101(46.1) 254(26.9) 
31 <0.0001 
Positive 118(53.9) 689(73.1) 
SMC6L1 
n-c- 68(31.1) 134(14.2) 
63 <0.0001 
n+c+ 66(30.1) 545(57.8) 
n-c+ 52(23.7) 144(15.3) 
n+c- 33(15.1) 120(12.7) 
CHK1 
n-c- 20(12.7) 33(4.7) 
15.5 0.001 
n+c+ 36(22.8) 145(20.6) 
n-c+ 97(61.4) 498(70.7) 
n+c- 5(3.2) 28(4) 
CHK1.c 
Negative 25(15.8) 61(8.7) 
7 0.007 
Positive 133(84.2) 643(91.3) 
UBC9 
n-c- 116(49.4) 195(19.9) 
112 <0.0001 
n+c+ 40(17) 545(46.4) 
n-c+ 70(29.8) 243(24.8) 
n+c- 9(3.8) 86(8.8) 
UBC9.n 
Negative 186(79.1) 438(44.8) 
89.5 <0.0001 
Positive 49(20.9) 540(55.2) 
UBC9.c 
Negative 125(53) 282(28.8) 
50 <0.0001 
Positive 111(47) 698(71.2) 
1 QXPEHURIFDVHVF F\WRSODVPLFQ QXFOHDUH[SUHVVLRQ7KHFXWRIISRLQWVRISRVLWLYLW\ZHUHDVIROORZV+-score for BRCA1.c, 
DQG3 for BRCA1.n, >240 H-score for SMC6L1.n, DQG 230 H-score for SMC6L1.c. Ȗ+$;  +-VFRUH QXFOHDU 	  +-score 
cytoplasmic, UBC9; QXFOHDU+-score &cytoplasm; +-score, CHK1; 20 H-VFRUHQXFOHDU	+-score cytoplasmic, BARD1;  
+-score cytoplasmic & >0 H-score nuclear. 
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Table 6.6 Correlation between Nucleocytoplasmic Transport Markers with other Tumour 
Markers Continued. 
 
Markers 
KPNA2 
Negative 
N (%) 
positive 
N (%) X
2 P 
ER Negative 153(23.9) 447(63.8) 215 <0.0001 Positive 487(76.1) 254(36.2) 
PgR Negative 234(37.7) 473(71.5) 148 <0.0001 Positive 387(62.3) 189(28.5) 
Triple Negative Negative 533(85.3) 373(55.8) 134 <0.0001 Positive 92(14.7) 296(44.2) 
HER-2 Negative 585(90.4) 521(76.6) 45.5 <0.0001 Positive 62(9.6) 159(23.4) 
Ki-67 Negative 306(54.2) 105(17) 180 <0.0001 
Positive 259(45.8) 513(83) 
Rad51.c 
Negative 55(15.2) 25(5.7) 
20 <0.0001 
Positive 308(84.8) 416(94.3) 
Rad51.n 
Negative 222(60.7) 328(73.9) 
16 <0.0001 
Positive 144(39.3) 116(26.1) 
Rad51 
n-c- 35(9.6) 14(3.2) 
38 <0.0001 n+c+ 
121(33.3) 103(23.4) 
n-c+ 187(51.5) 313(71) 
n+c- 20(5.5) 11(2.5) 
Ȗ+$;F Negative 82(16) 40(6.2) 29 <0.0001 
Positive 429(84) 601(93.8) 
Ȗ+$;Q Negative 47(9.2) 111(17.3) 16 <0.0001 
Positive 463(90.8) 530(82.7) 
Ȗ+$; 
n-c- 9(1.8) 11(1.7) 
46.5 <0.0001 n+c+ 
390(76.5) 501(78.2) 
n-c+ 38(7.5) 100(15.6) 
n+c- 73(14.3) 29(4.5) 
BRCA1.n 
Negative 226(43.4) 429(72.5) 
97 <0.0001 
Positive 295(56.6) 163(27.5) 
BRCA1 
n-c- 119 (22.9) 218(36.9) 
96 <0.0001 n+c+ 
105 (20.2) 64 (10.8) 
n-c+ 107 (20.6) 209(35.4) 
n+c- 189 (36.3) 99 (16.8) 
*BARD1/BRCA1 Negative 
30(4.9) 60(9) 
8 0.005 
Positive 577(95.1) 605(91) 
SMC6L1.c Negative 
225(38.8) 153(23.3) 
35 <0.0001 
Positive 355(61.2) 503(76.7) 
SMC6L1 
n-c- 135(23.3) 84(12.8) 
39 <0.0001 n+c+ 
277(47.8) 365(55.6) 
n-c+ 78(13.4) 138(21) 
n+c- 90(15.5) 69(10.5) 
CHK1 
n-c- 39(9.2) 17(3.7) 
27 <0.0001 n+c+ 
107(25.2) 81(17.7) 
n-c+ 259(60.9) 348(76.1) 
n+c- 20(4.7) 11(2.4) 
CHK1.n Negative 
298(70.1) 365(79.7) 
11 0.001 
Positive 127(29.9) 93(20.3) 
CHK1.c Negative 
59(13.9) 28(6.1) 
15 <0.0001 
Positive 366(86.1) 429(93.9) 
N= number of cases. c. = cytoplasmic, n. = nuclear expression. TN= negativity of ER& PgR & HER-2. The cut off points of positivity 
were as follows: ER and PgR+(5- 40 H-score for %5&$FDQG3 for BRCA1.n, >240 H-score for SMC6L1.n, DQG 
230 H-score for SMC6L1.c. Ȗ+$;  +-VFRUH QXFOHDU 	  +-score cytoplasmic CHK1; 20 H-score nuclear 	  +-score 
cytoplasmic, BARD1 130 H-score cytoplasmic & >0 H-score nuclear, Ki-67; >34%,  +-score for Rad51.n DQG 80H-score for 
Rad51.c. During mitosis, NPM co-localises with BRCA1 and BARD1. *There is no consideration for cellular localisation, any expression 
was considered positive either in cytoplasm or nucleus for both proteins. 
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Table 6.6 Correlation between Nucleocytoplasmic Transport Markers with other Tumour 
Markers Continued. 
 
Markers 
KPNA2 
Negative 
N (%) 
positive 
N (%) X
2
 
P 
UBC9 
n-c- 175(30.1) 157(23.2) 
57 <0.0001 n+c+ 238(40.9) 279(41.3) 
n-c+ 104(17.9) 217(32.1) 
n+c- 65(11.2) 23(3.4) 
UBC9.n 
Negative 279(47.9) 374(55.3) 
7 0.009 
Positive 303(52.1) 302(44.7) 
UBC9.c Negative 
240(41.1) 181(26.7) 
29 <0.0001 
Positive 344(58.9) 496(73.3) 
PIAS1 
n-c- 88(22.4) 50(10.9) 
44.5 <0.0001 n+c+ 
46(11.7) 28(6.1) 
n-c+ 239(60.8) 373(81.3) 
n+c- 20(5.1) 8(1.7) 
PIAS1.c Negative 
111(28) 58(12.6) 
32 <0.0001 
Positive 286(72) 403(87.4) 
PIAS1.n 
Negative 327(83.2) 425(92.2) 
16.3 <0.0001 
Positive 66(16.8) 36(7.8) 
N= number of cases. c. = cytoplasmic, n. = nuclear expression. The cut off points of positivity were as follows: PIAS1; QXFOHDU+-score 
	F\WRSODVP+-score, UBC9QXFOHDUH-score &cytoplasm +-score. 
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Table 6.7 3HDUVRQ¶V Correlations of Nucleocytoplasmic Transport Markers with other 
Tumour Markers. 
Markers KPNA2 NPM 
HR Repair Markers 
BRCA1.c 
R 0.060 0.067 
P 0.044 0.027 
N 1113 1086 
BRCA1.n 
R -0.309 0.038 
P <0.0001 0.205 
N 1113 1086 
BARD1.n 
R -0.025 0.062 
P 0.377 0.030 
N 1250 1225 
BARD1.c 
R -0.017 0.229 
P 0.542 <0.0001 
N 1250 1225 
Rad51.c 
R 0.194 -0.036 
P <0.0001 0.312 
N 804 781 
Rad51.n 
R -0.202 0.029 
P <0.0001 0.415 
N 804 781 
SMC6L1.c 
R 0.186 0.197 
P <0.0001 <0.0001 
N 1237 1162 
SMC6L1.n 
R 0.075 0.415 
P 0.008 <0.0001 
N 1237 1162 
DNA Damage Signal Transducers and Repair Markers 
CHK1.c 
R 0.144 0.067 
P <0.0001 0.049 
N 882 862 
CHK1.n 
R -0.148 0.013 
P <0.0001 0.706 
N 882 862 
YH2AX.c 
R 0.143 0.055 
P <0.0001 0.072 
N 1152 1081 
YH2AX.n 
R -0.206 0.330 
P <0.0001 <0.0001 
N 1152 1081 
SUMO Markers 
PIAS1.n 
R -0.150 -0.050 
P <0.0001 0.148 
N 858 843 
PIAS1.c 
R 0.038 -0.0003 
P 0.262 0.921 
N 858 843 
UBC9.n 
R -0.160 0.363 
P <0.0001 <0.0001 
N 1259 1213 
UBC9.c 
R 0.155 0.203 
P <0.0001 <0.0001 
N 1259 1213 
Proliferation 
Ki-67 
R 0.46 -0.010 
P <0.0001 0.736 
N 1184 1136 
Hormone Receptors 
PgR 
R -0.313 0.058 
P <0.0001 0.069 
N 1024 984 
ER 
R -0.449 0.125 
P <0.0001 <0.0001 
N 1027 991 
The table represents continuous data for all the markers. N= number of cases. R= 3HDUVRQ¶VFRUUHODWLRQ, P=Probability value. 
c. = cytoplasmic, n. = nuclear expression. Cut-off points were as described in table 6.6.  
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6.6.3 Correlation of Nucleocytoplasmic Transport Markers with Clinico-Pathological 
Features 
 
Table 6.8 summarises the association between KPNA2, NPM and the various clinico-
pathological features of BC (Pearson X2). The majority of tumours with poor prognostic 
features, such as larger tumour size, higher tumour grade (grade III), higher nuclear 
pleomorphism, higher tubular formation and moderate NPI (all P<0.0001), were associated 
with KPNA2+. Both markers were investigated in conjunction with stage of tumour and the 
results were as follows: NPM (P=0.006) and KPNA2 (P=0.007). Both markers were mainly 
invasive ductal no special type BC (both P<0.0001). Details of significant and non-significant 
associations are summarised in Appendix 4. 
 
The high value of X 2 of the findings in this section can be referred to, i) a bias in the 
population of patients, ii) based on the data here, it does not seem to have any assumption 
issues, the main problem is normally when one of the expectation values is five or less, but in 
the results presented here a large X 2 is noticed when the expectations are not less than 5. 
However, the data just seem to show that it is very likely that the association is not due to 
chance.  
 
Table 6.8 Relationship between Nucleocytoplasmic Transport markers with Clinico-
Pathological Parameters. 
Parameters 
KPNA2 
Negative 
N (%) 
Positive 
N (%) X
2 P 
Age <50 205(30.5) 299(41.9) 20 <0.0001 
>50 468(69.5) 414(58.1) 
Size FP 239(35.6) 152(21.6) 33 <0.0001 
>1.5cm 432(64.4) 551(78.4) 
Stage 
1 434(64.4) 404(56.9) 
10 0.007 2 183(27.2) 218(30.7) 
3 57(8.5) 88(12.4) 
Grade 
1 145(21.5) 18(2.5) 
326 <0.0001 2 263(39) 84(11.8) 
3 266(39.5) 611(85.7) 
Tubules 
1 40(6.2) 7(1) 
104 <0.0001 2 251(38.7) 133(18.9) 
3 357(55.1) 565(80.1) 
Pleomorphism 
1 15(2.3) 3(0.4) 
220 <0.0001 2 295(45.7) 77(10.9) 
3 335(51.9) 624(88.6) 
Mitosis 
1 287(44.3) 57(8.1) 
316 <0.0001 2 141(21.8) 85(12.1) 
3 220(34) 563(79.9) 
NPI+ 
Excellent 88(13.1) 10(1.4) 
214 <0.0001 
Good 164(24.5) 36(5.1) 
Moderate 1 209(31.2) 248(35.4) 
Moderate 2 132(19.7) 225(32.1) 
Poor 61(9.1) 136(19.4) 
Very poor 16(2.4) 46(6.6) 
Tumour Type 
Invasive Ductal/NST 363 (55.3) 586 (82.9) 
169 <0.0001 
lobular 47 (7.2) 11 (1.6) 
Atypical Medullary 7 (1.1) 31 (4.4) 
*Mixed 206 (31.4) 68 (9.6) 
**other 34 (5.2) 11 (1.6) 
Cut-off for nuclear .31$ZDV+-score. There was no cytoplasmic expression detected. + and * and ** are presented in the next table. 
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Table 6.8 Relationship between Nucleocytoplasmic Transport markers with Clinico-
Pathological Parameters Continued. 
 NPM 
Parameters Negative N (%) 
Positive 
N (%) X
2 P 
Tumour Stage 
1 170(67.7) 622(57.5) 
10 0.006 2 65(25.9) 338(31.3) 
3 16(6.4) 121(11.2) 
Tumour Type 
Invasive Ductal/NST 164(67.2) 738 (68.8) 
20 <0.0001 
lobular 7 (2.9) 60 (5.6) 
Atypical Medullary 15 (6.1) 17 (1.6) 
*Mixed 52 (21.3) 223 (20.8) 
**other 6 (2.5) 35 (3.3) 
N= number of cases. Cut-off XVHG IRU 130 ZDV +-score. * Lobular or tubular mixed BCs. ** Mucinous, Alveolar Lobular, 
Miscellaneous including Metaplastic, Adenoid Cystic, Spindle, and Tubulolobular. + NPI= Nottingham Prognostic Index. Excellent NPI 
(2.08±2.4), good NPI (2.42 to င3.4), a moderate prognostic I NPI (3.42 to င4.4), moderate prognostic II NPI (4.42 to င5.4), poor NPI (5.42 
to င6.4), and a very poor NPI (6.5±6.8). NST= no special type. 
 
 
6.6.4 Relationship between Nucleocytoplasmic Transport Markers and 3DWLHQWV¶ 
Outcomes by Univariate analysis  
 
The positive expression of KPNA2 demonstrated a significant association with shorter 
BCSS and a shorter time to the induction of recurrence (P<0.0001 and P=0.003, Figures 6.4a- 
b respectively), while NPM had no association with patients¶ outcomes (Figures 6.4c-d). The 
DVVRFLDWLRQEHWZHHQ130	.31$PDUNHUVDQGWKHHIIHFWRIWUHDWPHQWRQSDWLHQW¶VRXWFRPH
is presented in Appendix 4.   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4 The associations between KPNA2 & NPM and BCSS or DFI. N; number of cases. Only patients who died 
from breast cancer were considered. a; shows association between KPNA2 and BCSS , and b; with DFI. c; shows 
association between NPM and BCSS , and d; with DFI. Where 0= negative and 1= positive expression. P<0.01 was 
considered significant. 
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6.6.5 Expression of Nucleocytoplasmic Transport Proteins and 3DWLHQWV¶Outcomes by 
Multivariate Analysis  
 
Table 6.9 and Figure 6.5 show Cox-regression analyses for predictors of BCSS and 
DFI for KPNA2. KPNA2 was not an independent prognostic marker for BC. Although NPM 
showed a trend for longer DFI in univariate analysis, it was a highly independent prognostic 
marker in multivariate analysis.  
 
 
Table 6.9 Cox-regression Analyses for Predictors of BCSS and DFI 
Parameters P-value 95.0% CI Parameters P-value 95.0% CI Lower Upper Lower Upper 
BCSS DFI 
Tumour Stage <0.0001 1.3 2.1 Tumour Stage <0.0001 1.3 1.9 
Tumour Grade 0.001 1.4 2.5 Tumour Grade 0.14 0.94 1.5 
Tumour Size 0.066 0.98 1.82 Tumour Size 0.06 0.99 1.6 
NPI 0.23 0.87 1.8 NPI 0.663 0.842 1.312 
BLBC 0.4 0.66 1.117 BLBC 0.5 0.6 1.0 
KPNA2 0.4 0.87 1.4 KPNA2 0.4 1.219 1.955 
Parameters P-value 95.0% CI 
Lower Upper 
DFI 
Tumour Stage <0.0001 1.452 2.234 
Tumour Grade 0.006 1.096 1.706 
Tumour Size 0.001 1.172 1.942 
NPI 0.839 0.710 1.321 
BLBC 0.004 0.495 0.872 
NPM <0.0001 0.50 0.81 
NPI=Nottingham prognostic index. BLBC= as defined by Triple negative +positive expression of CK5 and CK14 and CK17. Only markers 
in univariate analysis that were statistically significant with SDWLHQWV¶RXWFRPHV were applied for Cox regression (IBM SPSS 21.0) for 
multivariate analyses. However, positive expression of NPM showed a trend for longer DFI in univariate analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5 Multivariate Cox-regression analyses for BCSS and DFI for nuclear KPNA2 and nuclear NPM. Tumour 
grade, stage and size, NPI, and BLBC, were included. 0= negative expression, and 1=positive expression. 
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6.6.6 Expression of Nucleocytoplasmic Transport Markers in Cell Lines by Reverse 
Phase Protein Microarray 
 
RPPA was used to evaluate the expression levels of nucleocytoplasmic transport 
markers in different cell lines, such as BRCA1 deficient HeLaSilenciX® cell and its control 
(proficient BRCA1), MCF-7 and MDA-MB-436 cells. RPPA does not confirm the IHC 
results of KPNA2 and demonstrates higher levels of the expression of KPNA2 in the BRCA1 
control cell line (BRCA1.C) than the BRCA1 deficient HeLa (P=0.0004). Additionally, 
KPNA2 expression in BRCA1.C was significantly higher than MDA-MB-436 (P<0.0001), 
and finally BRCA1.C vs. MCF-7 showed a significant difference (P<0.0001). In line with 
IHC, the RRPA analysis of NPM highlighted similar expression amongst all the cell lines, 
and showed no statistical significant (Figure 6.6). 
  
 
 
 
 
 
 
Figure 6.6 The nucleocytoplasmic transport protein levels detected by reverse phase protein microarray in different cell 
lines (BRCA1 deficient HeLaSilenciX® cells and its control [BRCA1 and BRCA1.C respectively], MCF-7 and MDA-
MB-436 cells).  For image of nitrocellulose slide spotted with different cell lysates; the red square represents the 700 
channel for detection of mouse antibody while green square the 800 channel for rabbit antibody. Images of scanned 
nitrocellulose slides printed with extracted protein from cell lines and probed with the antibodies against the target 
proteins. Five 2-fold dilutions of each sample were printed in duplicate. Background was subtracted and the intensity of 
each spot was normalised to its corresponding GAPDH level. Each (R) represents different passage of each sample; 
therefore, three different passages of each sample were used. Error bars represent Mean (SD). HeLa BRCA1; between 
passage21 and 30, HeLa BRCA1 control; between passage 15 and 20, MCF-7; between passage 25 and 32, and MDA-
MB-436; between passage 12 and 20. A= BRCA1 vs. BRCA1.C, B= BRCA1 vs. MDA-MB-436, C= BRCA1 vs. MCF-
7, D= BRCA1.C vs. MDA-MB-436, E= BRCA1.C vs. MCF-7, and F= MDA-MB-436 vs. MCF-7. One way ANOVA 
test was used.  
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6.7 Discussion  
 
Profiling the localisation of proteins in several subcellular compartments is as 
important as profiling the expression of proteins and post-translational modification patterns. 
Understanding the localisation of proteins offers valuable insight into understanding state of 
activation, interaction networks and the biological functions of such proteins [580]. Such 
understanding may also aid the identification of potential targets in the process of drug 
discovery. For example, secreted proteins and plasma membrane proteins are conveniently 
accessible to targeted drugs, due to their particular localisation in the extracellular space or 
even on the surface of the cell [581].  
 
DNA-DSB repair markers are usually located in the nucleus of a cell. In this study, 
these markers, detected by IHC, showed additional cytoplasmic expression. Interestingly, the 
effects of nuclear expression on patient survival switched from being a good predictor of 
BCSS to a poor predictor of this, when expressed in the cytoplasm. This is consistent with the 
clinical observation that cytoplasmic expression in most of the markers investigated is 
associated with poor prognostic features, such as TN, negativity of ER, PgR, absence of 
BRCA1 and higher histological grade. Thus, the identification of specific action in some 
proteins that signals between nucleus and cytoplasm in BC may help to detect a novel 
therapeutic target. In the present study, two proteins known to play a role in subcellular 
localisation (KPNA2 and NPM) were investigated and correlated with the expression of any 
marker showed nuclear and cytoplasmic expression, in order to investigate the expression of 
NPM and KPNA2 with these markers.  
 
NPM is highly associated with the uncontrolled growth of cancer cells. The 
physiological function of NPM in tumorigenesis is unclear, but it possesses both tumour-
suppressive and oncogenic activity [582]. NPM may play a role in oncogenesis by activating 
the oncogenic potential of a fused protein partner; Anaplastic lymphoma kinase (ALK), or 
myeloid leukemia factor 1(MLF1) [583]. It has been documented that the protein NPM is 
overexpressed in different tumours, such as gastric [567], colon [572] and breast tumours 
[573]. It is anticipated that tumour cell growth requires a sustained supply of nutrients and is 
in need of continued biogenesis of ribosome. NPM is therefore a crucial factor in this process 
and it naturally follows that there should be an approach towards the use of NPM in the 
treatment of various cancers. Furthermore, considering that NPM has oncogenic potential, 
when over-expressed, the protein could possibly translate or even amplify multiple oncogenic 
signalling mechanisms throughout carcinogenesis [582]. Herein, the DFI rate was better in 
patients demonstrating a high expression of NPM and multivariate analysis indicated that 
expression of NPM is an independent prognostic factor in BC patients. In contrast, a study on 
oral squamous cell carcinoma showed that the DFI rate was significantly better in patients 
with a low expression of NPM [584]. However, the discrepancy in these findings could be 
referred to the tissue used; breast and oral squamous cancers. The mechanism by which the 
overexpression of NPM is involved in the progression of cancer has not yet been determined 
and thus requires further investigation. 
Chapter 6                                                                          Nucleocytoplasmic Transport in BC 
218 
 
During mitosis, NPM co-localises with BRCA1 and BARD1 [585]; however, it has 
been demonstrated that the expression of BRCA1 is cell-cycle dependent, with the most 
significant expression presenting in the G2 and M phases. Due to the fact that BRCA1 and 
BARD1 stabilise each other [586], it is quite possible that the activity of ubiquitin ligase of 
BRCA1-BARD1 is rapidly increased in these stages. The complex of BRCA1-BARD1 in 
cells leads to the stabilisation, rather than degradation, of NPM [585]. In the present study, 
the complex of BARD1-BRCA1 showed a trend for association with NPM (P=0.016; 
Appendix 4). Given the variety of overlapping roles between NPM and BRCA1, it may 
suggest that NPM is an effective candidate, in terms of being a substrate of the ubiquitin 
ligase of BRCA1-BARD1, and may very well be important in the role of BRCA1 as a tumour 
suppressor, participating in its subcellular localisation. The mechanism with which the 
activity plays a role in the biology of BRCA1 needs to be established. To validate the in vivo 
co-localisation of NPM with BRCA1-BARD1, the subcellular localisation of these proteins 
may be investigated. Cell lines such as proliferating Swiss 3T3 cells can be stained with the 
indicated antibodies, followed by fluorescein isothiocyanate (green) conjugated secondary 
antibodies. This will stain the nucleus, which indicates the co-localisation of NPM with 
BRCA1-BARD1 in mitosis [585]. In addition, immunoprecipitation and immunoblotting 
methods; detection of in vivo ubiquitinated substrates, as well as in vitro Ub ligation 
assay can be carried out in further studies.  
 
KPNA2 is a member of the family of various proteins associated with the active 
transport of cargo proteins, which contains an NLS from the cytoplasm to the nucleus. It has 
been reported as an important marker of tumorigenesis and progression of BC [587, 588]. 
Gluz et al support the findings in this study, highlighting the overexpression of nuclear 
KPNA2 in BCs, which was significantly associated with aggressive tumour features such as 
higher grade, negative hormone receptor status, shorter overall survival and DFI [564], 
although in the present study the effect of KPNA2 on SDWLHQWV¶RXWFRPHV was not independent 
prognostic marker. Consistent with BC studies, similar associations of the expression of 
KPNA2 with features of poor prognosis were observed in other types of cancer, such as 
melanoma and ovarian cancers [589, 590]. This is the first study to investigate the 
nucleocytoplasmic transport markers of various pathways, in terms of a large cohort and 
specific subtypes.   
 
The overexpression of cell-cycle genes such as BUB1, CDC6, CDC25A, E2F1, 
KNSL5 and UBCH10 is a sign of cell proliferation, which is known to be related to poor 
clinical outcome in BC [591]. Dai et al examined the molecular functions and biological 
processes of fifty prognostic genes, including KPNA2, and highlighted how the majority of 
the highly expressed genes in tumours with a poor outcome are cell-cycle associated genes 
[591]. In the present study, a strong correlation between KPNA2 protein expression and Ki-
67, it can be hypothesised that, the finding may highlight the essential role of KPNA2 in the 
proliferation signalling of BC. This finding is supported by Saki et al but in regards to 
Oesophageal Squamous Cell Carcinoma [592]. Thus, the expression of KPNA2 could 
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possibly be related to the induction of proliferation and the progressive nature of BC. 
However, further studies are warranted to confirm this hypothesis.  
 
KPNA2 mediates the transport of the nucleus of some tumour suppressors [561, 562]. 
Sandrock et al demonstrated that a low expression of KPNA2 inhibits the nuclear import of 
the small GTPase Ras-related C3 botulinum toxin substrate 1 (Rac1) [593]. However, the 
function of nuclear Rac1 regulates the signalling pathways that control gene expression and 
progression through the cell cycle [593, 594]. Tseng et al highlighted how KPNA2 controls 
both the nuclear localisation of the MRN complexes and the formation of radiation-induced 
focus [595] by demonstrating how the suppression of KPNA2 leads to the inactivation of 
double strand breaks (induced by IR) and the suppression of NSB-mediated DNA repair.  
 
It has been proposed that KPNA2 participates in the nuclear translocation of BRCA1. 
The role of BRCA1 in carcinogenesis is pinpointed towards functions in the repair of DNA, 
in addition to control of the cell cycle checkpoint [596]. The importance of NLS in the 
translocation of BRCA1 has been identified, together with the direct interaction between 
KPNA2 and BRCA1 [597]. The observation that a BRCA1 mutant deficiency of both NLSs 
can be observed in the nucleus [481, 598] has resulted in the identification of an alternative 
process in the importing of BRCA1 [480]. The value of the two alternative pathways 
continues to be identified. 
 
At least one of the nucleocytoplasmic transport markers studied in this chapter 
(KPNA2 and NPM) was highly associated with the negative nuclear and positive cytoplasmic 
expression of different markers such as Rad51, BRCA1 and PIAS1, although the mechanism 
inducing cytoplasmic localisation remains to be determined. In the present study, it is likely 
that nuclear expression of HR repair, DNA damage signal transducer and SUMO markers 
bind to or interact with another marker leading to change their role when expressed in the 
cytoplasm. The aberrant high expression of KPNA2 and NPM in cancer tissue has been 
related to unfavourable patient features, prompting the possibility that these proteins play a 
role in carcinogenesis. Additionally, both markers were highly associated with the early 
stages of tumours. These combined results suggest that NPM and/or KPNA2 may be useful 
as a diagnostic biomarker in differentiating between the various stages of the progression of 
BC. In line with a previous study on bladder cancer, the expression of NPM has been linked 
with the stage of tumour progression [599]. In general, KPNA2 or NPM showed a significant 
positive association with cytoplasmic expression of most of the markers in this study such as 
Rad51 and PIAS1, but a negative one with its nuclear expression. Although both markers are 
known to have role in nuclear import, each one has its own role on the direct of transport of 
protein. However, this is just a hypothesis drawn as result of the finding, but further studies 
are warranted. Therefore, in vitro system, digitonin-permeabilised vertebrate cells can be 
developed in order to investigate biochemical events in the macromolecules transport across 
the envelope of the nucleus. Figure 6.7 shows a summary of the key findings in this chapter. 
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Despite the fact that ions, small molecules and small proteins (less than 20 kDa) are 
able to easily pass through NPCs by diffusion, NPCs control and restrict the passage of 
macromolecules (more than 40 kDa) to those with the appropriate signals [555, 556]. In the 
present study, it is important to note that the exclusion of fusion proteins from the nucleus to 
the cytoplasm is not size-dependent, because some markers are more than 40 kDa such as 
BRCA1 (~220 kDa), PIAS1 (71kDa) and CHK1 (54 kDa). Therefore, it can hypothesise that 
there is a defect in NPCs leading to uncontrolled travel of the macromolecule from and to the 
nucleus. However, a biochemical assay for formation of annulate lamellae (several pairs of 
parallel, smooth membranes, each pair containing regularly spaced pores similar to those of 
the nuclear envelope) can be developed and used to investigate the mechanism of annulate 
lamellae assembly in general and individual nucleoporins assembly into pore complexes in 
particular.  
 
Again as described in the previous chapter the noticeable difference between IHC and 
RPPA used for the study of KPNA2 expression could be due to the difference in the samples 
used, for example using cervical cell lines (HeLa BRCA1 cell lines). Additionally, variations 
in environmental selection pressures may also clarify the differential patterns of the 
expression of protein in tumour tissue and the cell lines. 
 
In theory, if the nuclear import/export of any proteins investigated in this study 
(Rad51, BRCA1, BARD1, SMC6L1, CHK1, Ȗ+$;, PIAS1, and UBC9) is dependent on 
interaction with KPNA2 or NPM, then an increase in the expression of KPNA2 or NPM 
should occur and should have an effect on nuclear export to the cytoplasm. Thus, high levels 
of nuclear import proteins (KPNA2 or NPM) with other markers (HR repair, CHK1, and 
SUMO markers) in the cytoplasm caused a disappearance or the low expression of proteins 
(DNA-DSB or SUMO markers) in the nucleus. The expression of these markers (such as 
Rad51) in the cytoplasm of the cell may play a part in a poor prognosis of BC. From the 
results of this study, it can conclude that the poor prognosis of patients is largely associated 
with the negative nuclear and positive cytoplasmic expression of any marker tested here, such 
as Rad51. This finding may demonstrate the role of KPNA2 or NPM as nuclear export 
markers (by binding their cargo in the cytoplasm, after which they can interact with the 
nuclear pore complex and pass through its channel) [553]. The results of this study suggest 
that the expression of DNA-DSB repair marker (Rad51) and its nuclear vs. cytoplasmic 
compartmentalisation in breast tumour cells act as a prognostic marker, which may be utilised 
to facilitate the clinical management of patients. To conclude, further studies on the roles of 
the biology of subcellular localisation in breast oncogenesis, using cellular and animal 
models, are warranted, as are further clinical studies, in order to clarify whether subcellular 
localisation of proteins such as HR and SUMO markers can improve prognostication in BC.  
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Figure 6.7 A summary of the key findings of nucleocytoplasmic transport markers in BC. Where, KPNA2 was 
mainly associated with ER negative BC and positive expression of Ki-67, whereas, positive expression of 
NPM was an independent good prognostic marker in BC.  
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Chapter 7 
 
7.1 General Results  
 
7.1.1 Correlation of Biomarkers as Continuous Variables 
 
Table 7.1 shows the correlation of various markers analysed as continuous variables 
using 3HDUVRQ¶V FRUUHODWLRQ. Generally, the markers of this study are likely to show a 
significant positive association with any other markers but similar in cellular localisation, 
such as BRCA1.n with nuclear expression of HR repair; Rad51, SUMO markers; PIAS1, 
PIAS4 and UBC9, DNA-damage sensors and signal transducer markers; ATM, CHK1, and 
CHK2 except ATR, and only DNA-PK from NHEJ. Similarly was seen between other 
markers (e.g. Rad51.n with CHK1.n or CHK2 with PIAS4). In contrast, markers that were 
expressed in the cytoplasm had a negative significant association with those expressed in the 
nucleus such as the association between SMC6L1.c and CHK1.n/ BRCA1.n/PIAS1.n as well 
as the association between Rad51.c and BRCA1.n/ CHK1.n/ PIAS1.n.  
However, BARD1.c, but not nuclear expression, showed a positive association with 
most of the markers that were expressed in the nucleus such as CHK2, BRCA1.n, Rad51.n, 
and NPM. KU70/KU80 was positively associated with both cytoplasmic and nuclear 
expression of most of the markers such as Rad51, SMC6L1, and UBC9.   
Regarding ATM, it only showed a positive association with nuclear expression 
markers such as Rad51, PIAS1, UBC9, Ȗ+$; &+. DQG &+. EXW KRZHYHU ERWK
nuclear and cytoplasmic BRCA1 had a significant positive association with ATM, and finally 
ATM showed a negative association only with KPNA2.  
Finally, KPNA2 had a negative association with those markers that had a nuclear 
expression such as BRCA1, Rad51, CHK1, CHK2, Ȗ+$; 3,$6 and UBC9 except 
SMC6L1 and PIAS4. However, a positive association were noticed between the cytoplasmic 
expressions of the same markers with KPNA2.  
Figure 7.1 summarises the findings of this study, which demonstrates different 
pathways (HR and NHEJ repair, SUMO, DNA-damage sensors and signal transducers) that 
are known to have direct or indirect roles in the repair of DNA-DSB in BC. In response to 
DNA- damage the level of ATM should be increased leading to increase levels of BRCA1 
expression. Here the low level of ATM may explain a defect in the response to the damage or 
the cancer itself has other causes than a defect in DNA-DSB repair. Generally, the figure 
illustrates that, there are two hypotheses: first; there is no DSB which may be explained by 
the low level of ATM as result of no damage to be censored leading to low level of BRCA1 
expression, secondly; there is a DNA-'6%GXHWRWKHKLJKH[SUHVVLRQOHYHORIȖ+$;ZKLFK
is a general hallmark of DNA-DSB[600], but however, an error in the repair may occur. 
However, high level of NHEJ repair markers(error-prone repair pathway) [399, 428], and low 
expression level of HR repair (error- free repair pathway) [414, 601, 602], may have some 
role in defect of the repair.   
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 Table 7.1 3HDUVRQ¶V&RUUHODWLRQEHWZHHQall the Markers in this Study. 
 Markers BRCA1.c BRCA1.n BARD1.n BARD1.c Rad51.c Rad51.n SMC6L1.c SMC6L1.n 
BRCA1.c 
R 
* 
-0.129 -0.009 0.009 0.174 -0.064 0.090 0.093 
P <0.0001 0.764 0.748 <0.0001 0.047 0.003 0.002 
N 1756 1178 1178 955 955 1106 1106 
BRCA1.n 
R -0.129 
* 
0.044 0.218 -0.088 0.449 -0.122 0.002 
P <0.0001 0.129 <0.0001 0.007 <0.0001 <0.0001 0.953 
N 1756 1178 1178 955 955 1106 1106 
BARD1.n 
R -0.009 0.044 
* 
0.169 0.052 -0.024 0.037 0.051 
P 0.764 0.129 <0.0001 0.132 0.493 0.195 0.072 
N 1178 1178 1477 851 851 1237 1237 
BARD1.c 
R 0.009 0.218 0.169 
* 
0.085 0.131 0.212 0.201 
P 0.748 <0.0001 <0.0001 0.014 <0.0001 <0.0001 <0.0001 
N 1178 1178 1477 851 851 1237 1237 
Rad51.c 
R 0.174 -0.088 0.052 0.085 
* 
0.031 0.119 -0.027 
P <0.0001 0.007 0.132 0.014 0.283 0.001 0.436 
N 955 955 851 851 1178 813 813 
Rad51.n 
R -0.064 0.449 -0.024 0.131 0.031 
* 
-0.084 0.031 
P 0.047 <0.0001 0.493 <0.0001 0.283 0.016 0.382 
N 955 955 851 851 1178 813 813 
SMC6L1.c 
R 0.090 -0.122 0.037 0.212 0.119 -0.084 
* 
0.416 
P 0.003 <0.0001 0.195 <0.0001 0.001 0.016 <0.0001 
N 1106 1106 1237 1237 813 813 1387 
SMC6L1.n 
R 0.093 0.002 0.051 0.201 -0.027 0.031 0.416 
* P 0.002 0.953 0.072 <0.0001 0.436 0.382 <0.0001 
N 1106 1106 1237 1237 813 813 1387 
KU70/KU80 
R 0.119 -0.108 0.011 0.063 0.164 0.159 0.143 0.280 
P <0.0001 <0.0001 0.734 0.058 <0.0001 <0.0001 <0.0001 <0.0001 
N 1055 1055 918 918 1030 1030 869 869 
CHK1.c 
R 0.240 -0.052 0.019 0.202 0.300 0.011 0.125 0.194 
P <0.0001 0.090 0.558 <0.0001 <0.0001 0.722 <0.0001 <0.0001 
N 1081 1081 939 939 1037 1037 890 890 
CHK1.n 
R 0.010 0.352 -0.007 0.071 -0.150 0.457 -0.135 -0.004 
P 0.747 <0.0001 0.841 0.030 <0.0001 <0.0001 <0.0001 0.900 
N 1081 1081 939 939 1037 1037 890 890 
CHK2 
R 0.013 0.317 0.116 0.124 -0.081 0.208 0.129 0.256 
P 0.701 <0.0001 0.001 <0.0001 0.051 <0.0001 <0.0001 <0.0001 
N 858 858 808 808 580 580 790 790 
ATR 
R 0.091 -0.085 -0.032 0.055 -0.011 -0.042 0.235 0.098 
P 0.004 0.007 0.304 0.078 0.783 0.272 <0.0001 0.002 
N 1000 1000 1011 1011 673 673 991 991 
ATM 
R 0.119 0.234 0.016 0.038 0.022 0.157 -0.028 0.044 
P <0.0001 <0.0001 0.616 0.250 0.535 <0.0001 0.394 0.187 
N 1158 1158 940 940 780 780 906 906 
Ȗ+$;.c R 0.103 -0.033 -0.020 0.250 0.224 0.027 0.391 0.202 P 0.001 0.281 0.500 <0.0001 <0.0001 0.459 <0.0001 <0.0001 
N 1052 1052 1146 1146 773 773 1167 1167 
Ȗ+$;.n R 0.018 0.293 0.068 0.284 -0.038 0.263 0.042 0.439 P 0.561 <0.0001 0.021 <0.0001 0.298 <0.0001 0.151 <0.0001 
N 1052 1052 1146 1146 773 773 1167 1167 
PIAS4 
R 0.113 0.085 0.001 0.104 0.135 0.195 0.093 0.303 
P <0.0001 0.003 0.979 0.001 <0.0001 <0.0001 0.003 <0.0001 
N 1198 1198 1049 1049 1011 1011 992 992 
PIAS1.n 
R 0.004 0.324 -0.012 0.070 -0.166 0.422 -0.161 -0.013 
P 0.893 <0.0001 0.720 0.035 <0.0001 <0.0001 <0.0001 0.711 
N 1047 1047 912 912 1018 1018 868 868 
PIAS1.c 
R 0.157 0.040 0.044 0.256 0.368 0.138 00.155 0.104 
P <0.0001 0.197 0.184 <0.0001 <0.0001 <0.0001 <0.0001 0.002 
N 1047 1047 912 912 1018 1018 868 868 
UBC9.n 
R 0.046 0.287 0.061 0.266 -0.066 0.248 0.018 0.325 
P 0.111 <0.0001 0.029 <0.0001 0.053 <0.0001 0.518 <0.0001 
N 1184 1184 1298 1298 863 863 1265 1265 
UBC9.c 
R 0.110 -0.013 -0.032 0.269 0.130 0.028 0.284 0.146 
P <0.0001 0.665 0.255 <0.0001 <0.0001 0.420 <0.0001 <0.0001 
N 1184 1184 1298 1298 863 863 1265 1265 
KPNA2 
R 0.060 -0.309 -0.025 -0.017 0.194 -0.202 0.186 0.075 
P 0.044 <0.0001 0.377 0.542 <0.0001 <0.0001 <0.0001 0.008 
N 1113 1113 1250 1250 804 804 1237 1237 
NPM 
R 0.067 0.038 0.062 0.229 -0.036 0.029 0.197 0.415 
P 0.027 0.205 0.030 <0.0001 0.312 0.415 <0.0001 <0.0001 
N 1086 1086 1225 1225 781 781 1162 1162 
The table represents continuous data for all the markers. N= number of cases. R= 3HDUVRQ¶V FRUUHODWLRQ, P=Probability value. c. = 
cytoplasmic, n. = nuclear expression. * Analysis between the marker itself. The cut-off points were as described in table 2.6. 
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Table 7.1 3HDUVRQ¶V&RUUHODWLRQEHWZHHQDOOWKH0DUNHUVLQWKLV6WXG\Continued.  
 Markers  KU70/KU80 DNA-PK CHK1.c CHK1.n CHK2 ATR ATM Ȗ+$;.c 
BRCA1.c 
R 0.119 0.140 0.240 0.010 0.013 0.091 0.119 0.103 
P <0.0001 <0.0001 <0.0001 0.747 0.701 0.004 <0.0001 0.001 
N 1055 1090 1081 1081 858 1000 1158 1052 
BRCA1.n 
R -0.108 0.070 -0.052 0.352 0.317 -0.085 0.234 -0.033 
P <0.0001 0.020 0.090 <0.0001 <0.0001 0.007 <0.0001 0.281 
N 1055 1090 1081 1081 858 1000 1158 1052 
BARD1.n 
R 0.011 0.054 0.019 -0.007 0.116 -0.032 0.016 -0.020 
P 0.734 0.061 0.558 0.841 0.001 0.304 0.616 0.500 
N 918 1225 939 939 808 1011 940 1146 
BARD1.c 
R 0.063 0.280 0.202 0.071 0.124 0.055 0.038 0.250 
P 0.058 <0.0001 <0.0001 0.030 <0.0001 0.078 0.250 <0.0001 
N 918 1225 939 939 808 1011 940 1146 
Rad51.c 
R 0.164 0.021 0.300 -0.150 -0.081 -0.011 0.022 0.224 
P <0.0001 0.551 <0.0001 <0.0001 0.051 0.783 0.535 <0.0001 
N 1030 792 1037 1037 580 673 780 773 
Rad51.n 
R 0.159 0.077 0.011 0.457 0.208 -0.042 0.157 0.027 
P <0.0001 0.031 0.722 <0.0001 <0.0001 0.272 <0.0001 0.459 
N 1030 792 1037 1037 580 673 780 773 
SMC6L1.c 
R 0.143 0.208 0.125 -0.135 0.129 0.235 -0.028 0.391 
P <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 0.394 <0.0001 
N 869 1156 890 890 790 991 906 1167 
SMC6L1.n 
R 0.280 0.504 0.194 -0.004 0.256 0.098 0.044 0.202 
P <0.0001 <0.0001 <0.0001 0.90 <0.0001 0.002 0.187 <0.0001 
N 869 1156 890 890 790 991 906 1167 
KU70/KU80 
R 
* 
0.276 0.161 -0.039 0.027 0.076 0.026 0.072 
P <0.0001 <0.0001 0.181 0.485 0.037 0.446 0.039 
N 844 1173 1173 650 753 863 818 
CHK1.c 
R 0.161 0.205 
* 
-0.100 0.053 -0.016 0.013 0.195 
P <0.0001 <0.0001 <0.0001 0.171 0.654 0.70 <0.0001 
N 1173 867 1321 665 779 892 839 
CHK1.n 
R -0.039 0.078 -0.100 
* 
0.171 -0.053 0.125 -0.042 
P 0.181 0.021 <0.0001 <0.0001 0.138 <0.0001 0.222 
N 1173 867 1321 665 779 892 839 
CHK2 
R 0.027 0.340 0.053 0.171 
* 
0.112 0.107 0.016 
P 0.485 <0.0001 0.171 <0.0001 0.001 0.006 0.665 
N 650 758 665 665 912 648 760 
ATR 
R 0.076 0.202 -0.016 -0.053 0.112 
* 
-0.021 0.084 
P 0.037 <0.0001 0.654 0.138 0.001 0.549 0.009 
N 753 946 779 779 912 789 955 
ATM 
R 0.026 0.051 0.013 0.125 0.107 -0.021 
* 
0.039 
P 0.446 0.134 0.70 <0.0001 0.006 0.549 0.257 
N 863 871 892 892 648 789 866 
Ȗ+$;.c R 0.072 0.167 0.195 -0.042 0.016 0.084 0.039 * P 0.039 <0.0001 <0.0001 0.222 0.665 0.009 0.257 
N 818 1096 839 839 760 955 866 
Ȗ+$;Q R 0.173 0.376 0.114 0.155 0.354 0.116 0.180 0.250 P <0.0001 <0.0001 0.001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
N 818 1096 839 839 760 955 866 1298 
PIAS4 
R 0.464 0.370 0.228 0.136 0.162 0.078 0.073 0.085 
P <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 0.024 0.022 0.010 
N 1129 970 1145 1145 732 848 978 937 
PIAS1.n 
R -0.021 0.065 -0.100 0.794 0.106 -0.077 0.108 -0.081 
P 0.476 0.061 0.001 <0.0001 0.007 0.036 0.001 0.021 
N 1116 844 1197 1197 631 739 870 818 
PIAS1.c 
R 0.151 0.151 0.426 0.008 0.116 0.066 0.045 0.158 
P <0.0001 <0.0001 <0.0001 0.786 0.004 0.073 0.181 <0.0001 
N 1116 844 1197 1197 631 739 870 818 
UBC9.n 
R 0.135 0.432 0.095 0.179 0.386 0.101 0.105 0.125 
P <0.0001 <0.0001 0.004 <0.0001 <0.0001 0.001 0.001 <0.0001 
N 917 1221 931 931 848 1063 966 1234 
UBC9.c 
R 0.127 0.317 0.207 -0.061 0.121 0.173 -0.030 0.376 
P <0.0001 <0.0001 <0.0001 0.063 <0.0001 <0.0001 0.356 <0.0001 
N 917 1221 931 931 848 1063 966 1234 
KPNA2 
R -0.004 0.103 0.144 -0.148 -0.107 0.106 -0.109 0.143 
P 0.898 <0.0001 <0.0001 <0.0001 0.003 0.001 0.001 <0.0001 
N 865 1163 882 882 778 976 905 1152 
NPM 
R 0.143 0.438 0.067 0.013 0.219 0.188 -0.059 0.055 
P <0.0001 <0.0001 0.049 0.706 <0.0001 <0.0001 0.082 0.072 
N 846 1133 862 862 753 934 874 1081 
The table represents continuous data for all the markers. N= number of cases. R= 3HDUVRQ¶VFRUUHODWLRQ, P=Probability value. c. = cytoplasmic, n. = 
nuclear expression. * Analysis between the marker itself. The cut-off points were as described in table 2.6. 
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Table 7.1 3HDUVRQ¶V&RUUHODWLRQEHWZHHQDOOWKH0DUNHUVLQWKLV6WXG\Continued.  
 Markers  Ȗ+$;n PIAS4 PIAS1.n PIAS1.c UBC9.n UBC9.c KPNA2 NPM 
BRCA1.c 
R 0.018 0.113 0.004 0.157 0.046 0.110 0.060 0.067 
P 0.561 <0.0001 0.893 <0.0001 0.111 <0.0001 0.044 0.027 
N 1052 1198 1047 1047 1184 1184 1113 1086 
BRCA1.n 
R 0.293 0.085 0.324 0.040 0.287 -0.013 -0.309 0.038 
P <0.0001 0.003 <0.0001 0.197 <0.0001 0.665 <0.0001 0.205 
N 1052 1198 1047 1047 1184 1184 1113 1086 
BARD1.n 
R 0.068 0.001 -0.012 0.044 0.061 -0.032 -0.025 0.062 
P 0.021 0.979 0.720 0.184 0.029 0.255 0.377 0.030 
N 1146 1049 912 912 1298 1298 1250 1225 
BARD1.c 
R 0.284 0.104 0.070 0.256 0.266 0.269 -0.017 0.229 
P <0.0001 0.001 0.035 <0.0001 <0.0001 <0.0001 0.542 <0.0001 
N 1146 1049 912 912 1298 1298 1250 1225 
Rad51.c 
R -0.038 0.135 -0.166 0.368 -0.066 0.130 0.194 -0.036 
P 0.298 <0.0001 <0.0001 <0.0001 0.053 <0.0001 <0.0001 0.312 
N 773 1011 1018 1018 863 863 804 781 
Rad51.n 
R 0.263 0.195 0.422 0.138 0.248 0.028 -0.202 0.029 
P <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 0.420 <0.0001 0.415 
N 773 1011 1018 1018 863 863 804 781 
SMC6L1.c 
R 0.042 0.093 -0.161 0.155 0.018 0.284 0.186 0.197 
P 0.151 0.003 <0.0001 <0.0001 0.518 <0.0001 <0.0001 <0.0001 
N 1167 992 868 868 1265 1265 1237 1162 
SMC6L1.n 
R 0.439 0.303 -0.013 0.104 0.325 0.146 0.075 0.415 
P <0.0001 <0.0001 0.711 0.002 <0.0001 <0.0001 0.008 <0.0001 
N 1167 992 868 868 1265 1265 1237 1162 
KU70/KU80 
R 0.173 0.464 -0.021 0.151 0.135 0.127 -0.004 0.143 
P <0.0001 <0.0001 0.476 <0.0001 <0.0001 <0.0001 0.898 <0.0001 
N 818 1129 1116 1116 917 917 865 846 
CHK1.c 
R 0.114 0.228 -0.100 0.426 0.095 0.207 0.144 0.067 
P 0.001 <0.0001 0.001 <0.0001 0.004 <0.0001 <0.0001 0.049 
N 839 1145 1197 1197 931 931 882 862 
CHK1.n 
R 0.155 0.136 0.794 0.008 0.179 -0.061 -0.148 0.013 
P <0.0001 <0.0001 <0.0001 0.786 <0.0001 0.063 <0.0001 0.706 
N 839 1145 1197 1197 931 931 882 862 
CHK2 
R 0.354 0.162 0.106 0.116 0.386 0.121 -0.107 0.219 
P <0.0001 <0.0001 0.007 0.004 <0.0001 <0.0001 0.003 <0.0001 
N 760 732 631 631 848 848 778 753 
ATR 
R 0.116 0.078 -0.077 0.066 0.101 0.173 0.106 0.188 
P <0.0001 0.024 0.036 0.073 0.001 <0.0001 0.001 <0.0001 
N 955 848 739 739 1063 1063 976 934 
ATM 
R 0.180 0.073 0.108 0.045 0.105 -0.030 -0.109 -0.059 
P <0.0001 0.022 0.001 0.181 0.001 0.356 0.001 0.082 
N 866 978 870 870 966 966 905 874 
Ȗ+$;.c R 0.250 0.085 -0.081 0.158 0.125 0.376 0.143 0.055 P <0.0001 0.010 0.021 <0.0001 <0.0001 <0.0001 <0.0001 0.072 
N 1298 937 818 818 1234 1234 1152 1081 
Ȗ+$;Q R * 0.259 0.171 0.039 0.530 0.085 -0.206 0.330 P <0.0001 <0.0001 0.268 <0.0001 0.003 <0.0001 <0.0001 
N 937 818 818 1234 1234 1152 1081 
PIAS4 
R 0.259 
* 
0.047 0.207 0.246 0.195 0.091 0.228 
P <0.0001 0.118 <0.0001 <0.0001 <0.0001 0.004 <0.0001 
N 937 1124 1124 1041 1041 993 966 
PIAS1.n 
R 0.171 0.047 
* 
-0.090 0.182 -0.091 -0.150 -0.050 
P <0.0001 0.118 0.001 <0.0001 0.006 <0.0001 0.148 
N 818 1124 1278 912 912 858 843 
PIAS1.c 
R 0.039 0.207 -0.090 
* 
0.077 0.204 0.038 -0.003 
P 0.268 <0.0001 0.001 0.020 <0.0001 0.262 0.921 
N 818 1124 1278 912 912 858 843 
UBC9.n 
R 0.530 0.246 0.182 0.077 
* 
0.407 -0.160 0.363 
P <0.0001 <0.0001 <0.0001 0.020 <0.0001 <0.0001 <0.0001 
N 1234 1041 912 912 1481 1259 1213 
UBC9.c 
R 0.085 0.195 -0.091 0.204 0.407 
* 
0.155 0.203 
P 0.003 <0.0001 0.006 <0.0001 <0.0001 <0.0001 <0.0001 
N 1234 1041 912 912 1481 1259 1213 
KPNA2 
R -0.206 0.091 -0.150 0.038 -0.160 0.155 
* 
0.033 
P <0.0001 0.004 <0.0001 0.262 <0.0001 <0.0001 0.257 
N 1152 993 858 858 1259 1259 1152 
NPM 
R 0.330 0.228 -0.050 -0.003 0.363 0.203 0.033 
* P <0.0001 <0.0001 0.148 0.921 <0.0001 <0.0001 0.257 
N 1081 966 843 843 1213 1213 1152 
The table represents continuous data for all the markers. N= number of cases. R= 3HDUVRQ¶V FRUUHODWLRQ, P=Probability value. c. = 
cytoplasmic, n. = nuclear expression. * Analysis between the marker itself. The cut-off points were as described in table 2.6. 
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Figure 7.1 A summary of the findings in this thesis showing the pathways that have direct or indirect roles in 
the repair of DNA-DSB in BC. These pathways are; DNA-damage sensors and signal transducers, DNA-DSB 
repair pathways (HR and NHEJ), and finally SUMO. In addition, nucleocytoplasmic transport markers 
(KPNA2 and NPM) are included. X represents a defect in the response to DNA damage by showing low level 
expression of ATM.  High expression of SUMO biomarkers showed not only a strong expression of 
KU70/KU80 (NHEJ), but also a lack of expression of the HR-associated markers. Increased association 
between MTA1/ID4 and DNA-DSB repair markers may have roles in the low expression of BRCA1. 
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7.2 Heat Map by Reverse Phase Protein Microarray Analysis  
 
A heat map representing the differential protein expression within studied samples 
shows the wide range of variation of protein expression is shown in Figure 7.2, which 
represents the activated DNA repair intermediates molecules using RPPA in the cell lines 
used in this project (HeLa BRCA1 control (HeLa BRCA1C), HeLa deficient BRCA1, MCF-7 
and MDA-MB-436). Each row of the heat map constitutes cell lysates sample (three 
replicates from each cell line) organised in colour columns red and green; columns represent 
the different studied target proteins. Red and green denote markers that are present at high 
and low protein expression, respectively. This was achieved after background subtraction and 
normalisation to GAPDH. In general most of the markers were highly observed in HeLa 
BRCA1C and MCF-7 cell lines than HeLa deficient BRCA1 and MDA-MB-436 cell lines.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.3 Correlation between BRCA1/BARD1 Complex and DNA Damage Sensors and 
Signal Transducers 
 
Due to the fact that the BRCA1/BARD1 complex has an important role in DNA-DSB 
repair through the cell cycle [455], its expression was investigated with markers that have 
some roles in the cell-cycle control and DNA-damage sensor and signal transducer. However, 
the selection of the cellular localisation of BRCA1 and BARD1 was based on association 
with the worst clinico-pathological features or survival of BC. Thus, nuclear BRCA1 and 
cytoplasmic BARD1 were combined together. In addition, a recent study has further 
demonstrated that BARD1 shuttles between the nucleus and the cytoplasm: its location in the 
cell cytoplasm correlates with its apoptotic function, which is significantly decreased by 
Figure 7.2 Heat map representing the activated DNA repair intermediates molecules using reverse phase protein 
microarray in the four cell lines used in this project (HeLa BRCA1C, HeLa deficient BRCA1, MCF-7 and MDA-MB-
436). Heat map was created using Multi Experiment Viewer (MEV) software. The multiple different proteins of this study 
are outlined on the vertical axis, and the protein extracts representative of cell lines are on the horizontal axis. Red and 
green colours indicate high and low protein expression, respectively. BRCA1C= HeLa BRCA1 control. R represents 
different passage of each sample; therefore, three different passages of each sample were used. HeLa BRCA1; between 
passage21 and 30, HeLa BRCA1 control; between passage 15 and 20, MCF-7; between passage 25 and 32, and MDA-
MB-436; between passage 12 and 20. 
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BRCA1 [453, 454]. BRCA1-/BARD1+ showed a high association with P27-, P53-, 
Ȗ+$;Q+.c+, ATM-, Ki-67+, CHK2- and CHK1n-.c+ (P<0.0001 for all) (see Table 7.2). 
 
As previously discussed the high value of X 2 can be referred to, a) a bias in the 
population of patients, b) based on the data here, it does not seem to have any assumption 
issues, the main problem is normally when one of the expectation values is 5 or less, but in 
the results presented here a large chi squared value is resulted when the expectations are not 
less than 5. However, the data just seem to show that it is very likely that the association is 
not due to chance.  
 
 
Table 7.2 Correlation between BRCA1/BARD1 Complex and DNA Damage Sensors 
Proteins/ Cell Cycle Markers 
Complex 
P27 P21 
Negative 
N (%) 
Positive 
N (%) X
2
 
P Negative N (%) 
Positive  
N (%) X
2
 
P 
BRCA1n-
/BARD1c- 98(42.4) 26(11.8) 
74 <0.0001 
75(27.2) 50(26.7) 
1 0.8 
BRCA1n+ 
/BARD1c+ 35(15.2) 96(43.6) 85(30.8) 51(27.3) 
BRCA1n-
/BARD1c+ 96(41.6) 90(40.9) 109(39.5) 82(43.9) 
BRCA1n+/ 
BARD1c- 2(0.9) 8(3.6) 7(2.5) 4(2.1) 
Complex 
Ki-67 P53 
Negative  
N(%) 
Positive  
N (%) X
2 P Negative N (%) 
Positive  
N (%) X
2 P 
BRCA1n-
/BARD1c- 29(8.7) 148(21.7) 
77.5 <0.0001 
72 (10.1) 107 (23.7) 
89 <0.0001 
BRCA1n+ 
/BARD1c+ 171(51) 188(27.5) 334 (46.8) 112 (24.8) 
BRCA1n-
/BARD1c+ 108(32.2) 322(47.1) 261 (36.6) 222 (49.2) 
BRCA1n+/ 
BARD1c- 27(8.1) 25(3.7) 46 (6.5) 10(2.2) 
Complex 
Ȗ+$; 
n-c- 
N (%) 
n+c+ 
N (%) 
n-c+ 
N (%) 
n+c- 
N (%) X
2 P 
BRCA1n-
/BARD1c- 7(53.8) 108(14.7) 36(31.9) 12(15) 
69 <0.0001 
BRCA1n+ 
/BARD1c+ 1(7.7) 270(36.7) 17(15) 37(46.3) 
BRCA1n-
/BARD1c+ 4(30.8) 329(44.8) 58(51.3) 21(26.3) 
BRCA1n+/ 
BARD1c- 1(7.7) 28(3.8) 2(1.8) 10(12.5) 
c= cytoplasmic and n= nuclear expression and N= number of cases. The selection of the cellular localisation of BRCA1 
and BARD1 was based on association with the worst clinico-pathological features or survival of BC. Thus, nuclear 
BRCA1 and cytoplasmic BARD1 were combined together. Cut-off points were as follows; IRU3+-score for P27, 
IRU3DQG!34% for Ki-67. In addition, +-VFRUHIRU%5&$F93 for BRCA1.n and IRU%$5'F 
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Table 7.2 Correlation between BRCA1/BARD1Complex and DNA Damage Sensors Proteins/ Cell 
Cycle Markers Continued. 
Complex 
CHK1 CHK2 
n-c- 
N (%) 
n+c+  
N (%) 
n-c+ 
N (%) 
n+c- 
N (%) X
2
 
P Negative N (%) 
Positive 
N (%) X
2 P 
BRCA1n-
/BARD1c- 8(21.1) 30(17.4) 100(18.2) 2(7.1) 
40.5 <0.0001 
27(8.1) 19(5.8) 
33 <0.0001 
BRCA1n+ 
/BARD1c+ 12(31.6) 77(44.8) 194(35.3) 14(50) 114(34) 184(56.3) 
BRCA1n-
/BARD1c+ 13(34.2) 56(32.6) 244(44.4) 7(25) 173(51.6) 110(33.6) 
BRCA1n+/ 
BARD1c- 5(13.2) 9(5.2) 12(2.2) 5(17.9) 21(6.3) 14(4.3) 
Complex 
ATM ATR 
Negative 
N (%) 
Positive 
N (%) X
2
 
P Negative N (%) 
Positive   
N (%) X
2
 
P 
BRCA1n-
/BARD1c- 95(20.7) 50(14.5) 
28 <0.0001 
17(4.4) 30(7.2) 
3 0.3 
BRCA1n+ 
/BARD1c+ 131(28.5) 153(44.5) 185(47.8) 192(46.2) 
BRCA1n-
/BARD1c+ 219(47.7) 122(35.5) 159(41.1) 171(41.1) 
BRCA1n+/ 
BARD1c- 14(3.1) 19(5.5) 26(6.7) 23(5.5) 
The selection of the cellular localisation of BRCA1 and BARD1 was based on association with the worst clinico-pathological features 
or survival of BC. Thus, nuclear BRCA1 and cytoplasmic BARD1 were combined together. c= cytoplasmic and n= nuclear expression 
and N= number of cases. Cut-off points were as follows20 DQG80 H-score for nuclear and cytoplasmic CHK1 respectively105 H-score for 
&+.+-VFRUHIRU$75DQGIRUATM. +-VFRUHIRU%5&$FDQG3 for BRCA1.n. IRU%$5'F 
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Chapter 8 
 
8.1 General Discussion 
 
The diagnosis of DNA repair proteins as markers in BC is a particularly challenging 
task, as BC is a heterogeneous disease. There are also gaps remaining in our knowledge of 
susceptible genes, in terms of the repair of DNA-DSBs.     
 
As BRCA1 dysfunction appears to be related to poor prognostic, aggressive BCs, 
progressive knowledge of BRCA1 and its pathways act as an experimental model, leading to 
the improvement of patient care within this poor prognostic BC group. Currently, little 
progress has been made in recording cases with larger-scale genetic rearrangements, 
particularly in terms of amplifications that occur often and are characteristic of tumour cells 
[603]. These alterations need to be linked with established tumour characteristics, such as 
tumour subtypes. Considering specific lesions in relation to therapeutic response may also 
SURJUHVVDSDWLHQW¶VSHUVRQDOVWUDWLILFDWLRQOHDGLQJWRDPRUHDFFXUDWHSUHGLFWLRQRIWUHDWPHQW
response/resistance. Herein, the results of this thesis combine the power of 
immunohistochemical staining with the parallel analytic capability of protein microarrays. 
Protein microarrays have attracted recent attention because of their potential use in high-
throughput studies of protein function [604, 605]. Microarrays have been applied in the  
investigation of the expression profiles of different proteins [606, 607], protein-protein 
interactions [608] and the diagnosis of diseases such as cancer [609]. It is likely that gene 
microarray technology and proteomics will be very useful in the diagnosis of repair-deficient 
somatic cancers in the future [610]. The use of cell lines in RPPA is a possible limitation of 
this study; for this reason, a cohort of BC cases was required, in order to reliably report on the 
associations between the levels of the expression of different proteins and various clinico-
pathological factors. These were then compared and contrasted with the IHC findings.  
 
BC is a heterogeneous disease, distinguishing the variations between laboratory 
experiments and in vivo studies in humans, where associations between tumour and stroma, 
three dimensional effects and vascularisation become relevant [603]. Including clinical, 
radiological, pathological and genomic data in trial populations, with new trial designs, will 
help us to link and compare conventional markers to and with new technology in different 
settings [603]. Achievements are dependent upon multi punitive cooperation at an early 
phase, with the best quality histo-pathological and scientific progress. There are some points 
that could increase our knowledge of this heterogeneity in BC and, in particular, in cancers 
with DNA-DSB defects or TNBCs. In terms of gene expression, prognosis of these groups 
was compared to a better prognosis phenotype (luminal ER positive) and, as a heterogeneous 
phenotype, it is not surprising to see different levels of survival as a result of particular 
additional features such as ER positivity, which may respond to endocrine therapy [37].  
 
Gene signatures that are based on biological questions, such as therapy resistance, 
may be more likely to have an effect on treatment decisions than the prognostic gene method, 
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as recently reported, although there remains a significant problem with the use of gene 
expression analysis within the routine setting [611]. 
 
The findings in this study suggest the engagement of the pathways of DNA-DSB 
repair in carcinogenesis of BC and reveal the existence of a BC subtype characterised by a 
high level of cytoplasmic/low level of nuclear HR markers (Rad51, BRAC1, BARD1) or the 
nuclear expression only of NHEJ markers (KU70/KU80 and DNA-PK) and negative ER or 
PgR phenotypes. The determination of the expression levels of the DNA-DSB repair markers 
in BC has opened up the potential for enhanced molecular classification of mammary 
tumours, in addition to unlocking new scenarios in the management of BC patients. For 
example, Rad51 gene expression has been related to response to chemotherapy; thus, a 
probable exploitation of the expression of Rad51 as a predictive marker of response to anti-
cancer treatments should be taken into consideration. Furthermore, the expression of Rad51 
may represent an important aspect of new therapeutical strategies that target the pathway of 
DNA repair [461].  
 
The downregulation of HR leads to rearrangements of chromosomes, caused by the 
involvement of an alternative mechanism that is an error-prone DSB repair (like NHEJ). In 
contrast, hyper-recombination triggers various genome instability phenotypes, such as loss of 
heterozygosity, gene amplification and gene deletion [612]. Although all HR (but not NHEJ), 
6802&+.Ȗ+$;DQGRWKHUWXPRXUPDUNHUVGHPRQVWUDWHGF\WRSODVPLFH[SUHVVLRQLWLV
quite difficult to find an explanation for the aberrant cytoplasmic staining through IHC alone. 
The staining does not appear to represent an artefact; if so, the relevance of the discrepancies 
between the immunohistochemical results and RPPA must be high. Here, all the markers, 
with the exception of ATR, KPNA2 and PIAS1 showed similar expressions, in different 
cohorts (IHC), to the cell lines. It is thus plausible that some tumour markers were present in 
the cytoplasm. Taken together, these data demonstrate that, in terms of assessing the origin of 
subcellular localisation, this can possibly be obtained by pairing IHC with molecular 
analysis; if possible, both techniques should ideally be performed in parallel. In this study, 
although RPPA was applied to whole cell extracts, the findings were in-line with nuclear 
expression by IHC. It would be useful if cellular fractionation was conducted, in order to 
compare cellular localisation for each marker. Nevertheless, IHC may still represent a 
reasonable technique in screening procedures within laboratories, particularly in those in 
developing countries, which are not usually equipped for molecular studies. 
 
Both CHK1 and CHK2 are essential kinases for the repair of DNA and are important 
in the recruitment of the functional associations between BRCA1and Rad51 proteins; thus, 
they increase the HR-mediated repair of stalled replication forks [613]. CHK1 has been 
demonstrated to phosphorylate Rad51 and other proteins, such as  FANCD2, in order to 
promote DNA repair pathways [614]. In the present study (Table 7.1), there was a significant 
direct association between CHK1.n, BRCA1.n and Rad51.n, but negative or no association 
with cytoplasmic expression, however, CHK2 showed no association with the cytoplasmic 
expression of both Rad51 and BRCA1. Cases exhibiting low nuclear CHK1 and high 
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cytoplasmic expression or CHK2 might hypothetically possess a defect in response to DNA 
damage, leading to a more aggressive tumour. Bahassi et al studied the functional 
associations between BRCA2 and Rad51, in response to DNA damage and its regulation by 
CHK1 or CHK2. In UV-treated cells, the depletion of CHK1 from cells through the use of 
siRNA generates an entire loss of Rad51 localisation to nuclear foci, following block of 
replication [615]. Conversely, cells that show a truncated and non-functional CHK2 form 
have no noticeable defect in localisation at the foci of Rad51, suggesting that CHK1 is a 
participant in managing the interaction of BRCA2±Rad51, in response to block of replication. 
Cells deficient in CHK2 show an obvious impairment in the localisation of Rad51 
immediately after DNA-DSB: this is a direct result of treatment with IR [615].  
 
Fabbro et al used siRNA to deplete BRCA1 or BARD1 in 293T cell lines (human 
embryonic kidney carcinoma cell line)  and revealed that the BRCA1/BARD1 complex is 
essential for the ATM/ATR mediated phosphorylation of P53, following IR or UV radiation-
induced DNA damage [455]. In addition, the inhibition of the phosphorylation of P53 by 
BRCA1/BARD1 acute suppression compromises the induction of P21 and the checkpoint 
arrest of the G1/S phases [455]. In the present study, the co-expression of BRCA1.n-
/BARD1.c+ (the cellular localisation largely associated with poor prognostic features) was 
highly associated with the negative expression of P27, P53, in addition a strong association 
with Ȗ+$;n+.c+, CHK1n-.c+, CHK2-, and ATM- (Chapter 7, Table 7.1). It is thus possible to 
hypothesis that the co-expression of BRCA1/BARD1 might decrease the expression of P27 
(functions as a regulator of cell cycle progression at G1) [616] and may impair the G1/S cell-
cycle checkpoint, yet increase the level of P27 and induce cells to arrest in the G1 phase. To 
prove this hypothesis, it would be beneficial to utilise siRNA to deplete BRCA1 and BARD1, 
in order to determine that the BRCA1/BARD1 complex may be required for the cell cycle 
during the G1 phase, following IR- and UV radiation-induced DNA damage. 
 
This study found that CHK2- and CHK1.n- were highly associated with the HR 
markers Rad51.n- and BRCA1.n- and it is possible that the loss of HR markers, resulting from 
a lack of CHK1, may potentially cause further accumulation of DNA-DSB lesions. A 
previous study has indicated that loss of DNA-DSB repair pathways may protect cells from 
apoptosis induction [617]. Hinz et al highlighted how the loss of Rad51,which is required for 
DNA repair, did not enhance apoptosis levels, following treatment with low levels of 
camptothecin [617]. However, the interaction of the pathways of DNA-DSB repair with 
protein checkpoint kinases, such as CHK1 and CHK2, in apoptosis induction after replication 
stress of DNA remains unclear. DSBs can often arise throughout the S phase, due to the 
collapse of the replication-fork. CtIP functions cooperatively with the complex of MRN 
exclusively throughout the S and G2 phases of the cell cycle, in order to enhance the 
resection of DSB and HR [310, 618]. The activity of CDK encourages the resection stage of 
the HR reaction and inhibits NHEJ [305, 619]. The KU70/KU80 are able to bind to DSBs, 
with even more rapidly kinetics, when compared with factors of HR [620]; for this reason, a 
competition might possibly exist between NHEJ and HR, even throughout the S phase, which 
proposes that more factors could possibly suppress the binding of KU70/KU80 in favour of 
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HR proteins. Additionally, the topological complications that occur when two replicons 
merge with each other at termination are required to become fixed during S±G2, in order to 
be able to avoid breakage of chromosomes throughout segregation [621, 622]. When DSBs 
occur during the segregation of chromosomes, during which time chromosomes are 
remarkably compact and the search for homology is complicated, repair is likely to be 
achieved by NHEJ in the following G1 phase, if checkpoints or even caretaker genes had not 
triggered the arrest of the cell-cycle during the G2 and M phases [623-625]. As mentioned 
earlier in this chapter, ATM and DNA-PK largely act in response to DSBs, whereas ssDNA 
activates ATR [304]. Karlsson et al stated that, as a result of the inhibition of DNA-PK in the 
GM16147 cell line (XRCC4 deficient), ssDNA was produced within a repair time of one 
hour. The formation of ssDNA is actually cell-cycle dependent, as ssDNA ends were not 
detected in G1-synchronised NHEJ deficient cells. The generation of ssDNA possesses a 
great influence on the quantification of DSBs by pulsed-field gel electrophoresis, resulting in 
an underestimation of the amount of un-joined DSBs in cells deficient in NHEJ. These 
findings propose that the deficiency of NHEJ proteins via an S-phase specific approach are 
able to access the ends of DSB and, most probably, build long ends of ssDNA, in an attempt 
to repair the breaks [626]. The results here show that CHK1.n-.c+ and CHK2+ are highly 
associated with at least one of each of the HR and NHEJ markers. Interestingly, ATM 
showed no association with any of the NHEJ markers, whereas ATR had no or negative 
associations with the HR marker (nuclear expression), with the exception of the cytoplasmic 
expression of BRCA1 and BARD1 or nuclear and cytoplasmic SMC6L1 (positive 
associations), and was positively associated with NHEJ markers. Thus, NHEJ seems to be the 
major repair pathway in mammalian cells through ATR and HR by ATM. However, this 
needs further investigation to be confirmed. Real time PCR can be used in the future to detect 
the accumulation of KU70/KU80 or any markers at the damage site by using fluorescent 
proteins against the target markers, in order to investigate its expression after DNA damage. 
The UV Induced DNA Damage Response Antibody Sampler Kit can be used to investigate 
different proteins involved in the cellular response to UV-induced DNA damage.  
 
There are several important questions remaining, regarding the molecular details of 
exactly how posttranslational modifications of distinct repair factors have an impact on 
protein interactions, cellular distribution and efficiency of DNA-DSB repair. For example, 
the pathway through which SUMO regulates various repair functions or the repair pathway 
choice remains poorly understood. SUMO usually has an effect on its target, particularly 
within the area of cellular localisation, and yet are these types of repair activities 
compartmentalised within the cell? [302] How exactly does BRCA1 increase the function of 
HR and what are its specific targets in the process of recombination repair? Is the 
overexpression of NHEJ markers evidence of theirs fundamental role in the DNA-BSB repair 
and of out-competing their counterpart (HR)? However, homology directed repair studies are 
usually used on cell lines. A Direct Repeat (DR)-GFP reporter-based mouse model needs to 
be generated, in order to study HR repair in mice. The cells derived from the mammary 
epithelium may then be observed undergoing HR repair in I-SceI endonuclease-induced 
DSBs. In addition, the detection of the HR or NHEJ pathways in BC cells can be analysed 
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using in vivo fluorescent assays. Currently, with a number of genome projects including 
thousands of sequences of nucleotide to the public databases each day, the exploration of 
gene function usually starts with a sequence of DNA.  
 
Much of the recorded knowledge on the repair of DNA is the conclusion of biological 
experiments and clinical trials and there appears to be just a few approaches based on 
bioinformatics, which creates extra knowledge of DNA repair. An excellent approach in this 
is the Repair-FunMap, a functional database of the proteins of the human DNA repair 
pathways [627]: this utilises its knowledge on the list developed by Wood et al for the 
annotation of DNA repair genes in humans [628]. This list presents accession numbers, in 
order to ensure that genes can be referenced electronically. It is only lately that some 
additional repair-related analyses have utilised bioinformatics (for example, to determine 
phosphorylation sites [629]or to analyse a specific gene [630]). 
 
In terms of the mechanisms through which the activation function of checkpoints 
organise repair in a cell-cycle dependent-manner, the molecular mechanisms that control the 
effects of failed DNA-repair attempts and stimulate the arrest of the temporary cell cycle 
(senescence and apoptosis) may be effective research areas [302]. In the future, a much better 
understanding of the mechanisms that control DNA-DSB repair and an understanding of the 
organisation of repair with progression of cell cycle in order to protect genome integrity are 
required.  
 
The present study demonstrates that a substantial portion of the proteins involved in 
the emergence and progression of BC possess similar values of protein expression in TMA 
and cancer cell lines, showing the value of cultured cell lines in BC research. This study 
revealed the expression of different proteins in cell lines that have markedly different 
expression patterns, compared to those associated with breast tumour tissue. The composition 
of the cell culture medium may be precisely why patterns of protein expression differentiate 
cancer cell lines from breast tumour tissue. However, variations in environmental selection 
pressures may also clarify the differential patterns of the expression of protein in tumour 
tissue and the cell lines. Compounds may have a significant and diverse effect on the altered 
pathways between cell lines and tumour tissue. Regardless of whether cell lines can be made 
to mimic tumour cell protein expression patterns by simply modifying the conditions of the 
culture medium, this is yet to be fully investigated [345]. However, expression levels on the 
nitrocellulose of RPPA showed some variation for the same protein (GAPDH), this was 
expected since there is variation in the fluorescence intensity between different microarray 
experiments. Hence, the signals of each marker were normalised to the signals of GAPDH of 
the same experiment in the same day. However, one of the disadvantages of nitrocellulose is 
its high intrinsic fluorescence that leads to high levels of background, so limiting the assay 
sensitivity when fluorescently labelled antibodies are used for detection.  
 
The hypothesis of this thesis was that investigation of alterations in the different 
pathways of DNA-DSB will help in identifying tumours with impaired DNA-DSB repairs 
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pathways, improve our understanding of the role of DDR in the different molecular classes of 
BC, narrow down the number of target proteins and identifying subclasses of sporadic BC 
with defective DNA-DSB repair can potentially be used to guide targeted systemic therapy. 
Therefore, alterations of the different pathways of DNA-DSB repair contribute to the 
aggressive nature of BC, especially in terms of the BRCA1 tumour phenotype and BLBC 
[178]. The results of this work support this hypothesis by showing an aggressive 
characteristic of tumours that exhibit a defect (negative/low protein expression) in any 
pathway with a role in DNA-DSB repair. Herein, this relationship was confirmed, 
particularly in terms of loss of expression of HR repair-associated proteins and high NHEJ-
associated proteins (KU70/KU80 and DNA-PK) in the nucleus and high HR repair- 
associated proteins expressed in the cytoplasm (Rad51, BARD1). Cytoplasmic rather than 
nuclear expression was associated with a BLBC, lack of hormonal receptors, and 
negative/low expression of BRCA1 protein or in known BRCA1 germline mutations cancers. 
In addition, the high expression of CHK1.c (rather than nuclear expression) observed in the 
present study suggests that somehow defects in response to DNA damage in BC patients may 
be repaired before entering the M phase, which may hypothetically lead to an increase in 
resistance to chemotherapy (by showing no benefits from chemotherapy); further studies to 
investigate this hypothesis are warranted. As discussed in chapter 3, genome /exome 
sequencing can be performed on BC patients who received treatment, and then evaluate the 
response to the therapy. After sequencing, the data can be analysed and compared with the 
clinical data for each patient (object response to therapy). In addition, there was a high 
correlation between SUMO markers and cytoplasmic expression of HR and nuclear 
expression of NHEJ, but a negative correlation with nuclear expression of HR markers. It is 
known that SUMO modified proteins in order to function, and its modification plays an 
important role in the nuclear transport of proteins [631]. It would be better to test the 
expression of SUMO markers on cells that have a damaged DNA in order to test the 
effectiveness of these markers. 
 
This is the first study highlighting the importance of and differences in the subcellular 
localisation of DNA repair associated proteins in BC and the effect on SDWLHQWV¶RXWFRPHV. 
Particularly, HR repair markers (but not NHEJ) showed worse features with cytoplasmic 
location of expression, whereas nuclear expressions were associated with more favourable 
features. This finding may help in the classification of BC and therefore, targeting this 
pathway in the development of drugs would enhance better SDWLHQWV¶RXWFRPHV, in regards to 
DNA-DSB repair defects (negative/low protein expression) in BC. Major prognostic and 
predictive variables can be very important in choosing suitable patient treatment plans by 
identifying the risk of recurrence and classifying patients for clinical trials. However, this is 
the first study that shows the HR-repair marker Rad51.n, co-expression of Rad51.n.c, 
complex of HR and NHEJ repair markers (BRCA1.n&KU70/KU80) in non-TNBC, and a 
complex of NHEJ markers (KU70/KU80&DNA-PK) in TNBC are all independent prognostic 
markers for BC. The determination of DNA-DSB repair markers expression level alterations 
in BC opens up the potential for enhanced molecular classification of mammary tumours as 
well as unlocking new scenarios in the management of BC patients. However, progressive 
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knowledge of repair pathways act as an experimental model potentially leading to improved 
patient care of this poor prognostic group of BC.  
 
In conclusion, the DNA repair coordination processes have a critical role in providing 
the suitable development and survival of organisms. They are responsible for controlling 
several human diseases including cancer. Following on from the work presented in this 
thesis, further understanding of the molecular mechanisms through which the DDR works, in 
combination with the elucidation of the genetic interactions between various pathways of 
DDR or between DDR pathways and other cellular pathways, will certainly offer therapeutic 
opportunities for several human diseases. 
 
 
8.2 Limitation of the Study  
 
1. The number of tumours with known BRCA1 germline mutations was limited (24 
cases).   
 
2. RPPA was applied to cell lines and not to tissue sections from tumours tested using 
the same markers by IHC. 
 
3. Specificity of the proteins was detected by one method (Western blotting). Although 
it is reliable and a commonplace technique for detecting the specificity of antibodies, 
other techniques such as peptide blocking could be used to confirm the specificity. 
 
4. Although, there is strong evidence confirming the effectiveness and reliability of 
TMA for a large scale assessment of molecular markers with a high concordance rates 
between TMA and full face sections [279, 632], it may be worth using multiple cores 
per case. TMA is not very accurate for detecting a biomarker in a small subgroup of 
tumours. Previous studies by our research group have assessed the expression of 
different biomarkers such as ER, PgR, Ki67 and hypoxia related marker using TMA 
and compared the results to full face sections[633, 634] and this showed less 
sensitivity of TMA in subgroup analysis. In these studies, it was stated that TMA is 
more likely to produce false-negative results rather than false-positive ones. However, 
despite the fact that, these discordances between TMA and full face sections might 
not significantly change the overall association of these biomarkers with the other 
prognostic variables particularly in large scale studies, it is important to acknowledge 
these limitations of TMA method, in order to avoid misinterpretation of their results. 
 
5. For this historical patient cohort, relatively old paraffin blocks were used to study the 
expression of tissue marker. These tissues could possibly be potentially different from 
recently fixed and prepared tissue specimens, for example, therapeutic routines used 
at the time when patients of this study were treated tended to be less aggressive than 
those at present in practice and numerous methods are constantly growing.  
Chapter 8                                                                                                       General Discussion 
237 
 
 
 
8.3 Suggestions and Future Investigations  
 
1- A larger series of known BRCA1 germline mutations carrier cases to be investigated.   
 
2- Investigate more relevant and key markers that characterise different pathways of 
DDR such as base and nucleotide excision repair mechanisms to provide a 
comprehensive profiling of DDR in BC.  
 
3- Subcellular fractionation will be helpful in investigating the subcellular localisations. 
The Thermo Scientific Subcellular Protein Fractionation Kit can be used on tissue 
samples and then each extract (e.g. cytoplasmic extract, membrane extract, nuclear 
extract, chromatin-bound extract, and pellet extract) can be analysed by Western 
blotting. 
 
4- Pathway analysis and system biology techniques are very promising and informative 
techniques for assessment of complex biological process such as DDR. The 
complexity of analysis will be emphasised by the fact that subcellular localisation in 
addition to the level of expression and interaction between different known and 
unknown genes may affect the function of any specific genes and subsequently 
determination of pathways. Methods that combine different protein characteristics 
include expert systems [635], k-nearest neighbor [636-638], SVM [639], ANN [640], 
support description of vector data [641], as well as Bayesian networks [642], to be 
utilised.  
 
5- Investigate further mechanisms that have a role in nuclear transport, for example in 
vitro system, digitonin-permeabilised vertebrate cells can be developed in order to 
investigate biochemical events in the macromolecules transport across the envelope of 
the nucleus. 
 
6-  In terms of RPPA, a single series of tumour tissue samples representing invasive 
tumours is required, in order to reliably report on the associations between protein 
expression levels and various clinico-pathological parameters.   
 
7-   In this study, is remains unknown whether the cases suffer from a defect in repair or 
that the cancer was mainly due to DNA-DSBs thus, further studies are therefore 
warranted to investigate that. For instance, the Comet assay in individual cells of 
extremely small tissue samples, is a standard technique for evaluation of damage or 
repair or DNA, biomonitoring and genotoxicity testing [551, 552], which could be 
utilised in vivo and in vitro samples.  
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8- Real time PCR can be used in the future to detect the accumulation of KU70/KU80 
or any markers at the damage site by using fluorescent proteins against the target 
markers, in order to investigate its expression after DNA damage. The UV Induced 
DNA Damage Response Antibody Sampler Kit can be used to investigate different 
proteins involved in the cellular response to UV-induced DNA damage.
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Relationship between  DNA Damage Sensors Proteins  with  Clinico-Pathological Features 
Parameters 
CHK1 CHK2 
c- n- 
 N(%) 
c+ n+  
N(%) 
c+ n-  
N(%) 
c- n+  
N(%) X
2
 P Negative N(%) 
Positive 
N(%) X
2 P 
Age <50 24(31.2) 97(33) 311(35.2) 19(32.2) 1 0.8 165(31.7) 202(37.3) 4 0.05 
>50 53(68.8) 197(67) 573(64.8) 40(67.8) 356(68.3) 340(62.7) 
Size FP 31(40.3) 111(37.9) 257(29.3) 24(40.7) 12 0.008 150(28.8) 176(32.5) 2 0.2 
>1.5cm 46(59.7) 182(62.1) 620(70.7) 35(59.3) 371(71.2) 366(67.5) 
Stage 
1 50(64.9) 194(66) 511(57.9) 38(64.4) 
8.5 0.2 
314(60.3) 346(63.8) 
1 0.5 2 19(24.7) 75(25.5) 279(31.6) 18(30.5) 159(30.5) 150(27.7) 
3 8(10.4) 25(8.5) 92(10.4) 3(5.1) 48(9.2) 46(8.5) 
Grade 
1 14(18.2) 60(20.4) 84(9.5) 12(20.3) 
59 <0.0001 
63(12.1) 81(14.9) 
6 0.046 2 33(42.9) 83(28.2) 237(26.8) 29(49.2) 145(27.8) 176(32.5) 
3 30(39) 151(51.4) 563(63.7) 18(30.5) 313(60.1) 285(52.6) 
Tubules 
1 3(4.1) 19(6.8) 27(3.1) 3(5.1) 
16 0.01 
18(3.6) 22(4.2) 
0.4 0.8 2 28(38.4) 97(34.5) 241(28) 18(30.5) 155(30.6) 164(31.2) 
3 42(57.5) 165(58.7) 593(68.9) 38(64.4) 334(65.9) 340(64.6) 
Pleomorphism 
1 2(2.7) 9(3.2) 5(0.6) 3(5.1) 
77 <0.0001 
7(1.4) 8(1.5) 
7 0.03 2 40(54.8) 112(40) 214(24.9) 30(50.8) 153(30.2) 199(37.9) 
3 31(42.5) 159(56.8) 641(74.5) 26(44.1) 346(68.4) 318(60.6) 
Mitosis 
1 28(38.4) 90(32) 214(24.9) 34(57.6) 
39 <0.0001 
140(27.6) 170(32.3) 
4 0.1 2 14(19.2) 58(20.6) 156(18.1) 6(10.2) 92(18.1) 103(19.6) 
3 31(42.5) 133(47.3) 491(57) 19(32.2) 275(54.2) 253(48.1) 
NPI 
Excellent 8(10.5) 42(14.4) 55(6.3) 9(15.3) 
57 <0.0001 
46(8.9) 53(9.9) 
4 0.6 
Good 18(23.7) 57(19.6) 119(13.6) 15(25.4) 80(15.5) 100(18.7) 
Moderate I 27(35.5) 95(32.6) 276(31.4) 18(30.5) 151(29.2) 155(29) 
Moderate 10(13.2) 59(20.3) 262(29.8) 10(16.9) 141(27.3) 142(26.6) 
Poor 11(14.5) 24(8.2) 122(13.9) 7(11.9) 76(14.7) 65(12.2) 
Very Poor 2(2.6) 14(4.8) 44(5) 0 23(4.4) 19(3.6) 
Vascular 
Invasion 
Negative 39(61.9) 130(64) 371(59.7) 30(62.5) 1.3 0.7 275(59.9) 285(61.8) 0.3 0.5 Positive 24(38.1) 73(36) 250(40.3) 18(37.5) 184(40.1) 176(38.2) 
Tumour Type 
Invasive 39(52) 165(57.1) 630(72) 17(29.3) 
85 <0.0001 
340(66) 333(62.8) 
10.8 0.028 
lobular 7(9.3) 15(5.2) 40(4.6) 12(20.7) 19(3.7) 30(5.7) 
Atypical 2(2.7) 7(2.4) 21(2.4) 2(3.4) 21 (4.1) 10 (1.9) 
Mixed 22(29.3) 84(29.1) 165(18.9) 25(43.1) 124(24.1) 134(25.3) 
other 5(6.7) 18(6.2) 19(2.2) 2(3.4) 11(2.1) 23(4.3) 
Parameters 
Ȗ+$; 
c- n- 
 N(%) 
c+ n+  
N(%) 
c+ n-  
N(%) 
c- n+  
N(%) X
2
 
P 
Age <50 9(45) 351(34.7) 60(42.9) 44(35.8) 4 0.2 
>50 11(55) 660(65.3) 80(57.1) 79(64.2) 
Size FP 4(22.2) 292(29.1) 25(18.2) 48(39.3) 14 0.002 
>1.5cm 14(77.8) 713(70.9) 112(81.8) 74(60.7) 
Stage 
1 12(60) 602(59.7) 81(57.9) 84(86.3) 
12 0.06 2 3(15) 292(29) 48(34.3) 31(25.2) 
3 5(25) 114(11.3) 11(7.9) 8(6.5) 
Grade 
1 1(5) 118(11.7) 4(2.9) 13(10.6) 
58 <0.0001 2 4(20) 267(26.4) 14(10) 54(43.9) 
3 15(75) 626(61.9) 122(87.1) 56(45.5) 
Tubules 
1 0 39(3.9) 0 6(4.9) 
27.5 <0.0001 2 4(21.1) 305(30.5) 19(13.9) 29(23.8) 
3 15(78.9) 657(65.5) 118(86.1) 87(71.3) 
Pleomorphism 
1 0 15(1.5) 1(0.7) 2(1.6) 
48 <0.0001 2 7(36.8) 270(27) 13(9.5) 57(46.7) 
3 12(63.2) 715(71.5) 123(89.8) 63(51.6) 
Mitosis 
1 1(5.3) 264(26.4) 7(5.1) 49(40.2) 
64.5 <0.0001 2 5(26.3) 180(18) 16(11.7) 25(20.5) 
3 13(68.4) 557(55.6) 114(83.2) 48(39.3) 
NPI 
Excellent 1(6.7) 72(7.2) 2(1.4) 9(7.3) 
47.5 <0.0001 
Good 1(6.7) 152(15.2) 4(2.9) 30(24.4) 
Moderate I 8(53.3) 319(31.8) 50(35.7) 44(35.8) 
Moderate II 3(20) 276(27.5) 47(33.6) 26(21.1) 
Poor 1(6.7) 131(13.1) 31(22.1) 11(8.9) 
Very Poor 1(6.7) 52(5.2) 6(4.3) 3(2.4) 
Vascular 
Invasion 
Negative 5(55.6) 404(58.8) 50(57.5) 62(66) 2 0.5 Positive 4(44.4) 283(41.2) 37(42.5) 32(34) 
Tumour Type 
Invasive Ductal/NST 15(78.9) 699(69.8) 106(76.8) 69(58) 
 
92 
 
<0.0001 
lobular 1(5.3) 24(2.4) 4(2.9) 20(16.8) 
Atypical Medullary 0 22(2.2) 12(8.7) 2(1.7) 
Mixed 3(15.8) 221(22.1) 14(10.1) 25(21) 
other 0 35(3.5) 2(1.4) 3(2.5) 
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Relationship between DNA Damage Sensors Proteins with Clinico-Pathological Features Continued. 
Parameters 
ATM ATR 
Negative 
N(%) 
Positive 
N(%) X
2
 
P Negative N(%) 
Positive 
N(%) X
2 P 
Age 
<50 274 (36.8) 215 (33.4) 
1.7 0.2 
219(30.6) 196(34.9) 
3 0.1 
>50 470 (63.2) 428 (66.6) 497(69.4) 365(65.1) 
Size FP 222(29.9) 241 (38) 10 0.002 245(34.2) 151(26.9) 8 0.005 
>1.5cm 520(70.1) 393 (62) 471(65.8) 410(73.1) 
Stage 
1 444(59.7) 441(68.7) 
12.5 0.002 
479(66.9) 314(56) 
17 <0.0001 2 224(30.1) 155(24.1) 185(25.8) 185(33) 
3 76 (10.2) 46 (7.2) 52(7.3) 62(11.1) 
Grade 
1 61 (8.2) 135 (21) 
55.3 <0.0001 
152(21.2) 56(10) 
40 <0.0001 2 195(26.2) 186(28.9) 235(32.8) 163(29.1) 
3 489(65.6) 322(50.1) 329(45.9) 342(61) 
Tubules 
1 32 (4.4) 37 (5.9) 
30 <0.0001 
56(8.2) 19(3.4) 
13 0.002 2 170(23.2) 225(35.7) 216(31.7) 185(33) 
3 532(72.5) 369(58.5) 410(60.1) 357(63.6) 
Pleomorphism 
1 11 (1.5) 20(3.2) 
31 <0.0001 
24(3.5) 4(0.7) 
29 <0.0001 2 187(25.5) 239(38) 281(41.5) 174(31) 
3 535 (73) 370(58.8) 372(54.9) 383(68.3) 
Mitosis 
1 168(22.9) 240 (38) 
40.5 <0.0001 
269(39.4) 144(25.7) 
28 <0.0001 2 129(17.6) 110(17.4) 119(17.4) 103(18.4) 
3 437(59.5) 281(44.5) 294(43.1) 314(56) 
NPI 
Excellent 49(6.6) 95(15) 
56 <0.0001 
105(14.7) 35(6.4) 
57 <0.0001 
Good 101(13.7) 114(18) 139(19.5) 88(16) 
Moderate I 241(32.7) 213(33.6) 229(32.1) 143(26) 
Moderate 
II 
200(27.1) 155(24.4) 161(22.6) 159(28.9) 
Poor 112(15.2) 39(6.2) 63(8.8) 96(17.5) 
Very Poor 34(4.6) 18(2.8) 16(2.2) 29(5.3) 
Vascular 
Invasion 
Negative 297(59.6) 330(70.2) 11.8 0.001 429(67.5) 269(55.6) 16 <0.0001 
Positive 201(40.4) 140(29.8) 207(32.5) 215(44.4) 
Tumour Type 
Invasive 
Ductal/NST 525(71) 383(60.3) 
30 <0.0001 
397(56.6) 367(66.2) 
21 <0.0001 
lobular 44(6) 33(5.2) 41(5.8) 27(4.9) 
Atypical 
Medullary 25(3.4) 15(2.4) 25(3.6) 10(1.8) 
Mixed 114(15.4) 170(26.8) 190(27.1) 136(24.5) 
other 31(4.2) 34(5.4) 48(6.8) 14(2.5) 
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Correlation between DNA Damage Sensors Proteins with other Tumours Markers. 
 
Markers 
 
Ȗ+$; CHK1 CHK2 
c- n- 
 N(%) 
c+ n+  
N(%) 
c+ n-  
N(%) 
c- n+  
N(%) X
2
 
P c
- n- 
 N(%) 
c+ n+  
N(%) 
c+ n-  
N(%) 
c- n+  
N(%) X
2
 
P Negative N(%) 
Positive 
N(%) X
2
 
P 
ER Negativ 9(52.9) 426(43) 91(67.4) 30(24.8) 49 <0.0001 16(21.9) 100(35.6) 397(46) 11(18.6) 35 <0.0001 169(33.6) 135(25.9) 7 0.007 Positive 8(47.1) 564(57) 44(32.6) 91(75.2) 57(78.1) 181(64.4) 466(54) 48(81.4) 334(66.4) 386(74.1) 
PgR Negativ 14(73.7) 509(54.1) 101(75.4) 41(35.7) 43 <0.0001 28(73.3) 119(44.9) 467(56.3) 19(33.3) 26 <0.0001 241(48.6) 210(41.1) 6 0.017 Positive 5(26.3) 432(45.9) 33(24.6) 74(64.3) 47(62.7) 146(55.1) 362(43.7) 38(66.7) 255(51.4) 301(58.9) 
TN Negativ 10(55.6) 690(72) 61(45.9) 97(84.3) 52 <0.0001 62(86.1) 213(78.6) 581(69.2) 49(84.5) 20 <0.0001 396(78.6) 429(82.3) 2 0.1 Positive 8(44.4) 268(28) 72(54.1) 18(15.7) 10(13.9) 58(21.4) 258(30.8) 9(15.5) 108(21.4) 92(17.7) 
HER-2 Negativ 19(95) 798(82.4) 117(84.8) 104(88.1) 5 0.2 66(93) 241(86.1) 703(82) 55(94.8) 13 0.005 418(82.1) 455(86) 3 0.09 Positive 1(5) 170(17.6) 21(15.2) 14(11.9) 5(7) 39(13.9) 154(18) 3(5.2) 91(17.9) 74(14) 
CK5 Negativ 9(75) 560(76) 62(55.4) 74(83.1) 26 <0.0001 48(92.3) 159(75.4) 543(72.7) 39(92.9) 17.5 0.001 337(83.2) 328(82) 0.2 0.6 Positive 3(25) 117(24) 50(44.6) 15(16.9) 4(7.7) 52(24.6) 204(27.3) 3(7.1) 68(16.8) 72(18) 
CK17 Negativ 13(92.9) 589(80.1) 96(79.3) 70(85.4) 3 0.4 48(90.6) 191(86.4) 585(81.6) 32(91.4) 7 0.08 319(84.6) 322(86.8) 0.7 0.4 Positive 1(7.1) 146(19/9) 25(20.7) 12(14.6) 5(9.4) 30(13.6) 132(18.4) 3(8.6) 58(15.4) 49(13.2) 
CK14 Negativ 17(94.4) 811(87) 107(79.3) 101(87.8) 7 0.06 69(89.6) 227(84.7) 719(86.7) 50(92.6) 3 0.3 451(90.7) 449(89.1) 0.8 0.4 Positive 1(5.6) 121(13) 28(20.7) 14(12.2) 8(10.4) 41(15.3) 110(13.3) 4(7.4) 46(9.3) 55(10.9) 
BLBC Negativ 9(64.3) 674(78) 63(53.4) 95(86.4) 42.5 <0.0001 56(90.3) 207(81.2) 582(74.8) 51(96.2) 22 <0.0001 384(85) 410(86) 0.1 0.7 Positive 5(35.7) 190(22) 55(46.6) 15(13.6) 6(9.7) 48(18.8) 196(25.2) 2(3.8) 68(15) 67(14) 
P53 Negativ 8(47.1) 594(61.6) 69(50.4) 76(65) 9 0.03 58(81.7) 175(63.6) 516(61) 46(79.3) 19 <0.0001 340(69.1) 360(70.6) 0.3 0.6 Positive 9(52.9) 370(38.4) 68(49.6) 41(35) 13(18.3) 100(36.4) 330(39) 12(20.7) 152(30.9) 150(29.4) 
ID4. n Negativ 16(80) 751(84.5) 103(76.3) 89(86.4) 6.5 0.09 60(87) 208(79.1) 693(85.3) 45(84.9) 6 0.09 407(90.4) 399(88.9) 0.6 0.4 Positive 4(20) 138(15.5) 32(23.7) 14(13.6) 9(13) 55(20.9) 119(14.7) 8(15.1) 43(9.6) 50(11.1) 
ID4.c Negativ 7(35) 347(35) 50(35.5) 59(48.4) 8 0.038 46(58.2) 116(39.7) 286(32.5) 29(49.2) 27.5 <0.0001 180(34.4) 197(36.3) 0.4 0.5 Positive 13(65) 644(65) 91(64.5) 63(51.6) 33(41.8) 176(60.3) 594(67.5) 30(50.8) 343(65.6) 346(63.7) 
PTEN Negativ 10(100) 423(79.7) 64 (94.1) 43 (69.4) 15.6 0.001 36 (83.7) 99 (79.8) 359(82.7) 11 (47.8) 17.5 0.001 328(89.1) 226(72.4) 31 <0.0001 Positive 0 108(20.3) 4 (5.9) 19 (30.6) 7 (16.3) 25 (20.2) 75 (17.3) 12 (52.2) 40 (10.9) 86 (27.6) 
CHK1.n Negativ 11(84.6) 496(76.5) 83(84.7) 47(58) 19 <0.0001 
 
281(81) 233(73) 6 0.015 Positive 2(15.4) 152(23.5) 15(15.3) 34(42) 66(19) 86(27) 
CHK1.c Negativ 6(46.2) 47(7.3) 10(10.2) 16(19.8) 34 <0.0001 38(11) 35(11) 0 0.99 Positive 7(53.8) 600(92.7) 88(89.8) 65(80.2) 308(89) 284(89) 
Ki-67 Negativ 6(40) 287(32.8) 21(17.4) 56(52.8) 32.5 <0.0001 32(51.6) 95(39.4) 240(31.9) 29(55.8) 22 <0.0001 155(37) 179(40.6) 1.2 0.3 Positive 9(60) 588(67.2) 100(82.6) 50(47.2) 30(48.4) 146(60.6) 513(68.1) 23(44.2) 264(63) 262(59.4) 
CHK2 Negativ 7(63.6) 274(45.4) 63(84) 35(50) 41 <0.0001 30(62.5) 57(45.2) 251(53.9) 8(32) 9 0.028  Positive 4(36.4) 330(54.6) 12(16) 35(50) 18(37.5) 69(54.8) 215(46.1) 17(68) 
ATM Negativ 26(66.7) 80 (40.4) 368(59.8) 19 (47.5) 26 <0.0001 26(66.7) 84(42.4) 371(60.3) 19(47.5) 22.5 <0.0001 203(59.9) 147(47.6) 10 0.002 Positive 13(33.3) 118(59.6) 247(40.2) 21 (52.5) 13(33.3) 114(57.6) 244(39.7) 21(52.5) 136(40.1) 162(52.4) 
ATR Negativ 26(45.6) 109(67.3) 264(50.6) 19(51.4) 16 0.001 26(45.6) 109(67.3) 264(50.6) 19(51.4) 16 0.001 
 
257(57.1) 219(47.6) 8 0.004 Positive 31(54.4) 53(32.7) 258(49.4) 18(48.6) 31(54.4) 53(32.7) 258(49.4) 18(48.6) 193(42.9) 241(52.4) 
MTA1.n Negativ 15(75) 294(31.7) 105(75.5) 36(31.9) 113 <0.0001 35(66) 73(38.8) 264(42.2) 14(37.8) 13 0.004 187(46.2) 123(31.1) 19 <0.0001 Positive 5(25) 634(68.3) 34(24.5) 77(68.1) 18(34) 115(61.2) 361(57.8) 23(62.2) 218(53.8) 272(68.9) 
MTA1.c Negativ 9(45) 172(17) 19(13.5) 65(52.4) 139 <0.0001 26(49.1) 26(13.8) 70(11.2) 11(29.7) 63 <0.0001 85(20.9) 41(10.4) 16.7 <0.0001 Positive 11(55) 841(83) 122(86.5) 59(47.6) 27(50.9) 162(86.2) 556(88.8) 26(70.3) 322(79.1) 354(89.6) 
P21 Negativ 8(61.5) 217(56.5) 43(64.2) 27(60) 1.5 0.6 26(61.9) 83(58) 195(62.1) 21(63.6) 0.8 0.8 91(59.5) 95(68.3) 2.5 0.1 Positive 5(38.5) 167(43.5) 24(35.8) 18(40) 16(38.1) 60(42) 119(37.9) 12(36.4) 62(40.5) 44(31.7) 
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Correlation between DNA Damage Sensors Proteins with other Tumours Markers Continued. 
Markers  
Ȗ+$; CHK1 CHK2 
c- n- 
 N(%) 
c+ n+  
N(%) 
c+ n-  
N(%) 
c- n+  
N(%) X
2
 
P c
- n- 
 N(%) 
c+ n+  
N(%) 
c+ n-  
N(%) 
c- n+  
N(%) X
2
 
P Negative 
n(%) 
Positive 
n(%) X
2
 
P 
P27 Negative 7(58.3) 179(46.9) 50(72.5) 18(46.2) 16 0.001 16(37.2) 67(47.5) 156(49.8) 10(31.3) 6 0.1 37(25) 40(29.4) 0.7 0.4 Positive 5(41.7) 203(53.1) 19(53.8) 21(53.8) 27.8)(6 74(52.5) 157(50.2) 22(68.8) 111(75) 96(70.6) 
Ȗ+$;Q Negative 
  
70(18.5) 16(4.3) 38.5 <0.0001 Positive 309(81.5) 365(95.8) 
Ȗ+$;F 
 
Negative 42(11.1) 39(10.2) 0.1 0.7 Positive 337(88.9) 342(89.8) 
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Correlation between DNA Damage Sensors Proteins  with  Clinico-Pathological Features 
 
Parameters 
 
ATM ATR 
Negative 
n(%) 
Positive 
n(%) X
2 P Negative 
n(%) 
Positive 
n(%) X
2 P 
ER 
Negative 362 (49.3) 221 (34.9) 
29 <0.0001 
193(28.3) 141(26) 
0.8 0.3 
Positive 372 (50.7) 413 (65.1) 488(71.7) 401(74) 
PgR 
Negative 415 (58.7) 265 (44.1) 
27.7 <0.0001 
303(45) 217(41.3) 
2 0.2 
Positive 292 (41.3) 336 (55.9) 370(55) 309(58.7) 
Triple 
Negative 
Negative 475 (66.5) 485 (78.9) 
25 <0.0001 557(81.4) 447(82.6) 0.3 0.6 
Positive 239 (33.5) 130 (21.1) 127(18.6) 94(17.4) 
HER-2 
Negative 596 (82.8) 523 (85) 
1.2 0.26 
607(86.8) 459(83.9) 
2 0.1 
Positive 124 (17.2) 92 (15) 92(13.2) 88(16.1) 
CK5 
Negative 427 (73.7) 338(76.3) 
.867 .352 
402(82.2) 383(85.3) 
2 0.2 
Positive 152 (26.3) 105(23.7) 87(17.8) 66(14.7) 
CK17 
Negative 451 (81.1) 360(85.1) 
2.7 0.1 
425(89.9) 314(81.8) 
12 0.001 
Positive 105 (18.9) 63 (14.9) 48(10.1) 70(18.2) 
BLBC Negative 
478 (74.9) 456 (82.2) 
9 0.002 
531(86.6) 427(86.4) 
0.008 0.9 
Positive 160 (25.1) 99 (17.8) 82(13.4) 67(13.6) 
P53 
Negative 443 (60.9) 417(66.1) 
3.8 0.05 
471(70.9) 368(69.2) 
0.4 0.5 
Positive 284 (39.1) 214(33.9) 193(29.1) 164(30.8) 
CHK1.n Negative 
397(79.2) 257(65.6) 
21 <0.0001 
290(69.2) 289(80.3) 
12 <0.0001 
Positive 104(20.8) 135(34.4) 129(30.8) 71(19.7) 
CHK1.c 
Negative 45(9) 34(8.7) 
0.03 0.9 
45(10.8) 49(13.6) 
1.5 0.2 
Positive 455(91) 358(91.3) 373(89.2) 311(86.4) 
Ki-67 
Negative 221 (34.7) 233 (43.8) 
10 0.001 
278(51.1) 151(31.8) 
39 <0.0001 
Positive 416 (65.3) 299(56.2) 266(48.9) 324(68.2) 
ATR 
Negative 211(51.6) 228(60.2) 6 0.016  
Positive 198(48.4) 151(39.8) 
P21 
Negative 191(62) 164(59.4) 0.4 0.5 154(62.1) 84(64.1) 0.1 0.7 
Positive 117(38) 112(40.6) 94(37.9) 47(35.9) 
Ȗ+$;Q Negative 81(16.6) 37(9.8) 8.4 0.004 66(13.4) 37(8) 7 0.007 
Positive 407(83.4) 341(90.2) 427(86.6) 425(92) 
Ȗ+$;F Negative 45(9.2) 46(12.1) 2 0.2 57(11.6) 50(10.8) 0.1 0.7 
Positive 443(90.8) 333(87.9) 436(88.4) 413(89.2) 
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Correlation between DNA Damage Sensors and Signal Transducers Proteins with other Tumour Markers Regardless Co-
expression of Cellular Localisation. 
Ȗ+$;F 
Markers Negative N (%) 
Positive 
N (%) 
P-value 
X2 
 
CHK1.n 
Negative 58 (61.7) 580 (77.6) 0.001 
11.5 Positive 36 (38.3) 167 (22.4) 
CHK1.c Negative 
22 (23.4) 57 (7.6) <0.0001 
24 Positive 72 (76.6) 689 (92.4) 
PgR 
Markers Negative 
N (%) 
Positive 
N (%) 
P-value 
X2 
CHK1.c Negative 
47 (7.4) 85 (14.3) <0.0001 
15 Positive 586 (92.6) 508 (85.7) 
CHK1.n Negative 
495 (78.1) 409 (69) <0.0001 
13 Positive 139 (21.9) 184 (31) 
Ȗ+$;F Negative 55 (8.3) 79 (14.5) 0.001 12 Positive 611 (91.7) 465 (85.5) 
Ȗ+$;Q Negative 115 (17.3) 38(7) <0.0001 28.7 Positive 550(82.7) 506 (93) 
P53 
Markers Negative N (%) 
Positive 
N (%) 
P-value 
X2 
 
CHK1.n Negative 
574 (72.1) 343 (75.4) 0.2 
1.5 Positive 222 (27.9) 112 (24.6) 
CHK1.c Negative 
104 (13.1) 25 (5.5) <0.0001 
18 Positive 691 (86.9) 430 (94.5) 
ER 
Markers Negative N (%) 
Positive 
N (%) 
P-value 
X2 
 Ȗ+$;Q Negative 100(18) 52 (7.4) <0.0001 33 Positive 456 (82) 655 (92.6) 
Ȗ+$;F Negative 39 (7) 99 (14) <0.0001 15.7 Positive 518 (93) 608 (86) 
CK5 
Markers Negative N (%) 
Positive 
N (%) 
P-value 
X2 
 
Ȗ+$;F Negative 83 (11.8) 18 (7.3) 0.05 4 Positive 622 (88.2) 228 (92.7) 
Ȗ+$;Q Negative 71 (10.1) 53 (21.6) <0.0001 21 Positive 634 (89.9) 192 (78.4) 
CHK1.n Negative 
591 (74.9) 208 (78.8) 0.2 
1.6 
 
Positive 198 (25.1) 56 (21.2) 
CHK1.c Negative 
87 (11) 7 (2.7) <0.0001 
17 Positive 702 (89) 256 (97.3) 
PTEN 
 
Markers Negative N (%) 
Positive 
N (%) 
P-value 
X2 
 Ȗ+$;Q Negative 74 (13.7) 4 (3.1) 0.001 11.6 Positive 466 (86.3) 127 (96.9) 
Ȗ+$;F Negative 53 (9.8) 19 (14.5) 
 
0.1 
2 Positive 487 (90.2) 112 (85.5) 
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Correlation between DNA Damage Sensors and Signal Transducers Proteins with other Tumour Markers Regardless Co-
expression of Cellular Localisation. 
Ȗ+$;F 
Markers Negative N (%) 
Positive 
N (%) 
P-value 
X2 
 
CHK1.n 
Negative 58 (61.7) 580 (77.6) 0.001 
11.5 Positive 36 (38.3) 167 (22.4) 
CHK1.c Negative 
22 (23.4) 57 (7.6) <0.0001 
24 Positive 72 (76.6) 689 (92.4) 
PgR 
Markers Negative N (%) 
Positive 
N (%) 
P-value 
X2 
 
CHK1.c Negative 
47 (7.4) 85 (14.3) <0.0001 
15 Positive 586 (92.6) 508 (85.7) 
CHK1.n Negative 
495 (78.1) 409 (69) <0.0001 
13 Positive 139 (21.9) 184 (31) 
Ȗ+$;F Negative 55 (8.3) 79 (14.5) 0.001 12 Positive 611 (91.7) 465 (85.5) 
Ȗ+$;Q Negative 115 (17.3) 38(7) <0.0001 28.7 Positive 550(82.7) 506 (93) 
P53 
Markers Negative N (%) 
Positive 
N (%) 
P-value 
X2 
 
CHK1.n 
Negative 574 (72.1) 343 (75.4) 0.2 
1.5 Positive 222 (27.9) 112 (24.6) 
CHK1.c Negative 
104 (13.1) 25 (5.5) <0.0001 
18 Positive 691 (86.9) 430 (94.5) 
ER 
Markers Negative N (%) 
Positive 
N (%) 
P-value 
X2 
 Ȗ+$;Q Negative 100(18) 52 (7.4) <0.0001 33 Positive 456 (82) 655 (92.6) 
Ȗ+$;F Negative 39 (7) 99 (14) <0.0001 15.7 Positive 518 (93) 608 (86) 
CK5 
Markers Negative N (%) 
Positive 
N (%) 
P-value 
X2 
 
Ȗ+$;F Negative 83 (11.8) 18 (7.3) 0.05 4 Positive 622 (88.2) 228 (92.7) 
Ȗ+$;Q Negative 71 (10.1) 53 (21.6) <0.0001 21 Positive 634 (89.9) 192 (78.4) 
CHK1.n 
Negative 591 (74.9) 208 (78.8) 0.2 
1.6 
 
Positive 198 (25.1) 56 (21.2) 
CHK1.c Negative 
87 (11) 7 (2.7) <0.0001 
17 Positive 702 (89) 256 (97.3) 
PTEN 
 
Markers Negative N (%) 
Positive 
N (%) 
P-value 
X2 
 Ȗ+$;Q Negative 74 (13.7) 4 (3.1) 0.001 11.6 Positive 466 (86.3) 127 (96.9) 
Ȗ+$;F Negative 53 (9.8) 19 (14.5) 
 
0.1 
2 Positive 487 (90.2) 112 (85.5) 
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Appendix 2 
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Detection of Rad51 and KU70/KU80 proteins level by Western blot in a 
mixture of cell lines MDA-MB-231, MCF- DQG +H/D %5&$DQG LW¶V
control. 
KU70/KU80     Rad51 
76 
37 
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Relationship between DNA-DSB Repair Markers with Clinico-Pathological Parameters. 
Parameters 
Rad51 BRCA1 BARD1.c 
c- n- 
 N(%) 
c+ n+  
N(%) 
c+ n-  
N(%) 
c- n+  
N(%) X
2
 
P c
- n- 
N(%) 
c+ n+ 
N(%) 
c- n+ 
N(%) 
c+ n-  
N(%) X
2
 
P Negative 
n(%) 
Positive 
n(%) X
2
 
P 
NPI 
Excellent 9(12.5) 45(13.1) 28(4) 7(12.7) 
111 <0.0001 
28 (6) 37 (13.2) 93 (16.6) 16 (3.8) 
148 <0.0001 
13(4.5) 89(7.7) 
8 0.1 
Good 22(30.6) 80(23.3) 61(8.8) 14(25.5) 50 (10.7) 62 (22.1) 131(23.4) 38 (9) 38(13.1) 202(17.4) 
Moderate1 16(22.2) 94(27.3) 250(36) 17(30.9) 151(32.2) 75 (26.8) 171(30.5) 146 (34.5) 102(35.1) 367(31.6) 
Moderae2 16(22.2) 83(24.1) 205(29.5) 16(29.1) 137(29.2) 69 (24.6) 104(18.6) 134 (31.7) 79(27.1) 300(25.8) 
Poor 6(8.3) 33(9.6) 109(15.7) 1(1.8) 76 (16.2) 26 (9.3) 50 (8.9) 63 (14.9) 46(15.8) 152(13.1) 
Very poor 3(4.2) 9(2.6) 41(5.9) 0 27 (5.8) 11 (3.9) 11 (2) 26 (6.1) 13(4.5) 51(4.4) 
Vascular 
Invasion 
Negative 40(65.6) 186(65.3) 230(55.4) 32(71.1) 
10 0.019 
182(56.9) 159(62.6) 322(67.8) 137(60.4) 
10 0.015 
81(64.8) 536(60.4) 
0.9 0.3 
Positive 21(34.4) 99(34.7) 185(44.6) 13(28.9) 138(43.1) 95(37.4) 153(32.2) 90(39.6) 44(35.2) 351(39.6) 
Age 
<50 22(30.6) 104(29.9) 264(37.8) 15(27.3) 
8 0.039 
176(38.3) 99(34.5) 186(33.2) 165(37.2) 
3.5 0.3 
113(38) 421(35.9) 
0.5 0.5 
>50 50(69.4) 244(70.1) 435(62.2) 40(72.7) 284(61.7) 188(65.5) 375(66.8) 279(62.8) 184(62) 752(64.1) 
Size 
FP 30(41.7) 138(39.8) 177(25.7) 19(34.5) 
25.5 <0.0001 
128(27.1) 88 (31.1) 229(40.5) 108 (25.9) 
31 <0.0001 
76(26.6) 356(30.4) 
1.5 0.2 
>1.5cm 42(58.3) 209(60.2) 512(74.3) 36(65.5) 345(72.9) 195(68.9) 337(59.5) 309 (74.1) 210(73.4) 816(69.6) 
Stage 
1 44(61.1) 217(62.4) 402(57.7) 35(63.6) 
4.2 0.6 
276(60) 184(63.9) 361(64.3) 269(60.9) 
5 0.5 
188(63.5) 711(60.7) 
2 0.4 2 20(27.8) 102(29.3) 220(31.6) 17(30.9) 140(30.4) 78(27.1) 160(28.5) 126(28.5) 76(25.7) 345(29.4) 
3 8(11.1) 29(8.3) 75(10.8) 3(5.5) 44(9.6) 26(9) 40(7.1) 47(10.6) 32(10.8) 116(9.9) 
Grade 
1 14(19.4) 67(19.3) 47(6.7) 9(16.4) 
140 <0.0001 
41 (8.6) 57 (20.1) 128(22.6) 24 (5.6) 
285 <0.0001 
27(9.1) 148(12.6) 
28 <0.0001 2 31(43.1) 129(37.1) 139(19.9) 32(58.2) 91 (19.2) 93 (32.9) 255(45.1) 66 (15.3) 50(16.8) 350(29.8) 
3 27(37.5) 152(43.7) 513(73.4) 14(25.5) 342(72.2) 133 (47) 183(32.3) 340 (79.1) 220(74.1) 676(57.6) 
Tubules 
1 3(4.5) 21(6.2) 14(2) 1(1.9) 
44.5 <0.0001 
18 (3.9) 16 (5.8) 38 (6.9) 12 (2.8) 
51 <0.0001 
12(4.1) 45(3.9) 
33 <0.0001 2 29(43.3) 117(34.6) 160(23.4) 24(44.4) 108(23.5) 105(37.9) 198(35.8) 99 (23.4) 43(14.8) 366(31.9) 
3 35(52.2) 200(59.2) 509(74.5) 29(53.7) 334(72.6) 156(56.3) 317(57.3) 312 (73.8) 235(81) 738(64.2) 
Pleomorphism 
1 1(1.5) 9(2.7) 1(0.1) 0 
104.5 <0.0001 
3 (0.7) 9 (3.2) 14 (2.5) 2 (0.5) 
319 <0.0001 
5(1.7) 16(1.4) 
10 0.007 2 32(47.8) 142(42.1) 139(20.4) 32(59.3) 97 (21.1) 99 (35.7) 322(58.4) 42 (10) 61(21) 348(30.4) 
3 34(50.7) 186(55.2) 541(79.4) 22(40.7) 359(78.2) 169 (61) 215 (39) 378 (89.6) 224(77.2) 780(68.2) 
Mitosis 
1 28(41.8) 135(39.9) 117(17.1) 25(46.3) 
104 <0.0001 
82 (17.8) 103(37.2) 276(49.9) 58 (13.7) 
228.6  
<0.0001 
57(19.7) 328(28.5) 
16 <0.0001 2 16(23.9) 65(19.2) 120(17.6) 16(29.6) 78 (17) 57 (20.6) 106(19.2) 76 (18) 43(14.8) 215(18.7) 
3 23(34.3) 138(40.8) 446(65.3) 13(24.1) 300(65.2) 117(42.2) 171(30.9) 289 (68.3) 190(65.5) 606(52.7) 
Tumour Type 
Invasive 
Ductal/NST 35(49.3) 188(54.7) 535 (77.3 17 (31.5) 
137 <0.0001 
355(75.4) 167(60.1) 236(42.1) 353 (83.3) 
286 <0.0001 
211 (72.5) 782 (67.4) 
22 <0.0001 
lobular 8 (11.3) 24 (7) 20 (2.9) 13 (24.1) 10 (2.1) 7 (2.5) 87 (15.5) 6 (1.4) 19 (6.5) 50 (4.3) 
Atypical 
Medullary 1 (1.4) 5 (1.5) 21 (3) 
0 
 
18 (3.8) 8 (2.9) 6 (1.1) 10 (2.4) 7 (2.4) 29 (2.5) 
Mixed 21(29.6) 109(31.7) 98 (14.2) 22 (40.7) 70 (14.9) 80 (28.8) 195(34.8) 46 (10.8) 36 (12.4) 265 (22.8) 
Other 6 (8.5) 18 (5.2) 18 (2.6) 2 (3.7) 18 (3.8) 16 (5.8) 36 (6.4) 9 (2.1) 18 (6.2) 34 (2.9) 
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Relationship between DNA-DSB Repair Markers with Clinico-Pathological Parameters Continued. 
Parameters 
SMC6L1 KU70/KU80 DNA-PK 
c- n- 
 N(%) 
c+ n+  
N(%) 
c+ n-  
N(%) 
c- n+  
N(%) X
2 P Negative 
 N(%) 
Positive 
 N(%) X
2
 
P Negative 
 N(%) 
Positive  
N(%) X
2
 
P 
Age 
<50 87(35.4) 252(35.3) 86(38.4) 71(36.2) 0.7 0.9 55(32.7) 389(34.5) 0.2 0.6 59(29.9) 427(37.6) 4 0.04 
>50 159(64.6) 462(64.7) 138(61.6) 125(63.8) 113(67.3) 737(65.5) 138(70.1) 709(62.4) 
Size FP 75(30.9) 198(27.9) 54(24.2) 65(33.7) 5 0.1 57(33.9) 357(32) 0.2 0.6 63(32.1) 313(27.8) 1.5 0.2 
>1.5cm 168(69.1) 512(72.1) 169(75.8) 128(66.3) 111(66.1) 758(68) 133(67.9) 811(72.2) 
Stage 
1 161(65.4) 384(53.9) 147(65.9) 129(65.8) 
24 0.001 
115(68.5) 664(59) 
6 0.059 
134(68) 660(58.1) 
7 0.03 2 68(27.6) 240(33.7) 61(27.4) 61(27.4) 38(22.6) 348(30.9) 46(23.4) 350(30.8) 
3 17(6.9) 89(12.5) 15(6.7) 15(6.7) 15(8.9) 113(10) 17(8.6) 125(11) 
Grade 
1 34(13.8) 70(9.8) 21(9.3) 26(13.3) 
22 0.001 
26(15.5) 139(12.4) 
8 0.01 
23(11.7) 115(10.1) 
1 0.5 2 72(29.3) 189(26.5) 40(17.8) 65(33.2) 60(35.7) 30(27.1) 56(28.4) 292(25.7) 
3 140(56.9) 455(63.7) 164(72.9) 105(53.6) 82(48.8) 681(60.5) 118(59.9) 730(64.2) 
Tubules 
1 8(3.4) 19(2.7) 7(3.2) 9(4.8) 
10 0.1 
6(3.7) 44(4) 
9.5 0.008 
4(2.1) 36(3.2) 
0.7 0.7 2 66(27.8) 226(31.9) 49(22.6) 48(25.5) 63(38.7) 295(26.9) 55(28.9) 314(28) 
3 163(68.8) 463(65.4) 161(74.2) 131(69.7) 94(57.7) 756(69) 131(68.9) 771(68.8) 
Pleomorphism 
1 8(3.4) 6(0.8) 1(0.5) 4(2.1) 
44 <0.0001 
2(1.2) 13(1.2) 
5 0.09 
5(2.6) 10(0.9) 
6 0.046 2 83(35.2) 169(23.9) 40(18.5) 72(38.3) 63(38.6) 330(30.2) 59(31.1) 300(26.8) 
3 145(61.4) 531(75.2) 175(81) 112(59.6) 98(60.1) 750(68.6) 126(66.3) 809(72.3) 
Mitosis 
1 61(25.7) 172(24.3) 38(17.5) 68(36.2) 
27 <0.0001 
53(32.5) 314(28.7) 
1.5 0.5 
50(26.3) 280(25) 
0.2 0.9 2 48(20.3) 138(19.5) 30(13.8) 27(14.4) 30(18.4) 189(17.3) 32(16.8) 188(16.8) 
3 128(54) 398(56.2) 149(68.7) 93(49.5) 80(49.1) 592(54.1) 108(56.8) 653(58.3) 
NPI 
Excellent 22(9.1) 41(5.8) 14(6.3) 14(7.2) 
24 0.07 
19(11.4) 91(8.2) 
7.4 0.2 
15(7.7) 70(6.2) 
4.3 0.5 
Good 36(14.9) 105(14.9) 23(10.3) 39(20) 33(19.8) 165(14.8) 31(15.9) 166(14.8) 
Moderate1 92(38) 218(30.8) 77(34.4) 66(33.8) 47(28.1) 357(32) 68(34.9) 351(31.3) 
Moderate2 58(24) 188(26.6) 69(30.8) 48(24.6) 46(27.5) 294(26.4) 52(26.7) 308(27.4) 
Poor 26(10.7) 117(16.5) 31(13.8) 21(10.8) 17(10.2) 152(13.6) 20(10.3) 172(15.3) 
Very poor 8(3/3) 38(5.4) 10(4.5) 7(3.6) 5(3) 56(5) 9(4.6) 56(5) 
Vascular Invasion 
Negative 126(66) 241(51.6) 109(66.9) 93(66) 
21 <0.0001 
168(100) 935(83.7) 
32 <0.0001 
93(61.2) 463(60.4) 
0.04 0.8 
Positive 65(34) 226(48.4) 54(33.1) 48(34) 0 182(16.3) 59(38.8) 305(39.6) 
Tumour Type 
Invasive Ductal/NST 160 (66.7) 506 (71.8) 165 (75.3) 111 (57.2) 
49 <0.0001 
106(63.5) 738(66.4) 
2 0.7 
130 (67.4) 791(70.2) 
3 0.6 
lobular 14 (5.8) 22 (3.1) 2 (0.9) 19 (9.8) 9(5.4) 77(6.9) 9(4.7) 49(4.3) 
Atypical Medullary 11 (4.6) 13 (1.8) 9 (4.1) 3 (1.5) 6(3.6) 29(2.6) 8(4.1) 25(2.2) 
Mixed 45 (18.8) 151(21.4) 37 (16.9) 52 (26.8) 40(24) 226(20.3) 41(21.2) 228(20.2) 
Other 10 (4.2) 13 (1.8) 6 (2.7) 9 (4.6) 6(3.6) 41(3.7) 5(2.6) 34(3) 
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Correlation between DNA- DSB Repair Markers with other Tumour Markers Continued. 
Parameters 
Rad51 
c- n- 
 N(%) 
c+ n+  
N(%) 
c+ n-  
N(%) 
c- n+  
N(%) X
2 P 
KU70/KU80 Negative 
24(36.9) 24(7.5) 58(9.7) 11(23.4) 55 <0.0001 
Positive 41(63.1) 294(92.5) 542(90.3) 36(76.6) 
DNA-PK 
Negative 13(31) 24(10.5) 82(16.5) 1(4) 
15 0.002 
Positive 29(69) 205(89.5) 414(83.5) 24(96) 
SMC6L1.n Negative 
17(36.2) 75(31) 171(34.5) 5(17.9) 
4 0.2 
Positive 30(63.8) 167(69) 325(65.5) 23(82.1) 
SMC6L1.c Negative 
26(55.3) 84(34.7) 131(26.4) 8(28.6) 
19.5 <0.0001 
Positive 21(44.7) 158(65.3) 365(73.6) 20(71.4) 
ID4.n 
Negative 52(81.3) 271(88) 539(82.5) 43(87.8) 5.5 0.1 
Positive 12(18.8) 37(12) 114(17.5) 6(12.2) 
ID4.c 
Negative 41(57.7) 113(32.3) 236(34.3) 24(43.6) 
19 <0.0001 
Positive 30(42.3) 237(67.7) 452(65.7) 31(56.4) 
PTEN 
Negative 27 (69.2) 151 (76.3) 250 (89) 14 (53.8) 31 <0.0001 
Positive 12 (30.8) 47 (23.7) 31 (11) 12 (46.2) 
CHK1.n Negative 
50(73.5) 190(60.5) 518(85.6) 18(35.3) 
114 <0.0001 
Positive 18(26.5) 124(39.5) 87(14.4) 33(64.7) 
CHK1.c Negative 
18(26.5) 21(6.7) 37(6.1) 15(29.4) 
61 <0.0001 
Positive 50(73.5) 292(93.3) 568(93.9) 36(70.6) 
CHK2 Negative 
20 (52.6) 88 (43.3) 191 (60.8) 8 (32) 
20 <0.0001 
Positive 18 (47.4) 115 (56.7) 123 (39.2) 17 (68) 
ATM 
Negative 20 (64.5) 98 (44.7) 311 (62.8) 13 (37.1) 
26.5 <0.0001 
Positive 11 (35.5) 121 (55.3) 184 (37.2) 22 (62.9) 
Ki-67 
Negative 32(55.2) 139(50) 149(24.1) 22(53.7) 
77 <0.0001 
Positive 26(44.8) 139(50) 469(75.9) 19(46.3) 
BARD1.c 
Negative 12(26.7) 23(9.5) 148(27.9) 3(8.8) 37 <0.0001 
Positive 33(73.3) 218(90.5) 383(72.1) 31(91.2) 
BARD1.n 
Negative 42(93.3) 211(87.6) 492(92.7) 32(97) 
7 0.07 
Positive 3(6.7) 30(12.4) 39(7.3) 1(3) 
MTA1.n 
Negative 19(46.3) 82(34) 250(48.2) 10(30.3) 
16 0.001 
Positive 22(53.7) 159(66) 269(51.8) 23(69.7) 
MTA1.c 
Negative 15(35.7) 26(10.8) 63(12.1) 9(27.3) 
25 <0.0001 
Positive 27(64.3) 215(89.2) 456(87.9) 24(72.7) 
P21 
Negative 18(64.3) 74(58.7) 199(59.4) 14(63.6) 
0.4 0.9 
Positive 10(35.7) 52(41.3) 136(40.6) 8(36.4) 
P27 
Negative 12(44.4) 34(28.6) 203(59.2) 8(34.8) 
36 <0.0001 
Positive 15(55.6) 85(71.4) 140(40.8) 15(65.2) 
Ȗ+$;Q Negative 4(11.1) 8(3.6) 93(19.2) 1(3.7) 34 <0.0001 
Positive 32(88.9) 217(96.4) 392(80.8) 26(96.3) 
Ȗ+$;F Negative 8(22.2) 24(10.7) 37(7.6) 7(25.9) 17 0.001 
Positive 28(77.8) 201(89.3) 448(92.4) 20(74.1) 
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Correlation between DNA- DSB Repair Markers with other Tumour Markers Continued. 
 
Parameters 
 
Rad51 
c- n- 
 N(%) 
c+ n+  
N(%) 
c+ n-  
N(%) 
c- n+  
N(%) X
2 P 
ER 
Negative 23(33.3) 81(24.4) 387(56.7) 5(9.4) 
126 <0.0001 
Positive 46(66.7) 251(75.6) 295(43.3) 48(90.6) 
PgR 
Negative 30(46.9) 127(38.7) 426(65.4) 6(12.5) 
100 <0.0001 
Positive 34(53.1) 201(61.3) 225(34.6) 42(87.5) 
Triple Negative 
Negative 52(78.8) 284(86.3) 397(60.5) 49(94.2) 88 <0.0001 
Positive 14(21.2) 45(13.7) 259(39.5) 3(5.8) 
HER-2 
Negative 59(89.4) 289(84.8) 549(81.8) 50(96.2) 9.5 0.02 
Positive 7(10.6) 52(15.2) 122(18.2) 2(3.8) 
CK5 Negative 
46(86.8) 235(83.9) 376(67.5) 41(95.3) 
42 <0.0001 
Positive 7(13.2) 45(16.1) 181(32.5) 2(4.7) 
CK17 
Negative 51(94.4) 215(84.6) 463(79.3) 36(90) 
11.5 0.009 
Positive 3(5.6) 39(15.4) 121(20.7) 4(10) 
CK14 
Negative 62(93.9) 280(87) 555(84.2) 46(93.9) 
8 0.046 
Positive 4(6.1) 42(13) 104(15.8) 3(6.1) 
BLBC Negative 
49(87.5) 278(88) 406(68.1) 45(93.8) 58 <0.0001 
Positive 7(12.5) 38(12) 190(31.9) 3(6.3) 
P53 Negative 
47(75.8) 233(71) 370(55.1) 40(80) 
37 <0.0001 
Positive 15(24.2) 95(29) 302(44.9) 10(20) 
Rad51.c 
Negative 
 
Positive 
Rad51.n 
Negative 
Positive 
 
Correlation between DNA- DSB Repair Markers with other Tumour Markers Continued. 
 
Markers  
BRCA1 
c- n- 
N (%) 
c+ n+ 
N (%) 
c- n+ 
N (%) 
c+ n- 
N (%) 
X2 
 
P 
ER 
Negative 253 (53.9) 68 (24.2) 76 (13.7) 270 (63.2) 325 <0.0001 
Positive 216 (46.1) 213 (75.8) 478 (86.3) 157 (36.8) 
PgR 
Negative 301 (65.6) 96 (34.3) 155 (28) 269 (67.1) 
225 <0.0001 
Positive 158 (34.4) 184 (65.7) 399 (72) 132 (32.9) 
Triple Negative 
Negative 276 (60) 239 (84.8) 498 (90.2) 240 (60) 
179.8 <0.0001 
Positive 184 (40) 43 (15.2) 54 (9.8) 160 (40) 
HER-2 
Negative 391 (84.6) 237 (85.3) 515 (92.1) 307 (75.2) 52.6 <0.0001 
Positive 71 (15.4) 41 (14.7) 44 (7.9) 101 (24.8) 
CK5 
Negative 247 (67.5) 194 (87.4) 363 (90.1) 190 (65.3) 
95 <0.0001 
Positive 119 (32.5) 28 (12.6) 40 (9.9) 101 (34.7) 
CK17 Negative 
292 (78.5) 171 (85.9) 319 (91.1) 265 (78.4) 
28 <0.0001 
Positive 80 (21.5) 28 (14.1) 31 (8.9) 73 (21.6) 
CK14 Negative 
396 (86.8) 249 (89.2) 498 (92.1) 330 (81.7) 
24 <0.0001 
Positive 60 (13.2) 30 (10.8) 43 (7.9) 74 (18.3) 
BLBC Negative 
277 (67.7) 232 (88.5) 491 (94.6) 237 (67.7) 
154 <0.0001 
Positive 132 (32.3) 30 (11.5) 28 (5.4) 113 (32.3) 
P53 Negative 
277 (59.1) 185 (66.1) 449 (81.3) 204 (47.8) 
126.9 <0.0001 
Positive 192 (40.9) 95 (33.9) 103 (18.7) 223 (52.2) 
ID4.n 
Negative 354 (83.3) 194 (85.1) 419 (90.3) 308 (80.8) 
16 0.0001 
Positive 71 (16.7) 34 (14.9) 45 (9.7) 73 (19.2) 
ID4.c 
 
Negative 181(39.5) 111(38.5) 243(43.3) 155(35.2) 
7 0.07 
Positive 277(60.5) 177(61.5) 318(56.7) 285(64.8) 
PTEN 
Negative 186 (90.3) 126 (81.3) 198 (71.5) 102 (79.7) 
26 <0.0001 
Positive 20 (9.7) 29 (18.7) 79 (28.5) 26 (20.3) 
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Correlation between DNA- DSB Repair Markers with other Tumour Markers Continued. 
Markers 
BRCA1 
c- n- 
N (%) 
c+ n+ 
N (%) 
c- n+ 
N (%) 
c+ n- 
N (%) 
X2 
 
P 
CHK1.n Negative 
259 (80.9) 111 (67.3) 214 (65.6) 210 (78.1) 
25.5 <0.0001 
Positive 61 (19.1) 54 (32.7) 112 (34.4) 59 (21.9) 
CHK1.c Negative 
32 (10) 12 (7.3) 53 (16.3) 7 (2.6) 
33 <0.0001 
Positive 288 (90) 153 (92.7) 272 (83.7) 262 (97.4) 
CHK2 Negative 
159 (62.6) 69 (40.8) 117 (41.5) 90 (58.8) 
34.5 <0.0001 
Positive 95 (37.4) 100 (59.2) 165 (58.5) 63 (41.2) 
Ki-67 
Negative 109 (26.2) 93 (41.7) 255 (57.7) 102 (25.6) 
125 <0.0001 
Positive 307 (73.8) 130 (58.3) 187 (42.3) 297 (74.4) 
ATR 
Negative 150 (55.8) 97 (51.1) 213 (57.6) 66 (38.8) 
17.8 <0.0001 
Positive 119 (44.2) 93 (48.9) 157 (42.4) 104 (61.2) 
ATM 
Negative 233 (71) 72 (38.3) 159 (47.5) 168 (55.3) 
62.8 <0.0001 
Positive 95 (29) 116 (61.7) 176 (52.5) 136 (44.7) 
MTA1.n 
 
Negative 159 (48.2) 64 (36.8) 108 (34.7) 126 (39.7) 
13 0.004 
Positive 171 (51.8) 110 (63.2) 203 (65.3) 191 (60.3) 
MTA1.c 
Negative 41 (12.4) 25 (14.3) 68 (21.8) 26 (8.2) 
25 <0.0001 
Positive 289 (87.6) 150 (85.7) 244 (78.2) 291 (91.8) 
P27 
 
Negative 103 (57.5) 21 (27.6) 45 (25.4) 131 (61.5) 
70 <0.0001 
Positive 76 (42.5) 55 (72.4) 132 (74.6) 82 (38.5) 
P21 
Negative 105(60) 55(66.3) 114(65.5) 126(55.3) 5 0.1 
Positive 70(40) 28(33.7) 60(34.5) 102(44.7) 
Ȗ+$;.n 
 
Negative 74 (23.4) 7 (4.5) 17 (6.2) 40 (13.2) 51 <0.0001 
Positive 242 (76.6) 148 (95.5) 258 (93.8) 264 (86.8) 
Ȗ+$;.c 
 
Negative 33 (10.4) 20 (12.9) 46 (16.7) 15 (4.9) 
21.6 <0.0001 
Positive 283 (89.6) 135 (87.1) 229 (83.3) 290 (95.1) 
BARD1.n 
Negative 313(91.8) 166(89.7) 294(91.3) 297(90.5) 0.7 0.9 
Positive 28(8.2) 19(10.3) 28(8.7) 31(9.5) 
BARD1.c 
Negative 97 (28.5) 22 (11.9) 36 (11.1) 83 (25.3) 
44 <0.0001 
Positive 243 (71.5) 163 (88.1) 287 (88.9) 245 (74.7) 
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Correlation between DNA -DSB Repair Markers with other Tumour Markers Continued. 
 
Parameters 
 
SMC6L1 BARD1.c 
c- n- 
N(%) 
c+ n+ 
N(%) 
c+ n- 
N(%) 
c- n+ 
N(%) X
2 P Negative  N(%) 
positive  
N(%) X
2
 
P 
ER Negative 86(37.9) 299(42.7) 111(50.5) 72(38.1) 9 0.027 188(65.7) 437(38.6) 68 <0.0001 Positive 141(62.1) 402(57.3) 109(49.5) 117(61.9) 98(34.3) 696(61.4) 
PgR Negative 122(52.4) 345(52.8) 132(60.6) 93(52) 5 0.2 180(69) 552(50.7) 28 <0.0001 Positive 111(47.6) 308(47.2) 86(39.4) 86(48) 81(31) 536(49.3) 
TN Negative 169(75.4) 498(74.2) 128(59) 132(72.1) 21 <0.0001 137(52.7) 830(75.2) 52 <0.0001 Positive 55(24.6) 173(25.8) 89(41) 51(27.9) 123(47.3) 273(24.8) 
HER-2 Negative 198(83.9) 544(79.9) 190(86.4) 165(88.7) 11 0.01 243(86.8) 922(82.1) 3 0.06 Positive 38(16.1) 137(20.1) 30(13.6) 21(11.3) 37(13.2) 201(17.9) 
CK5 Negative 128(77.1) 397(75.5) 107(63.3) 114(83.8) 18 <0.0001 132(60.3) 676(78.5) 31 <0.0001 Positive 38(22.9) 129(24.5) 62(36.7) 22(16.2) 87(39.7) 185(21.5) 
CK17 Negative 146(86.4) 422(80.2) 129(72.9) 113(86.9) 14 0.003 189(77.5) 683(82.4) 3 0.08 Positive 23(13.6) 104(19.8) 48(27.1) 17(13.1) 55(22.5) 146(17.6) 
CK14 Negative 197(86.4) 581(88.4) 178(83.6) 153(85) 4 0.3 218(83.2) 953(87.4) 3 0.08 Positive 31(13.6) 76(11.6) 35(16.4) 27(15) 44(16.8) 138(12.6) 
BLBC Negative 160(82.5) 476(79.2) 127(62.6) 135(80.8) 30 <0.0001 138(59.5) 799(80.3) 45 <0.0001 Positive 34(17.5) 125(20.8) 76(37.4) 32(19.2) 94(40.5) 196(19.7) 
P53 Negative 154(67.8) 401(58.9) 126(58.3) 116(64.4) 7 0.06 149(53.4) 706(64.2) 11 0.001 Positive 73(32.2) 280(41.1) 90(41.7) 64(35.6) 130(46.6) 394(35.8) 
Rad51.c Negative 14(10.6) 33(7.7) 8(5.9) 20(17.1) 12 0.008 15(8.1) 64(9.6) 0.4 0.5 Positive 118(89.4) 395(92.3) 128(94.1) 97(82.9) 171(91.9) 601(90.4) 
Rad51.n Negative 85(63.9) 284(66) 103(74.6) 72(61.5) 6 0.1 160(85.6) 417(62.2) 36 <0.0001 Positive 48(36.1) 146(34) 35(25.4) 45(38.5) 27(14.4) 253(37.8) 
KU70/KU80 Negative 38(26.8) 41(8.9) 18(12.3) 18(15.3) 31 <0.0001  Positive 104(73.2) 422(91.1) 128(87.7) 100(84.7) 
SMC6L1.n Negative 
 
97(38.6) 318(32.3) 4 0.05 Positive 154(61.4) 668(67.7) 
SMC6L1.c Negative 98(39) 278(28.2) 11 0.001 Positive 153(61) 708(71.8) 
ID4.n Negative 185(83.7) 531(86.3) 164(81.6) 137(79.7) 6 0.1 214(77) 882(85.9) 13 <0.0001 Positive 36(6.3) 84(13.7) 37(18.4) 35(20.3) 64(23) 145(14.1) 
ID4.c Negative 101(40.7) 261(37.4) 73(32.7) 84(43.3) 6 0.1 147(51.9) 389(33.4) 33 <0.0001 Positive 147(59.3) 437(62.6) 150(67.3) 110(56.7) 136(48.1) 774(66.6) 
PTEN Negative 120 (81.6) 284 (79.8) 111 (91) 78 (70.3) 16 0.001 87 (91.6) 558 (79.5) 8 0.005 Positive 27 (18.4) 72 (20.2) 11 (9) 33 (29.7) 8 (8.4) 144 (20.5) 
CHK1.n Negative 104(70.7) 353(75.6) 121(79.1) 83(66.9) 7 0.08 147(73.1) 550(74.4) 0.1 0.7 Positive 43(29.3) 114(24.4) 32(20.9) 41(33.1) 54(26.9) 189(25.6) 
CHK1.c Negative 27(18.4) 31(6.6) 16(10.5) 13(10.5) 18 0.001 27(13.4) 62(8.4) 5 0.03 Positive 120(81.6) 436(93.4) 136(89.5) 111(89.5) 174(86.6) 676(91.6) 
CHK2 Negative 93 (60) 160 (40.2) 84 (64.6) 51 (47.7) 32.6 <0.0001 62 (60.8) 333 (47.2) 6.6 0.01 Positive 62 (40) 238 (59.8) 46 (35.4) 56 (52.3) 40 (39.2) 373 (52.8) 
ATM Negative 74 (50.7) 260 (53.7) 101 (64.3) 69 (58) 7 0.06  Positive 72 (49.3) 224 (46.3) 56 (35.7) 50 (42) 
ATR Negative 132 (67.7) 207 (42.2) 79 (49.1) 106 (73.6) 65 <0.0001 63(51.2) 454(51.2) 0 0.99 Positive 63 (32.3) 283 (57.8) 82 (50.9) 38 (26.4) 60(48.8) 432(48.8) 
Ki-67 Negative 83(40.5) 194(31.3) 52(27.4) 73(45.6) 19 <0.0001 81(29) 356(36.7) 6 0.017 Positive 122(59.5) 426(68.7) 138(72.6) 87(54.6) 198(71) 613(63.3) 
P27 Negative 38(39.2) 143(51.1) 42(53.2) 39(47.6) 5 0.2 114(68.3) 170(39.8) 39 
 
<0.0001 
 Positive 59(60.8) 137(48.9) 37(46.8) 43(52.4) 53(31.7) 257(60.2) 
BARD1.c Negative 58(28.3) 114(17.5) 39(18.6) 40(23.4) 13 0.006  Positive 147(71.7) 537(82.5) 171(81.4) 131(76.6) 
BARD1.n Negative 190(92.7) 587(90.3) 191(91) 159(92.4) 1.5 0.7 297(99.7) 1043(88.6) 35 <0.0001 Positive 15(7.3) 63(9.7) 19(9) 13(7.6) 1(0.3) 134(11.4) 
MTA1.n 
 
Negative 126(58.1) 181(27.3) 150(68.8) 40(23.4) 170 <0.0001 141(54) 365(35.9) 28 
 
<0.0001 
 Positive 91(41.9) 482(72.7) 68(31.2) 131(76.6) 120(46) 651(64.1) 
MTA1.c 
 
Negative 78(35.9) 34(5.1) 18(8.3) 59(34.5) 185 <0.0001 74(28.4) 111(10.9) 51 
 
<0.0001 
 Positive 139(64.1) 630(94.9) 200(91.7) 112(65.5) 187(71.6) 906(89.1) 
Ȗ+$;Q 
 
Negative 47(25.3) 28(4.4) 71(37.8) 6(3.7) 180 <0.0001 59(24.5) 90(9.9) 35.5 
 
<0.0001 
 
Positive 139(74.7) 603(95.6) 117(62.2) 156(96.3) 182(75.5) 815(90.1) 
Ȗ+$;F 
 
Negative 36(19.3) 29(4.6) 7(3.7) 44(27.2) 100 <0.0001 38(15.8) 76(8.4) 11.6 0.001 Positive 151(80.7) 602(95.4) 181(96.3) 118(72.8) 203(84.2) 830(91.6) 
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Correlation between DNA-DSB Repair Markers with other Tumour Markers Continued. 
Markers 
KU70/KU80 DNA-PK 
Negative 
N(%) 
Positive 
N(%) X
2 P Negative N(%) 
Positive 
N(%) X
2 P 
ER 
Negative 51(32.7) 489(44.6) 
8 0.005 
79(42.7) 496(44.5) 
0.2 0.6 
Positive 105(67.3) 607(55.4) 106(57.3) 619(55.5) 
PgR 
Negative 76(47.8) 568(54.7) 3 0.1 103(56.3) 574(54.3) 0.2 0.6 
Positive 83(52.2) 470(45.3) 80(43.7) 483(45.7) 
TN 
Negative 124(78.5) 744(70.7) 
4 0.04 
133(71.9) 749(70.1) 
0.2 0.6 
Positive 34(21.5) 309(29.3) 52(28.1) 320(29.9) 
HER-2 
Negative 136(84) 906(83.7) 0.005 0.9 160(83.8) 903(82.8) 0.1 0.7 
Positive 26(16) 176(16.3) 31(16.2) 187(17.2) 
CK5 Negative 
110(81.5) 665(73.2) 
4.2 0.03 
119(78.3) 617(73.7) 
1 0.2 
Positive 25(18.5) 244(26.8) 33(21.7) 220(26.3) 
CK17 
Negative 118(88.1) 734(82.3) 
3 0.09 
126(86.3) 668(79.8) 
3 0.07 
Positive 16(11.9) 158(17.7) 20(13.7) 169(20.2) 
CK14 
Negative 38(85.2) 896(86.7) 
0.26 0.6 
165(90.2) 910(85.8) 
2 0.1 
Positive 24(14.8) 138(13.3) 18(9.8) 150(14.2) 
BLBC Negative 
116(81.7) 746(76.3) 
2 0.1 
128(79) 735(75.6) 
0.9 0.3 
Positive 26(18.3) 232(23.7) 34(21) 237(24.4) 
P53 Negative 
114(74.5) 653(60.9) 
11 0.001 
127(68.6) 639(59.1) 
6 0.01 
Positive 39(25.5) 420(39.1) 58(31.4) 443(40.9) 
KU70/KU80 Negative    
37(28.2) 68(9.5) 
35.5 <0.0001 
Positive 94(71.8) 645(90.5) 
ID4.n 
Negative 116(81.1) 857(83.4) 0.5 0.5 140(77.8) 845(84.4) 5 0.028 
Positive 27(18.9) 170(16.6) 40(22.2) 156(15.6) 
ID4.c 
Negative 82(48) 402(36.2) 
9 0.003 
82(41.2) 398(35.5) 
2 0.1 
Positive 89(52) 709(63.8) 117(58.8) 722(64.5) 
PTEN 
Negative 7(25.9) 42(12.6) 
4 0.05 
124 (93.9) 469 (78.7) 
16.6 <0.0001 
Positive 20(74.1) 292(87.4) 8 (6.1) 127 (21.3) 
CHK1.n Negative 
113(73.4) 766(75.1) 
0.2 0.6 
100(77.5) 553(74.8) 
0.4 0.5 
Positive 41(26.6) 254(24.9) 29(22.5) 186(25.2) 
CHK1.c Negative 
40(26) 83(8.1) 
45 <0.0001 26(20.2) 53(7.2) 22 <0.0001 
Positive 114(74) 936(91.9) 103(79.8) 685(92.8) 
CHK2 Negative 
44(47.8) 301(53.9) 
1.2 0.3 
104 (77.6) 274 (43.9) 50 <0.0001 
Positive 48(52.2) 257(46.1) 30 (22.4) 350 (56.1) 
ATM 
Negative 45 (51.1) 442 (57) 
1 0.3 
84 (63.6) 414 (56) 
2.60 0.1 
Positive 43 (48.9) 333(43) 48 (36.4) 325 (44) 
ATR 
Negative 84 (65.1) 325 (52.2) 
7 0.007 
106 (67.9) 360 (45.7) 
25.8 <0.0001 
Positive 45 (34.9) 298 (47.8) 50 (32.1) 428 (54.3) 
Ki-67 
Negative 42(36.2) 340(35.5) 
0.03 0.9 
63(40.9) 315(31.8) 
5 0.026 
Positive 74(63.8) 619(64.5) 91(59.1) 675(68.2) 
BARD1.c 
Negative 21(16.8) 179(22.6) 
2.1 0.1 
67(36.2) 176(16.9) 
37 <0.0001 
Positive 104(83.2) 614(77.4) 118(63.8) 864(83.1) 
BARD1.n 
Negative 113(90.4) 721(90.9) 0.03 0.8 172(93) 935(89.9) 2 0.2 
Positive 12(9.6) 72(9.1) 13(7) 118(9.6) 
MTA1.n 
Negative 59(52.7) 329(42.4) 
4 0.04 
129(69) 340(33.8) 
82 <0.0001 
Positive 53(47.3) 447(57.6) 58(31) 667(66.2) 
MTA1.c 
Negative 37(33) 88(11.3) 38 <0.0001 73(39) 88(8.7) 124 <0.0001 
Positive 75(67) 689(88.7) 114(61) 920(91.3) 
P21 
Negative 38(52.1) 294(63) 
3.2 0.07 
51(58) 260(59.1) 
0.04 0.8 
Positive 35(47.9) 173(37) 37(42) 180(40.9) 
P27 
Negative 24(32) 233(51.2) 9.5 0.002 32(38.1) 220(49.7) 4 0.05 
Positive 51(68) 222(48.8) 52(61.9) 223(50.3) 
Ȗ+$;Q Negative 18(20.9) 96(13.1) 4 0.048 53(32.9) 92(9.8) 64 <0.0001 
Positive 68(79.1) 636(86.9) 108(67.1) 843(90.2) 
Ȗ+$;F Negative 16(18.4) 77(10.5) 5 0.029 29(18) 76(8.1) 15.5 <0.0001 
Positive 71(81.6) 655(89.5) 132(82) 860(91.9) 
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Correlation between HR Repair Proteins with other Tumour Markers Regardless Co-expression of Cellular Localisation 
Markers 
BRCA1.n BRCA1.c 
Negative 
N (%) 
Positive 
N (%) 
P 
X2 
Negative 
N (%) 
Positive 
N (%) 
P 
X2 
ER 
Negative 526(58.5) 144 (17.2) <0.0001 
312 
329(32.2) 338(47.7) <0.0001 
43 Positive 373(41.5) 693 (82.8) 694(67.8) 370(52.3) 
PgR 
Negative 572(66.4) 252 (30.1) <0.0001 
223 
456(45) 365(53.6) 0.001 
12 Positive 290(33.6) 584 (69.9) 557 (55) 316(46.4) 
CK5 Negative 
438(66.5) 559 (89.2) <0.0001 
95 
610(79.3) 384(74.9) 0.06 
3 Positive 221(33.5) 68 (10.8) 159(20.7) 129(25.1) 
P27 
Negative 235(59.6) 66(26.1) <0.0001 
70 
148(41.6) 152(52.6) 0.005 
7.9 Positive 159(40.4) 187 (73.9) 20 (58.4) 137(47.4) 
SMC6L1.n Negative 
219(34.5) 158 (33.5) 0.7 
0.1 
225(36.5) 152(31.1) 0.06 
3 Positive 416(65.5) 314 (66.5) 392(63.5) 336(68.9) 
MTA1.n 
Negative 286(44.1) 172 (35.4) 0.003 
8.6 
267(41.7) 190(38.7) 0.3 
1 Positive 363(55.9) 314 (64.6) 374(58.3) 301(61.3) 
CHK1.c 
Negative 40 (6.8) 65 (13.2) <0.0001 
12.7 
85 (13.2) 19 (4.4) <0.0001 
23 Positive 551(93.2) 427 (86.8) 560(86.8) 415(95.6) 
CHK1.n Negative 
470(79.5) 326 (66.1) <0.0001 
24.7 
473(73.2) 321(74) 0.8 
0.07 Positive 121(20.5) 167 (33.9) 173(26.8) 113 (26) 
CHK2 Negative 
249(61.2) 186 (41.2) <0.0001 
34 
276(51.5) 159(49.4) 0.5 
0.4 Positive 158(38.8) 266 (58.8) 260(48.5) 163(50.6) 
Ȗ+$;Q Negative 114(18.3) 24 (5.6) <0.0001 36 
91(15.4) 47(10.2) 0.014 
6 Positive 508 (81.7) 407(94.4) 500(84.6) 412(89.8) 
Ȗ+$;F Negative 49 (7.9) 66(15.3) <0.0001 14.5 
79(13.4) 35(7.6) 0.003 
9 Positive 574(92.1) 365 (84.7) 512 (86.6) 425(92.4) 
Rad51.n 
Negative 440(81.5) 195(46.2) <0.0001 
131 
348(62.6) 285(70.7) 0.009 
6.9 Positive 100(18.5) 227(53.8) 208 (37.4) 118(29.3) 
BARD1.c 
Negative 181 (27) 58(11.4) <0.0001 
43.8 
133 (20.1) 105(20.5) 0.8 
0.03 Positive 489 (73) 452 (88.6) 530(79.9) 408(79.5) 
Markers 
Rad51.n Rad51.c 
Negative 
N (%) 
Positive 
N (%) 
P 
X2 
Negative 
N (%) 
Positive 
N (%) 
P 
X2 
CK17 Negative 
514(80.4) 255 (85.3) 0.07 
3 
87 (92.6) 678(80.9) 0.005 
7.8 Positive 125(19.6) 44(14.7) 7 (7.4) 160(19.1) 
P27 
Negative 216(58.2) 42 (29.6) <0.0001 
33.7 
20 (40) 237(51.3) 0.1 
2 Positive 155(41.8) 100 (70.4) 30 (60) 225(48.7) 
SMC6L1.n Negative 
188(34.6) 83 (30.3) 0.2 
1.5 
22 (29.3) 246(33.3) 0.5 
0.5 Positive 356(65.4) 191 (69.7) 53 (70.7) 492(66.7) 
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Correlation between HR Repair Proteins with other Tumour Markers Regardless Co-expression of Cellular Localisation Continued. 
Markers 
Rad51.n Rad51.c 
Negative 
N (%) 
Positive 
N (%) 
P 
X2 
Negative 
N (%) 
Positive 
N (%) 
P 
X2 
ID4.c 
Negative 277(36.4) 139 (33.9) 0.4 
0.7 
65 (51.6) 349(33.6) <0.0001 
16 Positive 483(63.6) 271 (66.1) 61 (48.4) 689(66.4) 
MTA1.n 
Negative 269 (48) 93 (33.5) <0.0001 
16 
29 (39.2) 332(43.7) 0.4 
0.5 Positive 292 (52) 185 (66.5) 45 (60.8) 428(56.3) 
CHK1.c Negative 
56 (8.3) 37 (10.1) 0.3 
0.9 
33 (27.7) 58 (6.3) <0.0001 
60 Positive 618(91.7) 331 (89.9) 86 (72.3) 860(93.7) 
CHK2 Negative 
212(60.1) 97 (41.8) <0.0001 
18.7 
28 (44.4) 279 (54) 0.1 
2 Positive 141(39.9) 135 (58.2) 35 (55.6) 238 (46) 
ATM 
Negative 332 (63) 112 (43.8) <0.0001 
26 
33 (50) 409(57.3) 0.2 
1.3 Positive 195 (37) 144 (56.3) 33 (50) 305(42.7) 
MTA1.c 
Negative 78 (13.9) 36 (12.9) 0.7 
0.1 
24 (32) 89 (11.7) <0.0001 
24 Positive 484(86.1) 242 (87.1) 51 (68) 671(88.3) 
Ȗ+$;Q Negative 97 (18.6) 9 (3.5) <0.0001 33 
5 (7.9) 101(14.2) 0.2 
2 Positive 425(81.4) 248 (96.5) 58 (92.1) 609(85.8) 
Ȗ+$;F Negative 45 (8.6) 33 (12.8) 0.06 3 
15 (23.8) 61(8.6) <0.0001 
15 Positive 477(91.4) 224 (87.2) 48 (76.2) 649(91.4) 
BRCA1.c Negative 
348 (55) 208 (63.8) 0.009 
7 
67 (71.3) 486(56.6) 0.006 
7.5 Positive 285 (45) 118 (36.2) 27 (28.7) 373(43.4) 
DNA-PK 
Negative 95 (17.6) 25 (9.8) 0.004 
8 
14 (20.9) 106(14.6) 0.2 
1.8 Positive 444 (82.4) 231 (90.2) 53 (79.1) 619(85.4) 
Markers 
SMC6L1.n SMC6L1.c 
Negative 
N (%) 
Positive 
N (%) 
P 
X2 
Negative 
N (%) 
Positive 
N (%) 
P 
X2 
CK5 
Negative 235 (70.1) 511 (77.2) 0.01 
5.8 
242 (80.1) 504 (72.5) 0.01 
6.5 Positive 100 (29.9) 151 (22.8) 60 (19.9) 191 (27.5) 
CK17 
Negative 275 (79.5) 535 (81.6) 0.4 
0.6 
259 (86.6) 551 (78.4) 0.002 
9 Positive 71 (20.5) 121 (18.4) 40 (13.4) 152 (21.6) 
Ȗ+$;Q Negative 118 (31.6) 34 (4.3) <0.0001 166 
53 (15.2) 99 (12.1) 0.1 
2 Positive 256 (68.4) 759(95.7) 295 (84.8) 720 (87.9) 
BRCA1.n Negative 
219 (58.1) 416 (57) 0.7 
0.12 
158 (47.3) 477 (61.7) <0.0001 
20 Positive 158 (41.9) 314(43) 176 (52.7) 296 (38.3) 
Ki-67 
Negative 135 (34.2) 267 (34.2) 0.098 
0 
156 (42.7) 246 (30.4) <0.0001 
17 Positive 260 (65.8) 513 (65.8) 209 (57.3) 564 (69.6) 
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Appendix 3 
 
 
Chapter10                                                                                                                  Appendices                                                                                                                   
286 
 
Relationship between SUMO markers with Clinico-Pathological Parameters 
Parameters 
PIAS1 PIAS4 
c- n- 
N(%) 
c+ n+ 
N(%) 
c- n+ 
N(%) 
c+ n- 
N(%) X
2 P Negative N(%) 
Positive 
N(%) X
2 P 
Age 
<50 62(31.8) 36(32.4) 22(34.4) 313(35.1) 0.9 0.8 105(33.5) 407(35.4) 0.4 0.5 
>50 133(68.2) 75(67.6) 42(65.6) 580(64.9) 208(66.5) 743(64.6) 
Size FP 72(36.9) 47(42.3) 24(37.5) 256(29) 12 0.006 90(29.2) 367(32.1) 0.9 0.3 
>1.5cm 123(63.1) 64(57.7) 40(62.5) 628(71) 218(70.8) 775(67.9) 
Stage 
1 126(64.6) 77(68.8) 39(60.9) 526(59) 
8 0.22 
214(68.6) 665(57.9) 
13 0.002 2 46(23.6) 28(25) 20(31.3) 275(30.9) 69(22.1) 367(31.9) 
3 23(11.8) 7(6.3) 5(6.8) 90(10.1) 29(9.3) 117(10.2) 
Grade 
1 38(19.5) 33(29.5) 11(17.2) 74(8.3) 
90 <0.0001 
45(14.4) 129(11.2) 
4.1 0.1 2 64(32.8) 33(29.5) 33(51.6) 228(25.5) 75(24) 330(28.7) 
3 93(47.7) 46(41.1) 20(31.3) 591(66.2) 193(61.7) 691(60.1) 
Tubules 
1 12(6.3) 8(7.6) 1(1.7) 25(2.9) 
24 0.001 
11(3.8) 44(3.9) 
0.2 0.9 2 49(25.9) 45(42.9) 22(37.9) 250(28.7) 81(27.7) 329(29.1) 
3 128(67.7) 52(49.5) 35(60.3) 595(68.4) 200(68.5) 757(67) 
Pleomor
phism 
1 3(1.6) 2(1.9) 3(5.2) 5(0.6) 
84 <0.0001 
5(1.7) 11(1) 
3.2 0.2 2 84(44.4) 52(49.5) 29(50) 201(23.2) 96(33) 326(28.9) 
3 102(54) 51(48.6) 26(44.8) 661(76.2) 190(65.3) 792(70.2) 
Mitosis 
1 79(41.8) 46(43.8) 32(5.2) 178(20.5) 
85 <0.0001 
71(24.3) 302(26.7) 
2.2 0.3 2 24(12.7) 20(19) 13(22.4) 168(19.3) 50(17.1) 221(19.6) 
3 86(45.5) 39(37.1) 13(22.4) 524(60.2) 171(58.6) 607(53.7) 
NPI 
Excellent 28(14.4) 24(22) 9(14.1) 40(4.5) 
80 <0.0001 
33(10.6) 78(6.9) 
12.4 0.029 
Good 34(17.5) 25(22.9) 13(20.3) 126(14.2) 42(13.5) 181(15.9) 
Moderate 1 49(25.3) 30(27.5) 21(32.8) 304(34.3) 113(36.3) 357(31.4) 
Moderate 2 51(26.3) 19(17.4) 18(28.1) 252(28.4) 81(26) 306(26.9) 
Poor 24(12.4) 10(9.2) 2(3.1) 116(13.1) 28(9) 162(14.2) 
Very poor 8(4.1) 1(0.9) 1(1.6) 48(5.4) 14(4.5) 53(4.7) 
Vascular 
Invasion 
Negative 98(69) 53(65.4) 36(66.7) 352(57.7) 
8 0.046 
144(63.2) 470(61) 
0.3 0.6 
Positive 44(31) 28(34.6) 18(33.3) 258(42.3) 84(36.8) 300(39) 
Tumour 
Type 
Invasive 
Ductal/NST 106(55.2) 58(52.3) 25(39.7) 649(73.5) 
92 <0.0001 
198(64.7) 774(68) 
15 0.006 
lobular 23(12) 5(4.5) 9(14.3) 27(3.1) 12(3.9) 63(5.5) 
Atypical 
Medullary 4(2.1) 1(0.9) 1(1.6) 27(3.1) 18(5.9) 23(2) 
Mixed 48(25) 40(36) 24(38.1) 158(17.9) 65(21.2) 239(21) 
other 11(5.7) 7(6.3) 4(6.3) 22(2.5) 13(4.2) 40(3.5) 
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Relationship between SUMO Markers with Clinic-Pathological Parameters Continued. 
Parameters 
UBC9 
c- n- 
N(%) 
c+ n+  
N(%) 
c- n+  
N(%) 
c+ n-  
N(%) X
2 P 
Age 
<50 129(33.6) 228(37.6) 40(28.4) 129(37.7) 5.5 0.1 
>50 255(66.4) 379(62.4) 101(71.6) 213(62.3) 
Size FP 108(28.6) 190(31.4) 56(40) 81(23.8) 14 0.003 
>1.5cm 270(71.4) 416(68.6) 84(60) 259(76.2) 
Stage 
1 261(68) 355(58.4) 84(59.6) 197(58.1) 
18 0.005 2 88(22.9) 188(30.9) 37(26.2) 116(34.2) 
3 35(9.1) 65(10.7) 20(14.2) 26(7.75) 
Grade 
1 47(12.2) 84(13.8) 20(14.2) 22(6.4) 
45 <0.0001 2 101(26.3) 164(27) 61(43.3) 72(21.1) 
3 236(61.5) 360(59.66) 60(42.6) 248(72.5) 
Tubules 
1 14(3.8) 32(5.3) 3(2.2) 8(2.4) 
8.5 0.2 2 106(28.6) 178(29.7) 42(30.7) 89(26.3) 
3 250(67.6) 390(65) 92(67.2) 242(71.4) 
Pleomorphism 
1 4(1.1) 7(1.2) 6(4.4) 3(0.9) 
47 <0.0001 2 114(30.9) 183(30.6) 60(43.8) 62(18.3) 
3 251(68) 409(68.3) 71(51.8) 273(80.8) 
Mitosis 
1 95(25.7) 169(28.3) 60(43.8) 58(17.1) 
55 <0.0001 2 67(18.1) 115(19.2) 30(21.9) 48(14.2) 
3 208(56.2) 316(52.7) 47(34.3) 233(68.7) 
NPI 
Excellent 28(7.3) 48(8) 16(11.6) 16(4.7) 
43 <0.0001 
Good 62(16.2) 99(16.6) 35(25.4) 32(9.4) 
Moderate 1 139(36.4) 186(31.1) 38(27.5) 118(34.7) 
Moderate 2 98(25.7) 156(26.1) 25(18.1) 101(29.7) 
Poor 35(9.2) 87(14.5) 19(13.8) 52(15.3) 
Very poor 20(5.2) 22(3.7) 5(3.6) 21(6.2) 
Vascular 
Invasion 
Negative 157(63.6) 262(59.8) 66(68) 139(59.7) 3 0.4 
Positive 90(36.4) 176(40.2) 31(32) 94(40.3) 
Tumour Type 
Invasive Ductal /NST 253(67.3) 418(69.6) 63(45) 253(74.9) 
97.6 <0.0001 
lobular 17(4.5) 18(3) 26(18.6) 4(1.2) 
Atypical Medullary 13(3.5) 11(1.8) 3(2.1) 11(3.3) 
Mixed 79(21) 132(22) 42(30) 61(18) 
other 14(3.7) 22(3.7) 6(4.3) 9(2.7) 
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Correlation between SUMO Markers with other Tumour Markers Continued. 
 
Markers 
PIAS1 PIAS4 
c- n- 
N(%) 
c+ n+ 
N(%) 
c- n+ 
N(%) 
c+ n- 
N(%) X
2 P Negative N(%) 
Positive 
N(%) X
2 P 
ER 
Negative 72(37.7) 28(26.7) 17(27) 408(46.9) 
26 <0.0001 
145(48.8) 487(43.3) 
3 0.09 
Positive 119(62.3) 77(73.3) 46(73) 462(53.1) 152(51.2) 637(56.7) 
PgR 
Negative 96(52.7) 41(38.3) 21(36.2) 463(55.4) 
17.6 0.001 
175(59.7) 546(51.5) 
6 0.012 
Positive 86(47.3) 66(6.7) 37(63.8) 373(44.6) 118(40.3) 515(48.5) 
TN 
Negative 130(71) 86(81.9) 50(82) 596(70.4) 9 0.026 186(64.6) 783(72.6) 7 0.008 
Positive 53(29) 19(18.1) 11(18) 250(29.6) 102(35.4) 296(27.4) 
HER-2 
Negative 170(92.9) 100(92.6) 59(93.7) 679(79) 35 <0.0001 257(86) 912(82.9) 1.5 0.3 
Positive 13(7.1) 8(7.4) 4(6.3) 181(21) 42(14) 188(17.1) 
CK5 
Negative 117(74.1) 63(77.8) 41(85.4) 535(72.4) 5 0.2 171(69.5) 654(74.2) 2 0.1 
Positive 41(25.9) 18(22.2) 6(14.6) 204(27.6) 75(30.5) 227(25.8) 
CK17 
Negative 128(83.1) 66(83.5) 47(97.9) 590(81.6) 
8 0.037 
203(84.6) 723(82.1) 
0.8 0.4 
Positive 26(16.9) 13(16.5) 1(2.1) 133(18.4) 37(15.4) 158(17.9) 
CK14 Negative 
157(87.7) 91(87.5) 50(84.7) 721(85.8) 
0.7 0.8 
253(85.5) 913(86.1) 
0.08 0.7 
Positive 22(12.3) 13(12.5) 9(15.3) 119(14.2) 43(14.5) 147(13.9) 
BLBC Negative 
128(77.6) 81(83.5) 48(85.7) 592(75.6) 
6 0.1 
184(71.6) 769(77.8) 
4.4 0.035 
Positive 37(22.4) 16(16.5) 8(14.3) 191(24.4) 73(28.4) 219(22.2) 
P53 Negative 
130(71.4) 74(70.5) 39(72.2) 517(60.2) 
13 0.005 190(65.3) 668(60.9) 2 0.2 
Positive 52(28.6) 31(29.5) 15(27.8) 342(39.8) 101(34.7) 428(39.1) 
Rad51.c 
Negative 36(26.5) 13(15.9) 15(34.1) 44(5.9) 81.5 <0.0001 35(16.4) 64(8.1) 13 <0.0001 
Positive 100(73.5) 69(84.1) 29(65.9) 707(94.1) 179(83.6) 731(91.9 
Rad51.n 
Negative 106(77.4) 28(33.3) 18(40.9) 511(67.9) 
60 <0.0001 
159(74.3) 453(56.8) 
21.5 <0.0001 
Positive 31(22.6) 56(66.7) 26(59.1) 242(32.1) 55 (25.7) 344(43.2) 
KU70/KU80 
Negative 38(22.4) 12(13.3) 15(27.3) 78(9.8) 
30 <0.0001 
72(28.5) 69(7.9) 
76 <0.0001 
Positive 132(77.6) 78(86.7) 40(72.7) 717(90.2) 181(71.5) 806(92.1) 
DNA-PK 
Negative 40(30.5) 7(10.6) 4(13.8) 79(12.9) 
27 <0.0001 
67(35.6) 79(10.1) 
77 <0.0001 
Positive 91(69.5) 59(89.4) 25(86.2) 533(87.1) 121(64.4) 702(89.9) 
SMC6L1.n Negative 
52(39.7) 23(31.1) 7(20.6) 209(33.5) 5 0.2 99(49) 236(29.9) 26 <0.0001 
Positive 79(60.3) 51(68.9) 27(79.4) 415(66.5) 103(51) 553(70.1) 
SMC6L1.c Negative 
55(42) 24(32.4) 18(52.9) 157(25.2) 
25 <0.0001 86(42.6) 222(28.1) 15.6 <0.0001 
Positive 76(58) 50(67.6) 16(47.1) 467(74.8) 116(57.4) 567(71.9) 
ID4. n 
Negative 151(84.8) 72(76.6) 41(77.4) 706(84.8) 6 0.1 237(80.9) 864(83.8) 1.4 0.2 
Positive 27(15.2) 22(23.4) 12(22.6) 127(15.2) 56(19.1) 167(16.2) 
ID4.c 
Negative 103(52.8) 45(40.5) 39(60.9) 264(29.7) 58 <0.0001 134(42.5) 397(35.1) 6 0.015 
Positive 92(47.2) 66(59.5) 25(39.1) 625(70.3) 181(57.5) 734(64.9) 
PTEN 
Negative 85(85) 29(65.9) 13 (52) 354(84.9) 
26 <0.0001 
133(86.9) 414(82) 
2 0.15 
Positive 15(15) 15(34.1) 12(48) 63(15.1) 20 (13.1) 91 (18) 
CHK1.n Negative 
159(85) 21(20) 9(16.1) 699(82.6) 
302 <0.0001 
225(86.9) 695(78.4) 
9.5 0.003 
Positive 28(15) 83(79.8) 47(83.9) 147(17.4) 34(13.1) 191(21.6) 
CHK1.c Negative 
54(28.9) 10(9.6) 16(28.6) 25(3) 
157 <0.0001 149(57.5) 352(39.8) 14 <0.0001 
Positive 133(71.1) 94(90.4) 40(71.4) 820(97) 110(42.5) 533(60.2) 
CHK2 Negative 
60(59.4) 19(39.6) 11(40.7) 239(53.1) 
6.7 0.08 
109(64.5) 268(47.6) 
15 <0.0001 
Positive 41(40.6) 29(60.4) 16(59.3) 211(46.9) 60(35.5) 295(52.4) 
Ki-67 
Negative 82(47.7) 36(42.4) 29(53.7) 219(29) 34 <0.0001 76(31.8) 350(35.2) 1 0.3 
Positive 90(52.3) 49(57.6) 25(46.3) 535(71) 163(68.2) 643(64.8) 
ATM 
Negative 84(64.1) 30(38.5) 13(38.2) 360(57.8) 
18.4 <0.0001 
129(62.3) 422(54.8) 
10 0.019 
Positive 47(35.9) 48(61.5) 21(61.8) 263(42.2) 78 (37.7) 348(45.2) 
ATR 
Negative 68(60.7) 48(70.6) 20(58.8) 259(49.9) 
13 0.004 
128(66.7) 330(50.5) 
15.7 <0.0001 
Positive 44(39.3) 20(29.4) 14(41.2) 260(50.1) 64(33.3) 324(49.5) 
Ȗ+$;Q Negative 18(14.6) 1(1.5) 1(3.4) 93(15.6) 12.6 0.006 50(26.7) 85(11.3) 28.7 <0.0001 
Positive 105(85.4) 65(98.5) 28(96.6) 503(84.4) 137(73.3) 664(88.7) 
Ȗ+$;F Negative 24(19.5) 11(16.7) 11(37.9) 41(6.9) 44 <0.0001 25(13.4) 73(9.7) 2 0.1 
Positive 99(80.5) 55(83.3) 18(62.1) 556(93.1) 162(86.6) 677(90.3) 
BARD1.c 
Negative 59(40.7) 14(19.4) 8(22.2) 119(18.2) 35 <0.0001 65(29.7) 168(20.3) 9 0.003 
Positive 86(59.3) 58(80.6) 28(77.8) 535(81.8) 154(70.3) 661(79.7) 
BARD1.n 
Negative 138(95.2) 67(95.7) 34(94.4) 580(88.7) 9 0.029 203(92.3) 743(89.8) 1.2 0.3 
Positive 7(4.8) 3(4.3) 2(5.6) 74(11.3) 17(7.7) 84(10.2) 
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Correlation between SUMO Markers with other Tumour Markers 
 
Markers  
PIAS1 PIAS4 
c- n- 
N (%) 
c+ n+ 
N(%) 
c- n+ 
 N (%) 
c+ n- 
N (%) X
2 P Negative N (%) 
Positive 
N (%) X
2 P 
BRCA1.c Negative 
119(73.5) 44(51.2) 32(68.1) 414(55.6) 
21 
 
<0.0001 
 
170(71.1) 534(55.9) 
18 <0.0001 
Positive 43(26.5) 42(48.8) 15(31.9) 331(44.4) 69 (28.9) 421(44.1) 
BRCA1.n Negative 
88(54.3) 30(34.9) 13(27.1) 453(60.6) 
38 <0.0001 
151(63.2) 525(54.7) 5.5 0.019 
Positive 74(45.7) 56(65.1) 35(72.9) 295(39.4) 88(36.8) 439(45.3) 
MTA1.n 
Negative 72(52.9) 22(30.1) 14(37.8) 266(42.4) 
11 0.01 
108(51.2) 318(39.9) 
9 0.003 
Positive 64(71.1) 51(69.9) 23(62.2) 362(57.6) 103(48.8) 478(60.1) 
MTA1.c 
Negative 46(33.8) 11(15.1) 9(24.3) 57(9.1) 
60 <0.0001 
45(21.3) 99(12.4) 
11 0.001 
Positive 90(66.2) 62(84.9) 28(75.7) 572(90.9) 166(78.7) 698(87.6) 
P27 
Negative 32(45.7) 23(41.8) 9(32.1) 182(50) 
4.4 0.2 
62(40.5) 234(51.1) 5.1 0.02 
Positive 38(54.3) 32(58.2) 19(67.9) 73(46.8) 91(59.5) 224(48.9) 
 
 
  
Chapter10                                                                                                                  Appendices                                                                                                                   
290 
 
Correlation between SUMO Markers with other Tumour Markers 
 
Parameters 
UBC9 
c- n- 
N (%) 
c+ n+ 
N (%) 
c- n+ 
N (%) 
c+ n- 
N (%) X
2 P 
ER 
Negative 182(49.3) 217(37) 36(26.7) 183(54.8) 
48 <0.0001 
Positive 187(50.7) 369(63) 99(73.3) 151(45.2) 
PgR 
Negative 213(60.2) 268(48) 56(44.4) 205(62.7) 
28 <0.0001 
Positive 141(39.8) 290(52) 70(55.6) 122(37.3) 
TN 
Negative 231(65.3) 440(78) 114(87.7) 198(60.7) 54 <0.0001 
Positive 123(34.7) 124(22) 16(12.3) 128(39.3) 
BLBC Negative 
233(72.6) 415(80.7) 111(94.1) 196(68.8) 
38 <0.0001 
Positive 88(27.4) 99(19.3) 7(5.9) 89(31.2) 
Rad51.c 
Negative 23(9.6) 30(9.2) 9(12.3) 16(7.1) 
2 0.6 
Positive 216(90.4) 297(90.8) 64(87.7) 208(92.9) 
Rad51.n 
Negative 184(76.7) 176(53.5) 44(59.5) 181(80.4) 
58 <0.0001 
Positive 56(23.3) 153(46.5) 30(40.5) 44(19.6) 
KU70/KU80 Negative 
50(18.9) 32(9) 12(16.4) 21(9.4) 
17 0.001 
Positive 214(81.1) 325(91) 61(83.6) 202(90.6) 
DNA-PK 
Negative 97(31.8) 22(4.3) 7(7.3) 54(17.8) 
122 <0.0001 
Positive 208(68.2) 494(95.7) 89(92.7) 250(82.2) 
SMC6L1.n Negative 
140(42.6) 114(22.1) 26(24.8) 151(47.9) 
74.5 <0.0001 
Positive 189(57.4) 402(77.9) 79(75.2) 164(52.1) 
SMC6L1.c Negative 
149(45.3) 126(24.4) 60(57.1) 66(21) 
89 <0.0001 
Positive 180(54.7) 390(75.6) 45(42.9) 249(79) 
CHK1.n 
Negative 205(79.5) 267(72.8) 45(55.6) 182(80.5) 
24 <0.0001 
Positive 53(20.5) 100(27.2) 36(44.4) 44(19.5) 
CHK1.c 
Negative 38(14.7) 23(6.3) 13(16) 12(5.3) 
22 <0.0001 
Positive 222(85.3) 343(93.7) 68(84) 214(94.7) 
CHK2 Negative 
147(70.3) 117(32.1) 27(37.5) 125(61.9) 
97 <0.0001 
Positive 62(29.7) 248(67.9) 45(62.5) 77(38.1) 
Ki-67 
Negative 122(38.7) 183(35.4) 53(45.7) 68(23.2) 
26 <0.0001 
Positive 193(61.3) 334(64.6) 63(54.3) 228(76.8) 
ATM 
Negative 151 (56.6) 201 (52.9) 37 (44) 150 (63.8) 
12 0.007 
Positive 116 (43.4) 179 (47.1) 47 (56) 85 (36.2) 
ATR 
Negative 181(69.3) 203(43.6) 56(58.3) 116(48.7) 
47 <0.0001 
Positive 80(30.7) 263(56.4) 40(41.7) 122(51.3) 
Ȗ+$;Q Negative 62(19.4) 15(2.9) 4(4.1) 77(26.4) 114 <0.0001 
Positive 257(80.6) 511(97.1) 93(95.9) 215(73.6) 
Ȗ+$;F Negative 53(16.6) 39(7.4) 22(22.7) 8(2.7) 54 <0.0001 
Positive 267(83.4) 487(92.6) 75(77.3) 284(97.3) 
BARD1.n 
Negative 308(91.1) 485(90.1) 95(91.3) 293(92.1) 0.99 0.8 
Positive 30(8.9) 53(9.9) 9(8.7) 25(7.9) 
BARD1.c 
Negative 112(33.2) 77(14.3) 19(18.3) 60(18.9) 
47 <0.0001 
Positive 225(66.8) 463(85.7) 85(81.7) 258(81.1) 
BRCA1.c Negative 
196(65.1) 246(51) 74(66.7) 160(55.6) 
19.5 <0.0001 
 Positive 105(34.9) 236(49) 37 (33.3) 128(44.4) 
BRCA1.n Negative 
202(67.1) 239(49.4) 37(33) 201(69.8) 
70 <0.0001 
Positive 99(32.9) 245(50.6) 75(67) 87(30.2) 
MTA1.n 
Negative 180(53.7) 131(24.6) 13(12) 190(59.7) 
166 <0.0001 
Positive 155(46.3) 402(75.4) 95(88) 128(40.3) 
MTA1.c 
Negative 115(34.2) 32(6) 24(22.2) 24(7.5) 
149.2 <0.0001 
Positive 221(65.8) 502(94) 84(77.8) 294(92.5) 
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Correlation between PIAS1 and UBC9 with other Tumour Markers Regardless of Co-expression of Cellular Localisation. 
Markers 
PIAS1.c P 
X2 
 
PIAS1.n P 
X2 
 
Negative 
N (%) 
Positive 
N (%) 
Negative 
N (%) 
Positive 
N (%) 
ATM 
Negative 99(59.3) 391(55.6) 0.4 
0.4 
445(58.9) 44(38.6) <0.0001 
16.5 Positive 68(40.7) 312(44.4) 311(41.1) 70(61.4) 
BRCA1.c Negative 
152(72) 459(55) <0.0001 
20 
534(58.7) 78(57.8) 0.08 
0.45 Positive 59(28) 375(45) 375(41.3) 57(42.2) 
BRCA1.n Negative 
102(48.1) 485(57.9) 0.01 
7 
542(59.4) 44(32.4) <0.0001 
35 Positive 110(51.9) 352(42.1) 370(40.6) 92(67.6) 
ER 
Negative 89(34.6) 439(44.8) 0.003 
8.6 
481(45.2) 46(26.9) <0.0001 
20 Positive 168(65.4) 540(55.2) 582(54.8) 125(73.1) 
KU70/KU80 
Negative 53(23.2) 91(10.2) <0.0001 
27 
116(12) 27(18.5) 0.03 
5 Positive 175(76.8) 797(89.8) 851(88) 119(81.5) 
Ki-67 
Negative 113(49.3) 256(30.4) <0.0001 
28.7 
302(32.5) 68(47.9) <0.0001 
13 Positive 116(50.7) 587(69.6) 626(67.5) 74(52.1) 
BARD1.c 
Negative 67(36.6) 134(18.4) <0.0001 
28 
179(22.3) 22(20.4) 0.6 
0.2 Positive 116(63.4) 595(81.6) 622(77.7) 86(79.6) 
CHK1.n Negative 
170(69.1) 722(75.8) 0.03 
5 
860(83.1) 30(18.6) <0.0001 
304 Positive 76(30.9) 230(24.2) 175(16.9) 131(81.4) 
DNA-PK 
Negative 45(27.8) 86(12.6) <0.0001 
23 
119(16) 11(11.6) 0.3 
1.2 Positive 117(72.2) 596(87.4) 625(84) 84(88.4) 
MTA1.n 
Negative 88(50) 290(41.2) 0.03 
4.5 
339(44.3) 36(32.7) 0.02 
5 Positive 88(50) 414(58.8) 427(55.7) 74(67.3) 
SMC6L1.n 
Negative 61(36.3) 233(33.3) 0.4 
0.55 
262(34.6) 30(27.8) 0.2 
2 Positive 107(63.7) 467(66.7) 495(65.4) 78(72.2) 
Markers 
UBC9.n UBC9.c 
Negative 
N (%) 
Positive 
N (%) 
P 
X2 
P 
Negative 
N (%) 
Positive 
N (%) 
P 
X2 
P 
BRCA1.c 
Negative 356(60.4) 320(54) 0.02 
5 
270 (65.5) 407(52.8) <0.0001 
18 Positive 233(39.6) 273(46) 142(34.5) 364(47.2) 
BRCA1.n Negative 
403(68.4) 276(46.3) <0.0001 
59 
239(57.9) 441(57.1) 0.8 
0.07 Positive 186(31.6) 320(53.7) 174(42.1) 332(42.9) 
ER 
Negative 365(51.9) 253(35.1) <0.0001 
41 
219(43.4) 400(43.4) 0.99 
0 Positive 338(48.1) 468(64.9) 286(56.6) 522(56.6) 
PgR 
Negative 418(61.4) 324(47.4) <0.0001 
27 
270(56.1) 
 
474(53.4) 0.3 
0.9 Positive 263(38.6) 360(52.6) 211(43.9) 414(46.6) 
Rad51.n 
Negative 365(78.5) 220(54.6) <0.0001 
56 
228(72.6) 358(64.4) 0.01 
6 Positive 100(21.5) 183(45.4) 86(27.4) 198(35.6) 
Rad51.c 
Negative 39(8.4) 39(9.8) 0.5 
0.45 
32(10.3) 46(8.3) 0.3 
0.9 Positive 424(91.6) 361(90.3) 280(89.7) 507(91.7) 
CHK1.c 
Negative 387(80) 312(69.6) <0.0001 
13 
250(73.7) 449(75.6) 0.5 
0.4 Positive 97(20) 136(30.4) 89(26.3) 145(24.4) 
SMC6L1.c Negative 
215(33.4) 186(30) 0.2 
1.7 
210(48.3) 193(23.1) <0.0001 
83 Positive 429(66.6) 435(70) 225(51.7) 641 (76.9) 
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Appendix 4 
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Correlation between Nucleocytoplasmic Transport Markers with other Tumour Markers. 
Markers 
NPM KPNA2 
Negative 
N (%) 
positive 
N (%) X
2 P Negative N (%) 
positive 
N (%) X
2 P 
ER 
Negative 105(46.1) 465(43.6) 0.45 0.5 153(23.9) 447(63.8) 215  
<0.0001 Positive 123(53.9) 601(56.4) 487(76.1) 254(36.2) 
PgR 
Negative 133(56.4) 542(54) 0.4 0.5 234(37.7) 473(71.5) 148  
<0.0001 Positive 103(43.6) 461(46) 387(62.3) 189(28.5) 
Triple Negative 
Negative 154(67.8) 726(71.2) 
1 0.3 
533(85.3) 373(55.8) 
134  
<0.0001 Positive 73(32.2) 293(28.8) 92(14.7) 296(44.2) 
HER-2 
Negative 208(85.2) 851(82.4) 
1 0.3 
585(90.4) 521(76.6) 
45.5  
<0.0001 Positive 36(14.8) 182(17.6) 62(9.6) 159(23.4) 
Ki-67 Negative 78(37.9) 308(33.1) 1.7 0.2 306(54.2) 105(17) 180 <0.0001 
Positive 128(62.1) 622(66.9) 259(45.8) 513(83) 
Rad51.c 
Negative 10(6.6) 61(9.7) 
1.4 0.2 
55(15.2) 25(5.7) 
20  
<0.0001 Positive 142(93.4) 568(90.3) 308(84.8) 416(94.3) 
Rad51.n 
Negative 107(70.4) 422(66.6) 0.8 0.4 222(60.7) 328(73.9) 16  
<0.0001 Positive 45(29.6) 212(33.4) 144(39.3) 116(26.1) 
Rad51 
n-c- 9(5.9) 32(5.1) 
5 0.1 
35(9.6) 14(3.2) 
38 <0.0001 
n+c+ 44(28.9) 179(28.5) 121(33.3) 103(23.4) 
n-c+ 98(64.5) 389(61.8) 187(51.5) 313(71) 
n+c- 1(0.7) 29(4.6) 20(5.5) 11(2.5) 
Ȗ+$;F Negative 23(11.6) 89(10.1) 0.4 0.5 82(16) 40(6.2) 29 <0.0001 
Positive 175(88.4) 795(89.9) 429(84) 601(93.8) 
Ȗ+$;Q Negative 62(31.3) 83(9.4) 67 <0.0001 47(9.2) 111(17.3) 16 <0.0001 
Positive 136(68.7) 800(90.6) 463(90.8) 530(82.7) 
Ȗ+$; 
n-c- 7(3.5) 9(1) 
67 <0.0001 
9(1.8) 11(1.7) 
46.5 <0.0001 n+c+ 120(60.6) 720(81.5) 390(76.5) 501(78.2) 
n-c+ 55(27.8) 74(8.4) 38(7.5) 100(15.6) 
n+c- 16(8.1) 80(9.1) 73(14.3) 29(4.5) 
BARD1.c 
Negative 68(29.3) 180(18.1) 
14.5 <0.0001 122(20.9) 144(21.6)  0.09 0.8 Positive 164(70.7) 813(81.9) 461(79.1) 522(78.4) 
BARD1.n 
Negative 220(94.4) 885(89.3) 
 
6 0.018 
536(92.1) 598(89.8) 
 
2 0.1 Positive 13(5.6) 106(10.7) 46(7.9) 68(10.2) 
BARD1 
n-c- 69(29.6) 179(18.1) 
19 <0.0001 
123(21.1) 143(21.5) 
3 0.4 n+c+ 
13(5.6) 105(10.6) 46(7.9) 67(10.1) 
n-c+ 151(64.8) 706(71.2) 413(71) 455(68.3) 
n+c- 0 1(0.1) 0 1(0.2) 
BRCA1.c 
Negative 123(63.7) 487(54.7) 5 0.02 308 (59.2) 317(53.7) 3 0.06 
Positive 70 (36.3) 404(45.3) 212 (40.8) 273(46.3) 
BRCA1.n Negative 
118(61.1) 505(56.5) 
1.4 0.2 
226(43.4) 429(72.5) 
 
97 <0.0001 Positive 75(38.9) 389(43.5) 295(56.6) 163(27.5) 
BRCA1 
n-c- 74 (38.3) 236(26.5) 
11.5 0.009 
119 (22.9) 218(36.9) 
96 <0.0001 
n+c+ 26 (13.5) 137(15.4) 105 (20.2) 64 (10.8) 
n-c+ 44 (22.8) 267 (30) 107 (20.6) 209(35.4) 
n+c- 49 (25.4) 251(28.2) 189 (36.3) 99 (16.8) 
*BARD1 
/BRCA1 
Negative 23(10.2) 60(5.8) 6 0.016 30(4.9) 60(9) 8 0.005 
Positive 202(89.8) 971(94.2) 577(95.1) 605(91) 
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Correlation between Nucleocytoplasmic Transport markers with other Tumour Markers Continued. 
Markers 
NPM KPNA2 
Negative 
N (%) 
positive 
N (%) X
2 P Negative N (%) 
positive 
N (%) X
2 P 
SMC6L1.n 
Negative 120(54.8) 278(29.5) 
50.5 <0.0001 
213(36.7) 222(33.8) 
1 0.3 
Positive 99(45.2) 665(70.5) 367(63.3) 434(66.2) 
SMC6L1.c 
Negative 101(46.1) 254(26.9) 
31 <0.0001 
225(38.8) 153(23.3) 
35 <0.0001 
Positive 118(53.9) 689(73.1) 355(61.2) 503(76.7) 
SMC6L1 
n-c- 68(31.1) 134(14.2) 
63 <0.0001 
135(23.3) 84(12.8) 
39 <0.0001 
n+c+ 66(30.1) 545(57.8) 277(47.8) 365(55.6) 
n-c+ 52(23.7) 144(15.3) 78(13.4) 138(21) 
n+c- 33(15.1) 120(12.7) 90(15.5) 69(10.5) 
CHK1 
n-c- 20(12.7) 33(4.7) 
15.5 0.001 
39(9.2) 17(3.7) 
27 <0.0001 
n+c+ 36(22.8) 145(20.6) 107(25.2) 81(17.7) 
n-c+ 97(61.4) 498(70.7) 259(60.9) 348(76.1) 
n+c- 5(3.2) 28(4) 20(4.7) 11(2.4) 
CHK1.n 
Negative 117(74.1)) 531(75.3) 
0.1 0.7 
298(70.1) 365(79.7) 
 
11 0.001 Positive 41(25.9) 174(24.7) 127(29.9) 93(20.3) 
CHK1.c 
Negative 25(15.8) 61(8.7) 
7 0.007 
59(13.9) 28(6.1) 
 
15 <0.0001 Positive 133(84.2) 643(91.3) 366(86.1) 429(93.9) 
UBC9 
n-c- 116(49.4) 195(19.9) 
112 <0.0001 
175(30.1) 157(23.2) 
57 <0.0001 
n+c+ 40(17) 545(46.4) 238(40.9) 279(41.3) 
n-c+ 70(29.8) 243(24.8) 104(17.9) 217(32.1) 
n+c- 9(3.8) 86(8.8) 65(11.2) 23(3.4) 
UBC9.n 
Negative 186(79.1) 438(44.8) 
 
89.5 <0.0001 
279(47.9) 374(55.3) 
 
7 0.009 Positive 49(20.9) 540(55.22) 303(52.1) 302(44.7) 
UBC9.c 
Negative 125(53) 282(28.8) 
50 <0.0001 
240(41.1) 181(26.7) 
 
29 <0.0001 Positive 111(47) 698(71.2) 344(58.9) 496(73.3) 
PIAS1 
n-c- 27(16.9) 97(14.3) 
5.5 0.1 
88(22.4) 50(10.9) 
44.5 <0.0001 
n+c+ 19(11.9) 48(7.1) 46(11.7) 28(6.1) 
n-c+ 107(66.9) 506(74.7) 239(60.8) 373(81.3) 
n+c- 7(4.4) 26(3.8) 20(5.1) 8(1.7) 
PIAS1.c 
Negative 35(21.6) 125(18.4) 
0.9 0.3 
111(28) 58(12.6) 
32 <0.0001 
 Positive 127(78.4) 556(81.6) 286(72) 403(87.4) 
PIAS1.n 
Negative 135(83.9) 604(89.1) 
3 0.06 
327(83.2) 425(92.2) 
16.3 <0.0001 
Positive 26(16.1) 74(10.9) 66(16.8) 36(7.8) 
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Relationship between Nucleocytoplasmic Transport markers with Clinico-Pathological Parameters. 
Parameters 
NPM KPNA2 
Negative 
N (%) 
Positive 
N (%) 
X2 P Negative 
N (%) 
Positive 
N (%) 
X2 P 
Age 
<50 89(35.5) 389(35.9) 0.02 0.9 205(30.5) 299(41.9) 20 <0.0001 
>50 162(64.5) 694(64.1) 468(69.5) 414(58.1) 
Size FP 76(31) 320(29.7) 0.2 0.7 239(35.6) 152(21.6) 33 <0.0001 
>1.5cm 169(69) 757(70.3) 432(64.4) 551(78.4) 
Stage 
1 170(67.7) 622(57.5) 
10 0.006 
434(64.4) 404(56.9) 
10 0.007 2 65(25.9) 338(31.3) 183(27.2) 218(30.7) 
3 16(6.4) 121(11.2) 57(8.5) 88(12.4) 
Grade 
1 35(13.9) 104(9.6) 
4 0.1 
145(21.5) 18(2.5) 
326 <0.0001 2 65(25.9) 309(28.5) 263(39) 84(11.8) 
3 151(60.2) 671(61.9) 266(39.5) 611(85.7) 
Tubules 
1 8(3.4) 35(3.3) 
4 0.1 
40(6.2) 7(1) 
104 <0.0001 2 54(22.8) 316(29.4) 251(38.7) 133(18.9) 
3 175(73.8) 723(67.3) 357(55.1) 565(80.1) 
Pleomorphism 
1 5(2.1) 14(1.3) 
3 0.2 
15(2.3) 3(0.4) 
220 <0.0001 2 74(31.4) 288(26.8) 295(45.7) 77(10.9) 
3 157(66.5) 771(71.9) 335(51.9) 624(88.6) 
Mitosis 
1 60(25.3) 278(25.9) 
0.2 0.9 
287(44.3) 57(8.1) 
316 <0.0001 2 40(16.9) 191(17.8) 141(21.8) 85(12.1) 
3 137(57.8) 605(56.3) 220(34) 563(79.9) 
NPI 
Excellent 23(9.3) 61(5.7) 
11 0.05 
88(13.1) 10(1.4) 
214 <0.0001 
Good 39(15.9) 168(15.7) 164(24.5) 36(5.1) 
Moderate 1 91(37) 340(31.7) 209(31.2) 248(35.4) 
Moderate 2 58(23.6) 296(27.6) 132(19.7) 225(32.1) 
Poor 29(11.8) 153(14.3) 61(9.1) 136(19.4) 
Very poor 6(2.4) 54(5) 16(2.4) 46(6.6) 
Tumour Type 
Invasive Ductal /NST 164(67.2) 738 (68.8) 
20 <0.0001 
363(55.3) 586(82.9) 
169 <0.0001 
lobular 7 (2.9) 60 (5.6) 47(7.2) 11 (1.6) 
Atypical Medullary 15 (6.1) 17 (1.6) 7 (1.1) 31 (4.4) 
Mixed 52 (21.3) 223 (20.8) 206(31.4) 68 (9.6) 
other 6 (2.5) 35 (3.3) 34(5.2) 11 (1.6) 
Vascular 
Invasion 
Negative 117(66.1) 429(58.5) 3 0.06 330(63.6) 252(57.7) 3 0.06 
Positive 60(33.9) 304(41.5) 189(36.4) 185(42.3) 
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